WO2007102812A2 - Natively glycosylated mammalian biological molecules produced by eletromagnetically stimulating living mammalian cells - Google Patents

Abstract

The disclosure describes a method for producing natively glycosylated mammalian biological molecules by electromagnetically stimulating mammalian cells using an electromagnetic field. The mammalian cells can be grown in a cell culture chamber, and preferably in a bioreactor that is exposed to a time varying electromagnetic force. The biological molecules can be isolated from the cells and used for therapeutic, research, or other purposes.

Description

NATIVELY GLYCOSYLATED MAMMALIAN BIOLOGICAL MOLECULES PRODUCED BY ELECTROMAGNETICALLY STIMULATING LIVING

MAMMALIAN CELLS

The present invention relates generally to the field of production of natively glycosylated mammalian biological molecules. Specifically, the present invention relates to a system and process for producing natively glycosylated mammalian biological molecules by electromagnetically stimulating mammalian cells using an electromagnetic field.

Natively glycosylated mammalian biological molecules such as granulocyte-colony stimulating factor (G-CSF), granulocyte- macrophage colony stimulating factor (GM-CSF), interleukins 2 to 32, human growth factor (HGF), leukemia inhibitory factor (LIF), erythropoietin (EPO), some kinases, cytokines, interferons, tissue plasminogen activator, αl -antitrypsin, coagulation factor VIII, epidermal growth factor, follicle stimulating hormone and RANTES are extensively used in research and therapeutic treatment. It has been difficult or very expensive to produce these molecules for research or therapeutic use.

G-CSF, a glycoprotein of 25 kD containing internal disulfide bonds, induces the survival, proliferation, differentiation and function of neutrophilic granulocyte precursor cells and functionally activates mature neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukaemic myeloid cell lines. It is a protein that stimulates the growth and maturation of granulocytes. It is used to promote the recovery of white blood cells following chemotherapy. It can be used to accelerate neutrophil recovery from myelosuppressive treatments. G-CSF also decreases the morbidity of cancer chemotherapy by reducing the incidence of febrile neutropenia, the morbidity of high-dose chemotherapy supported by marrow transplantation, and the incidence and duration of infection in patients with severe chronic neutropenia.

Mouse granulocyte colony stimulating factor (G-CSF) was first recognized and purified in Australia in 1983, and groups from Japan and the U.S.A. cloned the human form in 1986. The natural human glycoprotein exists in two forms of

174 and 177 amino acids. The more abundant and more active 174 amino acid form has been used in the development of pharmaceutical products by recombinant DNA technology.

The two forms of recombinant human G-CSF in clinical use (filgrastim and lenograstim) are potent stimulants of neutrophil granulopoiesis and have demonstrated efficacy in preventing infectious complications of some neutropenic states. The recombinant human G-CSF synthesized in an E. coli expression system is called filgrastim. The structure of filgrastim differs slightly from the natural glycoprotein. Most published studies have used filgrastim and it was the first form of G- CSF to be approved for marketing in Australia. Another form of recombinant human G- CSF called lenograstim is synthesized in Chinese hamster ovary (CHO) cells. As this is a mammalian cell expression system, lenograstim is indistinguishable from the 174 amino acid natural human G-CSF. No clinical or therapeutic consequences of the differences between filgrastim and lenograstim have yet been identified, but there are no formal comparative studies.

G-CSF (filgrastim) is indicated for the prevention of febrile neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies. It reduces the duration and severity of post-chemotherapy neutropenia.

G-CSF (lenograstim) is also approved for use to reduce the incidence of infection associated with established cytotoxic chemotherapy,

While it is naturally produced in the human body, the isolation of human

G-CSF has not been commercially achieved. The production of G-CSF has been commercially accomplished only by synthetic means such as recombinant DNA technology producing G-CSF synthesized in an E. coli expression system or recombinant human G-CSF synthesized in Chinese hamster ovary (CHO) cells. Both of these "synthetic" processes are costly making the product achieved expensive and thereby creating an additional burden to the already over-burdened health care system.

There are extensive publications on techniques to increase natively glycosylated mammalian biological molecules in humans and laboratory animals and the therapeutic effect derived there from. However, like the problem associated with obtaining commercial quantities of reasonably priced G-CSF, obtaining reasonably priced quantities of GM-CSF, cytokines, interleukins, and other desired natively glycosylated mammalian biological molecules has not been accomplished.

Disadvantages of using existing processes for producing natively glycosylated mammalian biological molecules include the problem of obtaining commercial quantities of the molecules at a reasonable cost and in a timely and efficient manner.

Summary of the Invention

The present invention overcomes problems of prior processes and systems and provides an economical system for producing commercial quantities of natively glycosylated mammalian biological molecules.

The present invention relates to a process for producing natively glycosylated mammalian biological molecules from mammalian cells. A further aspect of the invention involves introducing mammalian cells into the culture chamber of a bioreactor and rotating the chamber at speeds and for a time sufficient to grow the cells and increase the amount of natively glycosylated mammalian biological molecules produced by the cells. The cells are preferably exposed to an electromagnetic field (EMF), which, in a preferred embodiment of the invention, is a time-varying electromagnetic field (TVEMF). Also, the process extends to exposing cells in a cell culture chamber as described herein to EMF, preferably TVEMF.

Another aspect of this invention is to provide a composition comprising one or more natively glycosylated mammalian biological molecules produced by electromagnetically stimulating living mammalian cells in accordance with the process described herein.

Still another aspect of this invention is to provide a composition comprising one or more of natively glycosylated mammalian biological molecules such as proteins, peptides, and polypeptides, including but not limited to, for instance, glycoproteins, cytokines, post-translational proteins, post-translational peptides, and post-translational polypeptides produced in accordance with the process of this invention. Yet another aspect of this invention relates to compositions containing one or more of these biological molecules and use of these molecules for therapeutic purposes, including inclusion in a pharmaceutical composition. It is still another object of this invention to produce a natively glycosylated mammalian biological molecule mixture for mammalian cells that can be separated into its individual component parts for later research or therapeutic use.

Another aspect of this invention relates to a pharmaceutical composition comprising a natively glycosylated mammalian biological molecule of this invention, preferably for use in treating a disease or otherwise for therapeutic uses known of the molecule in the state of the art. Also, the use of a natively glycosylated mammalian biological molecule of the present invention for the preparation for a medicament for the treatment of a disease is contemplated.

Other aspects, features and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

Brief Description of the Drawings

Figure 1 schematically illustrates a preferred embodiment of a culture carrier flow loop of a bioreactor.

Figure 2 is an elevated side view of a preferred embodiment of a Time Varying Electromagnetic Force (TVEMF) bioreactor that can be utilized in carrying out the present invention.

Figure 3 is a side perspective view of a bioreactor of Fig. 2

Figure 4 is a vertical cross sectional view of a bioreactor;

Figure 5 is a vertical cross sectional view of a TVEMF- bioreactor;

Figure 6 is an elevated side view of a time varying electromagnetic force device that can house, and provide a time varying electromagnetic force to, a bioreactor;

Figure 7 is a front view of the device shown in Figure 6; and Figure 8 is a front view of the device shown in Figure 6, further showing a bioreactor therein.

Figure 9- is a graphical representation of the data from Table II representing the concentration of G-CSF (pg/ml) over fifteen days derived from normal human neuronal progenitor cells in a TVEMF bioreactor, in a bioreactor without

TVEMF, and in a two-dimensional TVEMF petri dish system.

Figure 10- is a graphical representation of the data from Table II representing the concentration of FGF basic (pg/ml) over fifteen days derived from normal human neuronal progenitor cells in a TVEMF bioreactor, in a bioreactor without TVEMF, and in a two-dimensional TVEMF petri dish system.

Figure 11- is a graphical representation of the data from Table II representing the concentration of IL-6 (pg/ml) over nineteen days derived from normal human neuronal progenitor cells in a TVEMF bioreactor, in a bioreactor without TVEMF, and in a two-dimensional TVEMF petri dish system.

Figure 12- is a graphical representation of the data from Table II representing the concentration of GM-CSF (pg/ml) over fifteen days derived from normal human neuronal progenitor cells in a TVEMF bioreactor, in a bioreactor without TVEMF, and in a two-dimensional TVEMF petri dish system.

Figure 13- is a graphical representation of the data from Table II representing the concentration of VEGF (pg/ml) over fifteen days derived from normal human neuronal progenitor cells in a TVEMF bioreactor, in a bioreactor without TVEMF, and in a two-dimensional TVEMF petri dish system.

Figure 14-is a graphical representation of the data from Table II representing the concentration of IL-8 (pg/ml) over nineteen days derived from normal human neuronal progenitor cells in a TVEMF bioreactor, in a bioreactor without

TVEMF, and in a two-dimensional TVEMF petri dish system. Detailed Description of the Invention

The following definitions are meant to aid in the description and understanding of the defined terms in the context of the present invention. The definitions are not meant to limit these terms to less than is described throughout this application. Furthermore, several definitions are included relating to TVEMF and all of the definitions in this regard should be considered to complement each other, and not construed against each other.

As used throughout this application, the term "mammalian cell" refers to living mammalian cells, or mammalian origin. Preferably, mammalian cells of this invention are progenitor cells, neuronal cells, progenitor neuronal cells, lung cells, blood cells, or other tissue cells that make natively glycosylated mammalian biological molecules. Preferably, the cells are human cells. The cells may be obtained directly from a mammal (preferably human), or from a commercial source, or from tissue, or in the form for instance of cultured cells, prepared on site or purchased from a commercial cell source and the like.

As used throughout this application, the term "mammalian cell composition", or reference thereto, refers to mammalian cells which are in a liquid of some sort, such as, but not limited to, PBS (Phosphate Buffer Saline), growth medium (for example Dulbecco's), plasma, or blood, and can contain plasma, blood, albumin, cell culture medium, growth factor, copper chelating agent, hormone, buffer, or some other substance that is non-toxic and is preferably nurturing to the cells.

As used throughout this application, the term "carrier medium" is a fluid carrier such as cell culture media, cell growth media, buffer which provides sustenance to the cells and depending on the composition of the cell growth media allows the cells to replicate. The carrier medium can be refreshed and/or removed as needed. The carrier medium according to the present invention may also contain natively glycosylated mammalian biological molecules produced by mammalian cells according to this invention. It should be noted that this invention is preferably operated without the presence of proteases. Proteases are not to be present in the cell culture chamber because a focus of this invention is the production of natively glycosylated mammalian biological molecules, which are proteins, polypeptides, and peptides. Accordingly, a protease inhibitor may be present in the cell culture chamber. As used throughout this application, the term "natively glycosylated mammalian biological molecules" and other similar terms refers to a protein to which a glycosyl group has been added so that the glycosyl group is preferably present in its native and naturally-occurring, context. Molecules which are glycosylated by a mammalian cell are considered natively glycosylated. Natively glycosylated mammalian biological molecules comprise, but are not limited to, proteins, peptides, polypeptides, including and for example, glycoproteins, cytokines, post-translational proteins, post-translational peptides, and post-translational polypeptides including specifically G-CSF, GM-CSF, HGF, LIF, cytokines, EPO, some kinases, interferons, EGF, tissue plasminogen activator, αl -antitrypsin, coagulation factor VIII, epidermal growth factor, follicle stimulating hormone, RANTES and the interleukins, such as, but not limited to, IL-2, IL-6, IL-8 and IL-IO, produced in accordance with the process of this invention. Proteases are not to be present in the cell culture chamber, while protease inhibitors may be.

As used throughout this application, the term "natively glycosylated mammalian biological molecule mixture" and other similar terms refers to a mixture of natively glycosylated biological molecules produced as a result of exposure of a mammalian cell to an electromagnetic force, preferably TVEMF, and which comprises two or more natively glycosylated mammalian biological molecules. Typically, such a mixture may include a large number of molecules, some or all of which may be natively glycosylated mammalian biological molecules. The natively glycosylated mammalian biological molecule mixture after EMF stimulation preferably has a higher concentration of natively glycosylated mammalian biological molecules than prior to stimulation of the mammalian cells. See for instance the list of molecules set forth in Table I of the present invention, produced from a natively glycosylated mammalian biological mixture from exposure of NHNP cells to TVEMF in a TVEMF-bioreactor. Preferably, a natively glycosylated mammalian biological molecule of the present invention is present in a natively glycosylated mammalian biological molecule mixture in an amount of preferably over 100 pg/ml mixture, more preferably over 1000 pg/ml, and most preferably over 10,000 pg/ml.

However, smaller amounts may certainly be present in the mixture according to this invention. As used throughout this application, a "composition comprising a natively glycosylated mammalian biological molecule" refers to a composition having a natively glycosylated mammalian biological molecule of this invention separated from a natively glycosylated mammalian biological molecule mixture. The composition may be in a form ready for storage, research or other uses, preferably with an "acceptable carrier" such as but not limited to buffer, cryopreservative, water.

A composition comparing a natively glycosylated mammalian biological molecule that is ready for administration for instance to a mammal, preferably a human, is a "pharmaceutical composition" of this invention and may be selected from a form such as tablets, lozenges, capsules, powders, dragees, aqueous or oily suspensions, syrups, elixirs, and aqueous solutions. In most instances, however, it is mixed with a suitable carrier and injected into the bloodstream. A pharmaceutical composition of the present invention should include a pharmaceutically acceptable carrier, for instance as known in the art with regard to a natively glycosylated mammalian biological molecule. As used throughout this application, the term "pharmaceutically acceptable carrier" and other similar terms means an agent that will allow the introduction of a natively glycosylated mammalian biological molecule of this invention into a mammal, preferably a human.

As used throughout this application, the term "mammalian cell mixture" and other similar terms refers to a mixture of mammalian cells, or a mammalian cell composition, that may be placed into a cell culture chamber. The cells shall include a substance that allows the cells to expand (e.g. replicate), such as a carrier medium for growth of cells that may be placed in a cell culture chamber.

Preferably, the mammalian cell mixture comprises mammalian cells and a growth media, and more preferably, mammalian cells and GTSF-2 medium. Preferably, at least half of the mammalian cell mixture is a carrier medium such as GTSF-2 medium.

As used throughout this application, a "copper chelating agent" or other similar terms refers to any non-toxic copper chelating agent, and is preferably Penicillamine or Trientine Hydrochloride. More preferably, the Penicillamine is D(-)-2-Amino-3-Mercaptor-3-Methylbutanic Acid (Sigma- Aldrich), dissolved in DMSO and added to the mammalian cell mixture in an amount of about 10 ppm. The purpose of the copper chelating agent, whether added to the mammalian cell mixture itself or administered to a blood donor mammal, or both, is to reduce the amount of copper in the mammalian cell mixture prior to expansion, preferably

TVEMF-expansion. Not to be bound by theory, it is believed that the decrease in amount of available copper may enhance TVEMF-expansion. TVEMF-expansion may promote an increase in production of natively glycosylated mammalian biological molecules.

As used throughout this application, the term "cell culture chamber" and "chamber" or other similar words is meant to be a unit in which cells are free to live and preferably replicate, expand and grow including, but not limited to, such chambers as petri-dishes, bioreactor cell culture chambers or vessels, wells, and flasks. According to this invention, a mammalian cell mixture is placed in a cell culture chamber, and as the cells replicate and grow, a natively glycosylated mammalian biological molecule mixture is produced.

As used throughout this application, the term "placed into a TVEMF- bioreactor" and "placed into a cell culture chamber" and similar words is not meant to be limiting. The mammalian cell mixture may be made entirely outside of the cell culture chamber, for instance of a bioreactor or a TVEMF-bioreactor, and then the mammalian cell mixture placed inside the cell culture chamber thereof. Also, the mammalian cell mixture may be entirely mixed inside the chamber. For instance, the mammalian cells (or a cellular portion thereof) may be placed in a chamber and supplemented with GTSF-2 medium and 10% fetal bovine serum or other serum, more preferably human serum albumin or other serum useful in cell culture,either already in the chamber, added simultaneously to the chamber, or added after the mammalian cells are already in the chamber.

As used throughout this application, the term "electromagnetic force" (EMF) is preferably measured in Gauss and more preferably is exposed to mammalian cells of this invention in an amount of about 0.05 to about 6 gauss. An electromagnetic force according to this invention can be supplied to a culture chamber, preferably to a chamber of a bioreactor and/or a petri dish, to enhance the production of natively glycosylated mammalian biological molecules derived from a cell culture mix therein.

As used throughout this application, the term "TVEMF" refers to "Time Varying Electromagnetic Force". As discussed above, the TVEMF of this invention is a square wave (following a Fourier curve). Preferably, the square wave has a frequency of about 10 cycles/second, and the conductor has an RMS value of about 1 to 1000 mA, preferably 1 to 6 mA. However, these parameters are not meant to be limiting to the TVEMF of the present invention, as such may vary based on other aspects of this invention. TVEMF may be measured for instance by standard equipment such as an ENl 31 Cell Sensor Gauss Meter.

As used throughout this application, the term "bioreactor" refers to a rotating bioreactor, when the cell culture chamber is closed and rotated about its longitudinal axis, as discussed throughout the application. As used herein, preferably a bioreactor provides a closed cell culture chamber in which a mammalian cell mixture is placed and thereafter a natively glycosylated mammalian biological molecule mixture is produced.

As used throughout this application, the term "TVEMF-bioreactor" refers to a rotating bioreactor to which TVEMF is applied, as described more fully in the Description of the Drawings, below. The TVEMF applied to a bioreactor is preferably in the range of 0.05 to 6.0 gauss, and more preferably 0.05-0.5 gauss. See for instance Figures 2, 3, 4 and 5 herein for examples (not meant to be limiting) of a TVEMF- bioreactor. In a simple embodiment, a TVEMF-bioreactor of the present invention provides for the rotation of an enclosed mammalian cell mixture at an appropriate gauss level (with TVEMF applied), and allows the mammalian cells therein to live and preferably expand. Preferably, a TVEMF-bioreactor allows for the exchange of growth medium (preferably with additives) and for oxygenation of the mammalian cell mixture.

The TVEMF-bioreactor provides a mechanism for growing cells for several days or more. The TVEMF-bioreactor subjects cells in the bioreactor to TVEMF, so that TVEMF is passed through the cells, thus undergoing TVEMF-expansion. Preferably, a TVEMF- bioreactor provides for the production of a natively glycosylated mammalian biological molecule mixture.

As used throughout this application, the term "TVEMF-expanding" refers to the step of mammalian cells in a chamber, preferably a two-dimensional tissue culture system and/or a TVEMF-bioreactor, living and preferably growing and replicating (splitting and growing) in the presence of TVEMF. The mammalian cells preferably replicate without undergoing further differentiation.

As used throughout this application, the term "expanding" and related terms refers to the step of cells in a culture chamber, preferably a bioreactor, replicating

(splitting and growing). The mammalian cells preferably replicate without undergoing further differentiation.

It should be noted, however, that a focus of this invention is in the production of natively glycosylated mammalian biological molecules by culturing cells, preferably in a TVEMF bioreactor. While expansion is preferred, simple survival of cells is sufficient for the production of natively glycosylated mammalian biological molecules according to the present invention. When "expansion" is referred to throughout this application, it should be noted that such may include a low number of mammalian cell replications and that the focus is on the production of molecules.

As used throughout this application, the term "TVEMF-expansion" refers to the process of increasing the number of mammalian cells in a chamber, preferably a two-dimensional culture system and/or a TVEMF-bioreactor, by subjecting the cells to a TVEMF of about 0.05 to about 6.0 gauss. The increase in the number of cells per volume is the result of cell replication in the chamber, so that the total number of cells in the chamber increases. The increase in number of cells per volume is expressly not due to a simple reduction in volume of fluid, for instance, reducing the volume of growth medium from for example 70 ml to 10 ml and thereby increasing the number of cells per ml. TVEMF-expansion of mammalian cells in a TVEMF-bioreactor according to the present invention provides for mammalian cells that maintain, or have essentially the same, three-dimensional geometry and cell-to-cell support and cell-to-cell geometry as the mammalian cells prior to TVEMF-expansion. Not to be bound by theory, TVEMF- expansion not only provides for high concentrations of cells that maintain their three- dimensional geometry and cell-to-cell support but TVEMF may affect some properties of cells during TVEMF-expansion, for instance up-regulation of genes promoting growth, or down regulation of genes preventing growth. Overall, TVEMF-expansion results in promoting growth but not cell differentiation overall. As used throughout this application, the term "TVEMF-expanded cell" refers to a cell that has been subjected to the process of TVEMF-expansion.

As used throughout this application, the term "cell-to-cell geometry" refers to the geometry of cells including the spacing, distance between, and physical relationship of the cells relative to one another. For instance, TVEMF-expanded stem cells of this invention typically stay in relation to each other as in the body. The expanded cells may stay within the bounds of natural spacing between cells, in contrast to for instance two-dimensional expansion chambers, where such spacing is not kept.

As used throughout this application, the term "cell-to-cell support" refers to the support one cell provides to an adjacent cell. For instance, healthy tissue and cells maintain interactions such as chemical, hormonal, neural (where applicable/appropriate) with other cells in the body. In the present invention, these interactions are maintained typically within normal functioning parameters, meaning they do not for instance begin to send toxic or damaging signals to other cells (unless such would be done in the natural environment).

As used throughout this application, the term "three-dimensional geometry" refers to the geometry of cells in a three-dimensional state (same as or very similar to their natural state), as opposed to two-dimensional geometry for instance as found in cells grown in a Petri dish, where the cells may become flattened and/or stretched.

For each of the above three definitions, relating to maintenance of cell-to-cell support and geometry and three dimensional geometry of mammalian cells of the present invention, the term "essentially the same" means that normal geometry and support are provided in TVEMF-expanded cells of this invention, so that the cells are not changed in such a way as to be for instance dysfunctional, unable to repair tissue, or toxic or harmful to other cells.

As used throughout this application, the term "toxic substance" or related terms may refer to substances that are toxic to a mammalian cell, or to a human or non-human patient. In particular, the term toxic substance includes dead cells and macrophages. Other toxic substances are known and removal of these substances from mixtures and compositions of the present invention are known.

As used throughout this application, the term "natively" may refer to characteristics of molecules, which exist in nature. Preferably, natively glycosylated mammalian biological molecules are those that are glycosylated in a manner similar to that of the molecule occurring in nature, because the glycosylation occurs in a native environment; i.e., a mammalian cell.

As used throughout this application, the term "harvesting" refers to the process of separating natively glycosylated mammalian biological molecules from a natively glycosylated mammalian biological molecule mixture.

As used throughout this application, the term "harvestable amount" refers to an amount that is not negligible. Preferably a harvestable amount exists when enough of a natively glycosylated mammalian biological molecule, for instance GCSF, is present in a detectable amount, and more preferably, when there is more than 100 pg/ml. Even more preferably, more than 1000 pg/ml is present, and even more preferably, more than 10,000 pg/ml.

Other statements referring to the above-defined terms or other terms used throughout this application are not meant to be limited by the above definitions, and may contribute to the definitions. Information relating to various aspects of this invention is provided throughout this application, and is not meant to be limited only to the section to which it is contained, but is meant to contribute to an understanding of the invention as a whole.

A method for producing natively glycosylated mammalian biological molecules is described. Mammalian cells and a carrier medium (together a mammalian cell mixture) are placed into a cell culture chamber capable of sustaining cell growth.

Preferably, the chamber is part of a bioreactor, more preferably a TVEMF bioreactor, rotated about its axis at a rotational speed sufficient to prevent the cells from contacting the walls of the chamber. The rotation preferably continues at least until the natively glycosylated mammalian biological molecules are present in a harvestable amount in the carrier medium or until otherwise desired. The mammalian cells and carrier medium are maintained in the chamber under cell growth conditions. Carrier medium containing a mixture of natively glycosylated mammalian biological molecules or cells can be removed from the chamber, either during the expansion process (for instance by removing the non-cellular material from the bioreactor) or after expansion. Also when expansion is no longer desired from a particular cell or cells, the cells can be lysed and then any natively glycosylated mammalian biological molecules present inside the cells can be separated into individual molecular entities or mixtures of the natively glycosylated mammalian biological molecules. In some cases, the natively glycosylated mammalian biological molecules may be directly produced into the carrier medium and removed from the expanded cells, and in other cases it will be necessary to lyse the cells in order to obtain the natively glycosylated mammalian biological molecules. These natively glycosylated biological molecules can be used for instance for therapeutic purposes or for research.

In a preferred embodiment of the present invention, the cells are expanded in such manner so as to maintain, have the same or essentially the same, three- dimensional geometry and normally the same cell-to-cell support and cell-to-cell geometry as the cells prior to expansion. Typically this may be accomplished by maintaining the cells suspended in a carrier medium and preventing the cells from contacting a solid surface during the cell expansion, for example by maintaining the cells in a bioreactor which rotates about a horizontal axis.

In an embodiment of this invention a natively glycosylated mammalian biological molecule mixture is produced by electromagnetically stimulating living mammalian cells. Preferably, the natively glycosylated mammalian biological molecules are produced in an environment fostering three-dimensional mammalian cell conditions and the electromagnetic stimulation is provided by applying a time varying electromagnetic force, and, more specifically, a square wave.

In the simplest terms, a rotating TVEMF- bioreactor comprises a cell culture chamber and a time varying electromagnetic force source. In a more complex TVEMF- bioreactor system, the time varying electromagnetic force source can be integral to the TVEMF- bioreactor, as illustrated in Figures 2-5, but can also be adjacent to a bioreactor as in Figures 6-8. Furthermore, a carrier medium, which provides sustenance to the cells, can be periodically refreshed and/or removed. Preferred TVEMF- bioreactors are described herein. Referring now to Figure 1, illustrated is an embodiment of a culture carrier flow loop 1 in an overall bioreactor culture system for growing mammalian cells having a cell culture chamber 19, preferably a rotating cell culture chamber, an oxygenator 21, an apparatus for facilitating the directional flow of the carrier medium, preferably by the use of a main pump 15, and a supply manifold 17 for the selective input of such carrier medium requirements such as, but not limited to, nutrients 3, buffers 5, fresh medium 7, cytokines 9, growth factors 11, and hormones 13. In this embodiment, the main pump 15 provides fresh carrier medium to the oxygenator 21 where the carrier medium is oxygenated and passed through the cell culture chamber 19. The waste in the spent carrier medium from the cell culture chamber 19 is removed and delivered to the waste chamber 18 and the remaining carrier medium is returned to the manifold 17 where it receives a fresh charge, as necessary, before recycling by the pump 15 through the oxygenator 21 to the cell culture chamber 19.

In the culture carrier flow loop 1, the carrier medium is circulated through the living cell culture in the chamber 19 and around the culture carrier flow loop

1, as shown in Figure 1. In this loop 1, adjustments are made in response to chemical sensors (not shown) that maintain constant conditions within the cell culture reactor chamber 19. Controlling carbon dioxide pressures and introducing acids or bases corrects pH. Oxygen, nitrogen, and carbon dioxide are dissolved in a gas exchange system (not shown) in order to support cell respiration. The closed loop 1 adds oxygen and removes carbon dioxide from a circulating gas capacitance. Although Figure 1 illustrates one embodiment of a culture carrier flow loop that may be used in the present invention, the invention is not intended to be so limited. The input of oxygen, nutrients, buffers, fresh medium, cytokines, growth factors, hormones and/or other compounds, substances and/or elements into a bioreactor can also be performed manually, automatically, or by other control means, as can be the control and removal of waste and carbon dioxide. The amount of certain biological molecules produced may be influenced by factors such as changes in temperature, oxygen content, pH and composition of the carrier medium.

Figures 2 and 3 illustrate an embodiment of a time varying electromagnetic force (TVEMF) bioreactor 10 with an integral time varying electromagnetic force source. Figure 4 is a cross section of a rotatable TVEMF- bioreactor 10 for use in the present invention in a preferred form. The TVEMF- bioreactor 10 of Figure 4 is illustrated with an integral time varying electromagnetic force source. Figure 5 also illustrates a preferred embodiment of a TVEMF- bioreactor with an integral time varying electromagnetic force source. Figures 6-8 show a rotating bioreactor with an adjacent time varying electromagnetic force source.

The apparatus shown in Figure 2 includes a motor housing 111 supported by a base 112. A motor 113 is attached inside the motor housing 111 and connected by a first wire 114 and a second wire 115 to a control box 116 that has a control mechanism therein whereby the speed of the motor 113 can be incrementally controlled by turning the control knob 117. The motor housing 111 has a motor 113 inside set so that the motor shaft 118 extends through the housing 111 with the motor shaft 118 being longitudinal so that the center of the shaft 118 is horizontal at the location of a longitudinal chamber 119, the longitudinal chamber 119 is preferably made of a transparent material. Examples of transparent materials that can be used are glass and plastics. In an embodiment of the invention, the transparent material is plastic.

In an embodiment of the invention, the longitudinal chamber 119 is connected to the shaft 118 so that the chamber 119 rotates about its longitudinal axis horizontally. The chamber 119 is wound with a wire coil 120. The size of the wire coil and number of times it is wound around the chamber are such that when a square wave current of from 0.1mA to 1000mA is supplied to the wire coil 120, a time varying electromagnetic force preferably of from 0.05 gauss to 6 gauss is generated within the chamber 119. The wire coil 120 is connected to a first ring 121 and a second ring 122 at the end of the shaft 118 by wires 123 and 124. The rings 121 and 122 are then contacted by a first electromagnetic wire 125 and a second electromagnetic delivery wire 128 in such a manner that the chamber 119 can rotate while the current is constantly supplied to the coil 120. An electromagnetic generating device 126 is connected to the wires 125 and 128. The electromagnetic generating device 126 supplies a square wave to the wires 125, 128 and coil 120 by adjusting its output by turning an electromagnetic generating device knob 127.

In operation, the chamber 119 is opened and the mammalian cells and carrier medium is placed inside. The rotation of the chamber is adjusted visually so that the mammalian cells remain at or substantially about the longitudinal axis of the cylinder. The electromagnetic force can be determined by the number of windings of the coils and the current used by using the formula for Fourier curves (square waves).

Figure 3 is a side perspective view of the TVEMF-bioreactor 10 shown in Figure 2 that may be used in the present invention.

Turning now to the rotating TVEMF-bioreactor 10 illustrated in Figure 4 is a culture chamber 230 which is preferably transparent and adapted to receive mammalian cells in a carrier medium therein, further comprising an outer housing 220 which includes a first 290 and second 291 cylindrically shaped transverse end cap member having facing first 228 and second 229 end surfaces arranged to receive an inner cylindrical tubular glass member 293 and an outer tubular glass member 294.

Suitable pressure seals are provided. Between the inner 293 and outer 294 tubular members is an annular wire heater 296 which is utilized for obtaining the proper incubation temperatures for cell growth. The wire heater 296 can also be used as a time varying electromagnetic force device to supply a time varying electric field to the culture chamber 230 or, as depicted in Figure 5, a separate wire coil 144 can be used to supply a time varying electromagnetic force. The first end cap member 290 and second end cap member 291 have inner curved surfaces adjoining the end surfaces 228, 229 for promoting smoother flow of the mammalian cell mixture within the chamber 230. The first end cap member 290, and second end cap member 291 have a first central fluid transfer journal member 292 and second central fluid transfer journal member 295, respectively, that are rotatably received respectively on an input shaft 223 and an output shaft 225. Each transfer journal member 294, 295 has a flange to seat in a recessed counter bore in an end cap member 290, 291 and is attached by a first lock washer and ring 297, and second lock washer and ring 298 against longitudinal motion relative to a shaft 223, 225. Each journal member 294, 295 has an intermediate annular recess that is connected to longitudinally extending, circumferentially arranged passages. Each annular recess in a journal member 292, 295 is coupled by a first radially disposed passage 278 and second radially disposed passage 279 in an end cap member 290 and 291, respectively, to first input coupling 203 and second input coupling 204. Carrier medium in a radial passage 278 or 279 flows through a first annular recess and the longitudinal passages in a journal member 294 or 295 to permit access to the carrier medium through a journal member 292, 295 to each end of the journal 292, 295 where the access is circumferential about a shaft 223, 225. Attached to the end cap members 290 and 291 are a first tubular bearing housing 205, and second tubular bearing housing 206 containing ball bearings which relatively support the outer housing 220 on the input 223 and output 225 shafts. The first bearing housing 205 has an attached first sprocket gear 210 for providing a rotative drive for the outer housing 220 in a rotative direction about the input 223 and output 225 shafts and the longitudinal axis 221. The first bearing housing 205, and second bearing housing 206 also have provisions for electrical take out of the wire heater 296 and any other sensor.

The inner filter assembly 235 includes inner 215 and outer 216 tubular members having perforations or apertures along their lengths and have a first 217 and second 218 inner filter assembly end cap member with perforations. The inner tubular member 215 is constructed in two pieces with an interlocking centrally located coupling section and each piece attached to an end cap 217 or 218. The outer tubular member 216 is mounted between the first 217 and second inner filter assembly end caps.

The end cap members 217, 218 are respectively rotatably supported on the input shaft 223 and the output shaft 225. The inner member 215 is rotatively attached to the output shaft 225 by a pin and an interfitting groove 219. A polyester cloth 224 with a ten-micron weave is disposed over the outer surface of the outer member 216 and attached to O-rings at either end. Because the inner member 215 is attached by a coupling pin to a slot in the output drive shaft 225, the output drive shaft

225 can rotate the inner member 215. The inner member 215 is coupled by the first 217 and second 218 end caps that support the outer member 216. The output shaft 225 is extended through bearings in a first stationary housing 240 and is coupled to a first sprocket gear 241. As illustrated, the output shaft 225 has a tubular bore 222 that extends from a first port or passageway 289 in the first stationary housing 240 located between seals to the inner member 215 so that a flow of carrier medium can be exited from the inner member 215 through the stationary housing 240.

Between the first 217 and second 218 end caps for the inner member 235 and the journals 292, 295 in the outer housing 220, are a first 227 and second 226 hub for the blade members 50a and 50b. The second hub 226 on the input shaft 223 is coupled to the input shaft 223 by a pin 231 so that the second hub 226 rotates with the input shaft 223. Each hub 227, 226 has axially extending passageways for the transmittal of carrier through a hub.

The input shaft 223 extends through bearings in the second stationary housing 260 for rotatable support of the input shaft 223. A second longitudinal passageway 267 extends through the input shaft 223 to a location intermediate of retaining washers and rings that are disposed in a second annular recess 232 between the faceplate and the housing 260. A third radial passageway 272 in the second end cap member 291 permits carrier medium in the recess to exit from the second end cap member 291. While not shown, the third passageway 272 connects through piping and a Y joint to each of the passages 278 and 279.

A sample port is shown in Figure 4, where a first bore 237 extending along a first axis intersects a corner 233 of the chamber 230 and forms a restricted opening 234. The bore 237 has a counter bore and a threaded ring at one end to threadedly receive a cylindrical valve member 236. The valve member 236 has a complimentarily formed tip to engage the opening 234 and protrude slightly into the interior of the chamber 230. An O-ring 243 on the valve member 236 provides a seal. A second bore 244 along a second axis intersects the first bore 237 at a location between the O-ring 243 and the opening 234. An elastomer or plastic stopper 245 closes the second bore 244 and can be entered with a hypodermic syringe for removing a sample. To remove a sample, the valve member 236 is backed off to access the opening 234 and the bore 244. A syringe can then be used to extract a sample and the opening 234 can be reclosed. No outside contamination reaches the interior of the TVEMF-bioreactor 10.

In operation, carrier medium is input to the second port or passageway 266 to the shaft passageway and thence to the first radially disposed 278 and second radially disposed passageways 279 via the third radial passageway 272. When the carrier medium enters the chamber 230 via the longitudinal passages in the journals 292, 294 the carrier medium impinges on an end surface 228, 229 of the hubs 227, 226 and is dispersed radially as well as axially through the passageways in the hubs 227, 226. Carrier medium passing through the hubs 227, 226 impinges on the end cap members 217, 218 and is dispersed radially. The flow of entry carrier medium is thus radially outward away from the longitudinal axis 221 and flows in a toroidal fashion from each end to exit through the polyester cloth 224 and openings in filter assembly 235 to exit via the passageways 266 and 289. By controlling the rotational speed and direction of rotation of the outer housing 220, chamber 230, and inner filter assembly 235 any desired type of carrier action can be obtained. Of major importance, however, is the fact that a clinostat operation can be obtained together with a continuous supply of fresh carrier medium.

If a time varying electromagnetic force is not applied using the integral annular wire heater 296, it can be applied by another preferred time varying electromagnetic force source. For instance, Figures 6-8 illustrate a time varying electromagnetic force device 140 which provides an electromagnetic force to a cell culture in a bioreactor which does not have an integral time varying electromagnetic force, but rather has an adjacent time varying electromagnetic force device. Specifically, Figure 6 is a preferred embodiment of a time varying electromagnetic force device 140. Figure 6 is an elevated side perspective of the device 140 which comprises a support base 145, a cylinder coil support 146 supported on the base 145 with a wire coil 147 wrapped around the support 146. Figure 7 is a front perspective of the time varying electromagnetic force device 140 illustrated in Figure 6. Figure 8 is a front perspective of the time varying electromagnetic force device 140, which illustrates that in operation, an entire bioreactor 148 is inserted into a cylinder coil support 146 which is supported by a support base 145 and which is wound by a wire coil 147. Since the time varying electromagnetic force device 140 is adjacent to the bioreactor 148, the time varying electromagnetic force device 140 can be reused. In addition, since the time varying electromagnetic force device 140 is adjacent to the bioreactor 148, the device 140 can be used to generate an electromagnetic force in all types of bioreactors, preferably rotating.

Furthermore, in operation the present invention contemplates that an electromagnetic generating device is turned on and adjusted so that the square wave output generates the desired electromagnetic field in the mammalian cell mixture- containing chamber, preferably in a range of from 0.05 gauss to 6 gauss, more preferably in the range of 0.05 to 0.5 gauss. Preferably, the square wave has a frequency of about 2 to about 25 cycles/second, more preferably about 5 to about 20 cycles/second, and for example about 10 cycles/second, and the conductor has an RMS value of about 1 to about 1000 mA, preferably about 1 to about 6 niA. However, these parameters are not meant to be limiting to the TVEMF of the present invention, as such may vary based on other aspects of this invention. TVEMF may be measured for instance by standard equipment such as an ENl 31 Cell Sensor Gauss Meter.

In operation, during TVEMF- expansion, a TVEMF- bioreactor 10 of the present invention contains mammalian cells in the cell culture chamber. During TVEMF- expansion, the speed of the rotation of the mammalian cell mixture-containing chamber may be assessed and adjusted so that the mammalian cell mixture remains substantially at or about the longitudinal axis. Increasing the rotational speed is warranted to prevent wall impact. For instance, an increase in the rotation is preferred if the mammalian cells fall excessively inward and downward on the downward side of the rotation cycle and excessively outward and insufficiently upward on the upward side of the rotation cycle. When the mammalian cells increase in viscosity they may gravitate towards the wall of the chamber. To maintain their position in the center of the fluid filled chamber the rotational speed may be decreased so to maintain the cells in the center of the container and prevent the cells from colliding with the sides of the container. Thus, the cells are not damaged and are permitted to grow or expand at a significant rate. One method of monitoring the overall expansion of cells undergoing TVEMF-expansion is by visual inspection. Once the bioreactor begins to rotate and the TVEMF is applied, the cells preferably cluster in the center of the bioreactor chamber. Oxygenation and other nutrient additions often do not cloud the ability to visualize the cell cluster through a visualization (typically clear plastic) window built into the bioreactor. The mammalian cell mixture may preferably be visually assessed through the preferably transparent culture chamber and manually adjusted. The assessment and adjustment of the mammalian cell mixture may also be automated by a sensor (for instance, a laser), which monitors the location of the cells within a TVEMF- bioreactor 10. A sensor reading indicating too much cell movement will automatically cause a mechanism to adjust the rotational speed accordingly.

Formation of the cluster is important for helping the mammalian cells maintain their three-dimensional geometry and cell-to-cell support and cell-to-cell geometry; if the cluster appears to scatter and cells begin to contact the wall of the bioreactor chamber, the rotational speed is increased (manually or automatically) so that the centralized cluster of cells may form again. A measurement of the visualizable diameter of the cell cluster taken soon after formation may be compared with later cluster diameters, to indicate the approximate number increase in cells in the TVEMF-bioreactor. Measurement of the increase in the number of cells during TVEMF expansion may also be taken in a number of ways, as known in the art. An automatic sensor could also be included in the TVEMF-bioreactor to monitor and measure the increase in cluster size.

The TVEMF-expansion process may be carefully monitored, for instance by a person who will check cell cluster formation to ensure the cells remain clustered inside the bioreactor and will increase the rotation of the bioreactor when the cell cluster begins to scatter. An automatic system for monitoring the cell cluster and viscosity of the mammalian cell mixture inside the bioreactor may also monitor the cell clusters. A change in the viscosity of the cell cluster may become apparent about 2 days after beginning the TVEMF-expansion process, and the rotational speed of the TVEMF- bioreactor may be increased around that time. The TVEMF-bioreactor speed may vary throughout TVEMF-expansion. Optimally, the user is advised to preferably select a rotational rate that fosters minimal wall collision frequency and intensity so as to maintain the mammalian cell three-dimensional geometry and their cell-to-cell support and cell-to-cell geometry. The preferred speed of the present invention is of from 5 to 120 RPM, preferably 10-40 RPM and more preferably from 10 to 30 RPM.

In one preferred embodiment of the present invention, a natively glycosylated mammalian biological molecule mixture may be taken from the carrier medium of the mammalian cell mixture during operation of the expansion procedure. In addition, after a period of time, the rotation of the bioreactor is stopped, the chamber opened, and at that time the natively glycosylated mammalian biological molecule mixture may also be isolated. As discussed below, cells may be lysed and the natively glycosylated mammalian biological molecules separated, or the desired natively mammalian biological molecules retrieved from the carrier medium alone.

During the time that the mammalian cell mixture is in a bioreactor, preferably a TVEMF-bioreactor, the mammalian cells are preferably fed nutrients and fresh media (preferably GTSF-2 with 10% human serum albumin), which may include hormones, cytokines, growth factors (preferably G-CSF) and/or a copper chelating agent; and toxic materials are removed. The copper chelating agent may, for example; be administered to a mammal, where mammalian tissue such as peripheral blood may then be directly collected from the mammal, such blood containing the mammalian cells designated to produce the desired natively glycosylated mammalian biological molecules. Preferably such administration is more than one day, more preferably more than two days, before collecting peripheral blood from the mammal. The purpose of the copper chelating agent, whether added to the mammalian cell mixture itself or administered to a blood donor mammal, or both, is to reduce the amount of copper in the peripheral blood prior to TVEMF-expansion. Not to be bound by theory, it is believed that the decrease in amount of available copper may enhance TVEMF-expansion.

Natively glycosylated mammalian biological molecules may be harvested at the same time that the toxic materials and used media are removed from the mammalian cell mixture in a bioreactor, preferably a TVEMF-bioreactor, or at the time of removal of mammalian cell mixture in a TVEMF-bioreactor. Toxic materials may include the toxic granular material of dying cells and the toxic material of granulocytes and macrophages. Also, a person, for instance once a day, or once every two days, manually (for instance with a syringe) insert fresh media and preferably other desired additives such as nutrients and growth factors, as discussed above, into the bioreactor, and draw off the used media containing cell wastes, toxins, and a mixture of natively glycosylated mammalian biological molecules. Natively glycosylated mammalian biological molecules in the mixture may then be separated from the mixture by techniques such as those well known in the art and for instance that are listed herein. Also, fresh media and other additives may be automatically pumped into the bioreactor, preferably a TVEMF-bioreactor, during expansion, preferably TVEMF-expansion, and wastes or other undesired materials automatically removed.

The TVEMF-expansion of the mammalian cells is controlled so that the cells preferably expand (increase in number per volume, or concentration) in a sufficient amount of time. Preferably, the mammalian cells undergo expansion, and preferably TVEMF-expansion, for at least 7 days to 10 days. Preferably, TVEMF-expansion may continue in a TVEMF-bioreactor for greater than 160 days. While TVEMF-expansion may occur for even longer than 160 days, such a lengthy expansion is not a preferred embodiment of the present invention. As indicated above and throughout this application, TVEMF-expanded mammalian cells of the present invention have essentially the same three-dimensional geometry and cell-to-cell support and cell-to-cell geometry as naturally-occurring, non-TVEMF-expanded mammalian cells. Preferably, TVEMF-expansion is carried out in a TVEMF-bioreactor at a temperature of about 26⁰C to about 41⁰C, and more preferably, at a temperature of about 37 ±2⁰C. Such expansion, preferably TVEMF expansion, results in a harvestable amount of natively glycosylated mammalian biological molecules.

Other bioreactors that may be used include, but are not limited to, those described in U.S. Patents 5, 153,133 (Schwartz et al., Method for culturing mammalian cells in a horizontally rotated bioreactor), 5,155,034 (Wolf et al., Three-dimensional cell to tissue assembly process), 5,155,035 (Schwartz et al. Method for culturing mammalian cells in a perfused bioreactor); 5,851,816 (Goodwin, Cultured high-fidelity three- dimensional human urogenital tract carcinomas and process); 6,485,963 (Wolf et al.

Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof) and 6,673,597 (Wolf et al. Growth Stimulation of biological cells and tissue by electromagnetic fields and uses thereof.).

As various changes could be made in rotating bioreactors subjected to a time varying electromagnetic force as are contemplated in the present invention, without departing from the scope of the invention, it is intended that all matter contained in the above description be interpreted as illustrative and not limiting.

A preferred embodiment of the invention provides a means for expansion of multipotential hematopoietic cells by growth of the cells in an environment in which they remain suspended, preferably under the influence of a time- varying electromagnetic force in a reaction medium comprising soluble interleukin 6 receptor (s- IL-6R), interleukin 6 (IL-6), stem cell factor (SCF), and copper chelating agents that stimulate growth of hematopoietic progenitor cells. Suitable cells for such a purpose are multipotential hematopoietic cells which can be progenitor and/or stem cells obtained by CD34+/CD38- cell selection. This method can be used to generate differentiated blood cell colonies of the type described in US Patent 5,861,315 and natively glycosylated mammalian biological molecules as discussed throughout this disclosure.

Mammalian cells for use in this invention may be collected directly or indirectly from a mammalian cell source, preferably a primate mammal, and more preferably a human, may be obtained from a depository or other repository of mammalian cells, from a commercial source, or other source and such mammalian cells can be pooled if desired. Depending on the source of the mammalian cells desired for the production of natively glycosylated mammalian biological molecules, the method of collecting and isolating the mammalian cells would vary. Methods of collecting tissue and/or peripheral blood from a mammal are well known in the art.

For example, methods of collecting peripheral blood include via a syringe. Peripheral blood would only be removed from a human in an amount that would not be threatening to the subject. Preferably, about 10 to about 500 ml peripheral blood would be collected; more preferably, 100-300 ml, even more preferably, 150-200 ml. The collection of mammalian cell sources including peripheral blood and tissues, according to this invention, is not meant to be limiting. Preferrably, mammalian peripheral blood and tissue are both sources of mammalian cells that can be used to produce a harvestable amount of natively glycosylated mammalian biological molecules according to this invention.

The mammalian cells may be isolated from tissue and cultured or separated from a cell suspension such as blood for instance through negative separation techniques, such as but not limited to sedimentation and centrifugation.

Many negative separation methods are well-known in the art. Positive selection techniques, to select for types of cells may also be used. Methods for isolating mammalian cells from blood and tissue are known in the art, and may be used so long as they do not lyse or otherwise irreversibly harm the desired mammalian cells. For instance, an affinity method selective for the particular mammalian cells may be used.

As discussed above, the term "mammalian cell mixture" comprises mammalian cells, or mammalian composition, with a substance that allows the cells to expand, such as a medium for growth of cells that will be placed in a TVEMF- bioreactor. Carrier medium, as discussed above, comprises cell growth media that allows cells to grow and expand, and such carrier medium are well-known in the art. Preferably, the substance that allows the cells to expand is cell growth media, and more preferably GTSF-2 medium. The components of the cell growth media must, of course, not kill or damage cells. Other components may also be added to the mammalian cell mixture prior to and/or during TVEMF-expansion. For instance, the mammalian cells may be placed in the bioreactor with GTSF-2 and further supplemented with 10% human serum albumin or other serum used in the art to supplement culture medium. Other additives to the mammalian cell mixture, including but not limited to growth factor, copper chelating agent, cytokine, hormone and other substances that may enhance expansion, preferably TVEMF-expansion, and increase the amount of harvestable natively glycosylated mammalian biological molecules may also be added to the mammalian cells outside or inside the chamber before being placed in the chamber. Preferably, the amount of mammalian cells used is about 1000 cells/ml to about 9 x 10⁹ cells/ml, more preferably about 10,000 cells to about 10⁷ cells/ml, even more preferably about 10⁵ to 10⁶ cells/ml, and for example 2.5 x 10⁵ cells/ml. Depending on the size and type of bioreactor or other cell culture chamber, the total volume of the mammalian cell mixture to be placed into the chamber is about 10 ml to about 1 IL. Preferably, GTSF-2 supplemented with 10% human serum albumin is mixed with the mammalian cells to form the mammalian cell mixture, however, other growth medium may be used as desired. In particular, in the event that the mammalian cells are already in a growth medium, no further medium need be added to the mammalian cells to prepare the mammalian cell mixture.

Optionally, prior to the introduction of the cells into the chamber, the cells may be expanded and/or treated so as to modify the regulation of growth- promoting genes and/or growth-inhibitory genes. For example, prior to the introduction of the cells into the chamber, but after collection of the mammalian cells from a mammalian cell source, the mammalian cells may be grown in tissue culture with compounds that can up-regulate growth-promoting genes and/or down-regulate growth inhibitory genes so as to modify the amount of natively glycosylated mammalian biological molecules produced. Not intending to limit this invention, but in theory, such treatment of the mammalian cells prior to expansion in a chamber should modify the production of desired natively glycosylated mammalian biological molecules.

The mammalian cell mixture is preferably subjected to an electromagnetic force until the desired natively glycosylated mammalian biological molecule mixture is present in the culture medium in harvestable amounts. Such stimulation of the mammalian cells can continue as indicated herein, so that for instance, the mammalian cells may produce several batches or even dozens of batches of natively glycosylated mammalian biological molecule mixtures. The natively glycosylated mammalian biological molecules will either be present in the carrier medium as a result of secretion or excretion by the mammalian cells. On the other hand, the desired natively glycosylated mammalian biological molecules may be present in the TVEMF expanded, or expanded, mammalian cells. In the case where the carrier medium has a harvestable amount of the natively glycosylated mammalian biological molecules, a sample of the carrier medium is removed and is assayed to identify the components of the carrier medium. The sample can be assayed using, for example, laboratory multianalyte profiling technology. An example of such a multianalyte profiling technology is the LUMINEX system (LabMAP¹™) which permits simultaneous quantitative analysis of different proteins, peptides and DNA molecules. Also, multi-immunoblotting techniques and techniques that utilize antibodies or probes can be used to identify the protein, peptides, DNA and RNA components of the carrier medium removed from the cell culture chamber. After establishing the presence of the desired component, the protein, peptide, DNA or RNA can be separated using methods such as but not limited to high pressure liquid chromatography, affinity chromatography, ion exchange chromatography and/or size exclusion chromatography, and protein extraction performed with reagents thereto and kits . The mammalian biological cells being expanded, preferably TVEMF expanded, are preferably human cells, such as, but not limited to, progenitor cells or neuronal cells, and more preferably mammalian cells that naturally make CSF and other desired natively glycosylated mammalian biological molecules.

Lysis of the cells may be required before the components in the carrier medium can be identified. In cases where the desired protein is not released extracellularly a variety of methods including mechanical methods such as, for example, by a homogenizer or a ball mill or use of ultrasonification may be used to lyse the cells. Alternatively, the intracellular proteins may be removed from the cells by the techniques such as use of a freeze/thaw cycle, or chemical means using solvents, salts or detergents or by biological means using enzymes and/or protease inhibitors. Irrespective of whether the desired protein is released from the cell by its own action or whether some external means is required, it is necessary to remove the desired protein from the resultant expanded, preferably TVEMF-expanded, mammalian cell mixture. This can be accomplished by conventional means such as precipitation followed by gel filtration and ion exchange chromatography. Compositions containing one or more of the natively glycosylated mammalian biological molecules such as proteins, peptides, polypeptides, glycoproteins, cytokines, post-translational proteins, post-translational peptides, and post-translational polypeptides produced in accordance with the process of this invention can be prepared. The natively glycosylated mammalian biological molecules are selected from but are not limited to proteins, peptides, polypeptides, glycoproteins, cytokines, post-translational proteins, post-translational peptides, and post-translational polypeptides, including specifically G-CSF, GM-CSF, HGF, LIF, cytokines, EGF and the interleukins, such as IL-2, IL-6, IL-8 and IL-IO.

As discussed above, a pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier that will allow the introduction of the same into a mammal, preferably a human. The term "introduction" of the composition to a mammal is meant to refer to "administration" of the composition to an animal. The pharmaceutical composition may be in a form selected from tablets, lozenges, capsules, powders, dragees, aqueous or oily suspensions, syrups, elixirs, and aqueous solutions. The nature of the composition employed will, of course, depend on the desired route of administration. The natively glycosylated mammalian biological molecule mixture can be administered orally, topically, rectally, nasally, transdermally, or parenterally (i.e., intramuscular, intravenous, and subcutaneous) or in any other suitable way. Intramuscular, intravenous, and subcutaneous introduction to a mammal are preferred.

This invention also includes a method of therapeutically treating mammals comprising producing the natively glycosylated mammalian biological molecules as described herein and thereafter administering a therapeutic amount of the natively glycosylated mammalian biological molecule alone or in combination with another molecule, drug, or the like to a mammal to achieve a therapeutic affect.

The preferred method for producing the natively glycosylated mammalian biological molecules comprises: (a) placing a mammalian cell mixture into a chamber; (b) rotating the chamber about its axis at a rotational speed sufficient to prevent the cells from substantially contacting the walls of the chamber; (c) continuing the rotation until there is an increase in the mammalian cells and/or the natively glycosylated mammalian biological molecules are present in a harvestable amount either in the carrier medium or in the expanded cells, preferably TVEMF- expanded; and (d) separating one or more of the natively glycosylated mammalian biological molecules from the carrier medium and/or from the expanded cells, preferably TVEMF-expanded, either directly or indirectly (e.g. first lysing the cells if natively glycosylated mammalian biological molecules are located therein).

While preferred embodiments have been herein described, those skilled in the art will understand the present invention to include various changes and modifications. The scope of the invention is not intended to be limited to the above- described embodiments.

Example I

Production of Natively Glycosylated Mammalian Biological Molecules in a TVEMF Bioreactor

Normal human neuronal progenitor cells (NHNP) were purchased from a cell bank supplier and were pooled from three donors to dimmish donor-to- donor variations in response. Initially, NHNP were grown in conventional tissue culture flasks, Corning T-75 flasks (Corning Inc., Corning, New York) to obtain the appropriate number of cells for each experiment following standard cell culturing procedures utilizing a specialized growth medium comprising a triple-sugar minimal essential medium ιx-L- 15, designated GTSF-2, base supplemented with 10% fetal bovine serum, Ciprofloxin and Fungizone (hereinafter "medium"). 1 X PBS, DNase,

Collegenase, and trypsin were purchased from Clonetics Corporation, San Diego, California.

Briefly, a small sample of the cells to be cultured were enzymatically dissociated with a Collegenase/Dnase cocktail and Trypsin from the T-75 flasks, washed once with 1 X Phosphate Buffer Saline- calcium and magnesium free (PBS-

CMF) and assayed for viability by trypan dye exclusion (GIBCO, Grand Island, New York). The results of the viability assay showed that of the sample of cells assayed, 98% were determined to be viable. Thereafter, the cells assayed were discarded. A) Two-dimensional Protocol without TVEMF Expansion

NHNP were taken from the T-75 flasks and seeded at a concentration of 2.5.x 10⁵ cells/ ml of medium in sterile 100 mm non-adherent petri dishes for controls. NHNP were cultured under the same conditions as cells subjected to TVEMF but without exposure to TVEMF.

Cell cultures were maintained in a humidified FormaC02incubator (Forma, Inc.) at 37⁰C at CO₂ concentration of 6%, and cultured for 19 days. The media used was GTSF-2, without any supplemental proteases. Feeding the NHNP in the petri dishes was matched to that required by the cells undergoing TVEMF expansion.

B) Three-dimensional TVEMF Expansion Protocol

For three-dimensional culture, NHNP in a concentration of 2.5.x 10⁵ cells/ ml of medium, was placed in a 55 ml TVEMF bioreactor chamber, for a total mammalian cell mixture volume of 55 ml, as in Figures 2 and 3 herein. NHNP were TVEMF- expanded for 19 days. TVEMF expansion was performed as described herein, with a waveform in a strength of 1-6 mA (AC) square wave, 10 Hz variable duty cycle, which was pulse-width modulated as described in the description of the drawings above. NHNP were subjected to the waves at a strength of about 1 Gauss, which are far less than the field strength of the Earth. All other conditions were identical to the two-dimensional experimental conditions of the NHNP in the petri dishes.

The results of Example I are shown in Table I herein. In Table I, "C" refers to natively glycosylated mammalian biological molecules from the control NHNP from the petri dishes, and "W" refers to the natively glycosylated mammalian biological molecules from the TVEMF-bioreactor expanded NHNP. The "fold change" refers to the fold increase of natively glycosylated mammalian biological molecule detected therein. "Title Affy" refers to the molecule directly measured by the Luminex system. Table I clearly shows that the present method provides a new and unique mixture of natively glycosylated mammalian biological molecules that can be separated into therapeutic amounts of highly desirable natively glycosylated mammalian biological molecules including G-CSF. Data such as in Table I has been generated from lung cells, with similar results (not provided here in view of the lengthy nature of the results). Also, other data such as in Table I have been generated, and not set forth herein in view of the lengthy nature of the data.

TABLE l

Mar42004 Sample Name ()* W

Fold

Systematic Change Normalized Raw Normalized Raw Common Title_Affy 218810 at 8092.03515 1 -41 8092.0356 77 .9 FLJ23231 hypothetical protein FLJ23231 Unknown (protein for IMAGE:4152599) [Homo sapiens],

221979_at 6246.78777 1 -29.05 6246.788 66.15 TP53BPL mRNA sequence potassium large conductance calcium-activated channel,

209948_at 5617.99877 1 -27.3 5617.999 60.15 KCNMB1 subfamily M, beta member 1 WW domain containing 221147_x_at 4900.00676 1 -16.9 4900.007 52.9 WWOX oxidoreductase low density lipoprotein receptor- κ>

205606_at 4842.1475 1 -27.5 4842.148 26.05 LRP6 related protein 6 219142_at 4789.3858 1 -6.9 4789.386 51.35 MGC2827 hypothetical protein MGC2827 222302_at 4126.59653 1 -33.2 4126.5967 -64.3 ESTs

Rho guanine nucleotide exchange

214355_x_at 4006.66004 1 -14.65 4006.6604 42.8 ARHGEF5 factor (GEF) 5

POM121 membrane glycoprotein- 214570_x_at 3707.94034 1 -12 3707.9407 39.85 POM121L1 like 1 (rat) lethal giant larvae homolog 1 206123_at 3355.37568 1 -16.85 3355.376 36.1 LLGL1 (Drosophila)

Unknown (protein for MGC:13137) 211050 x at 3133.83395 1 -17.7 3133.8342 33.45 [Homo sapiens], mRNA sequence solute carrier family 7 (cationic amino acid transporter, y+ system),

202752_x_at 2759.90477 1 101.05 2759.905 -16.1 SLC7A8 member 8

220126_at 2727.58592 1 -18.25 2727.5862 24.1 TSP50 testes-specific protease 50

211554_s_at 2642.51097 1^» -18.95 2642.5112 25.85 APAF1 apoptotic protease activating factor chromosome 17 open reading

220347 at 2626.13612 -9.1 2626.1362 28.15 FLJ14069 frame 31

mitogen-activated protein kinase

210482 x at 2599.99152 1 -11.05 2599.9917 28.2 MAP2K5 kinase 5

Homo sapiens, similar to hypothetical protein

DKFZp564N123.1 - human

(fragment), clone IMAGE:5220614,

212866_at 2389.33829 1 -27.2 2389.3384 25.75 mRNA, mRNA sequence 216212_s_at 2340.69216 1 -11.6 2340.6924 4.3 DKC1 dyskeratosis congenita 1 , dyskerin

Homo sapiens mRNA; cDNA

DKFZp434M0835 (from clone

DKFZp434M0835), mRNA

215344_at 2283.30568 1 -2.15 2283.306 20.45 sequence 206131_at 2280.80471 1 -39.05 2280.805 21.65 CLPS colipase, pancreatic 207557_s_at 2240.76809 1 -9.6 2240.7683 23.6 RYR2 ryanodine receptor 2 (cardiac) 206647_at 2231.31521 1 -40.8 2231.3154 2.85 HBZ hemoglobin, zeta wingless-type MMTV integration

205648_at 2210,81236 1 -14.2 2210.8125 23.55 WNT2 site family member 2 death associated transcription

218325_s_at 2137.99613 1 -41.1 2137.9963 -17.45 DATF1 factor 1 205291_at 2066.3883 1 -18.95 2066.3884 22.25 IL2RB interleukin 2 receptor, beta

Homo sapiens clone 24626 mRNA

214376_at 2060.64496 1 -8.95 2060.645 22.15 sequence 216355_at 2060.10644 1 -29.1 2060.1067 22 PCDHB17 protocadherin beta 17 pseudogene hexose-6-phosphate dehydrogenase (glucose 1-

206933_s_at 2032.80705 1 -30.85 2032.8073 14.15 H6PD dehydrogenase) 218621_at 2026.24393 1 -35.65 2026.2441 21.5 HEMK HEMK homolog 7kb wingiess-type MIWTV integration

221113_s_at 1980,81682 1 -26.8 1980.817 16,2 ¥tfNT16 site family, member 16 215293_s_at 1944.51336 1 -18.95 1944.5135 12.55 FRAG1 FGF receptor activating protein 1 216235_s_at 1933.55303 1 -63.05 1933.5532 6.3 EDNRA endothelin receptor type A

Homo sapiens cDNA: FLJ21535 fis, clone COL06131 , mRNA

216434_at 1891.01556 1 -51 1891.0157 -14.35 sequence 216984 x at 1848.47784 1 -15 1848.478 14.15 IGLJ3 immunoglobulin lambda joining 3

Homo sapiens mRNA; cDNA DKFZp434D024 (from clone

214418_at 1813.55657 1 -1.8 1813.5568 19.25 LOC 196993 DKF2p434D024), mRNA sequence chromosome 11 open reading

219050_s_at 1776.76241 1 -5 1776.7626 19.1 C11orf5 frame 5 uncharacterized bone marrow

219551_at 1732.49002 1 -7.25 1732.4902 18.5 EAF2 protein BM040 DNA (cytosine-5-)-

218457_s_at 1730.31818 1 -3.65 1730.3184 18.3 DMMT3A methyitransferase 3 alpha 209114_at 1720.86567 1 -26.45 1720.8658 -31.15 TSPAN-1 tetraspan 1 neurofibroma 1 (neurofibromatosis, von Recklinghausen disease,

211914_x_at 1701.96003 1 -16.1 1701.9602 11.75 NF1 Watson disease)

ATP-binding cassette, sub-family B

207321 _s_at 1683.05439 1 -4 1683.0546 -7.35 ABCB9 (MDR/TAP), member 9 protein tyrosine phosphatase, non¬

1320_at 1652.73966 1 -7.4 1652.7397 17.75 PTPN21 receptor type 21 prostate epithelium-specific Ets

220192_x_at 1645.20149 1 -14.75 1645.2017 17.85 PDEF transcription factor 218475_at 1635.79048 1 -44.55 1635.7906 -33.8 HTF9C Hpall tiny fragments locus 9C 213369_at 1564.89474 1 -21.45 1564.8949 15.65 KIAA1775 MT-protocadherin 216827_at 1560.1683 1 -4.45 1560.1685 10.15 dJ508D13.1 216710_x_at 1479.81967 1 -6.55 1479.8198 11.9 ZNF287 zinc finger protein 287 206774_at 1476.54723 1 -8.45 1476.5474 15.8 KIAA0967 KIAA0967 protein 216577 at 1471.70107 1 -19.1 1471.7012 15.65 dJ1060K6.1 aldo-keto reductase family 1 , member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol

210558_at 1467.03463 1 -5.1 1467.0348 15.65 AKR1C4 dehydrogenase 4) corticotropin releasing hormone 211897_s_at 1432.55588 1 -17.75 1432.556 7.6 CRHR1 receptor 1

Homo sapiens chromosome 21q22.1 anonymous mRNA

216472 at 1410.13255 1 -13.05 1410.1327 1.9 sequence

219255_x_at 1399.47117 1 -18.7 1399.4713 13 IL17BR interleukm 17B receptor

Fas apoptotϊc inhibitory

203619_s_at 1385.36986 1 -7,35 1385.37 15 KJAA0950 molecule 2

212469_at 1382.49217 1 -1.15 1382.4923 -25.85 IDN3 IDN3 protein spectrin, alpha, non-erythrocytic 1

214926_at 1375.9769 1 -13.8 1375.977 14.85 SPTAN 1 (alpha-fodrin)

208461_at 1327.21129 1 -5.75 1327.2114 12.95 HIC1 hypermethylated in cancer 1

221188_at 1314.39822 1 -21.85 1314.3964 4.75 FGF23 fibroblast growth factor 23 pleckstrin homology, Sec7 and

219183_s_at 1299.99579 1 -6.6 1299.9958 13.95 PSCD4 coiled/coil domains 4 achaete-scute complex

221161_at 1285.75072 1 -12.75 1285.7509 6.65 ASCL3 (Drosophila) homolog-like 3

Homo sapiens mRNA; cDNA

DKFZp547G044 (from clone

216799_at 1280.7311 1 -6.1 1280.7312 13.85 DKFZp547G044), mRNA sequence phosphoinositide-3-kinase, class 2,

204484_at 1258.11034 1 -17.05 1258.1105 5.25 PIK3C2B beta polypeptide (Jl aryl hydrocarbon receptor nuclear

210828_s_at 1223.05729 1 -12.65 1223.0574 13.05 ARNT translocator

209062_x_at 1189.0094 1 -20.9 1189.0095 10.35 NCOA3 nuclear receptor coactivator 3 chromosome 20 open reading

222044_at 1182.05749 1 -27.3 1182.0576 -2.95 C20orf67 frame 67

215080_s_at 1173.75929 1 -12.85 1173.7594 12.55 CENTG1 centaurin, gamma 1 hypothetical protein

215734_at 1153.6991 1 -31.1 1153.6992 2.9 IMAGE:4215339 IMAGE:4215339

207923_x_at 1133.0166 1 -6.15 1133.0167 12 PAX8 paired box gene 8 inter-alpha (globulin) inhibitor, H1

210888_s_at 1125.89713 1 -23.2 1125.8972 12.15 mm polypeptide

220416_at 1125.34082 1 -1.5 1125.341 10.55 KIAA1939 KIAA1939 protein ras responsive element binding

216648_s_at 1112.67519 1 -15.1 1112.6753 11.8 RREB1 protein 1

207504_at 1111.35909 1 -10.85 1111.3591 11.9 CA7 carbonic anhydrase VII

211350_s_at 1111.16162 1 -9.4 1111.1617 8.05 HGC6.1.1 HGC6.1.1 protein

219143_s_at 1106.87203 1 -3.05 1106.8721 11.85 FLJ20374 hypothetical protein FLJ20374

220918 at 1101.48145 1 -4.1 1101.4816 11.85 FLJ20856 hypothetical protein FLJ20856

alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; glycolicaciduria;

210326. _at 1082.80323 1 -47.05 1082.8033 -46.55 AGXT serine-pyruvate aminotransferase) single-minded homolog 2

208157_. _at 1068.58224 1 -26.6 1068.5823 11.35 SIM2 (Drosophila)

ESTs, Moderately similar to KNG_HUMAN Kininogen precursor (Alpha-2-thiol proteinase inhibitor)

217512. .at 1067.80444 1 -1.2 1067.8046 11.4 KNG [Contains: Bradykinin] [H.sapiens] prostate epithelium-specific Ets

214404_. _x_at 1060.02088 1 -9 1060.021 9.2 PDEF transcription factor

213985_. _s_at 1051.65106 1 -3.25 1051.6511 11.3 R32184_3 hypothetical protein MGC4022 Homo sapiens mRNA; cDNA DKFZp566C0546 (from clone DKFZp566C0546), mRNA

215748. .at 1044.9922 1 -4.4 1044.9923 6.4 sequence

210091. _s_at 1027.30115 1 -6.3 1027.3013 10.95 DTNA dystrobrevin, alpha

214063_. _s_at 1027.12167 1 -5.35 1027.1218 11 TF transferrin

214568_. .at 1018.56032 1 -9.15 1018.56036 -12.9 TPSD1 tryptase delta 1

205476. _at 1016.63386 1 -93.3 1016.634 -46.85 CCL20 chemokine (C-C motif) ligand 20

220151. _at 1011.90748 1 -10.95 1011.9076 -12.7 FLJ10490 hypothetical protein FLJ 10490 Homo sapiens cDNA FLJ13271 fis, clone OVARC1001000, mRNA

214782_. _at 1006.18199 1 -1.95 1006.18207 10.9 sequence

214342. _at 993.737857 1 -6.35 993.7379 10.6 MGC33190 hypothetical protein MGC33190 protein tyrosine phosphatase type

206574_ _s_at 983.686771 1 -1.5 983.6869 10.5 PTP4A3 IVA, member 3 solute carrier family 5 (sodium- dependent vitamin transporter),

204087_. _s_at 983.549147 1 -39.7 983.54926 8 SLC5A6 member 6 eukaryotic translation initiation

213966. .at 983.327823 1 -0.65 983.3279 10.6 EIF3S6 factor 3, subunit 6 48kDa

218591. _s_at 964.182958 1 -4.1 964.18304 10.3 FLJ14075 hypothetical protein FLJ 14075

204798 at 956.40531 1 -5.55 956.4054 10.3 MYB v-myb myeloblastosis viral

oncogene homolog (avian)

Homo sapiens cDNA: FLJ23105 fls, clone LNG07677, mRNA

216181_at 955.866888 1 -5.85 955.867 10.35 sequence 205972_at 954.06612 1 -18.8 954.06616 -11.55 SLC38A3 solute carrier family 38, member 3 zinc finger protein 145 (Kruppel- like, expressed in promyelocytic

205883_at 949.764472 1 -2.1 949.7645 10.15 ZNF145 leukemia) 220594_at 946.53379 1 -8.95 946.5339 10.15 FLJ23071 hypothetical protein FLJ23071

ESTs, Weakly similar to

HBEJHUMAN HEMOGLOBIN

216063_at 945.738115 1 -2.5 945.7382 9.25 EPSILON CHAIN [H.sapiens]

Homo sapiens cDNA FLJ13833 fis, clone THYRO1000676, mRNA

215601_at 937.021172 1 -3.15 937.02124 10.1 sequence piateiet-derived growth factor

216867_s_at 936,285297 1 -16.15 936,2854 7.05 PDGFA alpha polypeptide -4 tumor necrosis factor receptor

210847_x_at 935.63912 1 -20.7 935.63916 -4.75 TNFRSF25 superfamily, member 25 membrane-spanning 4-domains,

219666_at 922.064249 1 -28.55 922.06433 9.8 MS4A6A subfamily A, member 6A 206812_at 917.37972 1 -10.35 917.3798 7.05 ADRB3 adrenergic, beta-3-, receptor 217170_at 903.200583 1 -36.9 903.2007 -9.8 TRA@ T cell receptor alpha locus 210560_at 897.355389 1 -3.65 897.35547 9.65 GBX2 gastrulation brain homeo box 2 fucosyltransferase 3 (galactoside

3(4)-L-fucosyltransferase, Lewis

216010_x_at 889.021385 1 -1.6 889.0215 4.8 Ie1 blood group included) cytochrome P450, subfamily HA

(phenobarbital-inducible),

216334_s_at 879.568688 1 -12.1 879.5688 8.5 CYP2A7P1 polypeptide 7, pseudogene 1 likely ortholog of mouse solute carrier family 30 (zinc transporter),

220181_x_at 876.415724 1 -8.1 876.4158 9.45 SLC30A5 member 5 myeloid/lymphoid or mixed-lineage

210409 at 870.115869 1 -11.95 870.11597 6.2 MLLT4 leukemia (trithorax homolog,

Drosophila); translocated to, 4

204829_s_at 870.115869 1 -7 870.11597 -26.55 FOLR2 folate receptor 2 (fetal)

217232_x_at 865.3S94 1 22.85 865.3895 -24,1 HBB Blood formation Gene

204502_at 865.389429 1 -30.7 865.3895 2.55 SAMHD1 SAM domain and HD domain 1 coagulation factor Il (thrombin)

207221_at 823.767413 1 -1.65 823.76746 8.75 F2RL3 receptor-like 3 serologically defined colon cancer

221098_x_at 816.109424 1 -11.4 816.1095 8.75 SDCCAG 16 antigen 16

214261_s_at 813.39926 1 -15.7 813.39935 -7.2 ADH6 alcohol dehydrogenase 6 (class V)

Unknown (protein for MGC:40498)

217546_at 794.493683 1 -9.95 794.4938 5.45 MT1K [Homo sapiens], mRNA sequence

206712_at 792.29801 1 -10.45 792.2981 8.45 GRTP1 hypothetical protein FLJ22474 olfactory receptor, family 5,

208521_at 789.767304 1 -7 789.7674 -4.05 OR5I1 subfamily I, member 1 00

220101_x_at 789.665586 1 -16.3 789.66565 8.55 FLJ20014 hypothetical protein FLJ20014 retinoic acid receptor-beta

208412_s_at 785.896475 1 -3.95 785.89655 8.4 LOC51036 associated open reading frame

210800_at 784.041739 1 -4.55 784.0418 8.45 MGC 12262 hypothetical protein MGC12262

PRO2130 [Homo sapiens], mRNA

220871_at 775.588106 1 -22.15 775.5882 -11.6 sequence

Homo sapiens cDNA: FLJ21930 fis, clone HEP04301 , highly similar to HSU90916 Human clone 23815

212560_at 757.717614 1 -1.35 757.71765 8.15 mRNA sequence cytochrome P450, subfamily HA

(phenobarbital-inducible),

216340_s_at 754.068109 1 -3.95 754.0682 8.1 CYP2A7P2 polypeptide 7, pseudogene 2

F-box and leucine-rich repeat

220080_at 742.222208 1 -14.7 742.2223 8 FBXL8 protein 8

215711_s_at 737.777075 1 -65.85 737.77716 -1.95 WEE1 WEE1 homolog (S. pombe)

207720_at 737.54966 1 -29.9 737.5497 -6.55 LOR loricrin

220857_at 730.914821 1 -7.2 730.9149 7.85 PRO0514 [Homo sapiens], mRNA

sequence cytochrome P450, subfamily I

(aromatic compound-inducible),

207609_s_at 728.324256 1 -6.9 728.32434 -0.8 CYP 1A2 polypeptide 2 cyclic nucleotide gated channel

207342_at 714.163083 1 -1.85 714.16315 7.65 CNGB1 beta l myosin VA (heavy polypeptide 12,

217409_at 711.470792 1 -10.2 711.4708 7.6 MYO5A myoxin) protein phosphatase 2 (formerly

2A), regulatory subunit A (PR 65),

202885_s_at 704.692361 1 -9.25 704.69244 -11.65 PPP2R1B beta isoform 207293_s_at 700.88127 1 -4.15 700.88135 7.55 AGTR2 angiotensin Il receptor, type 2 matrix metalloproteinase 7

204259_at 700.695782 1 -4.1 700.6958 4.25 MMP7 (matrilysin, uterine) 208256_at 699.965921 1 -7.05 699.966 4.6 EFNA2 ephrin-A2 216936_at 695.239603 1 -22.45 695.2397 -22.65 207136_at 686.875592 1 -51.85 686.8756 -32.3 ARR3 arrestin 3, retinal (X-arrestin) 221252_s_at 678.864762 1 -4,5 678.8648 7.25 GSG1 germ cell associated 1 212741_at 678.206597 1 -19.75 678.20667 7.2 MAOA monoamine oxidase A 211419_s_at 676.334026 1 -15.25 676.3341 1 CHN2 chimerin (chimaerin) 2 microsomal NAD+-dependent

206753_at 676.334026 1 -19.05 676.3341 -10.1 RODH-4 retinol dehydrogenase 4 dickkopf homolog 4 (Xenopus

206619_at 668.03589 1 -29.15 668.03595 7.1 DKK4 laevis) 209867_s_at 662.154828 1 -8.1 662.1549 3.55 LEC3 KIAA0768 protein

Immunoglobulin kappa light chain variable region [Homo sapiens],

217145_at 660.79674 1 -0.25 660.7968 7.05 mRNA sequence chromosome 6 open reading frame

221301_at 657.428449 1 -13.2 657.4285 -1.55 C6orf27 27 216655_s_at 657.428449 1 -17.45 657.4285 6.6 ETV6 ets variant gene 6 (TEL oncogene) chromodomain protein, Y

207646_s_at 653.916598 1 -9 653.9166 7 CDY1 chromosome, 1

219764 at 645.421056 1 -6,35 645.4211 7 F2D10 frizzled homolog 10 (Drosophila)

217451_at 645.415 1 14.65 645.41504 5.6 COX5AP1 Nuclear mitochondria coding

215686_x_at 645.415025 1 -5.3 645.41504 5.55 TFAP2BL1

Unnamed protein product [Homo

222295_x_at 643.249312 1 -10.75 643.2494 4.05 FLJ39639 sapiens], mRNA sequence

Homo sapiens mRNA; cDNA

DKFZp434D179 (from clone

216728_at 642.070698 1 -11.95 642.07074 6.9 DKFZp434D179), mRNA sequence

215102_at 638.00243 1 -6.8 638.0025 6.8 LOC89231 LOC89231

208334_at 636.201647 1 -6.25 636.20166 2.15 NDST4 N-deacetylase/N-sulfotransferase 4

N-acetylglucosaminidase, alpha-

215880_at 634.472584 1 -11.9 634.47266 6.75 NAGLU (Sanfilippo disease WB)

209813_x_at 633.515301 1 -6.75 633.5154 6.85 TRG@ T cell receptor gamma locus

221354_s_at 631.594836 1 -26.8 631.59485 -1.15 GPR24 G protein-coupled receptor 24

205977_s_at 618.737905 1 -14.65 618.738 6.6 EPHA1 EphA1

210352_at 618.438757 1 -10.4 618.43884 6.65 SMAP skeletal muscle abundant protein

AFFX-DapX-5_at 612.216681 1 -3.85 612.21674 6.55

216477_at 611.139777 1 -4.45 611.13983 6.55 bA467l21.1

210615_at 608.806514 1 -19.25 608.8066 6.6 NRP1 neuropilin 1

208006_at 604.379249 1 -13.55 604.3793 6.5 FOXH forkhead box 11

213819_s_at 599.347768 1 -39.15 599.3478 -40.1 FLOT1 flotillin 1

221173_at 599.347768 1 -3.5 599.3478 -8.3 FLJ21290 hypothetical protein FLJ21290

NADH dehydrogenase

(ubiquinone) 1 alpha subcomplex,

209223_at 599.347768 1 -53.05 599.3478 -23.9 NDUFA2 2, 8kDa

D-cadherin precursor [Homo

221682_s_at 593.789757 1 -8.55 593.7898 6.35 sapiens], mRNA sequence

218723_s_at 590.134268 1 -1.5 590.1343 5.65 RGC32 RGC32 protein homogentisate 1 ,2-dioxygenase

214308_s_at 586.532642 1 -8.25 586.5327 2.2 HGD (homogentisate oxidase) butyrophilin, subfamily 3, member

207485_x_at 581.806324 1 -9.15 581.8064 -2.95 BTN3A1 A1 cholinergic receptor, nicotinic,

211039 at 576.314079 1 -19 576.3141 2.05 CHRNA1 aloha DolvoeDtide 1 (muscle)

203888_at 572.353505 1 -25.2 572.3536 1.85 THBD thrombomodulin luteinizing hormone/choriogonadotropin

207240_s_at 571.707329 1 -3.4 571.70734 5.7 LHCGR receptor

207800_at 548.721549 1 -38.8 548.7216 -42.1 AKAP5 A kinase (PRKA) anchor protein 5 chromosome 6 open reading frame

220362_at 548.721549 1 -9.2 548.7216 4.25 C6orf16 16

212949_at 548.673639 1 -3.35 548.67365 -19 BRRN1 barren homolog (Drosophila)

216390_at 548.320736 1 -7.5 548.3208 5.85 LCAT lecithin-cholesterol acyltransferase

215925_s_at 546.226781 1 -9.7 546.2268 5.9 CD72 CD72 antigen

204499_at 544.067011 1 -44.45 544.067 -11.65 AGTPBP1 ATP/GTP binding protein 1

216888_at 543.99517 1 -33.8 543.99524 3.1 LDB3 LIM domain binding 3 uncharacterized hematopoietic stem/progenitor cells protein

220590_at 531.628782 1 -5.95 531.62885 5.7 MDS028 MDS028

214713_at 529.816034 1 -40.3 529.8161 -5.1 ZAP3 ZAP3 protein

222246_at 528.996336 1 -4.7 528.9964 5.7

216013_at 527.799811 1 -3.7 527.79987 5.7 ZXDA zinc finger, X-linked, duplicated A

Homo sapiens mRNA; cDNA

DKFZp566F1224 (from clone

DKFZp566F1224), mRNA

216621_at 525.640011 1 -4.05 525.64 0.8 sequence

210181_s_at 525.089655 1 -0.75 525.0897 4.35 CABP1 calcium binding protein 1 (calbrain)

221288_at 521.158935 1 -0.65 521.159 5.55 GPR22 G protein-coupled receptor 22

218639_s_at 521.033322 1 -16.3 521.0333 -20.85 MGC11349 hypothetical protein MGC11349

205869_at 521.033322 1 -4.95 521.0333 0.2 PRSS1 protease, serine, 1 (trypsin 1 )

216856_s_at 516.426572 1 -7.05 516.4266 5.25 DLEU2 deleted in lymphocytic leukemia, 2

215727_x_at 516.426572 1 -10.25 516.4266 4.95 FLJ20811 hypothetical protein FLJ20811 protein tyrosine phosphatase,

203029_s_at 515.636836 1 -24.75 515.6369 -14.85 PTPRN2 receptor type, N polypeptide 2

208748_s_at 506.184078 1 -33.85 506.1841 -11 FLOT1 flotillin 1

214556_at 506.184078 1 -10.1 506.1841 -4.5 SSTR4 somatostatin receptor 4 chromosome 20 open reading

220213 at 506.184078 1 -10.5 506.1841 0.8 C20orf17 frame 17

208115_x_at 501.457729 1 -6.6 501.45776 0.7 FLJ21617 hypothetical protein FLJ21617 207676_at 501.457729 1 -11.1 501.45776 -2 ONECUT2 one cut domain, family member 2 UDP-N-acetyl-alpha-D- galactosamine:polypeptide N- acetylgalactosaminyltransferase 4

220442_at 496.73132 1 -2.15 496.73135 -6.45 GALNT4 (GalNAc-T4) 220415_at 495.313379 1 -5.65 495.31342 5.35 LOC51086 putative protein-tyrosine kinase cytochrome P450, subfamily NB (phenobarbital-inducible),

210272_at 492.00491 1 -29.1 492.00494 -2.55 CYP2B7 polypeptide 7 213232_at 492.00491 1 -3.7 492.00494 -0.75 KIAA1467 KIAA1467 protein son of sevenless homolog 2

217575_s_at 488.786194 1 -11.1 488.78625 1.35 SOS2 (Drosophila)

PRO2425 [Homo sapiens], mRNA

210914 at 485.980296 1 -12.35 485.98035 5.15 sequence integrin, alpha Ml {complement 4- component receptor 3, alpha; κ> also known as CD11b (p170), macrophage antigen aipha

205786_s_at 483.407687 1 -8.2 483.4077 5.2 ITGAM polypeptide) 210945_at 483.288043 1 -3.45 483.2881 5.2 COL4A6 collagen, type IV, alpha 6 211476 at 477.825773 1 -19.5 477.8258 3.65 MYOZ2 myozenin 2

ESTs, Highly similar to T47183 hypothetical protein DKFZp434K1822.1 - human

220861_at 474.965974 1 -4.15 474.96603 -3.75 (fragment) [H.sapiens] similar to RNA polymerase I 221714_s_at 473.099394 1 -8.7 473.09943 -11.5 LOC94431 transcription factor RRN3 defensin, alpha 6, Paneth cell-

207814_at 470.359254 1 -19.8 470.3593 -16.25 DEFA6 specific 209950 s at 470.359254 1 -11.3 470.3593 -1.85 VILL villin-like

Homo sapiens cDNA FLJ 12830 fis, clone NT2RP2003073, mRNA

214747_at 468.630253 1 -15.75 468.6303 5.05 sequence 210323 at 465.752535 1 -6.65 465.7526 2.85 TEKT2 tektin 2 (testicular)

216908_x_at 461.145815 1 -12.9 461.14587 -18.95 calcium channel, voltage-

206612_at 459.656102 1 -8.4 459.65613 4.95 CACNG 1 dependent, gamma subunit 1

Soluble interteukiπ-S receptor; sIL-βR [Homo sapiens], mRNA

217489_s_at 458,920196 1 -10J 458.92023 1.75 sequence

216564_at 458.920196 1 -12.2 458.92023 0.6 WUGSC:H_RG007J15.1

Homo sapiens clone HQ0085,

215642_at 456.539035 1 -11.8 456.5391 0.05 mRNA sequence

207149_at 454.193848 1 -1.95 454.19388 1.65 CDH12 cadherin 12, type 2 (N-cadherin 2) glioma-associated oncogene

206646_at 451.932346 1 -46.55 451.9324 -4.2 GLI homolog (zinc finger protein)

204712_at 449.964002 1 -5.25 449.96405 4.85 WIF1 WNT inhibitory factor 1

213569_at 449.467438 1 -12 449.46747 -0.35 KIAA1036 KIAA1036 protein

204924_at 446.075201 1 -16.95 446.07526 4.8 TLR2 toll-like receptor 2

215558_at 445.596594 1 -1.85 445.59662 4.8 hypothetical protein similar to beta- 4-

203866_at 444.741029 1 -40.35 444.74106 1.85 FLJ 10458 transducin family

SH2 domain containing

221239_s_at 444.741029 1 -7.5 444.74106 2.5 SPAP 1 phosphatase anchor protein 1

ESTs, Weakly similar to hypothetical protein FLJ20378

217537_x_at 440.01468 1 -16.7 440.0147 -0.7 [Homo sapiens] [H.sapiens]

216388_s_at 438.112126 1 -4.55 438.11218 -1.95 GPR16 leukotriene B4 receptor serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1, (angioedema,

200986_at 436.622413 1 -2.25 436.62244 4.7 SERPING1 hereditary) phosphatide acid phosphatase

209529_at 435.288271 1 -33.35 435.2883 -0.55 PPAP2C type 2C hairy/enhancer-of-split related with

219743_at 433.505406 1 -3.3 433.50546 2.35 HEY2 YRPW motif 2 granzyme A (granzyme 1, cytotoxic

T-lymphocyte-associated serine

205488 at 431.596908 1 -7 431.59695 4.6 GZMA esterase 3)

216197_at 428.898687 1 -6.15 428.89874 2.85 206291 _at 428.898687 1 -1.75 428.89874 2.45 NTS neurotensin

RT-LI [Homo sapiens], mRNA

216850_at 426.451706 1 -3.35 426.45172 4.6 sequence 213150_at 426.391869 1 -5.4 426.3919 4.55 HOXA10 homeo box A10

WNT1 inducible signaling pathway

210861_s_at 425.835513 1 -2.95 425.83554 1.95 WISP3 protein 3 huntingtin interacting protein-1-

209558_s_at 424.291937 1 -25.85 424.292 -18.25 HIP1 R related 210905_x_at 424.291937 1 -15.8 424.292 -1.3

Human clone 23948 mRNA

215304_at 424.291937 1 -6.25 424.292 3.4 sequence

ESTs, Moderately similar to hypothetical protein FLJ20489

217524_x_at 423.938984 1 -1.05 423.93903 4.5 [Homo sapiens] [H.sapiens] 204840_s_at 423.161202 1 -2.6 423.16125 4.55 EEA1 early endosome antigen 1 , 162kD immunoglobulin heavy constant

213674_x_at 419.685217 1 -6.8 419.68527 3.35 IGHG3 gamma 3 (G3m marker) 220704_at 417.956185 1 -1.55 417.95624 4.5 ZNFN1A1 hypothetical protein PRO0758

NK6 transcription factor related,

221366_at 416.382725 1 -6.9 416.38275 0.35 NKX6-1 locus 1 (Drosophila) 216670_at 415.078498 1 -13.05 415.07855 3.25 KLK13 kallikrein 13 ras responsive element binding

217411_s_at 410.471717 1 -7.45 410.47177 1.55 RREB1 protein 1

PRO1454 [Homo sapiens], mRNA

210928_at 408.742716 1 -2.05 408.74274 4.4 sequence 219803_at 407.725656 1 -5 407.7257 4.35 ANGPTL3 angiopoietin-like 3

RaI guanine nucleotide exchange

204199_at 403.717219 1 -3.9 403.71725 4.3 RALGPS1A factor RaIGPSIA

208222_at 402.203557 1 -24.45 402.20358 -14.15 ACVR1 B actϊvin A receptor, type IB 214944_at 402.203557 1 -19.4 402.20358 -30.25 KIAA0931 KIAA0931 protein

DNA directed RNA polymerase II

214740_at 401.258278 1 -4.3 401.25833 -4.75 POLR2J2 polypeptide J-related gene 214249 at 401.258278 1 -6.5 401.25833 -0.8 TRIM2 tripartite motif-containing 2

Homo sapiens mRNA; cDNA DKFZp566L0824 (from clone DKFZp566L0824), mRNA

216613_at 400.72584 1 -3.95 400.7259 4.3 sequence

220051_at 397.477178 1 -2.75 397.4772 2.95 PRSS21 protease, serine, 21 (testisin)

220852_at 396.651589 1 -8.95 396.65164 -1.25 PRO1768 P R01768 protein

ELK1 , member of ETS oncogene

210850_s_at 392.750799 1 -24.5 392.75082 -3.6 ELK1 family

Homo sapiens cDNA: FLJ21373 fis, clone COL03214, mRNA

216436_at 392.750799 1 -13.4 392.75082 -3.65 sequence chromosome 13 open reading

214668_at 384.452694 1 -10.6 384.45273 4.1 C13orf1 frame 1

B lymphocyte activator

219386_s_at 382.059582 1 -3.95 382.05963 4.1 BLAME macrophage expressed

Homo sapiens cDNA: FLJ20908 fis, clone ADSE00417, mRNA

216742_at 378.571632 1 -5.8 378.57166 1.35 sequence

Beta Il spectrin [Homo sapiens],

214856_at 373.845253 1 -10.8 373.84528 1.9 SPTBN1 mRNA sequence

215759_at 373.845253 1 -3 373.84528 2.9 FLJ 12056 hypothetical protein FLJ12056 hypothetical protein

215104_at 373.6179 1 -1.55 373.61795 -0.15 DKFZP761G1913 DKFZp761G191;

207745_at 365.547132 1 -3.3 365.54718 3.9 CABP2 calcium binding protein 2

Unknown (protein for

IMAGE.-3908182) [Homo sapiens],

215429_s_at 364.40443 1 -56.15 364.40448 -64 mRNA sequence glycophorin A (includes MN blood

211821_x_at 364.392464 1 -4.65 364.3925 2.75 GYPA group)

206886_x_at 364.392464 1 -25.15 364.3925 -27.2 GH1 growth hormone 1

205721_at 364.392464 1 -22.1 364.3925 -7.5 GFRA2 GDNF family receptor alpha 2

RAB7, member RAS oncogene

217267_s_at 359.79771 1 -3.6 359.79776 3.3 RAB7 family

217460 at 359.79771 1 -3.45 359.79776 3.05 TNP2 transition protein 2 (during histone

to protamine replacement)

215441_at 358.188353 1 -2.4 358.1884 3.85 ESTs

EST, Weakly similar to A42926 L6 surface protein - human

215033_at 357.949042 1 -3.95 357.94907 3.85 TM4SF1 [H. sapiens] pregnancy specific beta-1-

210196_s_at 355.196961 1 -2.1 355.197 3.85 PSG 1 glycoprotein 1 206230_at 354.939706 1 -6.4 354.93973 2.45 LHX1 LIM homeobox protein 1 213823_at 354.939706 1 -68.7 354.93973 -4.55 HOXA11 homeo box A11 205391_x_at 354.939706 1 -56.2 354.93973 -47.05 ANK1 ankyrin 1, erythrocytic

ESTs, Moderately similar to

PRO0478 protein [Homo sapiens]

217623_at 350.051772 1 -1.3 350.05182 3.75 [H. sapiens] 210147_at 349.333862 1 -7.7 349.3339 3.75 ART3 ADP-ribosyltransferase 3 215709_at 345.486918 1 -8.45 345.48694 -3.85 PRIM2A primase, polypeptide 2A, 58kDa

Homo sapiens mRNA full length 4- insert cDNA clone EUROIMAGE

215311_at 342.633156 1 -2.95 342.63318 3.65 21920, mRNA sequence 215793_at 337.787102 1 -2.65 337.78714 3.6 MTMR7 myotubularin related protein 7 217194_at 337.667458 1 -0.55 337.66748 3.6 purinergic receptor P2X, ligand-

207091_at 336.034129 1 -12.6 336.03415 -6.95 P2RX7 gated ion channel, 7 sarcoglycan, gamma (35kDa

207302_at 336.034129 1 -10.9 336.03415 0.65 SGCG dystrophin-associated glycoprotein) 207784_at 336.034129 1 -17.2 336.03415 0.05 ARSD arylsulfatase D

Homo sapiens cDNA: FLJ21499 fis, clone COL05634, mRNA

216766_at 333.120522 1 -14.1 333.12054 3.6 sequence

CD36 antigen (collagen type I

206488_s_at 331.30775 1 -3 331.30777 2.5 CD36 receptor, thrombospondin receptor) 212921_at 330.607782 1 -2 330.60782 3.5 HSKM-B HSKM-B protein 219145_at 327.550582 1 -17.75 327.55063 -3.8 FLJ 11939 hypothetical protein FLJ 11939

PRP31 pre-mRNA processing

214380 at 326.581372 1 -9.3 326.5814 -9.05 PRPF31 factor 31 homolog (yeast)

219756_s_at 326.581372 1 -2.2 326.5814 -2.45 POF1 B premature ovarian failure 1 B

210595_at 326.581372 1 -4.65 326.5814 -0.3 ZNF235 zinc finger protein 235 myeloproliferative leukemia virus

207550_at 324.146387 1 -1.15 324.14642 3.5 MPL oncogene

211605_s_at 322.943832 1 -19.85 322.94388 -22.95 RARA retinoic acid receptor, alpha

215002_at 322.291719 1 -4 322.29175 3.45 KIAA0220 KIAA0220 protein a disintegrin and metalloproteinase

216276_s_at 321.854993 1 -8.55 321.855 0.95 ADAM3A domain 3a (cyritestin 1)

207287_at 321.854993 1 -10.2 321.855 -0.25 FLJ14107 hypothetical protein FLJ14107

218863_s_at 318.337143 1 -10.85 318.3372 0.05 TNS tensin

213339_at 318.337143 1 -6.85 318.3372 -7.05 KIAA0495 KIAA0495

205572_at 317.684984 1 -2.6 317.685 3.4 ANGPT2 angiopoietin 2

217167_x_at 317.128583 1 -14.2 317.1286 -8.75

ATPase, H+ transporting,

220197_at 317.128583 1 -6.95 317.1286 -6.9 ATP6V0A4 lysosomal VO subunit a isoform 4

ESTs, Moderately similar to hypothetical protein FLJ20489

217581_at 312.402204 , 1 -5.15 312.40222 -1.9 [Homo sapiens] [H.sapiens] gene amplified in squamous cell

214861_at 309.123643 1 -17.8 309.1237 -8.3 GASC1 carcinoma 1

203998_s_at 307.753589 1 -4.1 307.7536 3.3 SYT1 synaptotagmin I olfactory receptor, family 1 ,

221445_at 307.675825 1 -6.95 307.67584 2.45 OR1A2 subfamily A, member 2 cytochrome P450, subfamily VIIA

(cholesterol 7 alpha-

207406_at 307.633929 1 -2.45 307.63397 3.3 CYP7A1 monooxygenase), polypeptide 1

206413_s_at 302.949446 1 -8.4 302.94946 -5.25 TCL1 B T-cell leukemia/lymphoma 1 B intercellular adhesion molecule

4, Landsteiner-Wieπer blood

207194_s_at 302.949448 1 -4.45 302.94946 -1.95 ΪCAM4 group

206548_at 299.910203 1 -12.45 299.91025 -6.45 FLJ23556 hypothetical protein FLJ23556

Protein G16 [Homo sapiens],

216018_at 298.223067 1 -22.35 298.22308 -4.35 mRNA sequence

AFFX-r2-Bs-lys-M at 296.565842 1 -3.8 296.56586 3.15

dopachrome tautomerase

(dopachrome delta-isomerase,

216513_at 295.303453 1 -11.7 295.3035 -0.2 DCT tyrosine-related protein 2) 206871_at 295.303453 1 -14.75 295.3035 -6.2 ELA2 elastase 2, neutrophil 209936_at 290.696734 1 -2.3 290.69678 -1.55 RBM5 RNA binding motif protein 5

Brain carboxylesterase hBr3 [Homo

208007_at 290.696734 1 -15.55 290.69678 -3.65 sapiens], mRNA sequence

208304_at 288.84805 1 -0.85 288.84808 3.1 CGR3 chemokϊne (C-C motif) receptor 3

215966_x_at 288.770279 1 -37 288.7703 -9.55 GK glycerol kinase

214485_at 288.770279 1 -2.3 288.7703 -8.15 ODF1 outer dense fiber of sperm tails 1

222090_at 288.249768 1 -2.3 288.2498 3.1 MGC20727 hypothetical protein MGC20727

208582_s_at 284.043869 1 -10.4 284.04388 -4.65 DUX3 double homeobox, 3

214770_at 284.043869 1 -3.95 284.04388 3 MSR1 macrophage scavenger receptor 1

220623_s_at 282.267015 1 -1.45 282.26703 3 TSG A10 testis specific, 10

Homo sapiens clone 24507 mRNA

215308 at 281.483264 1 -2.85 281.4833 -0.9 sequence

Homo sapiens mRNA; cDNA 00

DKFZp564M0616 (from clone

DKFZp564M0616), mRNA

215514_at 278.73717 1 -1.6 278.73718 2.95 sequence 203653_s_at 276.876514 1 -10.1 276.87656 -3.25 COIL coilin 208077_at 272.269825 1 -20.9 272.26987 0.9 PRO0365 PRO0365 protein 206071_s_at 269.864732 1 -9.6 269.86475 -3.4 EPHA3 EphA3 glutamyl aminopeptidase

204844_at 268.207492 1 -3.7 268.20752 2.85 ENPEP (aminopeptidase A) 220630_s_at 267.663075 1 -18.75 267.66312 -5.45 CHIA eosinophil chemotactic cytokine 207190_at 263.056325 1 -15.65 263.05637 -2.55 KIAA0399 KIAA0399 protein 208139_s_at 263.056325 1 -6.1 263.05637 -0.25 PRO1386 PRO1386 protein p53-regulated apoptosis-inducing

220403_s_at 263.056325 1 -2.25 263.05637 -2.7 P53AIP1 protein 1

205388_at 260.411944 1 -13.05 260.41196 -5.9 TNNC2 troponin C2, fast

207236_at 259.771774 1 -3.65 259.7718 2.8 ZNF345 zinc finger protein 345

G protein-coupled receptor kinase

204395 s at 258.449605 1 -61.55 258.44965 -8.4 GPRK5 5

213482_at 255.68558 1 -13.25 255.68561 -2.25 DOCK3 dedicator of cyto-kinesis 3 215081_at 255.68558 1 -2.6 255.68561 1.85 KIAA1024 KIAA1024 protein

CSE1 chromosome segregation 1-

210765_at 250.959201 1 -3.6 250.95923 -0.35 CSE 1 L like (yeast)

Homo sapiens mRNA; cDNA

DKFZp564D193 (from clone

216527_at 250.319005 1 -2.95 250.31903 2.7 DKFZp564D193), mRNA sequence

Homo sapiens cDNA FLJ12046 fϊs, clone HEMBB1001962, mRNA

215400_x_at 249.236151 1 -10.7 249.23618 0.45 sequence

BUB1 budding uninhibited by

216277_at 246.232792 1 -3.1 246.23282 0.8 BUB1 benzimidazoles 1 homoiog (yeast) tumor necrosis factor, alpha-

201208_s_at 246.232792 1 -23.7 246.23282 -38.2 TNFAIP1 induced protein 1 (endothelial) family with sequence similarity 13,

214914_at 244.455907 1 -10.05 244.45593 2.6 FAM13C1 member C1 220247_at 241.506413 1 -4.7 241.50644 -3.05 AF15Q14 AF15q14 protein 215137_at 241.506413 1 -52.15 241.50644 -7.7 KIAA0508 KIAA0508 protein 205862_at 241.506413 1 -5.05 241.50644 2.45 GREB1 GREB1 protein 214537_at 240.267972 1 -4.7 240.268 2.6 H1 F3 H1 histone family, member 3 guanylate cyclase activator 1 B

207003_at 239.660763 1 -18.85 239.66077 15.25 GUCA1 B (retina) nuclear transcription factor, X-box

210268_at 235.415947 1 -2.45 235.41597 -2.45 NFX1 binding 1 glycophorin A (includes MN blood

205837_s_at 232.053639 1 -1.25 232.05367 2.25 GYPA group) 36920_at 232.053639 1 -9.95 232.05367 0.25 MTM1 myotubular myopathy 1 pregnancy specific beta-1-

208134_x_at 232.053639 1 -8 232.05367 -7.45 PSG2 glycoprotein 2 207726_at 232.053639 1 -27 232.05367 -2.05 ESRRB estrogen-related receptor beta Histamine H3 receptor HH3R

221663_x_at 232.053639 1 -8.6 232.05367 0.35 [Homo sapiens], mRNA sequence tumor necrosis factor (ligand) superfamily, member 5 (hyper-lgM

207892 at 230.516062 1 -23.75 230.51608 2.45 TNFSF5 syndrome)

leukocyte immunoglobulin-like receptor, subfamily A (with TM

211102_s_at 228.840884 1 -12.1 228.84091 2.45 LILRA2 domain), member 2 207899_at 227.327261 1 -14.05 227.32729 0.2 GIP gastric inhibitory polypeptide DEAD/H (Asp-Glu-Ala-Asp/His) box

219945_at 227.327261 1 -1.95 227.32729 -1.6 DDX25 polypeptide 25 217026_at 226.202492 1 -13.6 226.20251 -7.05 214957_at 222.600851 1 -72.35 222.60088 -69.85 LOC81569 actin like protein 208529_at 222.600851 1 -4.15 222.60088 -0.65 BTF3L1 basic transcription factor 3, like 1 205979 at 221.595773 1 -2.75 221.5958 -2.5 SCGB2A1 secretoglobin, family 2A, member 1 AFFX-r2-Bs-dap- 3_at 221.595773 1 -2.2 221.5958 1.15 210838_s_at 217.874472 1 -42 217.8745 2.3 ACVRL1 activin A receptor type If-Hke 1 pregnancy specific beta-1-

215821_x_at 216.989023 1 -16.55 216.98904 -7.9 PSG3 glycoprotein 3 220978_at 216.989023 1 -4.55 216.98904 -0.35 KRTAP1-3 keratin associated protein 1 -3

Ul Homo sapiens mRNA; cDNA O DKFZp564F212 (from clone

216614_at 216.456558 1 -8.6 216.45657 2.3 DKFZp564F212), mRNA sequence solute carrier family 16 (monocarboxylic acid transporters),

207038_at 213.584827 1 -16.25 213.58484 2.3 SLC16A6 member 6

Mucin [Homo sapiens], mRNA

217182_at 213.148093 1 -1.9 213.14812 -12.25 sequence 216721_at 212.382288 1 -15.5 212.38231 -0.1 syntrophin associated

217231_s_at 212.382288 1 -27 212.38231 -7.1 SAST serine/threonine kinase potassium voltage-gated channel,

211301_at 208.421699 1 -12.6 208.42172 0.35 KCN D3 Shal-related subfamily, member 3 G antigen, family B, 1 (prostate

206897_at 208.421699 1 -6.7 208.42172 1.45 GAGEB1 associated) 220064_at 207.775568 1 -12 207.77559 -0.75 FLJ 11457 hypothetical protein FLJ11457 211192_s_at 207.775568 1 -5.1 207.77559 -8 CD84 CD84 antigen (leukocyte antigen) macrophage stimulating,

215563 s at 207.775568 1 -1.75 207.77559 0.85 MSTP9 pseudogene 9

220431_at 205.567921 1 -1.7 205.56793 2.2 DESC 1 DESC1 protein lectin, galactoside-binding, soluble,

208450_at 203.69532 1 -11.3 203.69534 -1.3 LGALS2 2 (galectin 2)

Hypothetical protein [Homo

215085_x_at 203.69532 1 -17.65 203.69534 -21.3 sapiens], mRNA sequence Homo sapiens cDNA: FLJ20953 fis, clone ADSE01979, mRNA

216745_x_at 203.168833 1 -14.8 203.16885 -2.9 sequence

PADI-H protein [Homo sapiens],

211412_at 200.841527 1 -7.15 200.84155 2.15 mRNA sequence aldehyde dehydrogenase 1 family,

212224_at 198.968926 1 -7 198.96895 0.25 ALDH1A1 member A1

RAB7, member RAS oncogene

217268_at 198.968926 1 -2.15 198.96895 0.75 RAB7 family eukaryotic translation initiation

204409_s_at 198.968926 1 -5.75 198.96895 -1.15 EIF1AY factor 1 A, Y chromosome 215673_at 198.968926 1 -10.1 198.96895 -1.1 KIAA1655 Kl AA 1655 protein hepsin (transmembrane protease,

204934_s_at 198.562114 1 -6.6 198.56213 -6.55 HPN serine 1 ) 208193_at 194.242531 1 -6.15 194.24255 -0.8 IL9 ϊrtterleukin 9 Homo sapiens clone

215188_at 194.242531 1 -8.05 194.24255 -0.95 IMAGE:1963178, mRNA sequence zinc finger protein 36, C3H type-

213284_at 193.955364 1 -3.1 193.95538 2.05 ZFP36L1 like 1 protein phosphatase 1 , regulatory (inhibitor) subunit 3A (glycogen and sarcoplasmic reticulum binding

211169_s_at 193.955364 1 -5.75 193.95538 1.65 PPP1 R3A subunit, skeletal muscle) 210279_at 193.955364 1 -7.4 193.95538 -3.85 GPR18 G protein-coupled receptor 18 220059_at 192.465647 1 -7.1 192.46567 2.05 BRDG1 BCR downstream signaling 1 Homo sapiens clone 24649 mRNA

213715_s_at 189.516152 1 -14.95 189.51617 -1.4 sequence

AML1/AMP19 fusion protein [Homo

211182_x_at 189.516152 1 -13.2 189.51617 -36.2 sapiens], mRNA sequence 213669 at 189.516152 1 -9.95 189.51617 -2.9 KIAA0290 KIAA0290 protein

206828_at 189.348614 1 -11.5 189.34863 -7.15 TXK TXK tyrosine kinase

221162_at 189.348614 1 -96.45 189.34863 -21.05 HHLA1 HERV-H LTR-associating 1

Unknown (protein for

IMAGE:3690478) [Homo sapiens],

216844_at 189.348614 1 -3.5 189.34863 -2.55 mRNA sequence

Homo sapiens cDNA FLJ11662 fis, clone HEMBA1004629, mRNA

215578_at 188.696508 1 -3.35 188.69652 2 sequence olfactory receptor, family 11 ,

221343_at 184.789773 1 -3.7 184.7898 1.85 OR11A1 subfamily A, member 1

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a,

214360_at 184.789773 1 -23.2 184.7898 -6.8 SMARCA4 member 4

Homo sapiens clone

216154_at 184.789773 1 -18.95 184.7898 -8.15 IMAGE:205688, mRNA sequence

Homo sapiens cDNA FLJ11976 fis, κ> clone HEMBB1001253, mRNA

215614_at 184.741894 1 -14.8 184.74191 -0.45 sequence putative DNA/chromatin binding

201547_at 184.741894 1 -1.65 184.74191 -1.4 PLU-1 motif

222372_at 184.741894 1 -12.4 184.74191 -13 ESTs

216260_at 180.135175 1 -6 180.1352 1.45 DICER1 Diceri, Dcr-1 homolog (Drosophila)

206575_at 180.135175 1 -27.45 180.1352 0.45 CDKL5 cyclin-dependent kinase-like 5

210547_x_at 180.135175 1 -19.35 180.1352 -9.8 ICA1 islet cell autoantigen 1 , 69kDa

206977_at 180.063379 1 -5.85 180.0634 -0.6 PTH parathyroid hormone

Homo sapiens clone 23892 mRNA

215736_at 180.063379 1 -4.1 180.0634 1.85 sequence

208202_s_at 180.063379 1 -11.6 180.0634 -0.75 KIAA0239 KIAA0239 protein

Homo sapiens cDNA: FLJ21524 fis, clone COL05921, mRNA

216765_at 178.166843 1 -3 178.16685 1.9 sequence

207326_at 177.49263 1 -0.3 177.49263 11.2 BTC betacellulin

220318_at 176.730987 1 -2.8 176.731 1.9 EPN3 epsin 3

215151_at 175.528424 1 -4.4 175.52844 1.4 KIAA0694 KIAA0694 gene product

PR domain containing 2, with ZNF

216433_s_at 175.528424 1 -1.45 175.52844 -1.8 PRDM2 domain ubiquitin-conjugating enzyme E2D

215957_at 175.528424 1 -0.4 175.52844 1.35 UBE2D1 1 (UBC4/5 homolog, yeast) 215021_s_at 175.336985 1 -4.6 175.337 1.55 NRXN3; KIAA0743 neurexin 3 chromobox homolog 1 (HP1 beta

210921_at 175.336985 1 -3.9 175.337 -0.3 CBX1 homolog Drosophila ) Cas-Br-M (murine) ecotropic

208348_s_at 170.921705 1 -3 170.92172 0.15 CBLB retroviral transforming sequence b cyclic nucleotide gated channel

211099_s_at 170.921705 1 -5 170.92172 -3.55 CNGB1 beta l solute carrier family 22 (extraneuronal monoamine

205421_at 170.921705 1 -2.85 170.92172 0.75 SLC22A3 transporter), member 3 leukocyte immunoglobulin-like receptor, subfamily B (with TM and

210146_x_at 169.43199 1 -3.65 169.432 1.8 LILRB2 ITIM domains), member 2

20S29G_s_at 166.828188 1 -2,3 166.62819 17.6 BMP2 bone morphogenetic protein 2 Ul Homo sapiens cDNA: FLJ21553 fis, clone COL06329, mRNA

216777_at 165.884212 1 -4.7 165.88423 1.7 sequence likely ortholog of mouse myocytic

214846_s_at 165.884212 1 -16.35 165.88423 1.75 MIDORI induction/differentiation originator 207675_x_at 165.884212 1 -12.25 165.88423 -15.05 ARTN artemin doublesex and mab-3 related

220493_at 161.708235 1 -16.55 161.70825 -9.1 DMRT1 transcription factor 1

Homo sapiens cDNA FLJ14136 fis, clone MAMMA1002744, mRNA

215392_at 157.466466 1 -1.95 157.46649 1.7 sequence

PAS domain containing

206594_at 157.103882 1 -20 157.10388 10.8 PASK serine/threonine kinase 220824_at 157.101516 1 -11.25 157.10153 -6.05 FLJ20123 hypothetical protein FLJ20123 211124_s_at 156.431439 1 -6.4 156.43146 -0.05 KITLG KIT ligand beaded filament structural protein

207399 at 156.431439 1 -62.45 156.43146 -34.65 BFSP2 2, phakinin

220144_s_at 156.431439 1 -3.7 156.43146 -0.5 ANKRD5 ankyrin repeat domain 5

220837_at 156.431439 1 -5.65 156.43146 -2.8 FLJ20413 hypothetical protein FLJ20413

207741_x_at 152.494781 1 -21.7 152.4948 -21.35 TPS1 tryptase, alpha

ESTs, Moderately similar to hypothetical protein FLJ20378

217577_at 152.494781 1 -5.25 152.4948 -2.9 [Homo sapiens] [H.sapiens] enhancer of zeste homolog 1

211310_at 149.210238 1 -2.35 149.21025 1.6 EZH 1 (Drosophila)

215268_at 147.888046 1 -7.25 147.88806 -6.1 KIAA0754 KIAA0754 protein

Fc fragment of IgG, low affinity Ha,

210992_x_at 146.978665 1 -30.7 146.97868 -4.55 FCGR2A receptor for (CD32)

Homo sapiens cDNA FLJ30057 fis, clone ADRGL2000006, mRNA

215141_at 143.406949 1 -8.4 143.40697 1.55 C4orf10 sequence

ATPase, Ca++ transporting,

207521_s_at 143.281311 1 -29.35 143.28133 -18.5 ATP2A3 ubiquitous protein tyrosine phosphatase, non¬

208010_s_at 142.252271 1 -5.7 142.25229 0.55 PTPN22 receptor type 22 (lymphoid)

UDP glycosyltransferase 2 family,

207245_at 142.252271 1 -1.95 142.25229 -5.1 UGT2B17 polypeptide B17

210893_at 142.252271 1 -10.5 142.25229 -3.25 ESTs

205086_s_at 142.252271 1 -5.85 142.25229 -6.85 384D8-2 hypothetical protein 384D8_6

221322_at 138.674576 1 -7.05 138.67459 1.05 RFRP RFamide-related peptide precursor

Human clone 23908 mRNA

213403_at 138.674576 1 -2.8 138.67459 -0.05 sequence

222227_at 138.674576 1 -3.3 138.67459 1.5 ZNF236 zinc finger protein 236

207750_at 137.525892 1 -3.55 137.52591 -0.8 PR01866 hypothetical protein PRO1866 cytochrome P450, subfamily XXXIX

(oxysterol 7 alpha-hydroxylase),

220432_s_at 137.525892 1 -1.85 137.52591 0.05 CYP39A1 polypeptide 1

Homo sapiens cDNA: FLJ21284 fis, done COL01911 , mRNA

215589_at 135.749015 1 -2.35 135.74902 1.45 sequence luteinizing hormone beta

214471_x_at 134.067857 1 -6.35 134.06787 -10.6 LHB polypeptide

cat eye syndrome chromosome

219505_at 134.067857 1 -8 134.06787 -9.35 CECR1 region, candidate 1

PRO0843 [Homo sapiens], mRNA

207731_at 132.799513 1 -2.25 132.79953 -1 sequence putative metallopeptidase (family

220179_at 132.799513 1 -13.3 132.79953 -5.65 LOC64180 M19) 213949_s_at 132.799513 1 -5.5 132.79953 -8.5 MGC4293 hypothetical protein MGC4293

Homo sapiens clone 24629 mRNA

215262_at 132.799513 1 -2.25 132.79953 -0.15 sequence prostaglandin D2 synthase,

206726_at 132.695874 1 -0,8 132.69588 20.25 PGDS hematopoietic claudin 5 (transmembrane protein deleted in velocardiofacial

204482_at 131.979876 1 -12.95 131.97989 1.4 CLDN5 syndrome)

Unnamed protein product [Homo

215542_at 131.620905 1 -2.95 131.62091 1.4 sapiens], mRNA sequence

(Jl 211796_s_at 130.304695 1 -6.8 130.3047 1.4 TRB@ T cell receptor beta locus (Jl metallothionein-like 5, testis-

219786_at 128.073127 1 -19.4 128.07314 1.25 MTL5 specific (tesmin) 203902_at 126.056927 1 -8.9 126.05694 1.35 HEPH hephaestin solute carrier family 24

(sodium/potassium/calcium

57588_at 126.056927 1 -6.05 126.05694 1.35 SLC24A3 exchanger), member 3

Homo sapiens cDNA FLJ11568 fis, clone HEMBA1003278, mRNA

215626_at 124.854395 1 -6.2 124.8544 -2.9 sequence 206065_s_at 124.854395 1 -11.6 124.8544 -21.4 DPYS dihydropyrimidinase 205155 s at 124.854395 1 -2.3 124.8544 -10.45 SPTBN2 spectrin, beta, non-erythrocytic 2

ESTs, Weakly similar to

DPG1JHUMAN DNA polymerase gamma subunit 1 (Mitochondrial

DNA polymerase catalytic subunit)

217636_at 124.854395 1 -13.4 124.8544 -7 (PolG-alpha) [H.sapiens]

210855_at 124.854395 1 -10.85 124.8544 -2.35 GREB1 GREB 1 protein

204765 at 124.854395 1 -5.1 124.8544 -2.35 ARHGEF5 Rho guanine nucleotide exchange

factor (GEF) 5

208350_at 123.346732 1 -4.95 123.34674 -2.85 CSN1S1 casein, alpha caspase 10, apoptosis-related

205467_at 122.358635 1 -2.95 122.35863 24.6 CASP 10 cysteine protease microtubule-associated protein,

213489_at 118.620353 1 -19.5 118.62036 -21.5 MAPRE2 RP/EB family, member 2 220218_at 118.620353 1 -7.55 118.62036 -4.95 FLJ 10058 hypothetical protein FLJ10058 220639_at 118.620353 1 -10.3 118.62036 0.4 FLJ22800 hypothetical protein FLJ22800

Homo sapiens cDNA: FLJ23601 fis, clone LNG 15501, mRNA

216805_at 117.681052 1 -2.8 117.68106 1.25 sequence

Unc93 (C.elegans) homolog A

214382_at 115.640933 1 -3.3 115.64094 -2.8 [Homo sapiens], mRNA sequence amyloid beta (A4) precursor-like

208701_at 115.640933 1 -46.05 115.64094 -14.3 APLP2 protein 2 216633_s_at 115.640933 1 -3.7 115.64094 -0.95 KIAA1069 KIAA1069 protein

Ul 206519_x_at 115.640933 1 -1 115.64094 -1.9 SIGLEC6 sialic acid binding Ig-like lectin 6 phosphodiesterase 6B, cGMP- specific, rod, beta (congenital stationary night blindness 3,

210304_at 115.640933 1 -22.05 115.64094 -1.5 PDE6B autosomal dominant) 214907_at 111.034206 1 -19.95 111.03421 1.15 R29124_1 hypothetical protein R29124_1 217072_at 111.034206 1 -6.05 111.03421 -2.3 CMRF-35H leukocyte membrane antigen 217454_at 109.167573 1 -7.35 109.16758 -1.55

Homo sapiens mRNA; cDNA

DKFZp434C0814 (from clone

DKFZp434C0814), mRNA

215509_s_at 109.167573 1 -7 109.16758 -4.2 sequence 215974_at 109.167573 1 -14.85 109.16758 -1.1 HCGIV-6 HCGIV-6 protein 221468_at 109.167573 1 -8.4 109.16758 -2.05 XCR1 chemokine (C motif) receptor 1 221244_s_at 106.427463 1 -2.75 106.42747 0.9 PRO0461 PRO0461 protein keratin 12 (Meesmann corneal

207811_at 104.441186 1 -5.6 104.44119 -1.25 KRT12 dystrophy) 211338 at 104.441186 1 -8.7 104.44119 -5.4 IFNA2 interferon, alpha 2

Down syndrome critical region

219864_s_at 104.441186 1 -5.55 104.44119 -9.55 DSCR1 L2 gene 1-like 2

215108_x_at 104.441186 1 -3.75 104.44119 -2.25 TNRC9 trinucleotide repeat containing 9 protein tyrosine phosphatase,

212587_s_at 104.441186 1 -2.55 104.44119 -1.8 PTPRC receptor type, C carbonic anhydrase VB,

207129_at 104.441186 1 -46.4 104.44119 -3.45 CA5B mitochondrial

215049_x_at 103.654538 1 -2.35 103.65454 2.95 GD163 CD163 antigen

207199_at 101.826714 1 -8.9 101.82672 1.1 TERT telomerase reverse transcriptase guanylate cyclase activator 2B

207502_at 101.820736 1 -22.9 101.82074 -26 GUCA2B (uroguanylin)

Homo sapiens mRNA; cDNA

DKFZp564J2116 (from clone

DKFZp564J2116), mRNA

216642_at 101.820736 1 -1.75 101.82074 -2 sequence v-src sarcoma (Schmidt-Ruppin A-

221284_s_at 101.820736 1 -7.65 101.82074 -8.05 SRC 2) viral oncogene homolog (avian) -4 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),

220626_at 100.849876 1 -0.2 100.849884 15.55 SERPINA10 member 10 proprotein convertase

204870_s_at 99.7147994 1 -3.6 99.714806 -6.5 PCSK2 subtilisin/kexin type 2

208215_x_at 97,2140012 1 -11 97.214005 -8.45 DRD4 dopamine receptor D4

217953_at 97.2140012 1 -1 97.214005 -0.35 PHF3

GARS-AIRS-GART [Homo

216990_at 97.2140012 1 -7.25 97.214005 -5.85 sapiens], mRNA sequence

221373_x_at 94.9884128 1 -28.75 94.98842 -20.95 PSPN persephin

222248_s_at 94.2884294 1 -24.05 94.28844 1 protein phosphatase 2 (formerly

201374_x_at 92.6072664 1 -10.3 92.60727 -2.25 PPP2CB 2A), catalytic subunit, beta isoform

Retina-derived POU-domain factor

207450_s_at 92.6072664 1 -3.85 92.60727 0.55 RPF-1 1

207921_x_at 92.6072664 1 -5.95 92.60727 0.05 PAX8 paired box gene 8

nuclear distribution gene C

210575_at 92.6072664 1 -3.75 92.60727 -8.55 NUDC homolog (A. nidulans) 216464_x_at 90.2620262 1 -0.85 90.26203 -10.5 GPR44 G protein-coupled receptor 44 transforming, acidic coiled-coil

217433_at 88.0005316 1 -18.8 88.000534 0.5 TACC 1 containing protein 1

Ig mu-chain V-region (V-D)

216706_x_at 88.0005316 1 -5 88.000534 -5 precursor, mRNA sequence bone rnorphogenetic

205430_at 88.0005316 1 •2,1 88.000534 -2.7 BMP5; MC protein 5 202988_s_at 85.5356396 1 -2.4 85.535645 0.75 RGS1 regulator of G-ρrotein signalling 1 potassium channel, subfamily K,

220540_at 85.5356396 1 -7.3 85.535645 0.45 KCN K15 member 15 par-6 partitioning defective 6

211907_s_at 85.5356396 1 -22.4 85.535645 -0.4 PARD6B homolog beta (C. elegans)

Homo sapiens cDNA FLJ12359 fis, clone MAMMA1002355, mRNA 00

215965_at 85.5356396 1 -6.7 85.535645 -1.65 sequence 217000_at 85.5356396 1 -8.8 85.535645 -3.95 219930_at 83.3938044 1 -12.2 83.39381 0.5 KLF8 Kruppel-like factor 8 protein tyrosine phosphatase, non¬

208011_at 83.3938044 1 -1.85 83.39381 -0.5 PTPN22 receptor type 22 (lymphoid) major histocompatibility complex,

209480_at 83.3938044 1 -1.4 83.39381 0.6 HLA-DQB1 class II, DQ beta 1 204704_s_at 83.3938044 1 -2.1 83.39381 -1.65 ALDOB aldolase B, fructose-bisphosphate bassoon (presynaptic cytomatrix

204586_at 81.4548675 1 -15.05 81.45487 6.65 BSN protein) 210066_s_at 80.809253 1 -7.85 80.80926 -2.95 AQP4 aquaporin 4 serine/threonine kinase 11 (Peutz-

204292_x_at 80.809253 1 -27.65 80.80926 -11.15 STK11 Jeghers syndrome) ESTs, Weakly similar to hypothetical protein FLJ20378

217536_x_at 80.809253 1 -3.25 80.80926 -1.6 [Homo sapiens] [H.sapiens] 208516_at 80.809253 1 -33.15 80.80926 -13.55 MTNR1 B melatonin receptor 1 B 215784 at 78.7870772 1 -6.6 78.78708 -1 CD1 E CD1E antigen, e polypeptide

wingless-type MMTV integration

208606_s_at 78.7870772 1 -12.7 78.78708 -11.6 WNT4 site family, member 4 transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-

206008_at 78.7870772 1 -7.9 78.78708 -1.7 TGM 1 gamma-glutamyltransferase)

206341_at 78.7870772 1 -10.55 78.78708 -5.65 1L2RA interleukin 2 receptor, alpha

214833_at 78.7870772 1 -36.25 78.78708 -16.15 KIAA0792 KIAA0792 gene product

Homo sapiens cDNA FLJ12601 fis, clone NT2RM4001414, mRNA

222135_at 76.0828664 1 -4.75 76.08287 -5.55 sequence transient receptor potential cation

208267_at 76.0828664 1 -17.8 76.08287 -14.75 TRPV5 channel, subfamily V, member 5

211188_at 76.0828664 1 -20.3 76.08287 -6.65 CD84 CD84 antigen (leukocyte antigen)

DNA (cytosine-5-)-

220139_at 74.1803424 1 -31.3 74.18034 -18.7 DNRΛT3L rπethyltransferase 3-iike

217402_at 71.3564722 1 -3.85 71.356476 -0.25

206203_at 71.3564722 1 -18.9 71.356476 -11 RCV1 recoverin

208547_at 71.3564722 1 -6.3 71.356476 -0.35 HIST1H2BB H2B histone family, member F

218035_s_at 71.3564722 1 -37.9 71.356476 -4.75 FLJ20273 RNA-binding protein

214589_at 71.3564722 1 -9.2 71.356476 -1.2 FGF12 fibroblast growth factor 12 guanine nucleotide binding protein

(G protein), alpha activating activity

206356_s_at 71.3564722 1 -3.35 71.356476 -1.8 GNAL polypeptide, olfactory type

216948_at 71.3564722 1 -1.2 71.356476 -0.05

207380_x_at 70.3573782 1 -0.45 70.357376 15.85 NOX1 NADPH oxidase 1 solute carrier family 16

(monocarboxylic acid transporters),

219915_s_at 69.8187218 1 -2.75 69.818726 7.3 SLC16A10 member 10

Homo sapiens cDNA FLJ13453 fis, clone PLACE1003205, mRNA

215627_at 69.5736075 1 -4.75 69.57361 -2.25 sequence

205766_at 69.5736075 1 -4.85 69.57361 -3.2 TCAP titin-cap (telethonin) solute carrier family 22 (organic

216599 x at 69.5736075 1 -15.2 69.57361 -4.7 SLC22A6 anion transporter), member 6

latent transforming growth factor

213176_s_at 69.5736075 1 -31.4 69.57361 -27.25 LTBP4 beta binding protein 4 sel-1 suppressor of lin-12-like (C.

202063_s_at 66.6355934 1 -4.55 66.63559 6.85 SEL1L elegans) placental growth factor, vascular endothelial growth factor-related

209652_s_at 66.6300932 1 -3.4 66.6301 -6.3 PGF protein

215122_at 66.6300932 1 -2.35 66.6301 0.3 TBX6 T-box 6 216319_at 64.9668804 1 -5.35 64.96688 -1.2 221611_s_at 64.9668804 1 -5.1 64.96688 -0.7 PHF7 PHD finger protein 7

ATPase, Na+/K+ transporting,

203295_s_at 64.9668804 1 -6.15 64.96688 -3 ATP1A2 alpha 2 (+) polypeptide glutamate receptor, ionotropic, N-

207036_x_at 64.3922058 1 -0.4 64.392204 28.65 GRIN2D methyl D-aspartate 2D cytochrome P450, subfamily IUA

(niphedipine oxidase), polypeptide

205765_at 61.9037028 1 -7.6 61.90371 -4.15 CYP3A5 5 220468_at 61.9037028 1 -1.4 61.90371 -0.5 FLJ22595 hypothetical protein FLJ22595 O 207155_at 61.9037028 1 -13.05 61.90371 -4.65 TBX5 T-box 5 208273_at 61.9037028 1 -12.05 61.90371 -3.6 LOC57116 zinc finger protein SBZF3 v-src sarcoma (Schmidt-Ruppin A-

221281_at 60.3601455 1 -12.45 60.360153 -12.9 SRC 2) viral oncogene homolog (avian) Homo sapiens mRNA; cDNA DKFZp434F104 (from clone

217443_at 60.3601455 1 -6.4 60.360153 0.5 DKFZp434F104), mRNA sequence 209469_at 60.3601455 1 -6.35 60.360153 -3.2 GPM6A glycoprotein M6A 211881_x_at 58.1536334 1 -0.6 58.153633 5.6 IGLJ3 immunoglobulin lambda joining 3 215731_s_at 58.1115994 1 -12.65 58.1116 -1.25 MPHOSPH9 M-phase phosphoprotein 9 220652_at 55.7534222 1 -2.8 55.75343 -2.15 KIF24 kinesin family member 24 cAMP responsive element binding

216208_s_at 55.7534222 1 -6.55 55.75343 -11.55 CREBL1 protein-like 1 uncharacterized hematopoietic stem/progenitor cells protein

220589 s at 55.7534222 1 -12.5 55.75343 -2.7 MDS028 MDS028

215036_at 52.6467784 1 -5.3 52.646782 5.35 IGL@ immunoglobulin lambda locus

220256_s_at 52.4509296 1 -14.15 52.450935 -1.5 OXCT2 3-oxoacid CoA transferase 2 glycophorin A (includes MN blood

205838_at 52.4509296 1 -4.75 52.450935 -8 GYPA group)

214528_s_at 52.4509296 1 -7.95 52.450935 -4.5 PAX8 paired box gene 8

220055_at 52.4509296 1 -6 52.450935 -7.6 ZNF287 zinc finger protein 287

220900_at 51.1466873 1 -9.5 51.146694 -0.55 FLJ 12078 hypothetical protein FLJ12078

ATPase, Ca++ transporting,

213042_s_at 51.1466873 1 -5.9 51.146694 -1.95 SERCA3 ubiquitous hepatocellular carcinoma-

220437_at 51.1466873 1 -18.85 51.146694 -10.15 LOC55908 associated gene TD26

222272_x_at 51.1466873 1 -10.35 51.146694 -15.4 SCIN scinderin

210925 at 49.7228522 1 -0.05 49.722855 17.6 MHC2TA MHC class Il transactivator

AFFX-r2-Bs-dap-

M_at 46.5759869 1 -0.4 46.57599 5.65 cerebellar degeneration-related c

\

207276_at 46.5399525 1 -2.3 46.53996 -1.05 CDR1 protein 1 , 34kDa membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I,

207496_at 46.5399525 1 -13.9 46.53996 -5.35 MS4A2 receptor for; beta polypeptide) eukaryotic translation initiation

204410_at 46.5399525 1 -6.85 46.53996 -3.5 EIF1AY factor 1A, Y chromosome

Homo sapiens clone 24587 mRNA

217132_at 45.8557167 1 -0.4 45.855717 8.2 sequence solute carrier family 4, sodium bicarbonate cotransporter, member

211494_s_at 43.374001 1 -1.15 43.374 25.7 SLC4A4 4 fucosyltransferase 6 (alpha (1,3)

211885_x_at 42.9981564 1 -20.95 42.99816 -3.45 FUT6 fucosyltransferase)

208298_at 42.9981564 1 -15.45 42.99816 -2.7 EVI5 ecotropic viral integration site 5 mannose-binding lectin (protein C)

207256_at 42.9981564 1 -2.15 42.99816 -2.9 MBL2 2, soluble (opsonic defect)

207087_x_at 42.0003021 1 -12 42.000305 71.15 ANK1 ankyrin 1, erythrocytic

Homo sapiens cDNA FU33407 fis, clone BRACE2010535, mRNA

205316_at 41.9332215 1 -4.5 41.933228 -8.4 sequence

Homo sapiens clone 25048 mRNA

213276_at 41.9332215 1 -23.9 41.933228 -14.2 sequence 220779_at 41.9332215 1 -25 41.933228 -31.2 PADI3 peptidyl arginine deiminase, type 111 214612_x_at 39.5323758 1 -0.65 39.532375 7.95 MAGE6 melanoma antigen, family A₁ 6 208040_s_at 39.430223 1 -28.35 39.43022 48.3 MYBPC3 myosin binding protein C, cardiac

Homo sapiens mRNA; cDNA

DKF2p586B0220 (from clone

DKFZp586B0220), mRNA

213817_at 38.2717698 1 -3.75 38.271774 -1.95 sequence soiute carrier family 6

(neurotransmitter transporter,

205921_s_at 38.2717698 1 -13.35 38.271774 -4.5 SLC6A6 taurine), member 6

Homo sapiens mRNA; cDNA

DKFZp566F1224 (from clone κ>

DKFZp566F1224), mRNA

216625_at 38.2717698 1 -5.85 38.271774 -2.3 sequence 216825_s_at 38.2717698 1 -9.75 38.271774 -7.65 pregnancy specific beta-1-

204830_x_at 38.2717698 1 -15.05 38.271774 -10.85 PSG5 glycoprotein 5

Homo sapiens mRNA; cDNA

DKFZp566G231 (from clone

215550_at 38.2717698 1 -3.9 38.271774 -6.05 DKFZp566G231), mRNA sequence catβnϊn {eadherϊn-associaiβd protein}, delta 2 (neural plakophilin-related arm-repeat

20961 S_at 38.2717898 1 -5.95 38.271774 -2 CTNND2 protein) potassium voltage-gated channel, shaker-related subfamily, beta

210078_s_at 37.3264905 1 -4.95 37.326496 -1.9 KCNAB1 member 1 211253_x_at 37.3264905 1 -15.9 37.326496 0.15 PYY peptide YY

Janus kinase 3 (a protein tyrosine

211109 at 37.3264905 1 -10.4 37.326496 -2.95 JAK3 kinase, leukocyte)

206285_at 36.4471796 1 -0.6 36.447178 4.7 NPHP1 nephronophthisis 1 Quvenile) calcium channel, voltage- dependent, L type, alpha 1 C

208020_s_at 36.0361554 1 -1.05 36.036156 18.95 CACNA1 C subunit

221183_at 36.020042 1 -4.25 36.020042 12.65 FLJ23604 hypothetical protein FLJ23604

206516_at 33.5453832 1 -1.65 33.545387 -1.55 AMH anti-Mullerian hormone

221035_s_at 33.5453832 1 -12.95 33.545387 -15.15 TEX14 testis expressed sequence 14

Fanconi anemia, complementation

218689_at 33.5453832 1 -4.5 33.545387 -2.9 FANCF group F

220971_at 33,5453832 1 -15.25 33.545387 -15 IL17E ϊnterleukin 17E

Skin-specific protein [Homo

216718_at 33.5453832 1 -8.15 33.545387 -4.55 sapiens], mRNA sequence

221121_at 33.5453832 1 -4.7 33.545387 -6.35 FLJ20527 hypothetical protein FLJ20527

207580_at 33.300298 1 -0.25 33.300297 6.65 MAGEB4 melanoma antigen, family B, 4

Parkinson disease (autosomal

207058_s_at 32.7197595 1 -3.9 32.71976 -3.6 PARK2 recessive, juvenile) 2, parkin natural cytotoxicity triggering

217088_s_at 32.7197595 1 -25.7 32.71976 -28.9 NCR1 receptor 1

211351_at 32.7197595 1 -7.05 32.71976 -2.15 HGC6.1.1 HGC6.1.1 protein

222330_at 32.7197595 1 -0.9 32.71976 -0.6

Homo sapiens mRNA full length insert cDNA clone EUROIMAGE

214905_at 32.7197595 1 -2.7 32.71976 -1.25 46866, mRNA sequence

207735_at 32.7197595 1 -17.75 32.71976 -3.4 FLJ20456 hypothetical protein FLJ20456

202940_at 31.5433977 1 -5.85 31.543398 11.3

220188_at 31.3635792 1 0.1 31.36358 29.1 JPH3 junctophiiin 3

210215_at 30.6391765 1 -10.85 30.639175 7.25 TFR2 transferrin receptor 2

ATP-binding cassette, sub-family B

208288_at 29.8079907 1 -1.85 29.807991 1.75 ABCB 11 (MDR/TAP), member 11

Homo sapiens cDNA FLJ13712 fis, clone PLACE2000394, mRNA

215555_at 29.8079907 1 -2.55 29.807991 -2 sequence chromosome 6 open reading frame

205597 at 28.8189966 1 -2.4 28.818998 -1.9 C6orf29 29

sema domain, immunoglobulin domain (Ig), short basic domain,

206941_x_at 28.8189966 1 -11.1 28.818998 -5.15 SEMA3E secreted, (semaphorin) 3E tumor necrosis factor receptor

211786_at 28.2338379 1 0.45 28.233837 14.9 TNFRSF9 superfamiiy, member 9 213964_x_at 28.1130304 1 -4.9 28.113033 -0.1 221225_at 28.1130304 1 -6.3 28.113033 -10.75 FLJ22955 hypothetical protein FLJ22955 tumor-associated calcium signal

202287_s_at 28.1130304 1 -8.8 28.113033 -2.45 TACSTD2 transducer 2

SA hypertension-associated

205942_s_at 28.1130304 1 -16.4 28.113033 -0.55 SAH homolog (rat) 219730_at 28.1130304 1 -12.05 28.113033 -2.85 FLJ20045 hypothetical protein FLJ20045 205390_s_at 28.1130304 1 -18.85 28.113033 -0.5 ANK1 ankyrin 1 , erythrocytic 211067_s_at 28.0076805 1 -5.85 28.007679 22.05 GAS7 growth arrest-specific 7 chromosome X open reading

219969_at 27.9881502 1 27.98815 6.6 CXorff S frame 15 c

\ ret finger protein-like 1

214120_at 26.6516545 1 -0.85 26.651653 hematopoietic stem cell antigen antisense pro-piatelet basic protein (chemokϊne (C-X-G motif) ligand

214146_s_at 26.6097196 1 -1.4 26.60972 4.05 PPBP 7) 206926_s_at 26.2731793 1 -0.35 26.27318 30.4 IL11 ϊnterieukϊn 11

215977_x_at 26.1657236 1 -13.25 26.165724 -1 GK glycerol kinase chemokine (G-X-C motif)

217028_at 26.1399711 1 0.1 26.13997 6.55 CXCR4 receptor 4 cytochrome P450, subfamily HC (mephenytoin 4-hydroxylase),

215103_at 25.5643891 1 -3.6 25.564388 8.9 CYP2C18 polypeptide 18 peroxisome proliferative activated

208510_s_at 25.3847524 1 -10.65 25.384754 23.15 PPARG receptor, gamma 207458_at 25.3214046 1 -6 25.321405 11.85 MGC3113 hypothetical protein MGC3113 adaptor-related protein complex 4,

220229_s_at 24.0926081 1 -7.2 24.09261 -2.35 AP4E1 epsilon 1 subunit 220673 s at 24.0926081 1 -4.15 24.09261 -6.1 KIAA1622 HEAT-like repeat-containing

protein potassium channel, subfamily K,

205952_at 24.0926081 1 -17.3 24.09261 -9.85 KCNK3 member 3

202178_at 24.0926081 1 -12.1 24.09261 -22.35 PRKCZ protein kinase C, zeta

216558_x_at 24.0926081 1 -7.05 24.09261 -4.9

206939_at 23.7900386 1 -5.7 23.79004 2.45 DCC deleted in colorectal carcinoma

Homo sapiens cDNA: FLJ21911 fis, clone HEP03855, mRNA

216788_at 23.5062956 1 -3.3 23.506298 -9.4 sequence dopa decarboxylase (aromatic L-

205311_at 23.5062956 1 -4.9 23.506298 -21.35 DDC amino acid decarboxylase)

220208_at 23.5062956 1 -18.7 23.506298 -10.25 major histocompatibility complex,

205671_s_at 23.5062956 1 -22.45 23.506298 -10.6 HLA-DOB class II, DO beta

202525_at 22.8195347 1 2.15 22.819534 63.9 PRSS8 protease, serine, 8 (prostasin) mitogen-activated protein kinase

214786_at 22.7202212 1 -0.5 22.720222 8 MAP3K1 kinase kinase 1 olfactory receptor, family 2, i

208508_s_at 20,8031154 1 0.2 20.803116 8.6 OR2J2 subfamily J, member 2 tumor necrosis factor receptor

216325_x_at 19.9304822 1 -0.5 19.930481 9.95 ΪNFRSF6B superfamily, member 6b, decoy

212598_at 19.9271294 1 -5.75 19.92713 10.65 ALFY ALFY

POU domain, class 2, associating

205267_at 19.6173832 1 -1.5 19.617382 0.65 POU2AF1 factor 1 chromosome 11 open reading

215692_s_at 19.5790351 1 -1.55 19.579035 1.3 C11orf8 frame 8 carbohydrate (chondroitin 6)

208252__s_at 19.5129529 1 -0.2 19.512955 5.75 CHST3 sulfotransferase 3

211645_x_at 19.3662215 1 -5.65 19.366222 -5.3 IGKC immunoglobulin kappa constant neurofilament, light polypeptide

221801_x_at 19.3662215 1 -8.4 19.366222 -5.15 NEFL 68kDa

Williams-Beuren syndrome

221581_s_at 19.2726262 1 -3.05 19.272627 -4.75 WBSCR5 chromosome region 5 ankylosis, progressive homolog

220076 at 18.9280187 1 -2.55 18.92802 5.55 ANKH (mouse)

216378_at 18.8995646 1 -5.9 18.899567 -6.35

221081_s_at 18.8995646 1 -16.95 18.899567 -9.2 FLJ22457 hypothetical protein FLJ22457

215382_x_at 18.8164967 1 -0.2 18.816498 9.95 TPS1 tryptase, alpha

Homo sapiens cDNA: FLJ21524 fis, clone COL05921, mRNA

216435_at 18.5868098 1 -2.45 18.586811 5.6 sequence

207278_s_at 18.4752982 1 0.3 18.475298 2.35 CD209 CD209 antigen

214889_at 18.1194171 1 -1.2 18.119417 8.55 DKFZP564J102 DKFZP564J102 protein

Homo sapiens cDNA: FLJ23257 fis, clone COL05579, mRNA

216419_at 17.8159125 1 -13.95 17.815912 -18.25 sequence

PC4 and SFRS1 interacting

210758_at 17,6720655 1 0.4 17.672066 7.1 PSIP1 protein 1

Homo sapiens clone 24533 mRNA

215998_at 17.6194392 1 -3.65 17.61944 2.7 sequence secreted protein of unknown

218406_x_at 17.4433878 1 -4.85 17.443388 20.5 SPUF function

209235_at 16.9788428 1 6.55 16.978842 112.2 CLCN7 chϊoride channel 7 O

220812_s_at 16.7109708 1 0.5 16.710972 8.35 HHLA2 HERV-H LTR-associatSng 2

Homo sapiens mRNA; cDNA

DKFZp564O1763 (from clone

DKFZp564O1763), mRNA

222085_at 16.365081 1 -4.7 16.365082 14.3 sequence

Homo sapiens cDNA FLJ 11353 fis, clone HEMBA1000042, mRNA

215597_x_at 15.3363125 1 -3.35 15.336312 2.75 sequence

206524_at 15.0400946 ~ 1 0.75 15.040094 67.65 T T, brachyury homolog (mouse)

Syntaxin 1B1; syntaxin IB

[Homo sapiens], mRNA

208207_at 14.952542 1 0.2 14.952541 9.6 sequence

220293_at 14,7838446 1 0 14.783645 8.7 FU14298 hypothetical protein FLJ14298

217184_s_at 14.6398349 1 -9.05 14.639836 -8 LTK leukocyte tyrosine kinase solute carrier family 4, sodium bicarbonate cotransporter, member

207603 at 14.6398349 1 -2.5 14.639836 -1.4 SLC4A7 7

206923_at 14.6398349 1 -4.35 14.639836 -0.55 PRKCA protein kinase C, alpha

FYN binding protein (FYB-

205285_s_at 14.4998305 1 1.05 14.49983 17.15 FYB 120/130) phosphatidylinositol (4,5)

213651_at 14.3488136 1 -3.25 14.348813 8.45 PIB5PA bisphosphate 5-phosphatase, A adenosine deaminase, RNA-

209979_at 14.2928346 1 -26.1 14.292835 -9.6 ADARB 1 specific, B1 (RED1 homolog rat) chromosome 12 open reading

220315_at 14.2928346 1 -4.2 14.292835 -2.45 C12orf6 frame 6

214551_s_at 14.2928346 1 -6.75 14.292835 -6.95 CD7 CD7 antigen (p41)

221101_at 14.2928346 1 -16.4 14.292835 -5.75 C14orf113 hypothetical protein FLJ20034

209914_s_at 14.2928346 1 -7.4 14.292835 -2.55 NRXN1 neurexin 1

DEAD/H (Asp-Glu-Ala-Asp/His) box

221630_s_at 14.2928346 1 -1.45 14.292835 -1.15 DDX4 polypeptide 4

214533_at 14.2641275 1 0.5 14.264127 11.95 CMA1 chymase 1, mast cell

207953_at 14.256511 1 -2.6 14.256511 33 AD7C-NTP neuronal thread protein

-4

209819_at 14.0257231 1 -2.85 14.0257225 4.15 HABP4 hyaluronan binding protein 4

NPC1 (Niemann-Pick disease, type

220106_at 13.7657476 1 -0.4 13.765747 7.45 NPC1L1 C1, gene)-like 1

218044_x_at 13.7247124 1 -5.65 13.724712 10.1 PTMS parathymosin

220550_at 13.5534557 1 0.45 13.553455 6.05 FBXO4 F-box only protein 4 matrix metalioproteinase 24

213171_s_at 13.4126167 1 0.9 13.412617 16.55 MMP24 {membrane-inserted)

ESTs, Weakly similar to

SP3 HUMAN TRANSCRIPTION

216403_at 13.3744139 1 -4.2 13.3744135 1.5 bA114G1.1 FACTOR SP3 (SPR-2) [H.sapiens]

220150_s_at 13.300639 1 0.95 13.300639 14.4 C6orf60 hypothetical protein FLJ13942

222320_at 12.6839933 1 -0.15 12.683993 5.2 ESTs

Paraneoplastic associated brain- testis-cancer antigen [Homo

209597_s_at 12.4251078 1 -2.9 12.425108 17.35 sapiens], mRNA sequence

ATP-binding cassette, sub-family

209993_at 12.3557487 1 0.7 12.355749 28.7 ABCB1 B (MDR/TAP), member 1

protein tyrosine phosphatase, non-receptor type 11 (Noonan

205867_at 12.2339686 1 1.35 12.233969 17.15 PTPN11 syndrome 1)

ATPase, Ca++ transporting,

205444_at 12.1629273 1 -3.9 12.162928 12.8 ATP2A1 cardiac muscle, fast twitch 1 immunoglobulin heavy constant

222285_at 12.0266012 1 -0.05 12.026602 6.35 IGHG3 gamma 3 (G3m marker) arginine-glutamic acid dipeptide

200939_s_at 11.9391655 1 -1.95 11.939166 15.85 RERE (RE) repeats 216999_at 11.392903 1 0.6 11.392902 2.85 EPOR erythropoietin receptor

DKFZp434A0131

221191_at 11.337555 1 -0.45 11.337555 11.65 DKFZP434A0131 protein 203193_at 11.2841109 1 -3.8 11.284111 27.55 ESRRA estrogen-related receptor alpha growth hormone releasing

214524_at 11.213022 1 -0.95 11.213022 9.85 GHRH hormone 221330_at 11.1848918 1 -4.45 11.184892 22.4 CHRM2 cholinergic receptor, muscarinic 2 Os advanced glycosylation end 00

217046_s_at 11.1412525 1 -5.3 11.141253 2.15 AGER product-specific receptor serum response factor (c-fos serum response element-binding

202400_s_at 11.0458506 1 -20.4 11.045851 4.05 SRF transcription factor)

Beta Ii spectrin [Homo sapiens],

215918_s_at 11.033144 1 1.75 11.033144 20.55 SPTBN1 mRNA sequence 216817_s_at 10.9883956 1 0.25 10.988396 4.95 6M1 -16*01 219722_s_at 10.9316656 1 0.95 10.931666 15.9 MGC4171 hypothetical protein MGC4171

Homo sapiens mRNA; cDNA

DKFZp761L23121 (from clone

DKFZp761L23121), mRNA

216147_at 10.8977249 1 -3.45 10.897724 10.75 sequence 203507_at 10.8315877 1 3.75 10.831588 46.55 GD68 CD68 antigen

Homo sapiens cDNA: FLJ21695 fis, clone COL09653, mRNA

216109_at 10.742313 1 0.3 10.742313 8.25 sequence 216522_at 10.7289135 1 4.25 10.728914 45.35 215670 s at 10.6692805 1 -5.9 10.669279 39.1 SCAND2 SCAN domain containing 2

proline-rich protein BstNI subfamily

207752_x_at 10.6636979 1 -4.25 10.663698 34.1 PRB1 1 211307_s_at 10.4603621 1 -13.35 10.460362 -1.25 FCAR Fc fragment of IgA, receptor for 208376_at 10.41762 1 -3.3 10.41762 19.5 CCR4 chemokine (C-C motif) receptor 4 variable charge protein on X with

207281_x_at 10.4106363 1 1.55 10.410637 17.95 VCX-2r two repeats

210163_at 10.0888819 1 -1.95 10.088882 3.5 CXCL11 chemokine (C-X-C motif) ligand 11 220745_at 9.95050706 1 -4.9 9.950507 11.85 !L19 interleukin 19 215086_at 9.9134473 1 -3.35 9.913448 -0.9 IBTK inhibitor of Bruton's tyrsoine kinase caspase 10, apoptosis-related

210708_x_at 9.9134473 1 -9.6 9.913448 -14.1 CASP10 cysteine protease 208542 x at 9.9134473 1 -18.65 9.913448 -15.4 ZNF208 zinc finger protein 208

ESTs, Moderately similar to B

Chain B, Crystal Structure Of

Human Carbonmonoxy-

Haemoglobin At 1.25 A Resolution

217683_at 9.9134473 1 -15.25 9.913448 -0.75 [H.sapiens]

211013_x_at 9.87228203 1 -9.7 9.872283 -17.7 PML promyelocyte leukemia

207712_at 9.86988365 1 1.1 9.869883 11.25 BAGE B melanoma antigen

211117_x_at 9.86371034 1 -1.3 9.86371 26.7 ESR2 estrogen receptor 2 (ER beta)

220659_s_at 9.86112536 1 0.05 9.861126 76,55 FLJ 10925 hypothetical protein FLJ10925

211638_at 9.74052547 1 -1.35 9.740525 -0.95 IGHM immunoglobulin heavy constant mu

220269_at 9.70900259 1 -5.35 9.7090025 7.95 FLJ23049 hypothetical protein FLJ23049

206537_at 9.68610164 1 -8.1 9.686102 -4.35 BIRC4 baculoviral IAP repeat-containing 4

221651_x_at 9.68610164 1 -18.5 9.686102 -48.65 IGKC immunoglobulin kappa constant

208518_s_at 9.50609238 1 1.15 9.506093 15.95 PER2 period homolog 2 (Drosophila)

205620_at 9.42524474 1 1.35 9.425244 29.95 F10 coagulation factor X

221324 at 9.32431881 1 -3.45 9.324319 14.15 TAS2R1 taste receptor, type 2, member 1

AFFX-r2-Bs-phe-

M_at 9.24282362 1 0.05 9.242825 1.75

Homo sapiens mRNA; cDNA DKFZp586J0323 (from clone DKFZp586J0323), mRNA

215447 at 9.22117853 1 -0.1 9.221178 2.3 sequence

205336_at 9.21203432 1 2.4 9.212034 38.55 PVALB parvalbumϊn glucosaminyl (N-acetyl) transferase

211020_at 9.10385692 1 -0.75 9.103857 5.35 GCNT2 2, l-branching enzyme rhodopsin (opsin 2, rod pigment) (retinitis pigmentosa 4,

206455_s_at 9.02923999 1 2.15 9.02924 39.7 RHO autosomal dominant) 214312_at 9.00711012 1 2.2 9.007111 20.45 FOXA2 forkheadl box A2 Homo sapiens cDNA FLJ25582 fls, clone JTH09579, mRNA

221621_at 8.9881084 1 . 1.8 8.988109 17.05 y sequence

ESTs, Weakly similar to cytokine receptor-like factor 2; cytokine receptor CRL2 precusor [Homo

217699_at 8.87843636 1 -8.35 8.878436 4.4 sapiens] [H.sapiens] 215886_x_at 8.71282816 1 1.85 8.712828 17.85 UBH1 ubiquϊtϊn specific protease 12 211129_x_at 8.62847776 1 -1.55 8.628477 8.55 ED1 ectodermal dysplasia 1, anhidrotic latent transforming growth factor

204442_x_at 8.62068126 1 1.4 &620681 35.2 LTBP4 beta binding protein 4 221420_at 8.49672765 1 -2.15 8.496728 6 a disintegπn and

208227_x_at 8.45895017 1 5 8.45895 44.25 ADAM22 metalloproteinase domain 22 212070_at 8.43009261 1 0.5 8.430093 17.65 GPR56 G protein-coupled receptor 56 regulator of G-protein signalling

220300_at 8.23223335 1 2.2 8.232233 20.6 RGS3 3 peroxisome proliferative activated

206870_at 8.14121356 1 1.6 8.141214 12.7 PPARA receptor, alpha variable charge protein on X with

220887_at 8.11891032 1 3.45 8.11891 28.7 PLPL eight repeats 214456_x_at 8.03049254 1 0.75 8.030492 5.25 SAA2 serum amyloid A2

222364_at 8.0209588 1 1.8 8.020958 23.7 ESTs

Homo sapiens cDNA: FLJ21385 fls, clone COL03356, mRNA

216758_at 8.01076332 1 -1.55 8.010763 2.85 sequence transmembrane gamma-

207291 at 7.99970336 1 -3.75 7.9997034 2.45 TMG4 carboxyglutamic acid protein 4

206408_at 7.99912472 1 3.1 7.9991245 29.55 LRRTM2 KIAA0416 protein tumor necrosis factor receptor

211282_x_at 7.94840079 1 -1.75 7.9484005 14 TNFRSF25 superfamily, member 25 chromosome 11 open reading

205413_at 7.92725303 1 -2.6 7.9272532 0.95 C11orf8 frame 8

Homo sapiens cDNA FLJ20286 fis, clone HEP04358, mRNA

216669_at 7,91741443 1 1.5 7.9174147 13.1 sequence

207299_s_at 7.8455396 1 -0.2 7.84554 5.75 GRM1 glutamate receptor, metabotropic 1 caicyon; D1 dopamine receptor-

219896 at 7.80378466 1 -1.15 7.8037844 13.65 CALCYON interacting protein thrombopoietin {myeloproliferative leukemia virus oncogene ligaπd, megakaryocyte growth and

211154_at 7.74985759 1 -0.8 7.749858 10.8 THPO development factor) cell recognition molecule

220436_at 7.74725534 1 3.15 7.747256 26.65 CASPR3 CASPR3

213662_at 7.72592805 1 -0.15 7.7259283 5.35 FLJ20152 hypothetical protein FLJ20152 lymphocyte antigen 6 complex,

221338_at 7.69142996 1 -0.2 7.6914296 23.25 LY6G6E locus G6E 220505_at 7.66210416 1 -1.65 7.662104 -2.8 LOC51198 susceptibility protein NSG-x 211466_at 7.66210416 1 -3.2 7.662104 -1.8 NFIB nuclear factor I/B ATPase, H+ transporting,

205703_at 7.65727969 1 -0.1 7.6572795 4.05 ATP6V0A2 lysosomal VO subunit a isoform 2 potassium inwardly-rectifying

207110_at 7.57162829 1 -6.45 7.5716286 0.75 KCN J12 channel, subfamily J, member 12 220401_at 7.5659161 1 -0.4 7.565916 7.05 FLJ21369 hypothetical protein FLJ21369 216030_s_at 7.45634159 1 0.05 7.4563417 1.2 SEMG2 semenogelin il 207579_at 7.44778109 1 0.4 7.447781 3.25 MAGEB3 melanoma antigen, family B, 3 220798_x_at 7.44613064 1 0.8 7.4461308 12.85 FLJ 11535 hypothetical protein FLJ11535 cytochrome P450, subfamily I (aromatic compound-ϊnducϊble),

205749_at 7.44553207 1 3.3 7.445532 30 CYP1A1 polypeptide 1 209470 s at 7.39168208 1 1.05 7.391682 11.25 GPM6A glycoprotein M6A

calcium channel, voltage-

210185_at 7.34143046 1 5.25 7.34143 42.45 GACNB1 dependent, beta 1 subunit 220490 at 7.33961312 1 1.9 7.339613 16.5 PRO0899 hypothetical protein PRO0899 ESTs, Moderately similar to kruppel-like zinc finger protein

222271 at 7.3376688 1 -0.05 7.337669 3.3 [Homo sapiens] [H.sapiens] Homo sapiens (clone 83B3E13) Huntϊngton's disease candidate region mRNA fragment, mRNA

217257 at 7.29068314 1 1.3 7.290683 9.3 sequence solute carrier family 10 (sodium/bile acid cotransporter family), member

207185_at 7.2659204 1 4.25 7.2659206 34.5 SLC10A1 1 204989_s_at 7.25505046 1 -5.05 7.25505 2.8 1TGB4 integrin, beta 4 testes-specific heterogenous

207208_at 7.22690822 1 2.1 7.2269077 17.65 HNRNPG nuclear ribonucleoprotein G-T killer cell lectin-like receptor -

210690_at 7.21915557 1 0.05 7.2191553 3.95 KLRC4 subfamily C, member 4 K 207879_at 7.18563084 1 0.65 7.185631 1.15 ATPase, mRNA sequence matrix metailoprotesnase 3

205828_at 7.16593325 1 41 7.165933 306.5 MMP3 (stromelysin 1, progelatinase) 210035 s at 7.10560242 1 0.2 7.1056023 4.4 RPL5 ribosomai protein L5 ESTs, Weakly similar to ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome; Ubiquitously transcribed TPR gene on Y chromosome [Homo sapiens]

215213_at 7.10560242 1 -7.05 7.1056023 0.6 [H.sapiens]

220858_at 7.0778623 1 -1.25 7.077862 9.4 PRO0618 PRO0618 protein ESTs, Moderately similar to hypothetical protein FLJ20378

217578_at 7.03135538 1 1.6 7.031356 11.35 [Homo sapiens] [H.sapiens]

204080_at 7.01305105 1 -1.75 7.013051 52.4 TOE1 hypothetical protein FLJ13949

221062 at 6.97137494 1 -3.55 6.971375 8.2 HS3ST3B1 heparan sulfate (glucosamine) 3-O-

sulfotransferase 3B1

222102_at 6.93212569 1 -12.3 6.9321256 -3.05 GSTA3 glutathione S-transferase A3 serine protease inhibitor. Kazal

206310_at 6.91202048 1 2.8 6.9120207 20.15 SP1NK2 type, 2 (acrosin-trypsin inhibitor) erythrocyte membrane protein

220119_at 6.91197642 1 1.15 6.911976 8.6 EPB41L4A band 4.1 like 4A dyneϊn, axonemai, light

205186_at 6.7990498 1 3.35 6.7990494 28.45 DNALH intermediate polypeptide 1 solute carrier family 22 (organic

210343_s_at 6.77727235 1 0.5 6.777272 20.3 SLC22A6 anion transporter), member 6 mediator of RNA polymerase Il transcription, subunit 6 homolog

207078_at 6.72501722 1 1.7 6.725017 11.4 MED6 (yeast)

PRO2007 [Homo sapiens], mRNA

207479_at 6.65244857 1 0.8 6.652449 16.3 sequence 214651_s_at 6.6238621 1 -0.5 6.6238623 5.4 HOXA9 homeo box A9 -4

ELK4, ETS-domain protein (SRF

206919_at 6.58212955 1 0.25 6.5821295 14.75 ELK4 accessory protein 1 ) guanine nucleotide exchange factor

204681_s_at 6.57282872 1 -0.7 6.5728283 6.75 GFR for Rap1 ; M-Ras-regulated GEF Homo sapiens clone GLSH-3

215811_at 6.55980914 1 3.9 6.5598087 39.1 similar to gliadin mRNA sequence Homo sapiens clone

215653_at 6.51516925 1 -1.25 6.515169 1.65 IMAGE:248602, mRNA sequence 210670_at 6.47406702 1 2 6.4740667 13 PPY pancreatic polypeptide thyroid hormone receptor- associated protein, 150 kDa

217847_s_at 6.46158179 1 -8.95 6.461581 21.1 TRAP 150 subunit

Homo sapiens cDNA: FLJ23194 fis, clone REC00490, mRNA

216795_at 6.45101549 1 0.35 6.4510155 8.5 sequence 205976_at 6.42375335 1 -1.35 6.4237533 4.9 KIAA0971 KIAA0971 protein 220122_at 6.35708563 1 -2.35 6.3570857 5.15 FLJ22344 hypothetical protein FLJ22344 217343 at 6.31314106 1 1.45 6.313141 9.7 COL4A6

solute carrier family 34 (sodium

204124_at 6.30738287 1 0.8 6.307383 9.55 SLC34A2 phosphate), member 2

Homo sapiens cDNA FLJ11627 fis, clone H EMBA1004225, mRNA

215469_at 6.30630713 1 0.55 6.306307 3.4 sequence 221812_at 6.30607511 1 -1.1 6.3060756 -4.45 KIAA1332 KIAA1332 protein mitogen-activated protein kinase

209952_s_at 6.30233674 1 2.15 6.3023367 14.3 MAP2K7 kinase 7 2G7902_at 6.28370949 1 -11.95 6.2837095 -0.05 1L5RA ϊnterieukiπ 5 receptor, afpha

UDP glycosyiiransferase 2 family,

217175_at 6.26476893 1 -3.6 6.264769 2.9 UGT2B15 polypeptide B15 leukocyte cell-derived chemotaxin

207409_at 6.24348491 1 -2.15 6.243485 4.95 LEGT2 2 206143_at 6.17798263 1 -0.3 6.1779833 -1.15 SLC26A3 solute carrier family 26, member 3 valosiπ-containing protein

(p97)/p47 complex-interacting

219810_at 6.16797721 1 -7.45 6.1679773 11.95 VCIP135 protein p135 220777_at 6.13595664 1 -1.65 6.1359572 12.65 KIF13A kinesin family member 13A 205642_at 8.12247962 1 -3.1 6.1224794 20,65 CEP1 centrosomaf protein 1 214655_at 6.11538856 1 -6.8 6.1153884 -1.1 GPR6 G protein-coupled receptor 6 214675_at 6.07191324 1 -2.05 6.071913 8.05 KIAA0169 KIAA0169 protein 209125_at 6.04979065 1 1.2 6.0497913 8.85 KRT6A keratin 6A

ESTs, Moderately similar to hypothetical protein FLJ20294

222332_at 6.01909564 1 -1.95 6.019096 8.05 [Homo sapiens] [H.sapiens] 210729_ai 5.97478205 1 -0.15 5.974782 2.25 NPY2R neuropeptide Y receptor Y2 hepatocyte nuclear factor 4,

216889_s_at 5.97377941 1 6.3 5.9737797 42.3 HNF4A alpha regenerating islet-derived 1 alpha

(pancreatic stone protein,

209752_at 5.96087397 1 -1.95 5.9608736 13.8 REG1A pancreatic thread protein)

Homo sapiens cDNA FLJ14343 fis, done THYRO1000916, mRNA

214964_at 5.92289401 1 3.35 5.922894 20.6 sequence 206718 at 5.90549356 1 9.45 5.9054937 60.85 LM01 UM domain oniy 1 (rhombotin 1)

ABO blood group (transferase A, alpha 1-3-N- acetylgalactosaminyltransferase; transferase B, alpha 1 «3-

216929_x_at 5.89781305 1 2 5.897813 12.5 ABO galactosyltransferase)

220414_at 5.86573688 1 1.2 5.865737 8.3 CLSP calmoduiin-Iike skin protein

208107_s_at 5.83385684 1 3.65 5.8338566 30.05 LOC81691 exonuclease NEF-sp chemokine (C-X-C motif) iϊgand 6

(granulocyte chemotactic protein

206336_at 5.78578974 1 49.15 5.78579 302 CXCL6 2)

207674_at 5.77717199 1 -1.55 5.777172 8.45 FCAR Fc fragment of IgA, receptor for 214991_s_at 5.71918059 1 3.75 5.7191806 21.35 PIGO phosphatidylinositol glycan class O cyciin-dependent kinase inhibitor

207530_s_at 5.67208086 1 -0.65 5.672081 3.95 CDKM2B 2B (p15, inhibits CDK4)

Putative zinc finger protein H140

215523_at 5.66436265 1 -0.45 5.6643624 5.5 [Homo sapiensj, mRNA sequence -4 219597_s_at 5.64973239 1 1 5.6497326 12.8 DUOX1 duaf oxidase 1 215142_at 5.64013329 1 1.05 5.640133 22 HYPM Huntingtin interacting protein IVJ 221153_s_at 5.62477303 1 1.5 5.624773 9.5 LOC57090 HRPAP20 short form transient receptor potential cation channel, subfamily M,

220226_at 5.62448947 1 2.95 5.6244893 16.35 TRPM8 member 8 215915_at 5.61217365 1 2.85 5.612173 16.75 CED-6 CED-6 protein sulfotransferase family, cytosolic,

205342_s_at 5.56947391 1 -0.65 5.5694733 4.7 SULT1C1 1C, member 1 216488_s_at 5.55990864 1 -9.35 5.559909 13.65 ATP11A ATPase, Class Vl, type 11 A 200724_at 5.5591047 1 4.3 5.559104 25.65 RPL10 ribosomal protein L10 axonal transport of synaptic

203849_s_at 5.54242396 1 0 5.5424237 19.2 ATSV vesicles tumor necrosis factor (ligand)

202687_s_at 5.5298889 1 1.15 5.529889 4.75 TNFSF10 superfamϊly, member 10

222342_at 5.52567213 1 -1.95 5.5256724 13.1

Hypothetical protein [Homo

215242 at 5.50152491 1 2.05 5.501525 15 sapiens], mRNA sequence

Homo sapiens cDNA FLJ12003 fis, clone HEMBB1001537, mRNA

215958_at 5.48444943 1 1.55 5.4844494 8.45 sequence

219546_at 5.45940966 1 -2.4S 5.459409 6 BIKE BMP-2 inducible kinase

MCF.2 celi line derived

208017_s_at 5.44624992 1 -1.85 5.44625 6.35 MCF2 transforming sequence 213920_at 5.44146378 1 1.25 5.4414644 8 CUTL2 cut-like 2 (Drosophila)

Homo sapiens cDNA FLJ31636 fis, clone NT2RI2003481, mRNA

215423_at 5.40972675 1 0.15 5.409727 25.9 sequence 207815_at 5.39076849 1 3.25 5.3907685 19.75 PF4V1 platelet factor 4 variant 1 butyrophilin, subfamily 2, member

208585_at 5.39056965 1 6.1 5.3905697 41.5 BTN2A3 A3 219387_at 5.39010728 1 0.9 5.3901076 6.6 LOC55580 hypothetical protein LOC55580 206602_s_at 5.384226 1 4.6 5.3842263 25.95 HOXD3 homeo box D3 219906_at 5.36353479 1 -0.65 5.363535 9.6 FLJ 10213 hypothetical protein FLJ10213 -4 colony stimulating factor 3

203591_s_at 5.34137527 1 6.75 5.3413754 37.4 GSF3R receptor (granulocyte)

Homo sapiens cDNA FLJ14061 fis, clone HEMBB1000749, mRNA

216158_at 5.30300936 1 -1.75 5.3030095 8.95 sequence a disintegrin and metalloproteinase

207664_at 5.28739371 1 -3.3 5.2873936 0.75 ADAM2 domain 2 (fertilin beta)

Homo sapiens clone HQ0085,

215644_at 5.25583646 1 -3.15 5.2558365 25.75 mRNA sequence 205392_s_at 5.2469101 1 0.05 5.24691 40.5 CCL14 chemokϊne (C-C motif) ligaπd 14

N-acylsphingosine amidohydroiase (acid

210979_at 5.24533539 1 1.65 5.2453356 9.35 ASAH1 ceramϊdase) 1 203407_at 5.22844684 1 1.55 5.228447 8.75 PPL periplakin secreted protein of unknown

213673_x_at 5.22840439 1 2.3 5.228404 15.85 SPUF function 216668 at 5.22689637 1 0.7 5.2268963 28.55

ESTs, Highly similar to

CFTRJ-IUMAN Cystic fibrosis transmembrane conductance regulator (CFTR) (cAMP- dependent chloride channel)

215703_at 5.21227378 1 0.8 5.2122736 6.15 CFTR [H.sapiens]

210493_s_at 5.19729377 1 0.15 5.1972938 -2.85 KIAA0626 KIAA0626 gene product

203771_s_at 5.18706022 1 -6 5.187061 -3.05 BLVRA biliverdin reductase A

Homo sapiens clone 24438 mRNA

215457_at 5.18706022 1 -2.9 5.187061 -1.9 sequence

214145_s_at 5.18706022 1 -10.85 5.187061 -1.9 KIAA0599 KIAA0599 protein

207487_at 5.17652163 1 1.15 5.176522 8.75 FLJ 11996 hypothetical protein FLJ11996

215889_at 5.14726079 1 3.25 5.1472607 16.95 SKIL SKI-Iike

220146_at 5.14564387 1 0.5 5.14S644 9.55 TLR7 toil-Hke receptor 7

Homo sapiens cDNA: FLJ21461 fis, clone COL04727, mRNA

216117_at 5.13193327 1 0.65 5.131933 14.4 sequence

222355_at 5.11946926 1 0.3 5.119469 9.25 ESTs

204447_at 5.11794862 1 10.15 5.1179485 52.45 PrøSAPiPI ProSAPiPI protein

207850_at 5.11617001 1 15.2 5.11617 85.45 CXCL3 chemokine (C-X-G motif) Iigand 3 proteasome (prosome, macropain)

214289_at 5.10546576 1 -6.7 5.1054654 7.05 PSMB1 subunit, beta type, 1

206569_at 5.10482477 1 7.6 5.104825 43.7 IL24 ϊnterieukϊn 24

220061_at 5.07937016 1 -15.55 5.0793705 -17.85 FLJ20581 hypothetical protein FLJ20581

203863_at 5.07937016 1 -10.15 5.0793705 -7.3 ACTN2 actinin, alpha 2

220222_at 5.07937016 1 -22.45 5.0793705 -14.95 PRO1905 hypothetical protein PR01905 matrix metalloproteinase 13

205959_at 5.07937016 1 -5.95 5.0793705 -10.95 MMP13 (collagenase 3)

221057_at 5.0726946 1 -0.6 5.0726943 -2.1 SPATA1 spermatogenesis associated 1

220850_at 5.06899306 1 -2.95 5.068993 3.9 MORC microrchidia homolog (mouse)

Homo sapiens cDNA: FLJ21198 fis, clone COL00220, mRNA

216749_at 5.05874759 1 -0.6 5.0587473 5.7 sequence

sperm adhesion molecule 1 (PH-

20 hyaiuronidase, zona pellucida

210536_s_at 5.05420342 1 1.75 5.054203 9.85 SPAM1 binding)

Homo sapiens cDNA FLJ11956 fis, clone HEMBB1000893, mRNA

215611_at 5.03770801 1 3.25 5.0377083 16.95 sequence 211029_x_at 5.03401414 1 -13.5 5.034014 10.6 FGF18 fibroblast growth factor 18

Unnamed protein product [Homo

208301_at 5.02781508 1 3.6 5.0278153 18.15 sapiens], mRNA sequence 206954_at 5.02129537 1 -1.65 5.0212955 11.3 WIT-1 Wilms turnor associated protein 221392_at 5.00068932 1 4.55 5.0006895 23.65 TAS2R4 taste receptor, type 2, member 4 synaptic nuclei expressed gene

215350_at 4.99304455 1 1.65 4.9930444 8.6 SYNE-1 1 203780_at 4.98238257 1 0.25 4.9823823 0.9 EVA1 epithelial V-Iike antigen 1 215094_at 4.95556545 1 2.15 4.9555655 11.05 LOC152185 hypothetical protein AY099107 219256_s_at 4.94598173 1 -8.4 4.945982 0.85 FLJ20356 hypothetical protein FLJ20356

Homo sapiens cDNA: FLJ20953 fis, clone ADSE01979, mRNA

216746_at 4.94060307 1 4.05 4.9406033 19.6 sequence 208917_x_at 4.85324843 1 7.8 4.8532486 42.1 FLJ13052 NAD kinase 208375_at 4.85087156 1 1.75 4.8508716 8.75 1FNA1 interferon, alpha 1

GiOT-2 for gonadotropin inducible

206810_at 4.845926 1 2.55 4.8459263 12.8 GIOT-2 transcription repressor-2 206223_at 4.84418526 1 6.9 4.844185 36 KPI2 kinase phosphatase inhibitor 2 207652_s_at 4.82503801 1 0.75 4.825038 18.8 CMKLR1 chemokine-like receptor 1 221683_s_at 4.80327334 1 0.15 4.803273 3.45 FLJ13615 hypothetical protein FLJ13615 211431_s_at 4.7862956 1 3.05 4.7862954 20.7 TYRO3 TYRO3 protein tyrosine kinase solute carrier family 7 (cationic amino acid transporter, y+ system),

217248_s_at 4.77950053 1 4.85 4.7795 25.35 SLC7A8 member 8 major histocompatibility

212671_s_at 4.71827314 1 3.55 4.718273 18.65 HLA-DQA1 complex, class If, DQ alpha 1 cell adhesion molecule with homology to L1 CAM (close

204591 at 4.71353822 1 -3 4.7135386 -2 CH L1 homolog of L1)

202901 _x_at 4.70787315 1 2.75 4.707873 14.85 CTSS cathepsin S

ATP-binding cassette, sub-family A

217504_at 4.700398 1 1.95 4.700398 10.5 ABCA6 (ABC1), member s 221716_s_at 4.66155207 1 -0.3 4.661552 18.95 PRTD-NY3 hypothetical protein PRTD-NY3 214974_x_at 4.65334791 1 7.5 4.653348 36.75 CXCL5 chemokine (C-X-C motif) iigand 5 205919_at 4.64206445 1 4.5 4.6420646 23.5 HBE1 hemoglobin, epsilon 1 217302_at 4.63787137 1 5.45 4.6378717 26.4 208027_s_at 4.63719911 1 1.35 4.6371994 5.75 TLL2 tolloid-like 2 cytochrome P450, subfamily NIA,

214235_at 4.63667715 1 -2.3 4.6366773 12.25 CYP3A5P2 polypeptide 5 pseudogene 2 solute carrier family 7 (cationic amino acid transporter, y+ system),

216604_s_at 4.60026028 1 13.75 4.6002607 66.6 SLC7A8 member 8 208475_at 4.59734356 1 0.6 4.597344 7 FLJ 10210 hypothetical protein FLJ10210

DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase

208159_x_at 4.59533966 1 8.05 4.59534 49.4 DDX11 homolog, S. cerevisiae) -4 220169_at 4.58230518 1 3.15 4.582305 16.55 FLJ23235 hypothetical protein FLJ23235 217209_at 4.57476201 1 2.6 4.574762 14.3 214058_at 4.5677158 1 6.15 4.567716 28.2

Homo sapiens mRNA; cDNA DKFZp434D115 (from clone

215133_s_at 4.5671196 1 4.9 4.5671196 23.7 DKFZp434D115), mRNA sequence 220575_at 4.56671357 1 6.7 4.5667133 32.8 FLJ 11800 hypothetical protein FLJ11800 alcohol dehydrogenase IB (class I),

209613_s_at 4.54852789 1 1.2 4.5485277 7.85 ADH 1 B beta polypeptide

MOZ/CBP [Homo sapiens], mRNA

216361_s_at 4.54528023 1 2.4 4.54528 10.7 sequence 216494_at 4.5431651 1 0.05 4.543165 -0.1 206884_s_at 4.49090944 1 -2.6 4.4909096 2.4 SCEL sciellin

5-hydroxytrypiamϊne (serotonin)

207577_at 4.49088207 1 4.9 4.490682 23.45 HTR4 receptor 4 207589_at 4.48355801 1 3.95 4.4835577 30.2 ADRA1B adrenergic, aipha-1B-, receptor 219702 at 4.48106237 1 -0.4 4.481062 20.5 PLAC1 placenta-specific 1

Homo sapiens mRNA; cDNA DKFZp434J1630 (from clone DKFZp434J1630), mRNA

216686_at 4.47498405 1 -2.1 4.474984 -2.8 sequence

207938_at 4.45939377 1 7.7 4.4593935 36.25 PI15 protease inhibitor 15 transmembrane phosphatase with

220205_at 4.44065154 1 2.55 4.4406514 12.5 TPTE tensin homology

205366_s_at 4.43179486 1 1.95 4.431795 36.6 HOXB6 homeo box B6

204525_at 4.41795634 1 3.55 4.4179564 16.45 KIAA0783 KIAA0783 gene product

205691_at 4.41493706 1 3.3 4.414937 14.7 SYNGR3 synaptogyrin 3

208565_at 4.37410078 1 1.65 4.374101 7.45 MC5R melanocortin 5 receptor

211506_s_at 4.37283433 1 146.35 4.3728347 733.65 1L8 interleukin 8

215187_at 4.36999626 1 1.75 4.369996 7.7 FLJ 11292 hypothetical protein FLJ11292

213054_at 4.35661865 1 0.4 4.356619 8.35 KIAA0841 KIAA0841 protein

217767_at 4.32663311 1 11.05 4.326633 51.85 C3 complement component 3

216082_at 4.30710333 1 2.05 4.307103 16.85 NEU3 sialidase 3 (membrane sialidase) O neuropeptide Y receptor Y6

210444_at 4.30679008 1 0.85 4.30679 17.9 NPY6R (pseudogene)

206715_at 4.29694277 1 2.05 4.2969427 14.5 TFEC transcription factor EC ESTs, Moderately similar to hypothetical protein FLJ20234

222375_at 4.29332632 1 2.15 4.2933264 15.1 [Homo sapiens] [H.sapiens]

205538_at 4.28920319 1 1.65 4.289203 23.65 CORO2A coronin, actin binding protein, 2A

215251_at 4.28196762 1 6.35 4.281967 35.6

217345_at 4.27730988 1 6.05 4.2773104 28.6 SMNP

215417_at 4.27508973 1 4.1 4.2750897 17.85 ESTs

Homo sapiens mRNA; cDNA

DKFZp564B076 (from clone

217628_at 4.27263838 1 1.1 4.2726383 4.55 DKFZp564B076), mRNA sequence

214793_at 4.26886545 1 9.3 4.2688656 51.05 DUSP7 dual specificity phosphatase 7

210309_at 4.26794351 1 0.95 4.267944 0.15 RECQL5 RecQ protein-like 5 calbindin 3, (vitamin D-dependent

207885_at 4.24802618 1 -4.95 4.2480264 8.35 CALB3 calcium binding protein)

221947 at 4.23979789 1 -1.15 4.239798 -13.95 IL-17RC interieukin 17 receptor C

proSine-serine-threonine

211178_s_at 4.23791039 1 3.65 4.2379103 15.95 PSTPIP1 phosphatase interacting protein 1 215532_x_at 4.23480331 1 5.35 4.234803 24.4 KIAA1473 KIAA1473 protein indoleamine-pyrroie 2,3

210029_at 4.22575968 1 3.8 4.2257595 35.6 INDO dioxygenase

34689_at 4.21894132 1 -4.25 4.218941 33.85 drn3 three prime repair exonuclease 1

217473_x_at 4.2127683 1 1.75 4.212768 28.75 chromosome 11 hypothetical

219430_at 4.14742034 1 8.65 4.1474204 40.3 C11ORF4 protein ORF4 218410_s_at 4.1469219 1 1.8 4.146922 15.65 MGC4692 hypothetical protein MGC4692 prostaglandin E receptor 3

210832_x_at 4.11553575 1 2.1 4.1155357 14.25 PTGER3 (subtype EP3) sodium channel, voltage-gated, 210383 at 4.10593322 1 4.65 4.105933 22 SCN1A type I, alpha polypeptide

Homo sapiens cDNA FLJ 1 1578 fis, clone HEMBA1003571, mRNA

215853_at 4.09608831 1 2.1 4.0960884 11.8 sequence 220225_at 4.06518172 1 0.55 4.0651817 -0.2 IRX4 iroquois homeobox protein 4 214572_s_at 4.06381171 1 -4.15 4.063812 11.35 INSL3 insulin-like 3 (Leydig cell) 220693_at 4.05179951 1 -2.3 4.0517993 1.55 HSPC048 HSPC048 protein phosphodiesterase 5A, cGMP-

206757_at 4.04269415 1 1.6 4.042694 7.15 PDESA speciflc 214361_s_at 4.04257217 1 -3.45 4.042572 11.5 RGS12 regulator of G-protein signalling 12

Usher syndrome 1 C (autosomal

205137_x_at 4.01212016 1 -2.95 4.0121202 7.7 USH1C recessive, severe) 206048 at 4.00055039 1 5.6 4.0005503 24.7 ZNF339 zinc finger protein 339 integrin, beta 1 (fibronectin receptor, beta polypeptide. antigen GD29 Includes MDF2,

215878_at 3.99895728 1 1.5 3.9989572 6.7 ΪTGB1 MSK12) 206893 at 3.97512782 1 0.5 3.9751277 2 SALL1 sal-like 1 (Drosophila)

Homo sapiens cDNA: FLJ21670 fis, clone COL09010, mRNA

216094_at 3.97081986 1 -0.2 3.97082 9.05 sequence 207217 s at .3.96919154 1 0.65 3.9691916 16.1 NOX1 NADPH oxidase 1

220720_x_at 3.96859694 1 8.15 3.968597 33.1 FLJ 14346 hypothetical protein FLJ 14346 natural killer cell receptor, immunoglobulin superfamily

207840_at 3.95517259 1 4.6 3.9551725 36.1 BY55 member 215δO3_x_at 3.95348281 1 7.05 3.9534826 30.9 GGT2 garnma-glutamyitransferase 2 solute carrier family 1 (glutamate

207355_at 3.94960799 1 2.55 3.949608 11.5 SLC1A7 transporter), member 7 220426 at 3.94412529 1 19.3 3.9441252 81.9 MGC5356 hypothetical protein MGC5356 caspase 2, apoptosϊs-reiated cysteine protease (neural precursor cell expressed, developmentally down-reguiated

209811_at 3.94073109 1 2.6 3.940731 5.2 CASP2 2} 214411_x_at 3.94002844 1 2.8 3.9400282 15.55 CTRB1 chymotrypsinogen B1 216476_at 3.93607049 1 -10.25 3.9360704 76.75 proprotein convertase

205559_s_at 3.92582494 1 1.7 3.925825 7.7 PCSK5 subtilisin/kexin type 5 κ> 215328_at 3.92553544 1 5.25 3.9255357 17.05 KIAA0953 KIAA0953 protein Homo sapiens mRNA; cDNA DKFZp586E2317 (from clone DKFZp586E2317), mRNA

215029_at 3.91899669 1 2.1 3.9189968 9.1 sequence protein tyrosine phosphatase, non¬

204852_s_at 3.87809355 1 -0.4 3.8780935 -8.95 PTPN7 receptor type 7 proteinase 3 (serine proteinase, neutrophil, Wegener

207341_at 3.87253845 1 7.2 3.8725386 29.55 PRTN3 granulomatosis autoantigen) fascin homolog 2, actin-bundling protein, retinal (Strongylocentrotus

207204_at 3.86856153 1 -3.55 3.8685613 15.2 FSCN2 purpuratus) adaptor-related protein complex 1 ,

214341_at 3.86426277 1 0.35 3.8642628 -0.95 AP1G2 gamma 2 subunit ADP-ribosylation factor guanine nucleotide-exchange factor 2

215927 at 3.85198979 1 0.35 3.8519897 7.9 ARFGEF2 (brefeldin A-inhibited)

210449_x_at 3.84987716 1 17.05 3.8498774 65.45 MAPK14 mitogen-activated protein kinase 14

220117_at 3.83268169 1 4.5 3.8326817 19.65 FLJ22419 hypothetical protein FLJ22419 hydroxyacid oxidase (glycolate

220224_at 3.83098477 1 -1.55 3.830985 2.85 HA01 oxidase) 1

Homo sapiens cDNA FLJ13754 fis, clone PLACE3000362, mRNA

215006_at 3.80028231 1 6.05 3.8002822 28.05 sequence

215072_x_at 3.79161043 1 -1.75 3.7916105 8.2 FLJ21617 hypothetical protein FLJ21617 chemokine (C-X-C motif) Hgand 1

(melanoma growth stimulating

204470_at 3.77880353 1 190.75 3.7788036 800.4 CXCL1 activity, alpha) a disintegrin and metalloproteinase

208268_at 3.77773615 1 2.15 3.7777357 12.55 ADAM28 domain 28

220016_at 3.76849903 1 2.6 3.7684994 10 MGC5395 hypothetical protein MGC5395

208797_s_at 3.75600759 1 0.9 3.7560077 5.9 GOLGlN-67 goigin-67 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP

207419_s_at 3.75589326 1 10.6 3.7558932 47.55 RAC2 binding protein Rac2)

Homo sapiens cDNA: FLJ21690 fis, clone COL09538, mRNA

216174_at 3.75497682 1 9.65 3.7549767 36.95 sequence

Homo sapiens mRNA; cDNA

DKFZp434D0326 (from clone

DKFZp434D0326), mRNA

216719_s_at 3.73025672 1 0.4 3.7302566 5.15 sequence

205888_s_at 3.72338175 1 -7.7 3.7233815 24.3 KIAA0555 KIAA0555 gene product

221996_s_at 3.72022895 1 -0.15 3.7202291 9.6 CLTB clathrin, light polypeptide (Lcb) chaperone, ABC1 activity of bd

218168_s_at 3.71618058 1 9.2 3.7161808 34.25 CABC1 complex like (S, pombe)

202312_s_at 3.7070194 1 0.75 3.7070193 9 COL1A1 collagen, type I, alpha 1 ankyrin repeat and SOCS box

217228_s_at 3.69883695 1 -2.9 3.6988368 18.8 WUGSC:H_GS303P24.1 containing 4 immunoglobulin kappa variable 1D-

216207 x at 3.69878869 1 4.45 3.698789 -5.65 IGKV1 D-13 13

chromosome 1 open reading frame

201793_. _x_at 3.69836941 1 4.55 3.6983695 19.3 C1orf16 16

Zic family member 3 heterotaxy 1

207197. _at 3.6952418 1 -1.05 3.695242 -0.95 ZIC3 (odd-paired homolog, Drosophila)

215318_. .at 3.67821647 1 4.65 3.6782162 21.45 CG012 hypothetical gene CG012

208170. _s_at 3.66434064 1 5.6 3.6643405 20.3 TRIM31 tripartite motif-containing 31

210583_. .at 3.66074013 1 -4 3.66074 -0.4 KIAA1649 KIAA1649 protein arginine vasopressin receptor 2

208111. _at 3.65177217 1 4.1 3.6517723 16.35 AVPR2 (nephrogenic diabetes insipidus)

220943. _s_at 3.65176654 1 2.7 3.6517665 11.05 PRO1853 hypothetical protein PR01853

220782_. _x_at 3.65114686 1 10.85 3.651147 46.85 KLK12 kallikrein 12

222137. _at 3.64857828 1 11.2 3.6485782 44.45 FLJ20241 hypothetical protein FLJ20241

Rhesus blood group, C

219554. _at 3.64761019 1 10 3.6476102 34.45 RHCG glycoprotein

219531. _at 3.64466907 1 3.25 3.644669 9.9 FLJ 10565 hypothetical protein FLJ10565

Immunoglobulin light chain variable region [Homo sapiens], mRNA

216573. _at 3.64266388 1 -6.2 3.6426637 -5.25 sequence

217236. _x_at 3.6417549 1 0.9 3.6417546 12.8 IGHM immunoglobulin heavy constant mu

215704. .at 3.6382189 1 2.1 3.638219 8.3 FLG fϋaggrin mannosyl (alpha-1 ,3-)-glycoprotein beta-1,4-N- acetylglucosaminyltransferase,

219797_ .at 3.63504647 1 4.75 3.6350465 17.95 MGAT4A isoenzyme A glutamate receptor, ionotrophic,

208464. _at 3.6199726 1 -0.7 3.6199725 4.45 GRIA4 AMPA 4

219440_. _at 3.60959209 1 3.5 3.6095922 12.35 RAI2 retinoic acid induced 2

220787. _at 3.59794439 1 -4.9 3.5979443 0.45 PRO2533 hypothetical protein PRO2533

219741_. _x_at 3.59699982 1 6.8 3.5969996 58.2 FLJ21603 hypothetical protein FLJ21603 chromosome 16 open reading

207615_. _s_at 3.59170884 1 -12.65 3.591709 2.35 C16orf3 frame 3 myosin VA (heavy polypeptide 12,

217417_ .at 3.58862563 1 -1.4 3.5886257 -0.1 MYO5A myoxin)

209942 x at 3.5865808 1 -0.05 3.5865808 17.25 MAGEA3 melanoma antigen, family A, 3

209774_x_at 3.S8282394 1 48.85 3.5828242 195.1 CXCL2 chemokrne (C-X-C motif) iigand 2

211514_at 3.57747389 1 5.2 3.5774736 22.4 KIAA0472 KIAA0472 protein small nuclear RNA activating

214592_s_at 3.57464615 1 9.95 3.5746465 36.1 SNAPC5 complex, polypeptide s, 19kDa ceroid-lipofuscinosis, neuronal

218161_s_at 3.57361112 1 6.15 3.573611 25.5 CLN6 6, late infantile, variant

Homo sapiens, clone

IMAGE:5759947, mRNA, mRNA

222314_x_at 3.56959211 1 4.05 3.5695922 15.15 sequence

220699_s_at 3.56348171 1 -4.1 3.5634816 14.7 PRO2214 hypothetical protein PRO2214

Homo sapiens clone 24571 mRNA

215290_at 3.56231032 1 3.65 3.5623102 13.9 sequence

220107_s_at 3.5575205 1 3.7 3.5575204 14.3 C14orf140 hypothetical protein FLJ23093

Putative transcription factor [Homo

216832_at 3.55352185 1 5.2 3.5535219 25.65 sapiens], mRNA sequence

Homo sapiens mRNA; cDNA

DKFZp564M0616 (from clone

DKFZp564M0616), mRNA

215763_at 3.54503063 1 -2.6 3.5450306 0.75 sequence

205707_at 3.54211666 1 18.25 3.5421166 70.7 IL17R ϊnterieukin 17 receptor

44040_at 3.53820449 1 1.65 3.5382044 10.7 KIAA1940 KIAA1940 protein

208083_s_at 3.53657955 1 1.8 3.5365798 8.7 ITG B6 integrin, beta 6

Homo sapiens clone 24468 mRNA

213967_at 3.53640295 1 1.35 3.5364027 24.9 LOC138046 sequence hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid

204515_at 3.51867417 1 -0.1 3.518674 10.65 HSD3B1 delta-isomerase 1

212524_x_at 3.51160088 1 9.9 3.51 16012 34.1 H2AFX H2A histone family, member X giutamate decarboxylase 2

(pancreatic islets and brain,

211264_at 3.50934495 1 2.2 3.509345 8.2 GAD2 65kDa)

216216_at 3.50667549 1 2.65 3.5066757 10.8 SLIT3 slit homolog 3 (Drosophila)

Neural cell adhesion molecule secreted isoform, mRNA

217359 s at 3.50605259 1 3.45 3.5060525 15 sequence

222267 at 3.50475442 2.45 3.5047543 23.5 FLJ14803 hypothetical protein FLJ 14803 ESTs, Moderately similar to FW1 AJHUMAN F-box/WD-repeat protein 1 B (F-box and WD-repeats protein beta-TrCP) (E3RSIkappaB) (plkappaBalpha-E3 receptor

222374_at 3.48944244 1 4.8 3.4894426 17.3 BTRC subunit) [H.sapiens] D site of albumin promoter

209783_at 3.48371531 1 5.1 3.483715 24.8 DBP (albumin D-box) binding protein recombining binding protein suppressor of hairless

221377_s_at 3.47177148 1 2.45 3.4717715 5.7 RBPSUHL (Drosophila)-like oligodendrocyte lineage

213824 at 3.46703532 1 6.35 3.4670353 21.85 OLIG2 transcription factor 2 integrin, beta 2 (antigen CD18 (p95), lymphocyte function- associated antigen 1 ; macrophage antigen 1 (mac-1) 9\

202803_s_at 3.46594707 1 4.85 3.4659472 16.5 ITG B2 beta subunit} 210159_s_at 3.46584965 1 4.95 3.4658499 18.75 TRIM31 tripartite motif-containing 31 transporter 2, ATP-binding

204770_at 3.46115129 1 5.05 3.4611511 22.05 TAP2 cassette, sub-family B (MDR/TAP) coagulation factor V (proaccelerin,

204713_s_at 3.46065493 1 13.45 3.460655 59.1 F5 labile factor)

A kinase (PRKA) anchor protein

215483_at 3.45955926 1 1.85 3.4595594 7.2 AKAP9 (yotiao) 9 205289_at 3.45442813 1 10.1 3.4544263 36.45 BMP2 bone morphogenetϊe protein 2 213663_s_at 3.43956469 1 0.35 3.4395645 0.5 FLJ20152 hypothetical protein FLJ20152 208179_x_at 3.43708358 1 6.45 3.4370832 34.7 KIR-023GB NK-receptor 218413_s_at 3.42196581 1 2.1 3.4219656 13.9 LOC51193 zinc finger protein ANC_2H01 Unnamed protein product [Homo

220913_at 3.4160743 1 1.35 3.416074 3.1 sapiens], mRNA sequence rat>3 GTPase-activating protein,

216057_at 3.40964808 1 1.35 3.409648 5.95 RAB3-GAP150 non-catalytic subunit (15OkD) 213972 at 3.39701681 1 21.9 3.3970165 79.2 FOXD1 forkhead box D1

213635 s at 3.39637544 5.05 3.3963754 32.6 SAFB scaffold attachment factor B Homo sapiens cDNA FLJ12365 fis, clone MAMMA1002392, mRNA

216118 at 3.39356416 3.2 3.393564 15.95 sequence

NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,

215850_s_at 3.38113232 1 -0.5 3.3811321 2.25 NDUFA5 5, 13kDa 207710 at 3.37746337 1 5 3.3774633 19.1 XP5 skin-specific protein potassium large conductance calcium-activated channel,

221583_s_at 3.37604368 1 12.85 3.3760436 48.9 KCNMA1 subfamiiy M, alpha member 1

DKFZP566F0546

206526_at 3.37456345 1 -2.8 3.3745635 10.9 DKFZP566F0546 protein likely ortholog of mouse zinc finger 220516_at 3.37254946 1 3 3.3725493 10.8 ZFP29 protein 29

Homo sapiens cDNA: FLJ23140 fis, clone LNG09065, mRNA 00 -4

216415_at 3.37046199 1 0.85 3.370462 6.7 sequence interleukin 5 (colony-stimulating 207952_at 3.35921111 1 2.35 3.3592112 8.7 IL5 factor, eosinophil) amyloid beta (A4) precursor protein-binding, family A,

209870_s_at 3.35732997 1 17.8 3.3573298 68.25 APBA2 member 2 (X11-like)

Homo sapiens mRNA; cDNA

DKFZp762C115 (from clone

215060 at 3.34935657 1 4.05 3.3493562 18 DKFZp762C115), mRNA sequence

Homo sapiens cDNA FLJ33742 fis, clone BRAWH2019053, highly similar to Homo sapiens BNPI mRNA for brain-specific Na- dependent inorganic phosphate

204229_at 3.34797807 1 4.7 3.347978 17.2 cotransporter, mRNA sequence chromosome 20 open reading

220456_at 3.34769316 1 0 3.3476932 0.7 C20orf38 frame 38 gap junction protein, alpha 4,

40687 at 3.34621315 1 -1.75 3.346213 26.65 GJ A4 37kDa (connexin 37)

219987_at 3.33862877 1 -4 3.338629 2.7 FLJ 12684 hypothetical protein FLJ12684 aldo-keto reductase family 1 , 206561 s at 3.33673388 1 5.95 3.3367338 22.9 AKR1B10 member B10 (aldose reductase)

Homo sapiens cDNA FLJ13876 fis, clone THYRO1001401, mRNA

215375_x_at 3.33196971 1 11.5 3.3319693 43.2 sequence

218272_at 3.32599173 1 -4.25 3.3259916 12.95 FLJ20699 hypothetical protein FLJ20699

220283_at 3.32524663 1 21.35 3.3252468 72.3 FLJ 13840 hypothetical protein FLJ13840

216045_at 3.32223044 1 -0.9 3.3222303 -0.5 KIAA0565 KIAA0565 gene product

210545_at 3.30622154 1 8.35 3.3062212 28.2 ITSN2 intersectin 2 matrix metalloproteinase 24

208387_s_at 3.29887887 1 7.45 3.2988787 28.95 MMP24 {membrane-inserted)

208136 s at 3.29467817 1 3.8 3.2946782 13.3 MGC3771 hypothetical protein MGC3771

Homo Sapiens (clone B3B3E13) chromosome 4p16.3 DNA

215745_at 3.29384776 1 4 3.2938476 14.45 fragment, mRNA sequence 90 wingless-type RIlMTV integration 00 207612_at 3.29132008 1 -4.5 3.29132 11.55 WNT8B site family, member 8B hepatocyte growth factor 209961_s_at 3.28981569 1 40.5 3.289816 145.65 HGF (hepapoietin A; scatter factor) sialyltransferase 4A (beta- galactoside alpha-2,3-

208322_s_at 3.28820877 1 -2.7 3.2882085 16.15 SIAT4A sialytransferase) serine protease inhibitor, Kazal 206239_s_at 3.28805824 1 1.35 3.2880583 6.45 SPINK1 type 1

Homo sapiens clone 24400 mRNA 215767_at 3.28770391 1 6.65 3.287704 22.6 sequence serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),

206386_at 3.28542669 1 5.45 3.2854266 19.5 SERPINA7 member 7 potassium voltage-gated channel, 204486 at 3.28298215 1 3.75 3.2829823 12.65 KCNQ1 KQT-like subfamily, member 1

ESTs, Highly similar to Rho guanine nucleotide exchange factor (GEF) 12; Rho guanine exchange factor (GEF) 12; leukemia- associated rho guanine nucleotide exchange factor; leukemia- associated rho GEF; similar to mouse Lsc oncogene [Homo

210741_at 3.27833147 1 -1.35 3.2783313 3 sapiens] [H.sapiens]

216096_s_at 3.27427842 1 2.2 3.2742786 7.65 NRXN1 neurexin 1

212743_at 3.26789232 1 3.65 3.2678924 13.4 ZNF363 zinc finger protein 363 axonal transport of synaptic

203850_s_at 3.26075544 1 3.65 3.2607555 12.8 ATSV vesicles solute carrier family 17 (sodium

207298_at 3.25812625 1 3.6 3.2581263 15.65 SLC17A3 phosphate), member 3 CCAAT/enhancer binding protein 213003_s_at 3.25153354 1 21.55 3.2515333 76.9 CEBPD (C/EBP), delta

Mucin [Homo sapiens], mRNA

217187_at 3.24112487 1 39.5 3.2411249 139.6 sequence 205770_at 3.23613594 1 2.95 3.236136 13.75 GSR glutathione reductase tumor necrosis factor receptor

207536_s_at 3.22770364 1 10.05 3.2277036 32.35 TNFRSF9 superfamily, member 9

215538_at 3.22625754 1 6.45 3.2262573 21.8 LARGE like-glycosyltransferase lymphoid-restricted membrane

35974 at 3.21317257 0.55 3.2131727 -1.2 Jaw1 protein suppression of tumorigenicity 14 (colon carcinoma, matriptase,

216905_s_at 3.20898539 1 0.1 3.2089853 6.75 ST14 epithin)

214615_at 3.206148 1 3.25 3.206148 10.65 P2Y10 putative purinergic receptor

216395_at 3.19114963 1 3.5 3.1911495 11.6 FLJ 11467 hypothetical protein FLJ 11467

216394_x_at 3.18929897 1 -9.85 3.1892989 2.75 IGL@ immunoglobulin lambda locus

213038_at 3.18743279 1 15.8 3.1874328 50.3 FLJ90005 hypothetical protein FLJ90005

220855_at 3.18295293 1 4.55 3.182953 14.4 PRO0456 PRO0456 protein myelin oligodendrocyte

214650 x at 3.18111777 1 2.25 3.1811175 11.95 MOG glycoprotein

214716_at 3.17890612 1 3.2 3.1789062 10 BiKE BR/lP-2 inducible kinase

210021_s_at 3.17835227 1 -5.5 3.1783524 9 UNG2 uracil-DNA glycosylase 2 protocadherin 16 dachsous-like

222101_s_at 3.17493825 1 5.85 3.1749382 46.95 PCDH16 (Drosophila)

220940_at 3.17433114 1 5.5 3.1743312 17.4 KIAA1641 KIAA1641 protein cytochrome P450, subfamily HD

(debrisoquine, sparteine, etc., -

215809_at 3.17232139 1 -14.35 3.1723213 0.7 CYP2D6 metabolizing), polypeptide 6

DKFZP564O0463

220843_s_at 3.16945852 1 1.45 3.1694586 5.75 DKFZP564O0463 protein

217856_at 3.16763923 1 6.2 3.1676393 38.3 RBM8A RNA binding motif protein 8A

212384_at 3.16695273 1 5.5 3.1669526 18.4 BAT1 HLA-B associated transcript 1

212657_s_at 3.16400993 1 24.4 3.16401 81 IL1 RN interleukin 1 receptor antagonist

5-hydroxytryptamine (serotonin)

210799_at 3.15812614 1 13.95 3.1581259 44.05 HTR1 B receptor 1 B

Homo sapiens clone 24970 mRNA

222197_s_at 3.14914117 1 5.8 3.149141 19.45 sequence O

206248_at 3.14886222 1 23.65 3.1488621 81.45 PRKCE protein kinase C, epsiion

Unnamed protein product [Homo

220905_at 3.14041739 1 1.3 3.1404176 6.95 sapiens], mRNA sequence nitric oxide synthase 1

20731 O_s_at 3.11975229 1 7.45 3.1197524 24.05 NOS1 (neuronal)

207006_s_at 3.11800651 1 -0.9 3.1180065 -1.3 HSU79303 protein predicted by clone 23882

205067_at 3.11665728 1 75.55 3.1166573 246.4 1L1B interieukin 1, beta

219744_at 3.10816642 1 1.45 3.1081665 4.7 FN3K fructosamine-3-kinase

217050_at 3.10360962 1 8.45 3.1036098 27.05 EPAG early lymphoid activation protein potassium voltage-gated channel, shaker-related subfamily, beta

208213_s_at 3.10350678 1 18.95 3.1035066 62.75 KCNAB 1 member 1

ESTs, Highly similar to AGRT agrin

222324_at 3.10214543 1 13.45 3.1021454 44.7 - rat [R.norvegicus] alcohol dehydrogenase IB (class I),

209614_at 3.09094932 1 2.7 3.0909495 8.75 ADH1 B beta polypeptide transporter 2, ATP-binding

208428_at 3.08715092 1 -2.5 3.087151 3.45 TAP2 cassette, sub-family B (MDR/TAP)

214142_at 3.08356395 1 2.8 3.0835643 7.55 ZG16 zymogen granule protein 16 203887_s_at 3.08260005 1 14.35 3.0825999 48.95 THBD thrombomodulin potassium voltage-gated channel,

211827_s_at 3.08085332 1 26.65 3.0808532 88.75 KCN D3 Shal-related subfamily, member 3

Homo sapiens mRNA; cDNA

DKFZp564N1662 (from clone

DKFZp564N1662), mRNA

214046_at 3.08014264 1 0.45 3.0801425 5.35 sequence 221192_x_at 3.07287162 1 25.7 3.0728717 86.15 ET hypothetical protein ET 217447_at 3.07195933 1 -25.8 3.071959 12.3 MAG myelin associated glycoprotein 204536_s_at 3.06667371 1 1.1 3.0666738 5.9 REST X2 box repressor, mRNA sequence hepatocyte nuclear factor 4,

208429_x_at 3.06237884 1 15.45 3.062379 46.8 HNF4A alpha mitogen-activated protein kinase

205699_at 3.06169467 1 2.6 3.0616944 9.6 MAP2K6 kinase 6 210713_at 3.0607357 1 4.9 3.0607357 17.9 ITSN 1 intersectin 1 (SH3 domain protein) VO 216151_at 3.0596133 1 -2 3.0596132 4.5 220231_at 3.05246453 1 4.15 3.0524645 24.25 C7orf16 G-substrate cadherin 1, type 1, E-cadherin

201130_s_at 3.04918866 1 1.65 3.0491886 7.3 CDH1 (epithelial)

Homo sapiens mRNA; cDNA DKFZp564E026 (from clone

217085_at 3.04565931 1 1.5 3.0456595 7.1 DKFZp564E026), mRNA sequence 204357_s_at 3.03246283 1 23.65 3.032463 82.9 LIMK1 LIM domain kinase 1 major histocompatibility complex,

217323_at 3.0256848 1 2.25 3.0256846 10.3 HLA-DRB6 class II, DR beta 6 (pseudogene) polymerase (RNA) Il (DNA

60815_at 3.02529243 1 3.05 3.0252924 9.75 POLR2J directed) polypeptide J, 13.3kDa 219504_s_at 3.01719762 1 -0.6 3.0171976 10.4 FLJ13150 hypothetical protein FLJ13150 solute carrier family 19 (folate

209777_s_at 3.01492009 1 -29.45 3.0149202 91.35 SLC19A1 transporter), member 1 ESTs, Weakly similar to hypothetical protein FLJ20489

217569 x at 3.01489895 1 -25.25 3.014899 -25.6 [Homo sapiens] [H.sapiens]

Homo sapiens cDNA FLJ 12327 fis, clone MAMMA1002140, mRNA

215203_at 3.01360217 1 11 3.0136023 35.65 sequence chemokine (C-C motif) receptor-

220351_at 3.0086054 1 0.45 3.0086055 6.1 CCRL1 like 1

Homo sapiens cDNA FLJ12295 fis, clone MAMMA1001818, mRNA

215376_at 2.99191148 1 3.15 2.9919114 18 sequence 205119_s_at 2.98748162 1 18.65 2.9874816 57.35 FPR1 formyl peptide receptor 1 pyruvate dehydrogenase kinase,

206686_at 2.98539695 1 10.3 2.9853969 34 PDK1 isoenzyme 1 mitochondrial solute carrier

218978_s_at 2.98520082 1 10.25 2.985201 34.55 MSCP protein myosin, light polypeptide 3, alkali;

205589_at 2.98119184 1 11.95 2.9811916 37.4 MYL3 ventricular, skeletal, slow 220736_at 2.98002353 1 0.8 2.9800234 10.9 SLC19A3 solute carrier family 19, member 3 210457_x_at 2.97542048 1 122.2 2.9754207 385.1 HMGA1 high mobility group AT-hook 1 κ> protein kinase, AMP-activated,

215231_at 2.97415349 1 1.5 2.9741535 4.7 PRKAG2 gamma 2 non-catalytic subunit 205767_at 2.97366359 1 20 2.9736638 66.6 EREG epiregulin 220691_at 2.97053586 1 -1.65 2.9705358 7.3 PRO0097 PRO0097 protein Homo sapiens cDNA: FLJ23181 fis, clone LNG 11094, mRNA

222061_at 2.96294865 1 0.7 2.9629488 3.35 sequence 205987_at 2.96076961 1 30 2.9607697 87.2 CD1 C CD 1 C antigen, c polypeptide 221442_at 2.96024349 1 6.65 2.9602432 22.05 MC3R melanocortin 3 receptor 211085_s_at 2.94434021 1 0 2.94434 0.6 STK4 serine/threonine kinase 4 runt-related transcription factor 1 (acute myeloid leukemia 1 ; aml1

210365_at 2.94294136 1 20.35 2.9429412 64.95 RUNX1 oncogene)

Homo sapiens mRNA; cDNA DKFZp566A193 (from clone

217440_at 2.93943936 1 2.45 2.9394393 8.3 DKFZp566A193), mRNA sequence 220665_at 2.93856925 1 60 2.9385693 187.2 HOM-TES-85 HOM-TES-85 tumor antigen 221631 at 2.9305962 1 13.6 2.9305964 41.4 CACN A11 calcium channel, voitage-

dependent, alpha 11 subunit

207909_x_at 2.92689725 1 0.2 2.9268973 7.35 DAZ2 deleted in azoospermia 2 ectodermal-neural cortex (with

201340_s_at 2.92610354 1 4.55 2.9261038 14.8 ENC1 BTB-Iike domain)

Homo sapiens cDNA FLJ39487 fis, clone PROST2015246, mRNA

217538_at 2.92241616 1 8.5 2.9224162 26.8 sequence

Homo sapiens mRNA; cDNA

DKFZp586B1722 (from clone

DKFZp586B1722), mRNA

214987_at 2.91665844 1 5.55 2.9166586 16.05 sequence serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),

211429_s_at 2.91366381 1 10.45 2.9136639 32 SERPINA1 member 1

POU domain, class 4, transcription

211341_at 2.91224477 1 -2.95 2.9122448 -0.05 POU4F1 factor 1

218951_s_at 2.91135735 1 3.5 2.91 13574 67.55 FLJ 11323 hypothetical protein FLJ11323

206457_s_at 2.91059514 1 9.5 2.9105952 27.3 D1O1 deiodinase, iodothyronine, type I

205284_at 2.90739826 1 7.1 2.9073982 22.45 KIAA0133 KIAA0133 gene product

Homo sapiens clone 23622 mRNA

214821_at 2.90600302 1 5.5 2.906003 19.1 sequence

221461_at 2.90551159 1 6.85 2.9055114 21.3 TAS2R9 taste receptor, type 2, member 9

U2 small nuclear ribonucleoprotein

214171_s_at 2.8946931 1 -5.75 2.8946931 0.75 U2AF65 auxiliary factor (65kD)

211823_s_at 2.8845047 1 11.4 2.8845048 68.4 PXN paxillin

Homo sapiens mRNA; cDNA

DKFZp434B2115 (from clone

DKFZp434B2115), mRNA

215970_at 2.88348385 1 2.2 2.883484 18.95 sequence

206731_at 2.88224048 1 0.3 2.8822405 7.4 CN K2 connector enhancer of KSR2

216056_at 2.88117699 1 1.8 2.881177 4.6

214357 at 2.87909469 1 15.5 2.8790946 49.2 LOC92346 LOC92346

Homo sapiens cDNA FLJ39951 fis, clone SPLEN2024530, moderately similar to ADP-ribosylation factor binding protein GGA1 , mRNA

217560_at 2.87792758 1 4.25 2.8779278 12.9 sequence

204504_s_at 2.87317611 1 14.25 2.873176 41.1 HIRIP3 HIRA interacting protein 3

Homo sapiens cDNA FLJ11740 fis, clone HEMBA1005500, mRNA

215643_at 2.86102635 1 5.4 2.8610265 16.45 sequence

205225_at 2.86101036 1 7.25 2.8610106 26.15 ESR1 estrogen receptor 1

215123_at 2.8541227-7 1 12.65 2.8541229 33 KIAA0220 KIAA0220 protein

ESTs, Weakly similar to neuronal thread protein [Homo sapiens]

217694_at 2.85378056 1 3 2.8537803 9.2 [H.sapiens]

ESTs, Weakly similar to neuronal thread protein [Homo sapiens]

217666_at 2.84588929 1 1.9 2.8458893 6.1 [H.sapiens]

216412_x_at 2.84360113 1 -1 2.843601 11.35 IGL@ immunoglobulin lambda locus

222120_at 2.84346521 1 16.4 2.8434653 48.55 MGC13138 hypothetical protein MGC13138

219115_s_at 2.84332204 1 0.55 2.8433223 δ.95 IL2QRA interieukin 20 receptor, alpha

217218_at 2.84146847 1 1.65 2.8414686 4.9 KIAA0261 KIAA0261 protein cytochrome P450, subfamily HC

(mephenytoin 4-hydroxylase),

220017_x_at 2.8388281 1 8.15 2.838828 36 CYP2C9 polypeptide 9

214282_at 2.8381108 1 10.6 2.838111 31.05 CP ceruloplasmin (ferroxidase)

215591_at 2.83638242 1 0.75 2.8363824 6.15 KIAA1034 KIAA1034 protein

218454_at 2.83388803 1 9.5 2.833888 29.8 FLJ22662 hypothetical protein FU22662

211679_x_at 2.82922603 1 12.7 2.8292258 39.25 GPR51 G protein-coupled receptor 51 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent

210556_at 2.82674008 1 4.3 2.8267398 13.8 NFATC3 3 gamma-aminobutyric acid

206525_at 2.82518031 1 11.05 2.82518 32.85 GABRR1 (GABA) receptor, rho 1 chromosome 22 open reading

206436 at 2.8237203 1 15.45 2.8237202 48.8 C22orf1 frame 1

aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-

207102_at 2.82137224 1 1.95 2.8213723 7.85 AKR1D1 5-beta-reductase) cytochrome P450, subfamily HC (mephenytoin 4-hydroxylase),

208147_s_at 2.82068704 1 0.15 2.820687 5.7 CYP2C8 polypeptide 8

213633_at 2.82035443 1 5.4 2.8203545 16.4 SH3BP1 SH3-domain binding protein 1

210318_at 2.80754912 1 9.6 2.807549 26.5 RBP3 retinol binding protein 3, interstitial amine oxidase, copper containing 3

204894_s_at 2.80503348 1 4.25 2.8050337 12.7 AOC3 (vascular adhesion protein 1) Gardner-Rasheed feline sarcoma

208438 s at 2.80344192 1 7.7 2.803442 29.3 FGR viral (v-fgr) oncogene homolog ESTs, Highly similar to solute carrier family 34 (sodium phosphate), member 1; sodium/phosphate co-transporter; solute carrier family 17 (sodium phosphate), member 2 [Homo 8

217530_at 2.79265179 1 2.4 2.7926517 10.5 sapiens] [H.sapiens] Homo sapiens cDNA: FLJ21699 fis, clone COL09829, mRNA

215660_s_at 2.79036287 1 5.2 2.7903628 25.25 sequence

G protein-coupled receptor 37

214586_at 2.78603753 1 -0.25 2.7860374 1.8 GPR37 (endothelin receptor type B-like) 208599_at 2.78546801 1 8.65 2.7854679 27.7 UREB1 210167_s_at 2.78166696 1 28.25 2.7816668 84.95 TEF thyrotrophic embryonic factor 205345_at 2.77842503 1 3.2 2.7784247 5.4 BARD1 BRCA1 associated RING domain 1 205320_at 2.77432597 1 15.1 2.7743258 44.45 APCL adenomatous polyposis coli like glutamic-pyruvate transaminase

206709_x_at 2.77393783 1 -7.1 2.7739382 -0.15 GPT (alanine aminotransferase) neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson

211094_s_at 2.77302223 1 -2.35 2.7730222 11.15 NF1 disease)

215455 at 2.77263614 1 7.65 2.772636 21.7 TIMELESS timeless homolog (Drosophila)

219669_at 2.77053207 1 -11.5 2.770532 11.6 PRV1 polycythemia rubra vera 1 egf-like module-containing mucin-

210724_at 2.76933573 1 3.15 2.7693357 8.35 EM R3 like receptor 3

213636_at 2.7651678 1 10.35 2.7651677 29.85 KIAA1045 KIAA1045 protein

ESTs, Highly similar to double- stranded RNA specific adenosine deaminase [Homo sapiens]

206228_at 2.76471937 1 11.75 2.7647192 36.6 [H.sapiens]

204907_s_at 2.75696933 1 32.7 2.7569695 96.55 BCL3 B-cell CLL/lymphoma 3

210189_at 2.75679371 1 -4.05 2.7567937 6.95 HSPA1 L heat shock 7OkDa protein 1-like agouti signaling protein, nonagouti

214498_at 2.75606497 1 10.35 2.7560651 31.2 ASIP homolog (mouse) potassium voltage-gated channel,

207103_at 2.75382232 1 1.7 2.7538223 5.3 KCN D2 Shal-related subfamily, member 2 cyclin-dependent kinase inhibitor

216894_x_at 2.75151094 1 22.65 2.7515109 68.4 CDKN1 C 1C (p57, Kip2)

215101_s_at 2.74824851 1 1.65 2.7482488 3.65 CXCL5 chemokine (C-X-C motif) ligand 5 ON

205207_at 2.74773067 1 300.4 2.7477307 900.15 iL6 interleukin 6 (interferon, beta 2) paired basic amino acid cleaving

211262_at 2.74520872 1 0.75 2.7452087 -2.4 PACE4 system 4 solute carrier family 19 (folate

209776_s_at 2.74173053 1 5.65 2.7417305 16.7 SLC19A1 transporter), member 1

207235_s_at 2.74104316 1 -3.95 2.741043 2.3 GRM5 glutamate receptor, metabotropic 5

219823_at 2.73939743 1 4.35 2.7393973 12.05 LIN-28 RNA-binding protein LIN-28 chromosome 1 open reading frame

220688_s_at 2.7354693 1 17.9 2.7354693 60.7 C1orf33 33 protein kinase, AMP-activated,

207709_at 2.73546139 1 13.5 2.7354615 39.75 PRKAA2 alpha 2 catalytic subunit

207588_at 2.73292212 1 4.05 2.732922 12.4 MYT2 myelin transcription factor 2

220534_at 2.73234781 1 39.25 2.7323477 112.75 TRI M48 tripartite motif-containing 48

Papillary thyroid carcinoma-

211421_s_at 2.73232067 1 3.8 2.7323208 10.95 encoded protein, mRNA sequence

221034_s_at 2.73215476 1 16.5 2.7321548 49.8 TEX13B testis expressed sequence 13B

221032 s at 2.73091388 1 12.45 2.7309139 34.3 TMPRSS5 transmembrane protease, serine 5

(spinesin) chromosome 21 open reading

219482_at 2.73086944 1 -1.55 2.7308695 -0.95 C21orf18 frame 18 a disintegrin-like and metalloprotease (reprolysin type)

220677_s_at 2.72975968 1 4.95 2.72976 15.45 ADAMTS8 with thrombospondin type 1 motif, 8 220836_at 2.72481725 1 1.2 2.7248173 3.6 ZNF407 zinc finger protein 407 206743_s_at 2.72144457 1 8.95 2.7214446 26.65 ASG R1 asialoglycoprotein receptor 1

UDP glycosyltransferase 2 family,

207392_x_at 2.71729379 1 -8.55 2.7172937 -9.65 UGT2B15 polypeptide B15 equilibrative nucleoside transporter

219344_at 2.71559367 1 9.85 2.7155938 35.6 ENT3 3 dual-specificity tyrosine-(Y)- phosphorylation regulated kinase

211079_s_at 2.71059533 1 5.6 2.7105954 15.3 DYRK1A 1A

MTAP [Homo sapiens], mRNA

217134_at 2.70779951 1 3 2.7077994 9.75 sequence -4 cadherin 15, M-cadherin

206327_s_at 2.70449845 1 19.35 2.7044983 56 CDH15 (myotubule)

Putative opioid receptor, mRNA

208192_at 2.70436784 1 -0.3 2.7043679 2.5 sequence

5-hydroxytryptamine (serotonin)

211479_s_at 2.70405261 1 10.6 2.7040527 29.65 HTR2C receptor 2C 220655_at 2.70161633 1 3 2.7016163 8.4 TNIP3 TNFAIP3 interacting protein 3

Homo sapiens cDNA FLJ14085 fis, clone HEMBB1002534, mRNA

215191_at 2.70153102 1 6.3 2.701531 15.8 sequence

ATP-binding cassette, sub-family C

208561_at 2.70080835 1 6.95 2.7008083 19.95 ABCC9 (CFTR/MRP), member 9 215640_at 2.69979783 1 24.9 2.6997976 71.4 KIAA1055 KIAA1055 protein 210843_s_at 2.69950534 1 2.05 2.6995056 6.95 KIAA0626 KIAA0626 gene product 204911_s_at 2.69917913 1 30.95 2.6991792 95.2 TRIM3 tripartite motif-containing 3 fucosyltransferase 7 (alpha (1,3)

210506_at 2.69427437 1 0.3 2.6942744 5.9 FUT7 fucosyltransferase) 220381 at 2.69260285 1 2.5 2.6926029 7.75 FLJ10312 hypothetical protein FLJ10312

205668_at 2.69182706 1 1.8 2.691827 6.05 LY75 lymphocyte antigen 75 solute carrier family 12,

(potassium-chloride transporter)

210040_at 2.68711445 1 6.35 2.6871145 25.35 SLC12A5 member 5

207174_at 2.68612055 1 -1.15 2.6861205 3.45 GPC5 glypican 5 cytotoxic T-lymphocyte-associated

221331_x_at 2.68423603 1 23.6 2.684236 81.6 CTLA4 protein 4

220667_at 2.68303866 1 -0.85 2.6830387 3.3 PRO2831 hypothetical protein PRO2831

40665_at 2.68140646 1 4.35 2.6814063 13.35 FMO2 flavin containing monooxygenase 3 solute carrier family 16

(monocarboxylic acid transporters),

210807_s_at 2.68043798 1 1.3 2.680438 4.45 SLC16A7 member 7

214279_s_at 2.67955518 1 2.4 2.679555 8.15 NDRG2 NDRG family member 2

206987_x_at 2.6743954 1 -12.75 2.6743953 3.45 FGF18 fibroblast growth factor 18 transcobalamin I (vitamin B12

205513_at 2.67422012 1 6.4 2.67422 17.05 TCN 1 binding protein, R binder family)

OO

204562_at 2.67407794 1 3.2 2.674078 15.95 IRF4 interferon regulatory factor 4

222309_at 2.67101709 1 12.1 2.6710172 34.8 ESTs

ISL1 transcription factor,

206104_at 2.66826659 1 3.65 2.6682663 10.45 ISL1 LIM/homeodomain, (islet-1) striated muscle contraction

210911_at 2.66548814 1 8.3 2.6654882 25 ID2B regulatory protein solute carrier family 21 (organic

207308_at 2.66344249 1 7.1 2.6634426 20.6 SLC21A3 anion transporter), member 3 likely ortholog of mouse exocyst component protein 70 kDa homolog (S. cerevisiae) Exo70: exocyst component protein 70 kDa

215413_at 2.66099921 1 2.3 2.6609993 28.05 EXO70 homolog (S. cerevisiae) inositol 1,4,5-triphosphate

201188_s_at 2.65763932 1 71.65 2.6576393 199.4 ITPR3 receptor, type 3

218798_at 2.65533636 1 -3.1 2.6553364 16.75 FLJ 12949 hypothetical protein FLJ12949 hypothetical protein

213546_at 2.65468325 1 19.85 2.654683 54.4 DKFZp586l1420 DKFZp586l1420

Human EST clone 22453 mariner transposon Hsmari sequence,

215962_at 2.65268357 1 3.3 2.6526835 9.55 mRNA sequence corticotropin releasing hormone

205984_at 2.65259311 1 13.05 2.6525931 - 39.75 CRHBP binding protein 220215_at 2.65154964 1 9.4 2.6515496 28.9 FLJ12606 hypothetical protein FLJ 12606 206398_s_at 2.64998957 1 5.95 2.6499896 16.05 CD19 CD 19 antigen 216406_at 2.64621655 1 7.15 2.6462166 20.35

DEAD/H (Asp-Glu-Ala-Asp/His) box

205001_s_at 2.64607868 1 0.35 2.6460786 8.05 DBY polypeptide, Y chromosome 207477_at 2.64203909 1 4.85 2.642039 14.7 PRO2958 hypothetical protein PRO2958 Homo sapiens cDNA FLJ10021 fis, clone HEMBA1000568, mRNA

215209_at 2.64081605 1 8.4 2.640816 24.85 sequence 213645_at 2.63163803 1 -8.85 2.631638 155.8

ESTs, Moderately similar to PCAF associated factor 65 beta [Homo

217573_at 2.63096736 1 2.75 2.6309671 10.5 sapiens] [H. sapiens] pregnancy specific beta-1-

211741_x_at 2.62900394 1 7.5 2.629004 34.7 PSG3 glycoprotein 3 220822_at 2.62698615 1 4.6 2.626986 13 EST 205889_s_at 2.62606156 1 6.3 2.6260614 16.9 KIAA0555 KIAA0555 gene product

Homo sapiens cDNA FLJ20827 fis, clone ADKA03543, mRNA

216675_at 2.62223517 1 0.35 2.622235 7.3 sequence 205773_at 2.62141687 1 0.3 2.6214168 2.55 KIAA0940 KIAA0940 protein glycoprotein 2 (zymogen granule

208473_s_at 2.62056593 1 -5.7 2.620566 12.2 GP2 membrane) 220881_at 2.62053013 1 8.85 2.6205301 26.15 PRO1787 hypothetical protein PRO1787 219435_at 2.61950986 1 23.55 2.61951 64.95 FLJ22170 hypothetical protein FLJ22170

206009_at 2.61708785 1 8.05 2.6170678 22.0S 1TGA9 integrin, alpha 9

Unknown [Homo sapiens], mRNA

216933_x_at 2.61656718 1 7.15 2.6165671 19.35 sequence 207195 at 2.610756 1 0.4 2.610756 4.85 CNTN6 contactin 6

209859_at 2.61003256 1 5.8 2.6100326 15.45 TRIM9 tripartite motif-containing 9 zinc finger protein 42 (myeloid- specific retinoic acid-

222098_s_at 2.60636775 1 9.45 2.6063678 25.4 ZNF42 responsive) paired box gene 3 (Waardenburg

207679_at 2.60431643 1 75.8 2.6043162 213 PAX3 syndrome 1 ) solute carrier family 27 (fatty acid

205768_s_at 2.59997201 1 1.35 2.599972 14.25 SLC27A2 transporter), member 2

Homo sapiens mRNA; cDNA

DKFZp434F172 (from clone

216838_at 2.59861052 1 8.15 2.5986104 22.25 DKFZp434F172), mRNA sequence

40560_at 2.59761834 1 45.9 2.5976183 129.65 TBX2 T-box 2

213371_at 2.59639438 1 14.95 2.5963945 40.75 LDB3 LIM domain binding 3 pleckstrin homology, Sec7 and

211521_s_at 2.59282531 1 25.55 2.5928252 71.25 PSCD4 coiled/coil domains 4

2',5'-oligoadenylate synthetase 1 ,

205552_s_at 2.58452648 1 6.55 2.5845265 19.35 OAS 1 40/46kDa

212844_at 2.58247144 1 10.1 2.5824714 26.2 KIAA0179 KIAA0179 protein protein phosphatase 4, regulatory

214373_at 2.58055794 1 18.55 2.5805578 52.55 PPP4R2 subunit 2 interleukϊn 1 receptor accessory

221112_at 2.5789147 1 1.55 2.5789146 21.4 IL1 RAPL2 protein-like 2 seizure related 6 homolog (mouse)

216047_x_at 2.5779895 1 10.1 2.5779896 26.95 SEZ6L like

221149_at 2.57142087 1 5.7 2.5714207 22.65 GPR77 G protein-coupled receptor 77 tumor necrosis factor, alpha-

206025_s_at 2.56802262 1 55.3 2.5680227 155.7 TNFAIP6 induced protein 6

206171_at 2.56344259 1 17 2.5634427 46.35 ADORA3 adenosine A3 receptor piccolo (presynaptic cytomatrix

210650_s_at 2.5628446 1 4.75 2.5628448 13.7 PCLO protein) v-rel reticuloendotheliosis viral

206036_s_at 2.56249193 1 6.4 2.562492 19.8 REL oncogene homolog (avian)

219456_s_at 2.56081605 1 24.8 2.560816 67.35 RIN3 Ras and Rab interactor 3

214851_at 2.55753612 1 -4 2.5575361 7.7 HNF4A hepatocyte nuclear factor 4, alpha

217280 x at 2.55459456 1 8.7 2.5545948 24.8 GABRA5

217158_at 2.55367288 1 -4.8 2.5536728 9.05

Homo sapiens mRNA; cDNA

DKFZp434O151 (from clone

214867_at 2.55258179 1 13.55 2.5525818 34.1 DKFZp434O151), mRNA sequence

206346_at 2.55126484 1 4.1 2.5512648 10.45 PRLR prolactin receptor

207989_at 2.55019397 1 6.75 2.550194 19.75. OPRM1 opioid receptor, mu 1

203805_s_at 2.54743777 1 18 2.5474377 46.7 FANCA hypothetical protein MGC45417

216650_at 2.54702024 1 0.05 2.5470202 8.75

221048_x_at 2.54561799 1 -1.9 2.5456178 8.15 FLJ20721 hypothetical protein FLJ20721

207322_at 2.54467903 1 5 2.5446787 13.25 ITSN 1 intersectin 1 (SH3 domain protein) bullous pemphigoid antigen 1 ,

204455_at 2.54194948 1 5.85 2.5419497 15.25 BPAG 1 230/24OkDa

217124_at 2.54185542 1 9.7 2.5418556 26.7 KIAA1023 KIAA1023 protein cyclin-dependent kinase inhibitor

219534_x_at 2.5410049 1 30.9 2.541005 84.9 CDKN1C 1C (p57, Kip2) oxidised low density lipoprotein

210004_at 2.54054818 1 45.5 2.540548 124 OLR1 (lectin-like) receptor 1 tumor necrosis factor, alpha-

206026_s_at 2.54032028 1 83.15 2.5403204 235.85 TNFAIP6 induced protein 6

215680_at 2.53830921 1 -8.1 2.538309 2.15 KIAA1654 KIAA1654 protein

215720_s_at 2.53667942 1 2.15 2.5366797 4.8 NFYA nuclear transcription factor Y, alpha gamma-aminobutyric acid (GABA)

204537_s_at 2.53582236 1 20.25 2.5358224 59.4 GABRE A receptor, epsilon

222337_at 2.53324114 1 2.85 2.5332413 13.7 cyclin D1 (PRAD1: parathyroid

214019_at 2.53214563 1 -1 2.5321457 4.8 CCND1 adenomatosis 1 )

ATPase, H+/K+ exchanging, beta

207546_at 2.53202745 1 17.35 2.5320277 46.8 ATP4B polypeptide

201965_s_at 2.53198549 1 7.05 2.5319858 42.15 KIAA0625 KIAA0625 protein

219302_s_at 2.52942901 1 3.05 2.529429 8.7 CNTNAP2 contactin associated protein-like 2

216562_at 2.52902237 1 23.6 2.5290222 61.05 dJ1057D4.1 metal-regulatory transcription factor

205322_s_at 2.52829566 1 25.2 2.5282955 62.7 MTF1 1

220133_at 2.52828511 1 7.85 2.5282853 20.55 FLJ20513 hypothetical protein FLJ20513

Homo sapiens cDNA: FLJ21710 fis, clone COL10087, mRNA

216431_at 2.52736568 1 -17.45 2.5273657 1.15 sequence serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),

209719_x_at 2.52714956 1 13.25 2.5271497 36.8 SERPINB3 member 3 220004_at 2.52643682 1 -1 2.5264368 2.6 HAGE DEAD-box protein 215065_at 2.52617002 1 5.85 2.52617 15.75 KIAA1111 KIAA1111 protein 207711_at 2.52597512 1 2.95 2.525975 5.5 KIAA0889 KIAA0889 protein Homo sapiens mRNA; cDNA DKFZp564E233 (from clone

216518_at 2.51901166 1 1.55 2.5190117 4.4 DKFZp564E233), mRNA sequence protein tyrosine phosphatase, non¬

203997_at 2.51894912 1 0.4 2.518949 2.25 PTPN3 receptor type 3 cadherin 6, type 2, K-cadherin

205533_s_at 2.51684063 1 2.1 2.5168405 4.2 CDH6 (fetal kidney) transient receptor potential cation

220552_at 2.51569599 1 -2 2.5156958 3.85 TRPC5 channel, subfamily C₁ member 5 κ> ESTs, Moderately similar to KI67_HUMAN Antigen KI-67

212022_s_at 2.51506067 1 -22.65 2.515061 -0.65 MKI67 [H.sapiens] proteasome (prosome, macropain)

208776_at 2.51439154 1 26.65 2.5143917 71.25 PSMD11 26S subunit, non-ATPase, 11 potassium inwardly-rectifying

211817_s_at 2.50896738 1 15.45 2.5089672 24.2 KCNJ5 channel, subfamily J, member 5 209826_at 2.50571967 1 8.3 2.5057197 30.35 PPT2 palmitoyl-protein thioesterase 2 221837_at 2.50543181 1 -7.55 2.505432 -22.95 FLJ 14360 hypothetical protein FLJ 14360 chromosome 20 open reading

221762_s_at 2.50402309 1 80 2.504023 210.9 C20orf67 frame 67 47553_at 2.50375382 1 8.5 2.503754 33.75 DKFZP434N014 DKFZP434N014 protein Homo sapiens mRNA; cDNA DKFZp434K1126 (from clone DKFZp434K1126), mRNA

216140_at 2.50322349 1 13.8 2.5032234 35.7 sequence 206157 at 2.50183205 1 168.7 2.501832 454.65 PTX3 pentaxin-related gene, rapidly

induced by IL-1 beta fibronectin type 3 and SPRY

219170_at 2.50166885 1 -6.75 2.501669 31.25 FSD1 domain-containing protein guanine nucleotide binding protein

205349_at 2.49793252 1 3.5 2.4979324 12.6 GNA15 (G protein), alpha 15 (Gq class)

217498_at 2.49703932 1 -0.9 2.4970393 -5.15 GDF11 ESTs

201452_at 2.49554467 1 5.1 2.4955447 14.4

205107_s_at 2.49547569 1 16.95 2.4954758 44.25 EFNA4 ephrin-A4 myeloid/lymphoid or mixed-lineage leukemia (trithorax homo^'log,

215451_s_at 2.49382439 1 -5.75 2.4938245 23.65 MLLT2 Drosophila); translocated to, 2

NK3 transcription factor related,

211497_x_at 2.49097349 1 -0.95 2.4909735 20.85 NKX3-1 locus 1 (Drosophila)

213114_at 2.4909126 1 9.6 2.4909127 26.95 RER1 similar to S. cerevisiae RER1 chloride channel, calcium activated

217528_at 2.49038538 1 0.25 2.4903853 2.65 CLCA2 family member 2 O

ATPase, aminophospholipid transporter (APLT), Class I, type

210192 at 2.48778364 1 6.5 2.4877834 17.4 ATP8A1 8A, member 1

222249_at 2.48671898 1 3.95 2.4867191 10.5

219488_at 2.48155503 1 8.75 2.481555 23.55 A4GALT alpha 1,4-gaIactosyitransferase

DNA segment on chromosome X and Y (unique) 155 expressed

210269_s_at 2.47842724 1 -8.05 2.4784272 18.15 DXYS155E sequence

215524_x_at 2.477098 1 0.6 2.4770977 9.7 TRA@ T cell receptor alpha locus

Homo sapiens cDNA FLJ14096 fis, clone MAMMA1000752, mRNA

216123_x_at 2.47619227 1 8.55 2.4761922 21.5 sequence low density lipoprotein-related

219643_at 2.4756617 1 -0.05 2.4756615 2.1 LRP 1 B protein 1B (deleted in tumors)

207526_s_at 2.47309787 1 9.55 2.4730978 25.5 1L1 RL1 interleukin 1 receptor-like 1

210267_at 2.47048528 1 2.05 2.4704852 9.5 DJ462O23.2 hypothetical protein dJ462O23.2

206002_at 2.47045149 1 12.15 2.4704518 31.6 GPR64 G protein-coupled receptor 64

206852 at 2.47034709 1 0.75 2.470347 2.6 EPHA7 EphA7

211606_at 2.46869359 1 5.45 2.4686935 13.6

Homo sapiens cDNA FLJ12339 fis, clone MAMMA1002250, mRNA

215624_at 2.46530629 1 -0.35 2.4653063 4 sequence 216370_s_at 2.46505539 1 2.35 2.4650552 10.9 TKTL1 transketolase-iike 1

Homo sapiens cDNA: FLJ21285 fis, clone COL01912, mRNA

215866_at 2.46469826 1 2.2 2.4646983 11 sequence phosphodiesterase 4D, cAWlP- specϊfϊc (phosphodiesterase E3

211840_s_at 2.46168581 1 30 2.4616857 82.6 PDE4D dunce homolog, Drosophiia) calcium/calmodulin-dependent protein kinase (CaM kinase) Il

213108_at 2.46165662 1 -29.85 2.4616566 31.7 CAMK2A alpha

ESTs, Weakly similar to cytokine receptor-like factor 2; cytokine receptor CRL2 precusor [Homo

217712_at 2.46141358 1 4.05 2.4614134 10.2 sapiens] [H. sapiens] ubiquitous tetratricopeptide

206169_x_at 2.45991008 1 6.3 2.4599102 13.95 RoXaN containing protein RoXaN 208075_s_at 2.4589507 1 24.45 2.4589508 64.65 CCL7 chemokine (C-C motif) ligand 7

Burkitt lymphoma receptor 1 , GTP binding protein (chemokine (C-X-C

206126_at 2.45501051 1 1.05 2.4550104 -8.9 BLR1 motif) receptor 5) 214509_at 2.45191002 1 8.15 2.45191 21 H3FF H3 histone family, member F lymphocyte cytosolic protein 2

(SH2 domain containing leukocyte

205269_at 2.45149725 1 1.65 2.4514976 ' 4.6 LCP2 protein of 76kDa) solute carrier family 18 (vesicular

205857_at 2.45077155 1 2.05 2.4507713 13.8 SLC18A2 monoamine), member 2 ribosome binding protein 1

213495_s_at 2.45057581 1 11.5 2.4505758 27.7 RRBP1 homolog 18OkDa (dog) phospholipase A2, group IB

206311_s_at 2.44741477 1 6.65 2.4474146 17.2 PLA2G1 B (pancreas) 221120 at 2.44473069 1 9.75 2.4447308 25.15 FLJ20306 hypothetical protein FLJ20306

Norepinephrine transporter isoform

2 [Homo sapiens], mRNA

216610_at 2.44467623 1 -0.1 2.4446764 11.55 sequence 214157_at 2.44419165 1 14.8 2.4441915 37.55 GNAS GNAS complex locus chromatin assembly factor 1 ,

204775_at 2.44222438 1 4.15 2.4422243 21.05 CHAF1 B subunit B (p60) killer cell immunoglobulin-like receptor, three domains, long

207313_x_at 2.44172926 1 10.5 2.441729 26 KIR3DL2 cytoplasmic tail, 2 214795_at 2.44110718 1 12.4 2.441107 33.1 PRKCBP1 protein kinase C binding protein 1 olfactory receptor, family 2,

221451_s_at 2.43350682 1 5.35 2.433507 13.4 OR2W1 subfamily W, member 1 211329_x_at 2.43335331 1 23.4 2.4333532 55.5 HFE hemochromatosis

Homo sapiens cDNA FLJ33527 fis, clone BRAMY2007078, mRNA

214729_at 2.42980555 1 1.6 2.4298055 11.85 TWISTNB sequence mitogen-activated protein kinase 8 O

213177_at 2.42909781 1 6.4 2.4290977 22.65 MAPK8IP3 interacting protein 3 210953_at 2.4282536 1 2.75 2.4282537 5.4 KIAA0669 KIAA0669 gene product

Homo sapiens cDNA FLJ10131 fis, clone HEMBA1003041 , mRNA

215024_at 2.42612241 1 1.9 2.4261222 24.35 sequence 203750_s_at 2.4214409 1 7.85 2.421441 30.6 RARA retinoic acid receptor, alpha

Bone morphogenetic protein

BMPY [Homo sapiens], mRNA

216369_at 2.42100265 1 5.85 2.4210024 14.4 sequence vitelliform macular dystrophy 2-like

207432_at 2.41946855 1 13.1 2.4194684 36.5 VMD2L1 protein 1 solute carrier family 18 (vesicular

207074_s_at 2.4173548 1 -2.55 2.4173548 -1.05 SLC18A1 monoamine), member 1

Unknown (protein for

IMAGE:4689522) [Homo sapiens],

221884_at 2.41399223 1 7.8 2.4139924 21 EVH mRNA sequence 215871 at 2.41177945 1 9.85 2.4117794 24.2 PLA2G5 phospholipase A2, group V

Homo sapiens cDNA FLJ31305 fis, clone LIVER1000104, moderately similar to Rattus norvegicus kidney- specific protein (KS) mRNA, mRNA

214069_at 2.41100628 1 3.75 2.4110062 19.85 sequence

CAP-binding protein complex

218811_at 2.40807695 1 6.95 2.4080768 17.45 CBCIP2 interacting protein 2

222177_s_at 2.40286827 1 5.8 2.4028683 15 SCAND2 SCAN domain containing 2

Homo sapiens germline mRNA

213678_at 2.39924555 1 20.1 2.3992457 51.05 sequence

217015_at 2.398776 1 -4.55 2.398776 -1.55

204101_at 2.39817245 1 9 2.3981724 21.05 MTM1 myotubular myopathy 1

BUB1 budding uninhibited by

216275_at 2.39679503 1 -0.2 2.396795 20.25 BUB1 benzimidazoles 1 homolog (yeast)

Homo sapiens mRNA; cDNA

DKFZp434M1812 (from clone

DKFZp434M1812), mRNA

216459_x_at 2.39601709 1 10.7 2.396017 28.8 sequence

Homo sapiens mRNA; cDNA

DKFZp564N2216 (from clone

DKFZp564N2216), mRNA

217177_s_at 2.39562199 1 2.3 2.3956218 11.3 sequence

214067_at 2.39507494 1 0.9 2.3950748 7.3 BAIAP3 BAH -associated protein 3

212326_at 2.39476164 1 -1 2.3947618 18.45 KIAA0453 KIAA0453 protein

ATP-binding cassette, sub-family A

204719_at 2.39320482 1 9.7 2.3932047 24.45 ABCA8 (ABC1), member 8

204592_at 2.39209024 1 17.5 2.3920903 43.5 DLG4 discs, large (Drosophila) homolog 4

217147_s_at 2.39184507 1 -2.8 2.3918452 -0.55 TRIM T-cell receptor interacting molecule inhibitor of growth family, member

213544_at 2.38671598 1 2.45 2.386716 7.85 ING1L 1-like

202357_s_at 2.386254 1 12.2 2.386254 35.9 BF B-factor, properdin apoptotic protease activating

211553_x_at 2.38254329 1 13.6 2.3825436 34.75 APAF1 factor

212701_at 2.38172979 1 27.25 2.3817298 64.05 TLN2 talin 2

222224 at 2.37642731 1 1.5 2.3764274 3.95 alpha-NAC

206745_at 2.37370006 1 42.7 2.3737001 111.45 HOXC11 homeo box C11

212475_at 2.37361643 1 9.7 2.3736162 26.25 KIAA0241 K1AA0241 protein killer cell lectin-like receptor

207229_at 2.37138717 1 5.2 2.3713872 13.5 KLRA1 subfamily A, member 1

ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B, isoform 1 (Renal tubular acidosis

205473_at 2.36711714 1 20.25 2.3671174 48.95 ATP6V1 B1 with deafness)

215199_at 2.36613948 1 19.8 2.3661394 51.55 CALD1 caldesmon 1

ADP-ribosylation factor guanine nucleotide-exchange factor 2

215931_s_at 2.36301727 1 4.9 2.363017 12.1 ARFGEF2 (brefeldin A-inhibited)

206224_at 2.36275997 1 4.95 2.3627598 12.25 CST1 cystatin SN

215806_x_at 2.36228685 1 7.95 2.362287 20.05 TRGC2 T cell receptor gamma constant 2 myosin, heavy polypeptide 8,

34471_at 2.36188928 1 -10.15 2.3618891 13.55 MYH8 skeletal muscle, perinatal

216502_at 2.36082861 1 11.55 2.3608286 27.5 FLJ 12671 hypothetical protein FLJ12671

210032_s_at 2.35603385 1 26.3 2.3560338 66 SPAG6 sperm associated antigen 6 adenylate cyclase activating polypeptide 1 (pituitary) receptor

207151_at 2.35549324 1 1.85 2.355493 14.75 ADCYAP1 R1 type I caspase 1 , apoptosis-related cysteine protease (interleukin 1 ,

206011_at 2.35384815 1 7.7 2.3538482 20.2 CASP1 beta, convertase)

219331_s_at 2.35269227 1 8.25 2.3526921 20.05 FLJ 10748 hypothetical protein FLJ10748

213192_at 2.35209787 1 16.05 2.352098 38.45 LOC90326 hypothetical protein BC005114 solute carrier family 16

(monocarboxylic acid transporters),

206599_at 2.35199356 1 0.6 2.3519936 4.5 SLC16A5 member 5

220702_at 2.35187965 1 9.7 2.3518796 23.4 PRO2037 hypothetical protein PRO2037

220270_at 2.35143628 1 -2.45 2.3514361 0.5 TDRD4 hypothetical protein FLJ 11045

216316_x_at 2.34950431 1 14 2.3495045 34.9 GKP1 solute carrier family 21 (organic

210542 s at 2.34801447 1 22.9 2.3480144 57.3 SLC21A11 anion transoorter), member 11

a disintegrin and metalloproteinase

208269_s_at 2.34706972 1 9.35 2.3470697 24.95 ADAM28 domain 28 210274_at 2.3467881 1 6.8 2.3467882 16.6 MAGEA8 melanoma antigen, family A, 8 206693_at 2.34654242 1 5.85 2.3465424 18.35 1L7 interleukin 7 205971_s_at 2.34482852 1 13.4 2.3448284 34.5 CTRB 1 chymotrypsinogen B1 cytochrome P450, subfamily IHA,

211442_x_at 2.34449744 1 20 2.3444974 50.25 CYP3A43 polypeptide 43 207227_x_at 2.34427135 1 13.95 2.3442714 34.35 RFPL2 ret finger protein-like 2

RAP2B, member of RAS oncogene

214488_at 2.34298746 1 2.55 2.3429875 6.3 RAP2B family interleukin 17 (cytotoxic T- iymphocyte-assocϊated serine

208402_at 2.34264516 1 8.35 2.3426452 20.65 IL17 esterase 8} nuclear matrix protein NMP200

203103_s_at 2.34227473 1 71.95 2.3422747 170.15 NMP200 related to splicing factor PRP19 214868_at 2.34079249 1 2.8 2.3407924 6.9 PIWIL1 piwi-Iike 1 (Drosophila)

O 205751_at 2.33925548 1 0.45 2.3392556 3.2 SH3GL2 SH3-domain GRB2-like 2 diacylglycerol kinase, epsilon

207518_at 2.33648691 1 14.3 2.3364868 35.2 DGKE 64kDa

215177_s_at 2.33547938 1 20.3 2.3354793 S2.8 ITGA6 integrin, alpha 8

IL-1 beta-regulated neutrophil survival protein [Homo sapiens],

211459_at 2.33334241 1 2.5 2.333342 8.7 mRNA sequence 219612_s_at 2.33281975 1 5.6 2.3328195 14.7 FGG fibrinogen, gamma polypeptide 211248_s_at 2.33202529 1 8.8 2.3320253 21.05 CHRD chordin chromosome 6 open reading frame

208469_s_at 2.33158751 1 7.7 2.3315873 19.8 C6orf8 8 corticotropin releasing hormone

214619_at 2.33155832 1 2.3 2.3315582 -3.6 CRHR1 receptor 1

CDC5 cell division cycle 5-like

222179_at 2.33087909 1 18.5 2.3308792 45.3 CDC5L (S. pombe) interleukin 12B (natural kiiler cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2,

207901 at 2.33060543 1 9.15 2.3306055 23.15 IL12B p40)

Homo sapiens cDNA FLJ11738 fis, clone HEMBA1005474, mRNA

213591_at 2.3291431 1 11.45 2.329143 27.85 sequence cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4

206515_at 2.32625935 1 7.05 2.3262591 17.3 CYP4F3 omega hydroxylase) regulatory factor X, 4 (influences 207672_at 2.32388043 1 -0.7 2.3238804 2.15 RFX4 HLA class Il expression) Homo sapiens cDNA: FLJ21335 fis, clone COL02546, mRNA

222214_at 2.32290856 1 10.8 2.3229084 25.5 sequence

Homo sapiens mRNA; cDNA DKFZp761G18121 (from clone DKFZp761G18121), mRNA

221625_at 2.32086194 1 4.6 2.3208618 11.25 sequence 216349_at 2.31802785 1 7.9 2.318028 20.95 A AKKAAPP1111 ;; F PRKA11; AKAP220; AKAP 220; FLJ11304; KIAA0629 brain-specific angiogenesis

204966_at 2.31703671 1 19.65 2.3170366 46.2 BAI2 inhibitor 2 O olfactory receptor, family 10, 208558_at 2.31698623 1 12.2 2.3169866 30.5 OR10H1 subfamily H, member 1 Skin-specific protein [Homo 216935_at 2.3150153 1 7.5 2.3150153 19.25 sapiens], mRNA sequence regulator of G-protein signalling 210258_at 2.31224794 1 1.7 2.312248 3.75 RGS13 13 hypothetical protein similar to beta- 203867_s_at 2.31096545 1 23.6 2.3109655 53.1 FLJ 10458 transducin family guanylate cyclase 1, soluble, alpha

206927_s_at 2.30620963 1 7.65 2.3062096 19.25 GUCY1A2 2 213844_at 2.29709128 1 3.45 2.2970915 9.3 HOXA5 homeo box A5 cytochrome P450, subfamily XIA

204309_at 2.29508115 1 6 2.2950811 14.65 CYP11A1 (cholesterol side chain cleavage) 210140_at 2.29449721 1 -6.7 2.294497 28.35 CST7 cystatin F (leukocystatin) diacylglycerol kinase, gamma

206395_at 2.29386477 1 21.95 2.293865 52 DGKG 9OkDa 204931 at 2.29264587 1 37.35 2.292646 92.6 TCF21 transcription factor 21

serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),

204614_at 2.28575308 1 29.75 2.2857533 73.15 SERPINB2 member 2

Homo sapiens clone 23758 mRNA

215473_at 2.28566314 1 6.55 2.2856631 16.8 sequence 220582_at 2.28523253 1 8.15 2.2852325 19.95 FLJ 12190 hypothetical protein FLJ12190 208282_x_at 2.2841331 1 -3.45 2.2841332 0.9 DAZ2 deleted in azoospermia 2 solute carrier family 17 (sodium

207097_s_at 2.27923641 1 -8.45 2.2792363 8.8 SLC17A2 phosphate), member 2 218900_at 2.27899004 1 20 2.27899 44.4 CNNM4 cyclin M4

Cdc42 guanine nucleotide

203263_s_at 2.27870362 1 -2.9 2.2787037 9.5 ARHGEF9 exchange factor (GEF) 9 eukaryotic translation initiation

220198_s_at 2.27720097 1 3.9 2.277201 35.1 EIF5A2 factor 5A2 retinoic acid receptor responder

206392_s_at 2.2770316 1 -2.9 2.2770317 -1.8 RARRES 1 (tazarotene induced) 1 217044_s_at 2.2764684 1 18.6 2.2764683 42.4 KIAA0599 KIAA0599 protein mitochondrial ribosomal protein

213863_s_at 2.27584505 1 4.5 2.275845 11 MRPL9 L9 myosin, heavy polypeptide 6, cardiac muscle, alpha

214468_at 2.27174369 1 -5.35 2.2717438 1.65 MYH6 (cardiomyopathy, hypertrophic 1 ) similar to rat nuclear ubiquitous

222027_at 2.26602185 1 0.5 2.2660217 -2.7 NUCKS casein kinase 2 chromosome 20 open reading

219310_at 2.2651143 1 5.45 2.2651143 13.15 C20orf39 frame 39 220710_at 2.263289 1 3.85 2.263289 9.35 FLJ 11722 hypothetical protein FLJ 11722 207763_at 2.25873288 1 11.5 2.258733 30.2 S100A5 S100 calcium binding protein A5 low density lipoprotein receptor- related protein 8, apolipoprotein e

208433_s_at 2.25813266 1 8.9 2.2581327 20.4 LRP8 receptor 212975_at 2.25576442 1 13.8 2.2557645 32.45 KIAA0870 KIAA0870 protein erythrocyte membrane protein

220120_s_at 2.25221319 1 7.55 2.252213 17.8 EPB41L4A band 4.1 like 4A 213568 at 2.25003456 1 3.45 2.2500348 8 OSR2 odd-skipped-related 2A protein

golgi associated, gamma adaptin ear containing, ARF binding protein

214189_s_at 2.24817813 1 8.5 2.248178 19.05 GGA2 2

208524_at 2.24679078 1 16.8 2.2467906 40.9 GPR15 G protein-coupled receptor 15

208889_s_at 2.24329758 1 29.8 2.2432976 71.05 NCOR2 nuclear receptor co-repressor 2

221076_at 2.24271479 1 1.2 2.242715 2.5 PR01770 PRO1770 protein

207393_at 2.2422322 1 10.65 2.2422323 24.75 HCRTR2 hypocretin (orexin) receptor 2

204912_at 2.24193163 1 3.55 2.2419317 10.7 IL10RA interleukin 10 receptor, aipha adaptor-related protein complex 3,

210974_s_at 2.24066756 1 22.5 2.2406676 61.95 AP3D1 delta 1 subunit hypothetical protein

221876_at 2.24032776 1 16.65 2.2403278 53.25 DKFZp762P2111 DKFZp762P2111

219844_at 2.23590459 1 3.25 2.2359045 7.85 FLJ 10188 CTCL tumor antigen L14-2

202746_at 2.23576736 1 4.9 2.2357674 11.85 ITM2A; E25A integral membrane protein 2A solute carrier family 2 (facilitated

220091_at 2.23454554 1 6.25 2.2345455 15.9 SLC2A6 glucose transporter), member 6

Similar to RIKEN cDNA

3000004N20 gene [Homo sapiens],

51226_at 2.23043305 1 11.05 2.230433 25.9 mRNA sequence

212000_at 2.2279393 1 3.15 2.2279394 10.9 KIAA0365 KIAA0365 gene product

Homo sapiens, clone

IMAGE:4711494, mRNA, mRNA

221477_s_at 2.22792345 1 228.15 2.2279234 558.35 sequence

52837_at 2.22377789 1 65.15 2.223778 141.85 KIAA1644 KIAA1644 protein

208303_s_at 2.22360823 1 -6.35 2.223608 0.05 CRLF2 cytokine receptor-like factor 2

207400_at 2.22282273 1 18.15 2.2228227 42.9 NPY5R neuropeptide Y receptor Y5

217630_at 2.22201876 1 5.45 2.2220187 14.75 LOC90806 similar to RIKEN cDNA 2610307121 cytochrome P450, subfamily XVII

(steroid 17-alpha-hydroxylase),

205502_at 2.21911409 1 21.2 2.219114 47.5 CYP17A1 adrenal hyperplasia

216192_at 2.2182874 1 26.15 2.2182875 61.1 FABP7 fatty acid binding protein 7, brain

213783 at 2.21757523 1 4.55 2.217575 19.4 MFNG manic fringe homolog (Drosophila)

translocase of inner mitochondrial

215168 at 2.21714462 2.05 2.2171445 4.65 TIMM17A membrane 17 homolog A (yeast)

ESTs, Highly similar to hepatocellular carcinoma associated protein; breast cancer assoc; hepatocellular carcinoma associated protein; breast cancer associated gene 1 [Homo sapiens]

214681_at 2.21611947 1 4.55 2.2161195 10.8 GK [H.sapiens]

5-hydroxytryptamine (serotonin) 207578_s_at 2.21598374 1 32.25 2.2159839 75.05 HTR4 receptor 4 sema domain, transmembrane domain (TM), and cytoplasmic

220574_at 2.21550964 1 12.9 2.2155094 29.2 SEMA6D domain, (semaphorin) 6D pregnancy specific beta-1- 203399_x_at 2.21422791 1 7.2 2.214228 16.7 PSG3 glycoprotein 3 acidic epididymal glycoprotein-like

216314_at 2.21056424 1 0.1 2.2105641 4.7 AEGL1 1 222089_s_at 2.20884793 1 12.35 2.208848 29.9 LOC146562 hypothetical protein AF447587

Homo sapiens cDNA: FLJ22066 fis, clone HEP10611 , mRNA

202409_at 2.20660205 1 7.7 2.206602 17.85 sequence prostaglandin E receptor 3 208169_s_at 2.20144438 1 18.7 2.2014446 44.7 PTGER3 (subtype EP3) likely homolog of rat kinase D-

214932_at 2.20113498 1 9.8 2.201135 23.05 KIDINS220 interacting substance of 220 kDa 213713 s at 2.20103788 1 29.15 2.201038 68.9 LOC89944 hypothetical protein BC008326 solute carrier family 24

(sodium/potassium/calcium

211842_s_at 2.19960701 9.15 2.199607 21.6 SLC24A1 exchanger), member 1 219429_at 2.19568772 22.35 2.1956875 52.75 FAAH fatty acid hydroxylase 221157_s_at 2.19567594 4.05 2.1956758 7.15 FBXO24 F-box only protein 24 205083_at 2.19414698 37.65 2.194147 85.35 AOX1 aldehyde oxidase 1

DnaJ (Hsp40) homolog, subfamily

220395 at 2.19398326 73.6 2.193983 169.4 DNAJA4 A, member 4

216391_s_at 2.19133849 1 13.15 2.1913385 30.95 KLHL1 kelch-like 1 (Drosophila)

221924_at 2.19070578 1 35.2 2.1907058 83.35 DKFZp76112123 KIAA1886 protein

215936_s_at 2.18988484 1 5.5 2.189885 13.4 KIAA1033 KIAA1033 protein

220258_s_at 2.18884962 1 -4.6 2.1888494 -15.65 FLJ 10385 hypothetical protein FLJ10385

216131_at 2.18620075 1 2.35 2.1862006 5.8 KIAA1013 KIAA1013 protein

Homo sapiens cDNA: FLJ21461 fis, clone COL04727, mRNA

216172_at 2.18511458 1 15.7 2.1851149 34.7 sequence

217143_s_at 2.18369272 1 10.25 2.1836927 23.85 TRD@ T cell receptor delta locus

Homo sapiens mRNA full length insert cDNA clone EUROIMAGE

214896_at 2.18278626 1 0.15 2.1827862 27.35 29222, mRNA sequence surfactant, pulmonary-associated

38691_s_at 2.18273604 1 25.45 2.182736 59.2 SFTPC protein C transient receptor potential cation

206479_at 2.179979 1 0.25 2.1799788 7.6 TRPM1 channel, subfamily M, member 1

Homo sapiens clone 24694 mRNA W

216006_at 2.17987284 1 9.75 2.179873 22.2 sequence

213827_at 2.17925339 1 19.9 2.1792536 44.85 SNX26 sorting nexin 26

219461_at 2.1789758 1 2.6 2.1789758 2.15 PAK6 p21(CDKN1A)-activated kinase 6

ESTs, Weakly similar to hypothetical protein FLJ20378

210717_at 2.17876305 1 4.05 2.1787632 8.95 [Homo sapiens] [H.sapiens]

T cell activation, increased late

206761_at 2.17562979 1 0.3 2.1756299 1.8 TACTILE expression

208506_at 2.17432551 1 10.15 2.1743257 22.7 HIST1 H3F H3 histone family, member I

205666_at 2.17205007 1 -1.05 2.17205 -11.3 FMO1 flavin containing monooxygenase 1

221813_at 2.1715637 1 77.2 2.1715636 175.85 KIAA1332 KIAA1332 protein

214745_at 2.17031908 1 13.65 2.170319 31.5 KIAA1069 KIAA1069 protein integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha

205785 at 2.16869938 1 29.05 2.1686995 67.8 ITGAM polypeptide)

keratin 1 (epidermolytic

205900_at 2.16758758 1 11.25 2.1675875 26.3 KRT1 hyperkeratosis)

219365_s_at 2.16586629 1 10.25 2.1658664 24.9 MGC8407 hypothetical protein MGC8407

215174_at 2.1655203 1 2.55 2.1655202 0.2 FLJ34218 hypothetical protein FLJ34218

DKFZP586A0522

209703_x_at 2.16358948 1 84.15 2.1635895 195 DKFZP586A0522 protein

221382_at 2.16314674 1 15.2 2.1631465 33.9 pregnancy specific beta-1-

206570_s_at 2.15989072 1 2.1 2.1598907 5 PSG11 glycoprotein 11

208216_at 2.15951127 1 9.7 2.1595113 22.45 DLX4 distal-less homeobox 4 tRNA selenocysteine associated

218977_s_at 2.1581571 1 21.9 2.1581573 51.3 SECP43 protein nudix (nucleoside diphosphate

212182_at 2.15606138 1 -0.05 2.1560614 4.3 NUDT4 linked moiety X)-type motif 4 phosphatase and tensin homolog (mutated in multiple

204054_at 2.15448368 1 11.4 2.1544836 26.3S PTEN advanced cancers 1) ^.

212991_at 2.15266629 1 4.7 2.152666 10.5 FBXO9 F-box only protein 9

55616_at 2.15243601 1 65.1 2.152436 143.6 CAB2 hypothetical gene MGC9753

TAF4b RNA polymerase II, TATA box binding protein (TBP)-

216226_at 2.14970302 1 20.5 2.149703 46.7 TAF4B associated factor, 105kDa

217261_at 2.14813691 1 19.25 2.148137 43.65 TTTY2 testis-specific transcript, Y-linked 2 prostaglandin E receptor 3

210831_s_at 2.14707114 1 4.05 2.1470714 9.15 PTGER3 (subtype EP3) cell division cycle 2-like 5

(cholinesterase-related cell division

210965_x_at 2.14701022 1 10.55 2.14701 23.85 CDC2L5 controller)

220784_s_at 2.14293451 1 2.75 2.1429343 6.15 UTS2 urotensin 2 dopachrome tautomerase

(dopachrome delta-isomerase,

205338_s_at 2.14279298 1 10.7 2.142793 26.6 DCT tyrosine-related protein 2) butyrophilin, subfamily 1 , member

207395_at 2.14192304 1 7.45 2.141923 15.8 BTN 1A1 A1

22G889_at 2.14168982 1 9 2.14169 22.15 NODAL hypothetical protein FLJ10314

D site of albumin promoter

209782_s_at 2.14159149 1 45.2 2.1415915 99.45 DBP (albumin D-box) binding protein 215681_at 2.14110527 1 0.25 2.1411052 17.75 KIAA1654 KIAA1654 protein

Skin-specific protein [Homo

217087_at 2.13971628 1 14.15 2.1397164 30.05 sapiens], mRNA sequence

Scm-related gene containing four

213370_s_at 2.1369493 1 10.65 2.1369493 24.5 SFMBT mbt domains selectin E (endothelial adhesion

206211_at 2.13681537 1 9 2.1368153 21 SELE molecule 1)

Homo sapiens clone 24734 mRNA

215456_at 2.13622164 1 15.85 2.1362216 37.2 sequence phosphodiesterase 4D, cAMP- specific (phosphodiesterase E3

210836_x_at 2.13613379 1 12.2 2.1361337 27.9 PDE4D dunce homolog, Drosophila)

Cbp/p300-interacting transactivator, with Glu/Asp-rich

207144_s_at 2.13582833 1 -4.4 2.1358283 14.9 CITED1 carboxy-terminal domain, 1

PRO2613 [Homo sapiens], mRNA

210491_at 2.13578278 1 2.45 2.1357827 5.45 sequence

RAB40A, member RAS

215782_at 2.13512082 1 -2.85 2.1351209 -6.05 LOC286526; RAR2 oncogene family 210234_at 2.13455683 1 20.6 2.1345568 44.45 GRM4 glutamate receptor, metabotropic 4 CDC42 effector protein (Rho

209850_s_at 2.13425672 1 -11.7 2.1342568 5.7 CDC42EP2 GTPase binding) 2

219800_s_at 2.13162934 1 5.3 2.1316295 11.95 FLJ22002 hypothetical protein FLJ22002 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4,

207881_at 2.13052678 1 8.4 2.1305268 19 PSMD4P pseudogene protein phosphatase 1 E (PP2C

205938_at 2.12963774 1 8.4 2.1296377 13.5 PPM1 E domain containing) gonadotropin-releasing hormone

207987_s_at 2.12742463 1 4.1 2.1274247 10 GNRH1 1 (leutinizing-releasing hormone) cholinergic receptor, nicotinic,

206735 at 2.12647602 1 7.25 2.126476 22.35 CHRNA4 alpha polypeptide 4

likely ortholog of mouse and zebrafish forebrain embryonic

221086_s_at 2.12642595 1 1.95 2.126426 3.75 FEZL zinc finger-like 221348_at 2.12598765 1 -4.35 2.1259878 -18.7 NPPC natriuretic peptide precursor C 220842_at 2.12587619 1 6.1 2.1258762 13.3 FLJ20069 hypothetical protein FLJ20069 222185_at 2.12250429 1 22.7 2.1225042 57.25 PKNOX2 PBX/knotted 1 homeobox 2 207301 _at 2.12126523 1 19.75 2.1212654 46.4 EFNA5 ephrin-A5 220752_at 2.1208086 1 11.8 2.1208086 26.3 LOC51145 erythrocyte transmembrane protein 212659_s_at 2.12057775 1 8.4 2.1205778 20.1 IL1RN interleukin 1 receptor antagonist 1-acylglycerol-3-phosphate O- acyltransferase 2 (lysophosphatidic

210678_s_at 2.11993665 1 29.35 2.1199365 64.6 AGPAT2 acid acyltransferase, beta) nuclear factor of kappa light polypeptide gene enhancer in B-

209973_at 2.11910361 1 16.1 2.1191037 34.9 NFKBIL1 cells inhibitor-like 1 219897_at 2.11761338 1 101.05 2.1176133 235.3 FLJ 12526 hypothetical protein FLJ12526 222384_at 2.11745745 1 5 2.1174574 11.4 DKFZP564C196 DKFZP564C196 protein 221658_s_at 2.11600894 1 1.7 2.116009 2.05 1L21R interleukin 21 receptor ESTs, Weakly similar to hypothetical protein FLJ20489

215067_x_at 2.11589964 1 12.05 2.1158996 27.4 [Homo sapiens] [H.sapiens] phospholipase A2, group VII (platelet-activating factor

206214_at 2.11484952 1 5.05 2.1148496 11.8 PLA2G7 acetylhydrolase, plasma) 221370_at 2.1140859 1 8.05 2.114086 19.3 ZNF73 zinc finger protein 73 (Cos12) retinal pigment epithelium-specific

207107_at 2.11407174 1 1.6 2.1140718 3.3 RPE65 protein 65kDa 212095_s_at 2.11364421 1 -2.05 2.1136441 4.05 ATIP1 AT2 receptor-interacting protein 1 220469_at 2.11269743 1 -2.35 2.1126974 -2.05 FLJ 13241 hypothetical protein FLJ13241 220854_at 2.11186485 1 -0.1 2.1118646 6.7 PRO0246 PRO0246 protein cytochrome b-245, beta polypeptide (chronic

203923_s_at 2.11166346 1 17 2.1116636 37.75 CYBB granulomatous disease) 219380 x at 2.11156482 1 8 2.1115646 17.25 POLH polymerase (DNA directed), eta

206819_at 2.11073762 1 16.55 2.1107378 38.25 DKFZP434P211 DKFZp434P211 protein Unknown (protein for MGC:11120)

217513_at 2.11025625 1 29.75 2.1102562 69.25 [Homo sapiens], mRNA sequence chromosome 20 open reading

222045_s_at 2.11015385 1 32.45 2.110154 76 C20orf67 frame 67

DEAD/H (Asp-GIu-Aia-Asp/His) box polypeptide 11 (CHL1-like helicase

208149_x_at 2.10966682 1 81.85 2.1096668 180.9 DDX11 homolog, S. cerevisiae) 216089_at 2.10542047 1 4.85 2.1054206 10.5

DNA-binding transcriptional

216188_at 2.10456894 1 7.3 2.104569 16.4 NCYM activator 221110_x_at 2.10404921 1 4.75 2.1040492 10.45 PDE11A phosphodiesterase 11A 204182_s_at 2.10189624 1 -11.1 2.101896 -5.75 ZNF297B zinc finger protein 297B dentatorubral-pallidoluysian

208871_at 2.10145617 1 63.25 2.1014562 138.7 DRPLA atrophy (atrophin-1 )

Homo sapiens cDNA FLJ20463 fis,

222031_at 2.09880064 1 4.4 2.0988004 9.55 clone KAT06143, mRNA sequence cyclin-dependent kinase inhibitor

213183_s_at 2.09653556 1 18.6 2.0965357 41.75 CDKN1C 1C (p57, Kip2) 211718_at 2.0939753 1 5.2 2.093975 11.8 MGC2889 hypothetical protein MGC2889 34260_at 2.09332627 1 50.9 2.0933263 121.5 KIAA0683 KIAA0683 gene product chromosome 1 open reading frame

215562_at 2.08852673 1 14.25 2.0885267 31.8 C1orf34 34 217131_at 2.0885109 1 30.5 2.0885108 71.75 204922_at 2.08810466 1 23.1 2.0881047 52.1 FLJ22531 hypothetical protein FLJ22531

PRO2289 [Homo sapiens], mRNA

221148_at 2.08727651 1 5.45 2.0872765 13.9 sequence 221385_s_at 2.08608789 1 -3.25 2.086088 1.55 GPR42 G protein-coupled receptor 42 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H

204748_at 2.08560052 1 172.7 2.0856006 397.2 PTGS2 synthase and cyclooxygenase)

Homo sapiens cDNA FLJ13849 fis, clone THYRO1000865, mRNA

215490 at 2.08532456 1 10.3 2.0853245 22.6 sequence

complement component 3a

209906_at 2.08494478 1 11.25 2.0849447 24.95 C3AR1 receptor 1

220928_s_at 2.08450488 1 11.2 2.0845048 25.5 PRDM16 PR domain containing 16

Similar to histamine N- methyltransferase [Homo sapiens],

211732_x_at 2.08264701 1 0.1 2.082647 5.6 mRNA sequence

206970_at 2.0820951 1 15.15 2.0820951 41.1 CNTN2 contactin 2 (axonal)

Similar to alpha thalassemia/mental retardation syndrome X-linked

(RAD54 (S. cerevisiae) homolog)

211022 s at 2.08182505 1 2.7 2.081825 5.6 [Homo sapiens], mRNA sequence

ESTs, Highly similar to

IP3S_HUMAN Inositol 1 ,4,5- trisphosphate receptor type 2 (Type

2 inositol 1 ,4,5-trisphosphate receptor) (Type 2 lnsP3 receptor)

(IP3 receptor isoform 2) (lnsP3R2)

202661_at 2.08155398 1 2.95 2.081554 8.05 [H.sapiens] low density lipoprotein-related

205710_at 2.08147079 1 12.45 2.081471 27.35 LRP2 protein 2 213439_x_at 2.08143158 1 3.25 2.0814314 7.6 RPIP8 RaP2 interacting protein 8 221359_at 2.08078056 1 -9.2 2.0807805 15.65 GDNF glial cell derived neurotrophic factor 37986_at 2.08058965 1 22.1 2.0805895 48.3 EPOR erythropoietin receptor 217350_at 2.07967794 1 1.7 2.0796778 14.35 LOC160313 keratin 19 pseudogene 206497_at 2.07706205 1 2.05 2.0770621 7.1 FLJ 10803 hypothetical protein FLJ10803 208498_s_at 2.07662791 1 3.55 2.0766277 8.05 AMY1A amylase, alpha 1A; salivary alpha-actinin-2-associated LIM

210170_at 2.07569313 1 9.25 2.0756931 20.4 ALP protein

Homo sapiens cDNA: FLJ21966 fis, clone HEP05644, mRNA

215590_x_at 2.07412938 1 6 2.0741293 22.05 sequence gap junction protein, alpha 7,

208460_at 2.07370347 1 45.3 2.0737035 102 GJA7 45kDa (connexin 45) spondin 1 , (f-spondin) extracellular

209437 s at 2.07332585 1 3.15 2.0733259 3.65 SPON1 matrix protein

205625_s_at 2.07100844 1 10.9 2.0710084 23.15 CALB1 calbindin 1 , 28kDa

216283_s_at 2.07007447 1 11.5 2.0700746 25.4 PVR poliovirus receptor chromosome 20 open reading

60474_at 2.06991101 1 9.35 2.069911 21.3 C20orf42 frame 42

217355_at 2.06900478 1 8.65 2.0690048 19.45 EIF3S7; MGC17258; elF3-p66; elF3-zeta

213716_s_at 2.0688557 1 25.65 2.0688558 54.9 SECTM 1 secreted and transmembrane 1 chromosome 14 open reading

219316_s_at 2.068708 1 6.2 2.0687082 14.55 C14orf58 frame 58

PDZ domain protein (Drosophila

214705_at 2.0681921 1 2.25 2.068192 4.9 INADL inaD-like)

221171_at 2.06662951 1 1.95 2.0666296 5.05 FLJ20972 hypothetical protein FLJ20972

POU domain, class 6, transcription

216330_s_at 2.06629524 1 3.7 2.0662951 8.85 POU6F1 factor 1

210467_x_at 2.06533146 1 2.9 2.0653315 6.45 MAGEA12 melanoma antigen, family A, 12

220027_s_at 2.06436598 1 15 2.0643659 32.05 FLJ20401 hypothetical protein FLJ20401

208156_x_at 2.0643616 1 4.3 2.0643616 10.05 EPPK1 epiplakin 1

205681_at 2.06355813 1 10.95 2.0635583 25.45 BCL2A1 BCL2-related protein A1 VO

204672_s_at 2.06155825 1 5.75 2.0615582 13.45 ANKRD6 ankyrin repeat domain 6

214023_x_at 2.06137908 1 4.9 2.061379 10.6 TUBB tubulin, beta polypeptide

214204_at 2.0604145 1 13.5 2.0604143 32 PACRG parkin co-regulated gene protein

Ser-Thr protein kinase related to the myotonic dystrophy protein

214464_at 2.05994909 1 2.95 2.0599492 7.05 PK428 kinase putative lymphocyte G0/G1 switch

213524_s_at 2.05927849 1 226.8 2.0592785 481.65 G0S2 gene

Homo sapiens full length insert cDNA clone ZC26G04, mRNA

217550_at 2.05855677 1 -0.85 2.0585568 -12.45 sequence chromosome 15 open reading

221300_at 2.05819851 1 6.7 2.0581985 13.95 C15orf2 frame 2

PTPRF interacting protein, binding

214375_at 2.05722511 1 18.3 2.0572252 40.05 PPFIBP1 protein 1 (liprin beta 1) gonadotropin-releasing hormone

216341 s at 2.05526334 1 20.45 2.0552635 43.35 GNRHR receptor

214108_at 2.0543983 1 15.15 2.0543983 34.15 MAX MAX protein carcinoembryonic antigen-related

206199_at 2.05324238 1 10.7 2.0532422 25.35 CEACAM7 cell adhesion molecule 7

217166_at 2.05267441 1 20.7 2.0526743 43.8

220915_s_at 2.05259651 1 3.8 2.0525966 8.45 FLJ 11871 hypothetical protein FLJ 11871 putative N-acetyltransferase

206963_s_at 2.0515717 1 19.3 2.0515716 39.35 CML2 Camello 2

206087_x_at 2.05143916 1 132.6 2.0514393 294.5 HFE hemochromatosis

DiGeorge syndrome critical region

215725_at 2.05069691 1 16.3 2.0506968 36.5 DGCR11 gene 11 cholinergic receptor, nicotinic,

216886_at 2.04700867 1 16.7 2.0470085 38.9 CHRNA4 alpha polypeptide 4

ESTs, Moderately similar to hypothetical protein FLJ20378

212172_at 2.04634988 1 24.85 2.04635 52.95 [Homo sapiens] [H.sapiens]

218033_s_at 2.04515844 1 15.5 2.0451584 51.65 SNN stannin κ> cytochrome P450, subfamily IHA, O

207773_x_at 2.04439728 1 13.55 2.044397 31.9 CYP3A43 polypeptide 43

AFFX-r2-Bs-lys-3_at 2.04325235 1 12.25 2.0432522 26.1 growth arrest and DNA-damage-

213560_at 2.04292625 1 -1.15 2.042926 -2.1 GADD45B inducible, beta nuclear receptor subfamily 4, group

216979_at 2.0428586 1 12.25 2.0428586 26.3 NR4A3 A, member 3

4-aminobutyrate

206527_at 2.04169727 1 18.75 2.041697 40.3 ABAT aminotransferase matrix metailoproteinase 12

204580_at 2.04123938 1 11.7 2.0412395 26 MMP12 (macrophage elastase)

207463_x_at 2.03842008 1 19.65 2.0384202 40.75 PRSS3 protease, serine, 3 (mesotrypsin) protein phosphatase 2A 48 kDa

219264_s_at 2.0378103 1 9.2 2.0378103 21.2 PR48 regulatory subunit

208399_s_at 2.0366416 1 17.35 2.0366416 38.45 EDN3 endothelin 3 melanocortin 2 receptor

208568_at 2.03593606 1 24.5 2.035936 51.6 MC2R (adrenocorticotropic hormone)

205929_at 2.03568393 1 21.8 2.0356839 47.95 GPA33 glycoprotein A33 (transmembrane)

203928_x_at 2.03511536 1 23.45 2.0351155 52.75 MAPT microtubule-associated protein tau

206088_at 2.03506303 1 10.9 2.035063 24.6 KIAA0563 KIAA0563 gene product 221851_at 2.03497523 1 28.2 2.0349755 63.7 LOC90379 hypothetical protein BC002926 218480_at 2.03465265 1 44.1 2.0346527 94.05 FLJ21839 hypothetical protein FLJ21839 neurofibromin 2 (bilateral acoustic

211017_s_at 2.03323793 1 10.1 2.033238 21.8 NF2 neuroma)

Super cysteine rich protein; SCRP

217321_x_at 2.03178179 1 6.45 2.031782 13.5 [Homo sapiens], mRNA sequence

POU domain, class 4, transcription

207725_at 2.03130895 1 9.3 2.0313087 19.65 POU4F2 factor 2 220792_at 2.03111255 1 9 2.0311127 19.2 PRDM5 PR domain containing 5 221209_s_at 2.03075498 1 9.85 2.030755 21.6 OTOR otoraplin 220785_at 2.03069597 1 5.9 2.030696 12.55 UTS2 urotensin 2 221674_s_at 2.02939952 1 17.3 2.0293994 37.45 CHRD chordin

ATP synthase, H+ transporting, mitochondrial FO complex, subunit

207552_at 2.02829354 1 6.8 2.0282936 10.65 ATP5G2 c (subunit 9), isoform 2 κ> 219082_at 2.0276203 1 25.35 2.0276203 58.9 CGI-14 CGI-14 protein

Homo sapiens mRNA; cDNA

DKFZp566M0524 (from clone

DKFZp566M0524), mRNA

216636_at 2.0264686 1 1.45 2.0264685 6.5 sequence 215750_at 2.02555424 1 10.9 2.0255542 23.3 KIAA1659 KIAA1659 protein 217438_at 2.02354219 1 0.25 2.0235424 2.75 210611_s_at 2.02271909 1 6.65 2.022719 14.9 DTNA dystrobrevin, alpha

Homo sapiens mRNA; cDNA

DKFZp564L102 (from clone

216467_s_at 2.02108842 1 20.2 2.0210886 42.85 DKFZp564L102), mRNA sequence 217342_x_at 2.02007884 1 21.25 2.0200787 45.55 FLJ 11292 hypothetical protein FLJ 11292 sulfotransferase family, cytosolic,

205343_at 2.0191394 1 2.45 2.0191393 9.35 SULT1C1 1C, member 1 acidic epididymal glycoprotein-like

207032_s_at 2.01816252 1 8.2 2.0181625 17.6 AEGL1 1 thyroid hormone receptor, alpha

214883 at 2.01732999 1 13.35 2.0173302 29.45 THRA (erythroblastic leukemia viral (v-

erb-a) oncogene homolog, avian)

213436_at 2.01704746 1 5.35 2.0170474 11.45 CNR1 cannabinoid receptor 1 (brain) zinc finger protein 137 (clone

207394_at 2.0168632 1 7.5 2.0168633 17.2 ZNF137 pHZ-30) 211227_s_at 2.01672453 1 11.35 2.0167246 24.15 PCDH11Y protocadherin 11 Y-linked 217185_s_at 2.0162949 1 43.5 2.016295 95.1 ZNF259P; 354J5

Homo sapiens mRNA; cDNA

DKFZp434N144 (from clone

216619_at 2.01581812 1 2.15 2.015818 4.7 DKFZp434N144), mRNA sequence 206289_at 2.01558483 1 3.4 2.0155847 15.25 HOXA4 homeo box A4 210701_at 2.01316184 1 8.45 2.0131617 17.95 CFDP1 craniofacial development protein 1 215239_x_at 2.0102424 1 15.95 2.0102425 35.1 ZNF273 zinc finger protein 273 207954_at 2.00961781 1 73.85 2.0096178 160.25 GATA2 GATA binding protein 2 dynein, axonemal, intermediate

221668_s_at 2.0096136 1 5.55 2.0096138 11.9 DNAI2 polypeptide 2 κ> integrin, beta 3 (platelet κ>

216261_at 2.00830852 1 10.7 2.0093086 23.4 ITGB3 glycoprotein Ilia, antigen CD6J) 206652 at 2.0084184 1 0.4 2.0084183 1.4 ZNF237 zinc finger protein 237

Homo sapiens cDNA: FLJ22268 fis, clone HRC03178, highly similar to AF247457 Homo sapiens myosin X (MYO10) mRNA, mRNA

216222 s at 2.00822017 1 14.25 2.0082202 29 sequence spinocerebellar ataxia 7

(olivopontocerebellar atrophy with

204516_at 2.0071508 1 24.95 2.007151 51.05 SCA7 retinal degeneration) 208947_s_at 2.00552367 1 14.05 2.0055237 28.1 RENT1 regulator of nonsense transcripts 1 219736_at 2.00478448 1 0.65 2.0047843 4.9 TRI M36 tripartite motif-containing 36

Homo sapiens cDNA FLJ35942 fis, clone TESTI2011712, mRNA

213804_at 2.00456536 1 22.9 2.0045652 50.85 INPP5B sequence chromosome 6 open reading frame

214847 s at 2.00280267 1 43.6 2.0028026 92.75 C6orf9 9

Homo sapiens cDNA: FLJ21419 fis, clone COL04084, mRNA

215405_at 2.00274098 1 16.65 2.0027409 36.45 sequence

Homo sapiens cDNA: FLJ21672 fis, clone COL09025, mRNA

216774_at 2.00203729 1 19.2 2.002037 39.95 sequence

205113_at 2.00175971 1 13.3 2.0017595 28.8 NEF3 neurofilament s (15OkDa medium)

219657_s_at 2.00097919 1 31.8 2.000979 65.35 KLF3 Kruppel-like factor 3 (basic)

217521_at 2.00059396 1 -0.2 2.000594 1.3 HAL histidine ammonia-lyase

213854_at 2.00006694 1 12.4 2.000067 44.45 SYNGR1 synaptogyrin 1

206545_at 1.99858105 1 13.6 1.9985809 29.25 CD28 CD28 antigen (Tp44) mannan-binding lectin serine

216968_at 1.99555545 1 5.8 1.9955554 15.7 MASP2 protease 2

220577_at 1.99541348 1 26.85 1.9954135 56 FLJ 13373 hypothetical protein FLJ13373

221644_s_at 1.99498794 1 4.75 1.9949881 9.5 MATP AIM-1 protein extracellular link domain containing

219059_s_at 1.99492176 1 7.9 1.9949217 17.65 XLKD1 1 κ>

218207_s_at 1.99483263 1 11.8 1.9948325 24.7 STM N3 stathmin-like 3

207492_at 1.99346988 1 2.15 1.9934698 0.45 FLJ 12409 hypothetical protein FLJ12409

211717_at 1.99274683 1 98.8 1.9927468 210.1 MGC15396 hypothetical protein MGC15396 gap junction protein, alpha 10,

221415_s_at 1.99131435 1 14.25 1.9913143 28.7 GJA10 59kDa

214423_x_at 1.98616642 1 47.95 1.9861662 103.65 ALDOB aldolase B, fructose-bisphosphate

37512_at 1.98462576 1 1.75 1.9846257 3.55 RODH 3-hydroxysteroid epimerase

RAB35, member RAS oncogene

205461_at 1.98453277 1 8.35 1.9845328 17.45 RAB35 family

208495_at 1.98365527 1 19.95 1.9836553 42.5 TLX3 T-cell leukemia, homeobox 3

205558_at 1.98203945 1 5.4 1.9820395 10.9 TRAF6 TNF receptor-associated factor 6

220149_at 1.98149681 1 14.45 1.9814968 31.6 FLJ22671 hypothetical protein FLJ22671

219871_at 1.98132721 1 3.5 1.9813272 7 FLJ13197 hypothetical protein FLJ13197

Human clone 295, 5cM region surrounding hepatocyte nuclear factor-1a/MODY3 mRNA, mRNA

215015_at 1.98087791 1 -4.95 1.9808779 33.8 LOC92558 sequence

hypothetical protein

221037_s_at 1.97987928 1 0.55 1.9798793 2.25 DKFZP434N1235 DKFZp434N1235 glutamate receptor, ionotropic,

214966_at 1.97854727 1 7.15 1.9785472 15.25 GRIK5 kainate 5 216819_at 1.97760077 1 1.45 1.9776008 4.5 zinc finger protein 142 (clone pHZ-

37586_at 1.97731244 1 30.65 1.9773123 64.05 KIAA0236 49) 217271_at 1.97620296 1 0.75 1.976203 3.8

ESTs, Weakly similar to hypothetical protein FLJ20489

217632_at 1.97611365 1 2.85 1.9761138 5.85 [Homo sapiens] [H.sapiens] 206727_at 1.97607249 1 1.45 1.9760725 3.05 C9 complement component 9

Homo sapiens cDNA: FLJ21220 fis, clone COL00546, mRNA

216115_at 1.97517311 1 40.95 1.975173 86.1 sequence 218177_at 1.97442812 1 121 1.9744282 263.7 CHMP1.5 CHMP1.5 protein

ATP-binding cassette, sub-family F

209246_at 1.97386439 1 19.4 1.9738646 44.05 ABCF2 (GCN20), member 2 219120_at 1.97380346 1 45.4 1.9738035 97.95 FLJ21945 hypothetical protein FLJ21945 proline-rich protein BstNI subfamily

210597_x_at 1.97277349 1 61.75 1.9727736 129.85 PRB1 1

Homo sapiens mRNA; cDNA

DKFZp586N1323 (from clone

DKFZp586N1323), mRNA

212550_at 1.9724829 1 11.35 1.9724829 46.4 sequence selectin P (granule membrane

206049_at 1.9720999 1 26.55 1.9720999 55.35 SELP protein 14OkDa, antigen CD62)

222366_at 1.97130057 1 66.4 1.9713007 132.75 ESTs

UDP-N-acetylglucosamine:a-1 ,3-D- mannoside beta-1 ,4-N- acetylglucosaminyltransferase IV-

207447_s_at 1.9699417 1 3.45 1.9699416 10.3 HGNT-IV-H homolog anaplastic lymphoma kinase (Ki-

208211 s at 1.96983182 1 11.85 1.9698317 24.7 ALK 1)

chromosome 1 open reading frame

209883_at 1.96845716 1 18.2 1.9684572 38.6 C1orf17 17 neurotrophic tyrosine kinase,

206462_s_at 1.96824068 1 17.8 1.9682405 36.7 NTRK3 receptor, type 3

211049_at 1.96795648 1 3.95 1.9679565 11.85 NCX NCX protein

216152_at 1.96749458 1 36.7 1.9674946 80.8 inositol 1 ,3,4-triphosphate 5/6

210197_at 1.96715891 1 23.75 1.9671588 47.5 ITPK1 kinase

ESTs, Highly similar to hypothetical protein PRO2266

220530_at 1.96697918 1 5.55 1.9669793 10.95 [Homo sapiens] [H.sapiens]

215427_s_at 1.96695639 1 3.3 1.9669564 9.05 BDG-29 BDG-29 proten

202341_s_at 1.96683574 1 3.55 1.9668356 7.6 TRI M2 tripartite motif-containing 2

205489_at 1.96656872 1 25.8 1.9665687 52.6 CRYM crystallin, mu cylicin, basic protein of sperm head

216778_s_at 1.96569604 1 8.65 1.9656961 19.05 CYLC1 cytoskeleton 1

Homo sapiens mRNA sequence, K)

215477_at 1.96549153 1 18.2 1.9654915 39.15 IMAGE clone 446411

DEAH-box RNA/DNA helicase

213420_at 1.96543992 1 27.2 1.9654399 56.35 LOC90957 AAM73547

Pancreatic ribonuclease; HP-

RNase [Homo sapiens], mRNA

217093_at 1.96216762 1 8.1 1.9621677 17.5 sequence

205747_at 1.96166897 1 12.95 1.961669 26.2 CBLN1 cerebellin 1 precursor

204898_at 1.96151411 1 17.7 1.961514 37.45 SAP30 sin3-associated polypeptide, 3OkDa syntrophin, beta 2 (dystrophin- associated protein A1 , 59kDa,

213814_s_at 1.96121287 1 5.2 1.9612129 11 SNTB2 basic component 2) neurofibromin 1 (neurofibromatosis, von Recklinghausen disease,

210631_at 1.96086009 1 -1.45 1.96086 8.05 NF1 Watson disease)

205808_at 1.96025592 1 24.4 1.9602559 50.9 ASPH aspartate beta-hydroxylase potassium voltage-gated channel,

22001 O_at 1.95999065 1 4.2 1.9599907 8.35 KCNE1L Isk-related family, member 1-like

210969 at 1.95891178 1 6.5 1.9589118 13.55 PRKCL2 protein kinase C-like 2

SRY (sex determining region Y)-

214178_s_at 1.95890465 1 11.75 1.9589047 25.9 SOX2 box 2 214616_at 1.95878378 1 24.7 1.9587839 47.85 H3FD H3 histone family, member D

FXYD domain containing ion

205674_x_at 1.95850688 1 23.35 1.9585071 48.05 FXYD2 transport regulator 2

GABA(A) receptors associated

211457_at 1.9575668 1 8.25 1.9575669 16.9 GABARAPL3 protein like 3 206840_at 1.95653468 1 21.55 1.9565346 46.4 AFM afamin 208045 at 1.95597678 1 4.8 1.9559767 9.85 SPAR surfactant protein A binding protein

Homo sapiens mRNA; cDNA

DKFZp586F1024 (from clone

DKFZp586F1024), mRNA

215805_at 1.95532426 1 16.35 1.9553244 33.15 sequence

Homo sapiens cDNA FLJ10270 fis, clone HEMBB1001096, mRNA

215314_at 1.95495823 1 2.3 1.9549582 1.65 sequence 214609_at 1.95242363 1 17.45 1.9524236 35.8 PHOX2A aristaless homeobox (Drosophila) KJ 59437_at 1.9522 1 31.9 1.9522002 68.55 MGC29761 hypothetical protein MGC29761

Type Il AF10 protein [Homo

216509_x_at 1.95148814 1 13.6 1.9514883 28.05 sapiens], mRNA sequence chemokine (C-X-C motif) 211469_s_at 1.95084185 1 2.2 1.9508418 2.9 CXCR6 receptor 6 thymus high mobility group box

204529_s_at 1.95018155 1 22.7 1.9501816 46.6 TOX protein TOX major histocompatibility complex, 213537_at 1.95002145 1 9.65 1.9500215 20.3 HLA-DPA1 class II, DP alpha 1 amiloride-sensitive cation channel

37953_s_at 1.94951659 1 28.4 1.9495165 57.15 hBNaC2 2, neuronal 206212_at 1.94918078 1 23.25 1.9491808 47.3 CPA2 carboxypeptidase A2 (pancreatic) 206271_at 1.94790703 1 9.45 1.947907 20.3 TLR3 toll-like receptor 3 likely ortholog of mouse embryonic

213113_s_at 1.94758165 1 117.7 1.9475818 252.2 EEG1 epithelial gene 1 32699_s_at 1.9463781 1 30.3 1.9463779 64.1 PVR poliovirus receptor 201224_s_at 1.94637686 1 37.25 1.9463768 78.7 SRRM 1 serine/arginine repetitive matrix 1 217332 at 1.9454565 1 6.25 1.9454565 20.15

210932_s_at 1.94520156 1 4.6 1.9452015 9.9 RNF6 ring finger protein (C3H2C3 type) 6 204156_at 1.94377402 1 28.85 1.943774 57 KIAA0999 KIAA0999 protein 208511_at 1.9431687 1 33.75 1.9431686 68.4 PTTG3 pituitary tumor-transforming 3 219495_s_at 1.94275856 1 13.6 1.9427587 26.75 ZNF180 zinc finger protein 180 (HHZ168) PRO0974 [Homo sapiens], mRNA

208187_s_at 1.94225611 1 -3.35 1.942256 15.35 sequence 208476_s_at 1.94205624 1 25.55 1.9420562 51.5 FLJ 10210 hypothetical protein FLJ10210 207211_at 1.94113767 1 26.5 1.9411377 52.9 USP2 ubiquitin specific protease 2 chromosome 14 open reading

202563_at 1.94006133 1 15.25 1.9400613 31.9 C14orf1 frame 1 testes-specific heterogenous

207207_at 1.93862993 1 7.2 1.93863 14.45 HNRNPG-T nuclear ribonucleoprotein G-T catenin (eadherln-assoeiated protein), cieϊta 2 (neurai plakophlϋn-rβiated arm-repeat

209617_s_at 1.93845141 1 3.85 1.9384513 8.2 CTOND2 protein) κ>

HIV-1 inducer of short transcripts -4 binding protein; lymphoma related

222082_at 1.93843281 1 26.05 1.9384328 53.85 FBH factor 205510_s_at 1.93830949 1 32.45 1.9383094 67.8 FLJ10038 hypothetical protein FU10038 cholinergic receptor, nicotinic,

206736_x_at 1.93789408 1 13.9 1.9378941 30.5 CHRNA4 alpha polypeptide 4 222195_s_at 1.93688134 1 -19.85 1.9368814 0.2 HSPC219 hypothetical protein HSPC219 215897_at 1.93533519 1 1.6 1.9353352 12.45 TCBAP0758 hypothetical protein TCBAP0758 steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha- steroid delta 4-dehydrogenase

206938_at 1.9351123 1 15.05 1.9351122 31.9 SRD5A2 alpha 2)

Hypothetical protein [Homo

214873_at 1.93428957 1 19.7 1.9342895 39.3 sapiens], mRNA sequence 210581_x_at 1.93428868 1 30.55 1.9342887 63.6 EWSR1 Ewing sarcoma breakpoint region 1 207786_at 1.93411535 1 13.05 1.9341152 27.75 MGC4663 hypothetical protein MGC4663 transforming growth factor, beta

207334_s_at 1.93375374 1 2.25 1.9337537 10.7 TGFBR2 receptor Il (70/8OkDa) 201367 s at 1.93370787 1 60.6 1.933708 120.25 ZFP36L2 zinc finger protein 36, C3H type-

like 2

209333_at 1.93343925 1 66.1 1.9334393 133.9 ULK1 unc-51-like kinase 1 (C. elegans) 221122_at 1.93263582 1 3.55 1.9326359 6.75 HRASLS2 HRAS-like suppressor 2

219726_at 1.93204126 1 7.85 1.9320413 17.15 NLGN3 neuroligin 3 215270_at 1.93105537 1 1.1 1.9310553 7.8 LFNG lunatic fringe homolog (Drosophila) 206591_at 1.93051899 1 6 1.9305191 12.5 RAG1 recombination activating gene 1 zinc finger protein 135 (clone

206142_at 1.9296148 1 -3.1 1.9296148 0.4 ZNF135 pHZ-17) superoxide dismutase 2,

216841_s_at 1.92943841 1 123.35 1.9294384 260.45 SOD2 mitochondrial 216400_at 1.92885798 1 0.3 1.928858 -5.5 spermidine/spermine N1-

213988_s_at 1.92815205 1 191.9 1.9281521 416.35 SAT acetyltransferase 38290_at 1.92809743 1 42.35 1.9280975 84.8 RGS14 regulator of G-protein signalling 14 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 9 (RNA helicase A, nuclear DNA helicase II; κ>

00

212105_s_at 1.92760235 1 15.2 1.9276023 30.45 DDX9 leukophysin)

Homo sapiens cDNA FLJ12032 fis, clone HEMBB1001880, mRNA

215475_at 1.92673642 1 5.4 1.9267366 10.95 sequence 214216_s_at 1.9267286 1 6.6 1.9267285 13.85 KIAA0217 KIAA0217 protein tumor necrosis factor, alpha-

20251 O_s_at 1.92622095 1 79.45 1.9262209 161 TNFAIP2 induced protein 2 gamma-aminobutyric acid (GABA)

207010_at 1.92550206 1 5.95 1.9255021 12.45 GABRB 1 A receptor, beta 1 protocadherin gamma subfamily A,

211880_x_at 1.92513031 1 23.9 1.9251304 48.55 PCDHGA1 1

Beta-galactoside-binding lectin,

216500_at 1.92429048 1 17.35 1.9242905 35.7 mRNA sequence killer cell immunoglobulin-like receptor, two domains, short

208198_x_at 1.92277327 1 16.15 1.9227734 33.55 KIR2DS1 cytoplasmic tail, 1 204667_at 1.92234975 1 13.2 1.9223497 27.55 FOXA1 forkhead box A1 219229 at 1.92160517 1 19.95 1.9216051 41.45 SLC21A11 solute carrier family 21 (organic

anion transporter), member 11 dynein, axonemal, heavy

210345_s_at 1.92118896 1 12 1.9211891 23.45 DNAH9 polypeptide 9

220227_at 1.91926438 1 108.2 1.9192646 213.25 FLJ22202 hypothetical protein FLJ22202

Homo sapiens mRNA; cDNA

DKFZp586F1622 (from clone

DKFZp586F1622), mRNA

217481_x_at 1.91893774 1 19.9 1.9189376 41.35 sequence

205147_x_at 1.91859199 1 -1.25 1.918592 8.5 NCF4 neutrophil cytosolic factor 4, 4OkDa

207222_at 1.91788787 1 23.6 1.9178879 48.05 PLA2G10 phospholipase A2, group X

RaI guanine nucleotide exchange

210552_s_at 1.91640325 1 10.9 1.9164033 24.25 RALGPS1A factor RaIGPSIA

214734_at 1.91631985 1 22.4 1.91632 45.95 SLAC2-B SLAC2-B

206826_at 1.91581589 1 6.95 1.9158158 14.15 PMP2 peripheral myelin protein 2

1487_at 1.9150825 1 55.1 1.9150826 156.3 hERRa estrogen-related receptor alpha

208352_x_at 1.91494301 1 19 1.914943 36.2 ANK1 ankyrin 1 , erythrocytic

209815_at 1.31374175 1 1.35 1.9137417 8 PTCH patched hornoiog (Drosophila)

206251_s_at 1.91366529 1 28.7 1.9136653 59.2 AVPR1A arginine vasopressin receptor 1A

215324_at 1.91222416 1 0.25 1.9122242 4.6 SEMA3D hypothetical protein MGC39708

219941_at 1.91151703 1 9 1.9115171 18.35 FLJ 10936 hypothetical protein FLJ10936

Homo sapiens mRNA; cDNA

DKFZp434G182 (from clone

216286_at 1.91062129 1 2.15 1.9106214 4.3 DKFZp434G182), mRNA sequence

204988_at 1.91055981 1 7.5 1.9105599 15.4 FGB fibrinogen, B beta polypeptide low density lipoprotein receptor

217173_s_at 1.91046303 1 13.2 1.9104629 27.85 LDLR (familial hypercholesterolemia)

206361_at 1.91005671 1 2.75 1.9100566 5.65 GPR44 G protein-coupled receptor 44

ESTs, Weakly similar to S22393

Ca2+-transporting ATPase (EC

3.6.1.38) 2, long splice form -

204685_s_at 1.90952385 1 10 1.909524 19.55 human [H.sapiens] cytochrome P450, subfamily HIA,

205939_at 1.90916014 1 12.35 1.9091601 24 CYP3A7 polypeptide 7

212193 s at 1.90788114 1 117 1.9078813 229.15 LARP likely ortholog of mouse Ia related

protein

207427_at 1.90672982 1 19.3 1.9067298 39.9 ACR acrosin

ESTs, Weakly similar to hypothetical protein FLJ20378

221886_at 1.9062503 1 6.45 1.9062502 12.7 [Homo sapiens] [H.sapiens] lymphocyte antigen 6 complex,

207114_at 1.90448731 1 76.3 1.9044874 153.9 LY6G6C locus G6C 220466_at 1.90421944 1 25.25 1.9042194 52.15 FLJ13215 hypothetical protein FLJ13215

MRE11 meiotic recombination 11

211334_at 1.90335697 1 9.2 1.903357 19.05 MRE11A homolog A (S. cerevisiae)

Homo sapiens cDNA: FLJ23214 fis, clone ADSU01585, mRNA

216792_at 1.90297026 1 6.5 1.9029703 13.5 sequence growth arrest and DNA-damage-

204121_at 1.90152866 1 4.8 1.9015288 9.65 GADD45G inducible, gamma 218780_at 1.90144461 1 47.4 1.9014447 93.85 HOOK2 hook2 protein cytosolic ovarian carcinoma

O

204644_at 1.90118856 1 15.55 1.9011886 30.5 COVA1 antigen 1 207949_s_at 1.90094787 1 12.85 1.9009479 26.4 ICA1 islet cell autoantigen 1, 69kDa chondroitin sulfate proteoglycan 5

39966_at 1.90092767 1 13.25 1.9009277 30.2 CSPG5 (neuroglycan C) 219181_at 1.9008925 1 17.6 1.9008925 36.35 LIPG lipase, endothelial 213797_at 1.89979309 1 7.2 1.899793 15.35 cig5 vipirin 203684_s_at 1.89913941 1 -14.5 1.8991394 -10 BCL2 B-cell CLL/lymphoma 2 206858_s_at 1.89891854 1 0.35 1.8989186 2.35 HOXC6 homeo box C6 219820_at 1.89842177 1 14.25 1.8984218 28 NTT5 NTT5 protein 215112_x_at 1.89813313 1 0.9 1.8981332 1.8 KIAA0861 KIAA0861 protein 204741_at 1.89772924 1 14.8 1.8977293 34.3 BICD1 Bicaudal D homolog 1 (Drosophila) guanylate cyclase activator 1 B

215841_at 1.89734244 1 14.35 1.8973423 28.65 GUCA1 B (retina) 214087_s_at 1.89555883 1 8.8 1.8955588 16.75 MYBPC1 myosin binding protein C, slow type

Homo sapiens cDNA: FLJ23203 fis, clone ADKA02487, mRNA

216793 x at 1.89260335 1 11.35 1.8926035 22.7 sequence

mitogen-activated protein kinase

213490_s_at 1.89057487 1 263 1.8905749 530.4 MAP2K2 kinase 2 delta-iike 1 homolog

209560_s_at 1.89028991 1 47.1 1.89029 93.7 DLKI (Drosophila) 205626_s_at 1.88925231 1 10.15 1.8892524 20.25 CALB1 calbindin 1 , 28kDa glutamate receptor, ionotropic, N-

211125_x_at 1.88826132 1 12.85 1.8882613 26.8 GRIN1 methyl D-aspartate 1 211386_at 1.88747192 1 4.5 1.8874719 9.4 MGC12488 hypothetical protein MGC12488

ESTs, Weakly similar to hypothetical protein FLJ20489

217534_at 1.88731735 1 1 1.8873174 13.6 [Homo sapiens] [H.sapiens] 214633_at 1.88707579 1 2.1 1.8870758 6.15 SOX3 EST 206415_at 1.88700575 1 10.45 1.8870058 20.45 TLL1 tolloid-like 1 216994_s_at 1.88686771 1 11.75 1.8868678 24.35 RUNX2 runt-related transcription factor 2 211173_at 1.88662958 1 35.35 1.8866296 71.35 CCKAR cholecystokinin A receptor

Homo sapiens clone

Ul

215893_x_at 1.88658095 1 7.8 1.886581 16.6 IMAGE:205688, mRNA sequence 213421_x_at 1.88651656 1 70.2 1.8865165 143.45 PRSS3 protease, serine, 3 (mesotrypsin) 211449_at 1.88524824 1 2.85 1.8852482 5.7 MSH6 mutS homolog 6 (E. coli) splicing factor 3b, subunit 1,

214305_s_at 1.88509971 1 36.35 1.8850998 77.3 SF3B1 155kDa transforming growth factor,

205016_at 1.88495154 1 14.65 1.8849517 28.9 TGFA alpha

Homo sapiens cDNA: FLJ21342 fis, clone COL02673, mRNA

216757_at 1.88454297 1 29.8 1.884543 63.65 sequence

Unc93 (C.elegans) homolog A

214640_at 1.88430787 1 5.8 1.8843077 10.85 [Homo sapiens], mRNA sequence 207893_at 1.88423648 1 9.65 1.8842365 11.9 SRY sex determining region Y 205650 s at 1.88273668^' 1 1.05 1.8827366 7.5 FGA fibrinogen, A alpha polypeptide

Homo sapiens cDNA FLJ39981 fis, clone SPLEN2030562, highly similar to DIHYDROOROTATE

DEHYDROGENASE

213631 x at 1.88268327 1 12.45 1.8826833 24.8 PRECURSOR (EC 1.3.3.1), mRNA

sequence

splicing factor, arginine/serine-rich

210077_s_at 1.88107681 3.7 1.8810768 7.5 SFRS5 5 205402 x at 1.87851691 19.55 1.8785169 40 PRSS2 protease, serine, 2 (trypsin 2) Homo sapiens cDNA FLJ11395 fis, clone HEMBA1000594, mRNA

216682 s at 1.87730943 11.7 1.8773094 21.95 sequence sema domain, transmembrane domain (TM), and cytoplasmic

215028 at 1.87685266 3.3 1.8768528 6.2 SEMA6A domain, (semaphorin) 6A leukocyte immunoglobulin-like receptor, subfamily A (with TM

210660_at 1.87669969 8.75 1.8766997 17.4 LILRA1 domain), member 1 HMT1 hnRNP methyltransferase-

207772_s_at 1.87637275 1 8.4 1.8763727 17.05 HRMT1L3 like 3 (S. cerevisiae) κ> 201323_at 1.87622594 1 289.1 1.876226 574.8 EBNA1BP2 EBNA1 binding protein 2 216404_at 1.87572712 1 23.2 1.875727 49.55 SCA8 spinocerebellar ataxia 8 202650 s at 1.87532783 1 127.55 1.8753278 255.25 KIAA0195 KIAA0195 gene product ESTs, Weakly similar to hypothetical protein FLJ20378

217591_at 1.87324953 1 27.9 1.8732495 57 [Homo sapiens] [H.sapiens] growth factor receptor-bound

210761_s_at 1.87316268 1 24.05 1.8731625 45.6 GRB7 protein 7

206091_at 1.8729384 1 17.75 1.8729384 34.8 MATN3 matrilin 3

Fc fragment of IgG, low affinity IHb,

204006 s at 1.87035819 1 2.05 1.8703582 4.8 FCGR3B receptor for (CD16) calcium channel, voltage- dependent, alpha 2/delta subunit

204811_s_at 1.86922931 1 12.75 1.8692293 26.6 CACNA2D2 2

220457_at 1.86909769 1 11.55 1.8690977 26.8 FLJ10211 hypothetical protein FLJ10211 ATP-binding cassette, sub-family A

203505_at 1.86785484 1 119.8 1.8678548 232.95 ABCA1 (ABC1), member 1 213178 s at 1.86755711 1 182.6 1.867557 368.55 MAPK8IP3 mitogen-activated protein kinase 8

interacting protein 3

216243_s_at 1.86679691 1 15.25 1.866797 29.05 IL1RN interieukin 1 receptor antagonist transition protein 1 (during histone

206568_at 1.86453212 1 8.3 1.8645322 17.4 TNP1 to protamine replacement)

ATPase, (Na+)/K+ transporting,

220556_at 1.86447 1 5.15 1.86447 9.7 ATP 1B4 beta 4 polypeptide

200790_at 1.86401242 1 612.75 1.8640125 1197.9 ODC1 ornithine decarboxylase 1

Homo sapiens cDNA FLJ 11682 fis, clone HEMBA1004880, mRNA

215128_at 1.86375671 1 43.7 1.8637567 86.45 sequence

213935_at 1.86364442 1 23.2 1.8636444 45.65 CGI-58 CGI-58 protein

206517_at 1.86361728 1 35.55 1.8636174 74.6 CDH 16 cadherin 16, KSP-cadherin ecotropic viral integration site

211742_s_at 1.86360293 1 15.65 1.8636029 30.9 EVI2B 2B

207851_s_at 1.86272603 1 24.85 1.862726 50 INSR insulin receptor small nuclear RNA activating

205658_s_at 1.86272216 1 20 1.8627222 38.7 SNAPC4 complex, polypeptide 4, 19OkDa dishevelled, dsh homolog 2

218759_at 1.86230321 1 27.4 1.8623033 57.1 DVL2 (Drosophila)

208368_s_at 1.8622038 1 1.4 1.8622036 5.8 BRCA2 breast cancer 2, early onset

CDP-diacylglycerol synthase

(phosphatidate cytidylyltransferase)

222063_s_at 1.86164448 1 6.85 1.8616445 14.25 CDS1 1

216555_at 1.86043107 1 17.05 1.860431 33.15 putative X-linked retinopathy

222247_at 1.86012328 1 19.55 1.8601234 39.4 DXS542 protein

206932_at 1.86011773 1 71.65 1.8601177 137.15 CH25H cholesterol 25-hydroxylase

205993_s_at 1.85985982 1 39.7 1.8598598 76.2 TBX2 T-box 2

212316_at 1.85957628 1 15.55 1.8595762 31.15 NUP210 nucleoporin 210

216698_x_at 1.85945264 1 15.8 1.8594527 39.8 OR7E12P

Homo sapiens mRNA; cDNA

DKFZp434C0814 (from clone

DKFZp434C0814), mRNA

215508 at 1.85945174 1 -1 1.8594518 0.65 sequence

215552_s_at 1.85939318 1 19.3 1.8593931 38.6 ESR1 estrogen receptor 1 220178_at 1.85855422 1 42.05 1.8585541 76.95 PP3501 hypothetical protein PP3501 tocopherol (alpha) transfer protein

(ataxia (Friedreich-like) with vitamin

210614_at 1.85764199 1 7.35 1.8576419 18.25 TTPA E deficiency) 207363_at 1.85726074 1 3.05 1.8572607 6 RS 1 retinoschisis (X-linked, juvenile) 1 216258_s_at 1.85664 1 -1.1 1.8566401 0.8 HSHUR7SEQ UV-B repressed sequence, HUR 7 sirtuin silent mating type information regulation 2 homolog 5

221010_s_at 1.85645729 1 3.55 1.8564572 9.3 SIRT5 (S. cerevisiae)

TYRO protein tyrosine kinase

204122_at 1.8560219 1 1.55 1.8560218 4.3 TYROBP binding protein 219560_at 1.85492796 1 20.75 1.854928 42.35 FLJ21125 hypothetical protein FLJ21125 219448_at 1.85475832 1 62.55 1.8547583 128.2 FLJ20533 hypothetical protein FLJ20533 207792_at 1.85423547 1 8.3 1.8542354 16.85 OPRD1 opioid receptor, delta 1 basic transcription element binding

203541_s_at 1.8532712 1 6.55 1.8532714 13.45 BTEB1 protein 1

4- 209346_s_at 1.85300152 1 9.2 1.8530015 24.15 PI4KII phosphatidylinositol 4-kinase type Il 218402_s_at 1.85257648 1 5.65 1.8525765 14 HPS4 Hermansky-Pudlak syndrome 4 216943_at 1.85116867 1 9.35 1.8511686 9.45 216859_x_at 1.85030843 1 5.15 1.8503084 -6.9 219178_at 1.85022662 1 25.3 1.8502264 49.85 FLJ 12960 hypothetical protein FLJ12960 bromodomain adjacent to zinc

201355_s_at 1.8497104 1 2.5 1.8497102 7.95 BAZ2A finger domain, 2A Homo sapiens mRNA; cDNA DKFZp564K133 (from clone

214997_at 1.84927816 1 5.8 1.8492782 12 DKFZp564K133), mRNA sequence FXYD domain containing ion

217897_at 1.84926417 1 7.85 1.8492641 23.1 FXYD6 transport regulator 6 207798_s_at 1.84719099 1 -0.85 1.847191 5.25 A2LP ataxin 2 related protein EST, Moderately similar to hypothetical protein FLJ20294

222213_x_at 1.84621583 1 9.2 1.8462157 17.7 [Homo sapiens] [H. sapiens] 214549 x at 1.84620154 1 37.7 1.8462017 71.5 SPRR1A small proline-rich protein 1A

leukemia inhibitory factor (cholinergic differentiation

205266_at 1.84579646 1 159.25 1.8457963 315.15 LIF factor)

210199_at 1.84548056 1 28.05 1.8454804 55.65 CRYAA crystallin, alpha A MAP-kinase activating death

38398_at 1.84459764 1 126.4 1.8445977 239.5 K1AA0358 domain

219995_s_at 1.84387457 1 2.8 1.8438746 5.6 FLJ 13841 hypothetical protein FLJ 13841 transducin-like enhancer of split 2

40837_at 1.84370668 1 25.7 1.8437068 49.15 TLE2 (E(sp1 ) homolog, Drosophila) 216004_s_at 1.84298846 1 5.3 1.8429885 11.2 PKNOX1 PBX/knotted 1 homeobox 1 ESTs, Highly similar to YA02_HUMAN HYPOTHETICAL

216001_at 1.84288341 1 37.65 1.8428833 74.05 LOC65121 PROTEIN DJ 1198H6.2 [H .sapiens] 211861_x_at 1.84229464 1 7.05 1.8422947 14.5 CD28 CD28 antigen (Tp44) olfactory receptor, family 2,

208573_s_at 1.84212131 1 22.65 1.8421214 44.2 OR2H3 subfamily H, member 3 201525_at 1.84143722 1 24.65 1.8414372 49.2 APOD apolipoprotein D Ul 214392_at 1.84077775 1 22.3 1.8407776 43.1 R30953J hypothetical protein R30953_1 Homo sapiens cDNA: FLJ20962 fis, clone ADSH00804, mRNA

216443_at 1.84052033 1 19.9 1.8405204 37.6 sequence 208421_at 1.8405171 1 9.25 1.840517 18.65 LOC51047 RIG-like 14-1 acid phosphatase 5, tartrate

204638_at 1.84047056 1 11.6 1.8404706 23.1 ACP5 resistant 210129_s_at 1.84043889 1 39.1 1.8404388 76.95 DKFZP434B103 DKFZP434B103 protein

DNA segment on chromosome 21

218758_s_at 1.83911512 1 17.75 1.8391151 36.55 D21S2056E (unique) 2056 expressed sequence 216177_at 1.83845614 1 26.85 1.838456 53.3 RPL29 ribosomal protein L29 potassium channel, subfamily K,

220412_x_at 1.83842794 1 4.5 1.8384279 9.25 KCN K7 member 7 hypothetical protein

219876_s_at 1.83791429 1 6.8 1.8379143 13.55 DKFZp434M0331 DKFZp434M0331 matrix metalloproteinase 16

208166 at 1.83778728 1 3.2 1.8377874 6.15 MMP16 (membrane-inserted)

216553. _x_at 1.83676113 1 6 1.8367612 11.8

219218. _at 1.83661355 1 31.05 1.8366135 59.3 FLJ23058 hypothetical protein FLJ23058

219710. _at 1.83655153 1 4.75 1.8365517 8.6 KIAA1985 KIAA1985 protein

ESTs, Moderately similar to hypothetical protein FLJ20489

217678. _at 1.83498151 1 96.65 1.8349816 182.35 [Homo sapiens] [H. sapiens]

211235. ~s_at 1.83474873 1 -9.1 1.8347487 1.9 ESR1 estrogen receptor 1 cyclic nucleotide gated channel

206417. _at 1.83373735 1 5.1 1.8337374 13.05 CNGA1 alpha 1

Homo sapiens mRNA; cDNA

DKFZp547l147 (from clone

216454. _at 1.83315063 1 10.05 1.8331506 19.3 DKFZp547l147), mRNA sequence

210259. _s_at 1.83261119 1 14.45 1.8326111 29.2 DLX4 distal-less homeobox 4

210941. _at 1.83211409 1 3.7 1.832114 7.15 PCDH7 BH-protocadherin (brain-heart)

RNA binding protein S1 , serine-rich

207939_, _x_at 1.83189089 1 263.45 1.831891 524.05 RNPS1 domain

207112_ _s_at 1.83161829 1 10.95 1.8316183 20.65 GAB1 GRB2-associated binding protein 1 cell division cycle 42 (GTP

214230_ .at 1.83150721 1 16.85 1.8315072 32.15 CDC42 binding protein, 25kDa) eukaryotic translation elongation

210699_, .at 1.83150439 1 -2.5 1.8315046 2.7 EEF1A1 factor 1 alpha 1 tumor necrosis factor receptor

213829. _x_at 1.83101435 1 147.35 1.8310144 286.1 TNFRSF6B superfamily, member 6b, decoy

206924. _at 1.8307885 1 93.05 1.8307886 183.15 1L11 interieukin 11

210112. .at 1.83049158 1 13.8 1.8304917 20.1 HPS1 Hermansky-Pudlak syndrome 1 nuclear receptor subfamily 5, group

208337. _s_at 1.83017975 1 15.25 1.8301797 28.75 NR5A2 A, member 2

204827. _s_at 1.82959294 1 19.85 1.829593 38.7 CCNF cyclin F

203661. _s_at 1.82959163 1 30.2 1.8295916 58.8 TMOD tropomodulin

209381. _x_at 1.82944125 1 91 1.8294413 170.9 SF3A2 splicing factor 3a, subunit 2, 66kDa

Homo sapiens clone 24407 mRNA

215284. .at 1.82885402 1 12.65 1.8288541 25.25 sequence integrin, beta 3 (platelet

204627 s at 1.82793824 1 31.75 1.8279384 61.5 ITG B3 glycoprotein Ilia, antigen CD61)

39402_at 1.82785902 1 86.25 1.827859 169.4 !L1B interleukin 1, beta protein tyrosine phosphatase,

205712_at 1.82768608 1 23.9 1.8276862 47.75 PTPRD receptor type, D glutamate receptor, ionotropic,

217509_x_at 1.82762945 1 108.7 1.8276294 218.75 GRIK5 kainate 5 207744_at 1.82730366 1 5.15 1.8273036 13.1 PRO0255 PRO0255 protein 211756_at 1.82696018 1 2.35 1.8269602 4.7 PTHLH parathyroid hormone-like hormone 218956_s_at 1.82652676 1 72.3 1.8265266 141.85 KIAA0632 KIAA0632 protein short-chain

202481_at 1.82643521 1 42.2 1.8264352 79.3 SDR1 dehydrogenase/reductase 1 216561_x_at 1.82555688 1 6.1 1.825557 11.4 SOX29

Homo sapiens cDNA FLJ12301 fis, clone MAMMA1001858, mRNA

215862_at 1.82521986 1 19.2 1.8252199 37.15 sequence

220028_at 1.82474577 1 36.9 1.8247458 73.55 ACVR2B actϊvirs A receptor, type HB 211751_at 1.82457454 1 5.8 1.8245746 11.25 LOC64182 similar to rat myomegalin Homo sapiens mRNA full length -4 insert cDNA clone EUROIMAGE

37590_g_at 1.82447077 1 8.7 1.8244708 19.1 26539, mRNA sequence Homo sapiens cDNA: FLJ22180 fis, clone HRC00936, mRNA

215856_at 1.8232482 1 38.65 1.8232481 77.25 sequence mannosidase, alpha, class 1A,

214242_at 1.82314003 1 9.95 1.8231399 20.85 MAN1A2 member 2

Homo sapiens cDNA FLJ14046 fis, clone HEMBA1006461, mRNA

217052_x_at 1.82310575 1 43.1 1.8231057 83.85 sequence protein tyrosine phosphatase, non¬

204935_at 1.82293724 1 4.5 1.8229373 8.55 PTPN2 receptor type 2

Homo sapiens cDNA FLJ13526 fis, clone PLACE1006017, mRNA

215575_at 1.82230219 1 1.65 1.8223021 3.2 sequence 210785_s_at 1.82228232 1 28.1 1.8222823 55.15 ICB-1 basement membrane-induced gene solute carrier family 11 (proton-

203125 x at 1.82177215 1 31.55 1.8217721 61.6 SLC11 A2 coupled divalent metal ion

transporters), member 2 nuclear receptor subfamily 4, group

209959_at 1.8198994 1 20.05 1.8198996 39.05 NR4A3 A, member 3 corticotropin releasing hormone

207897_at 1.81975638 1 15.35 1.8197564 28.7 CRHR2 receptor 2 47105_at 1.81973886 1 44.65 1.8197389 86.75 FLJ20399 hypothetical protein FLJ20399 likely ortholog of mouse ubiquitin conjugating enzyme 7 interacting

204040_at 1.8194785 1 74.7 1.8194783 145.35 RNF144 protein 4

Homo sapiens cDNA: FLJ22620 fis, clone HSI05629, mRNA

216785_at 1.81678151 1 1.2 1.8167815 3.3 sequence 216008_s_at 1.8167184 1 23.65 1.8167185 48 AR! H2 ariadne homolog 2 (Drosophila) plateiet/endothellal celt adhesion

208981_at 1.81620097 1 21.4 1.816201 43.25 PECAM 1 molecule (CD31 antigen) insulin promoter factor 1 ,

210937_s_at 1.8161463 1 5.55 1.8161461 11.3 IPF1 homeodomain transcription factor carcinoembryonic antigen-related

210789_x_at 1.81583089 1 33.4 1.815831 66.6 CEACAM3 cell adhesion molecule 3 p53-regulated apoptosis-inducing

220402_at 1.81556214 1 6.65 1.8155622 13.05 P53AIP1 protein 1 solute carrier family 5

(sodium/glucose cotransporter),

206628_at 1.81474912 1 36 1.8147491 72.75 SLC5A1 member 1 215512_at 1.81460479 1 10.5 1.8146048 21.75 TEB4 similar to S. cerevisiae SSM4 nasopharyngeal carcinoma

219437_s_at 1.81332063 1 -1.6 1.8133205 -3.2 LZ16 susceptibility protein 220684_at 1.81316817 1 29.75 1.8131683 55.8 TBX21 T-box 21

RAB3A, member RAS oncogene

204974_at 1.8131115 1 6.55 1.8131114 12.05 RAB3A family 207374_at 1.81271558 1 5.45 1.8127156 10.5 PLSCR2 phospholipid scramblase 2

Homo sapiens cDNA: FLJ20933 fis, clone ADSE01388, mRNA

216005 at 1.81235022 1 55.55 1.8123503 108.1 sequence

209204_at 1.81226205 1 52.6 1.812262 98.1 LMO4 LIM domain only 4

222356_at 1.81195367 1 3.55 1.8119537 6.05 FLJ32069 hypothetical protein FLJ32069

CH K2 checkpoint homolog (S.

210416_s_at 1.8108245 1 -82 1.8108245 -83.9 CHEK2 pombe)

LBP protein; likely ortholog of

219735_s_at 1.81033785 1 38.2 1.8103379 74.3 LBP-9 mouse CRTR-1

220839_at 1.81010872 1 19.45 1.8101087 39 HSPC133 HSPC133 protein

206434_at 1.80896762 1 4.05 1.8089675 9.35 SPOCK3 testican 3 solute carrier family 7 (cationic amino acid transporter, y+ system),

205864 at 1.80848513 1 26.45 1.8084853 47.7 SLC7A4 member 4

ESTs, Moderately similar to

VPP2_HUMAN Vacuolar proton translocating ATPase 116 kDa subunit A isoform 2 (V-ATPase

116-kDa isoform a2) (TJ6)

217603_at 1.80775717 1 -0.95 1.8077573 -9.85 [H.sapiens] guanine nucleotide binding protein

(G protein), alpha activating activity 206355_at 1.8075914 12.95 1.8075916 24.6 GNAL polypeptide, olfactory type uridine monophosphate synthetase

(orotate phosphoribosyl transferase 202707_at 1.80670715 1 -0.55 1.8067071 13.5 UMPS and orotidine-5'-decarboxylase)

Homo sapiens mRNA; cDNA

DKFZp564N1116 (from clone

DKFZp564N1116), mRNA

214803_at 1.80607435 1 6.3 1.8060744 10.6 sequence spectrin, alpha, non-erythrocytic 1

214925_s_at 1.80503045 1 36.35 1.8050303 74.6 SPTAN1 (alpha-fodrin) v-rel reticuloendotheliosis viral

206035_at 1.80491666 1 9.5 1.8049167 19.25 REL oncogene homolog (avian) gamma-aminobutyric acid (GABA)

208463_at 1.80218595 1 0.75 1.8021859 8.05 GABRA4 A receptor, alpha 4 207206_s_at 1.80161289 1 4.05 1.8016127 8.7 ALOX12 arachidonate 12-lipoxygenase 206738 at 1.80142911 1 29.55 ^' 1.8014293 57.35 APOC4 apolipoprotein C-IV

222023_at 1.80138992 1 6.3 1.8013898 11.85 AKAP 13 A kinase (PRKA) anchor protein 13 transient receptor potential cation

206425_s_at 1.80097563 1 22.1 1.8009757 42.65 TRPC3 channel, subfamily C, member 3 hypothetical protein

204096_s_at 1.80092372 1 14.3 1.8009238 25.6 DKFZp434l1916 DKFZp434l1916 heparin-binding growth factor

205014_at 1.80079973 1 19.25 1.8007997 37.35 HBP17 binding protein 213958_at 1.80074496 1 5.95 1.8007449 17.2 CD6 CD6 antigen aldehyde dehydrogenase 8 family,

220148_at 1.80066252 1 3.7 1.8006625 7.3 ALDH8A1 member A1

MAD, mothers against decapentaplegic homolog 5

205188_s_at 1.79885913 1 3.35 1.7988591 6.3 MADH5 (Drosophila) methyl-CpG binding domain protein

214397_at 1.79857647 1 10.35 1.7985765 19.45 MBD2 2 219474 at 1.79853392 1 14.95 1.7985339 28.95 FLJ23186 hypothetical protein FLJ23186

ESTs, Highly similar to transient receptor potential cation channel, subfamily M, member 2; transient receptor potential-related channel

7, a novel putative Ca2+ channel protein; transient receptor potential channel 7 [Homo sapiens]

205708_s_at 1.79751611 1 83.25 1.7975161 156.3 [H.sapiens] pfatelel-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene

218G55_at 1.79712281 1 23.8 1.7971228 45.3 PDGFB homoiog)

Homo sapiens cDNA FLJ14076 fis, clone HEMBB1001925, mRNA

216444_at 1.79628813 1 18.4 1.796288 34.85 sequence thyroid hormone receptor interactor 210760_x_at 1.79622679 1 29.35 1.7962267 55.55 TRIP11 11 solute carrier family 2 (facilitated 206603 at 1.79609106 1 5.6 1.7960908 10.95 SLC2A4 glucose transporter), member 4

204707_s_at 1.79514232 1 8.6 1.7951424 16.55 MAPK4 mitogen-activated protein kinase 4 Unknown (protein for IMAGE:3344506) [Homo sapiens],

216189_at 1.79492231 1 0.9 1.7949224 2 mRNA sequence alpha thalassemia/mental retardation syndrome X-linked

208859_s_at 1.79485077 1 7.05 1.7948508 12.85 ATRX (RAD54 homolog, S. cerevisiae) 39650_s_at 1.79476739 1 35.1 1.7947674 66.45 KIAA0435 KIAA0435 gene product cell adhesion molecule- related/down-regulated by

207230_at 1.79470098 1 4.65 1.7947011 23.95 CDON oncogenes cell division cycle 2-like 5 (cholinesterase-related cell

207319_s_at 1.79399567 1 29.85 1.7939956 56.65 CDC2L5 division controller) basement membrane-induced

207571_x_at 1.79345306 1 16.05 1.7934532 31 C1orf38 gene

207471_at 1.79264026 1 6.45 1.7926402 11.95 PRO19.92 PRO1992 protein

Homo sapiens cDNA FLJ 14152 Us, done MAMMA1003089, mRNA

215619_at 1.79258179 1 0.55 1.7925818 2.2 sequence potassium channel, subfamily K,

219883_at 1.79231487 1 40.25 1.792315 72.25 KCN K4 member 4 mesenchymal stem cell protein

208154_at 1.79169921 1 9.3 1.791699 17.45 LOC5133( DSCD28 202240_at 1.79137998 1 84.8 1.7913799 159.85 PLK polo-like kinase (Drosophila) BCG-induced gene in monocytes,

216504_s_at 1.79132628 1 18.2 1.7913263 33.55 BIGM103 clone 103 solute carrier family 13 (sodium/sulfate symporters),

220502_s_at 1.79071442 1 3.8 1.7907145 7.65 SLC13A1 member 1 219132_at 1.79049731 1 21.95 1.7904973 44.2 PELI2 pellino homolog 2 (Drosophila) splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate

201741_x_at 1.79031353 1 -1.45 1.7903134 5.4 SFRS 1 splicing factor) 211865 s at 1.78906716 1 17.45 1.7890673 32.45 FZR1 Fzr1 protein

Homo sapiens clone 24505 mRNA

214068_at 1.78884237 1 28 1.7888423 53.1 sequence 222306_at 1.78853155 1 11.7 1.7885315 22.45 ESTs 208332_at 1.78844929 1 18.5 1.7884493 34.8 PRY PTPN13-like, Y-linked 210821_x_at 1.78841293 1 39.25 1.7884129 74.75 CENPA centromere protein A, 17kDa 204153_s_at 1.78805394 1 12.45 1.788054 24 MFNG manic fringe homolog (Drosophila) mannosidase, alpha, class 1A,

217282_at 1.78545813 1 2.95 1.7854581 5.2 MAN1A2 member 2 transmembrane 4 superfamily

206242_at 1.78400177 1 49.7 1.7840018 96.65 TM4SF5 member 5 210360_s_at 1.7837196 1 15.2 1.7837195 28.55 KIAA0429 KIAA0429 gene product chemokine (C-X3-C motif) Iigand

823_at 1.78299075 1 12.8 1.7829907 24.4 CX3CL1 1

Fanconi anemia,

220255_at 1.7829491 1 40.9 1.7829492 77.65 FANCE complementation group E

221238_at 1.78290592 1 12.65 1.7829058 24.5 NSBP1 nucieosomal binding protein 1

Homo sapiens cDNA FLJ12349 fis, 4- κ> clone MAMMA1002308, mRNA

215612_at 1.78249196 1 -1.45 1.7824919 4.8 sequence sterol regulatory element binding

202308_at 1.78160846 1 183.4 1.7816083 348.85 SREBF1 transcription factor 1

Homo sapiens mRNA; cDNA

DKFZp547G044 (from clone

216802_at 1.78120465 1 7.05 1.7812047 14.15 DKFZp547G044), mRNA sequence collagen, type IV, alpha 3

216368_s_at 1.78111023 1 23.2 1.7811103 44 COL4A3 (Goodpasture antigen) type 1 tumor necrosis factor receptor shedding aminopeptidase

214034_at 1.78100014 1 13.45 1.7810001 25.4 ARTS-1 regulator 207753_at 1.78043368 1 19.6 1.7804337 37 ZNF304 zinc finger protein 304 dystrophia myotonica-containing

213231_at 1.78009768 1 22.7 1.7800977 40.8 DMWD WD repeat motif 209383_at 1.7799799 1 133.6 1.7799798 248.85 DDIT3 DNA-damage-inducible transcript 3

ESTs, Weakly similar to

210917 at 1.77791519 1 4.55 1.7779152 2.25 hypothetical protein FLJ20489

[Homo sapiens] [H.sapiens]

204377_s_at 1.7773564 1 27.1 1.7773565 53 KIAA0800 KIAA0800 gene product

209483_s_at 1.77694048 1 3.8 1.7769403 7.9 DC8 DKFZP566O1646 protein

211900_x_at 1.77636915 1 6.4 1.7763691 21.2 CD6 CD6 antigen

214768_x_at 1.77618281 1 16.95 1.7761828 29.7 IGKC immunoglobulin kappa constant

Homo sapiens cDNA FLJ20231 fis, clone COLF5511 , highly similar to

AB014590 Homo sapiens mRNA for KIAA0690 protein, mRNA

216360_x_at 1.77488933 1 26.75 1.7748893 62.6 sequence

FLJ00049 protein [Homo sapiens],

216455_at 1.77209473 1 28.75 1.7720947 56.1 mRNA sequence

HEAT-like repeat-containing

220672_at 1.77192977 1 5.6 1.7719297 11.05 KIAA1622 protein

220529_at 1.77141332 1 32.4 1.7714133 60.2 FLJ11710 hypothetical protein FLJ11710

4-

217010_s_at 1.77067399 1 16.65 1.770674 30.6 CDC25C cell division cycle 25C iron-responsive element binding

214666_x_at 1.76975791 1 42.4 1.7697577 78.4 IREB2 protein 2 leukocyte immunoglobulin-like receptor, subfamily B (with TM and

206856_at 1.76952151 1 19.9 1.7695215 39.35 LILRB5 ITIM domains), member 5

217227_x_at 1.768517 1 -0.05 1.7685169 6.25 IGL@ immunoglobulin lambda locus complement component 1 , q

202878_s_at 1.7683866 1 26.65 1.7683866 48.85 C1QR1 subcomponent, receptor 1 olfactory receptor, family 2,

216408_at 1.7683807 1 11 1.7683806 20.75 6M1 -10*01 subfamily B, member 2

221155_x_at 1.7677809 1 123.1 1.7677809 231.3 PRO1496 hypothetical protein PRO1496

Homo sapiens mRNA; cDNA

DKFZp564P116 (from clone

213362_at 1.76769808 1 10.2 1.7676978 18.85 DKFZp564P116), mRNA sequence

213977_s_at 1.76748939 1 225.15 1.7674894 418.8 CIZ1 Cip1 -interacting zinc finger protein

Rho GDP dissociation inhibitor

206889_at 1.76643466 1 8.1 1.7664347 16.3 ARHGDIG (GDI) gamma

219634 at 1.76567374 1 7.1 1.7656736 13.95 C4ST chondroitin 4-sulfotransferase

succinate dehydrogenase complex,

214166. _at 1.76480918 1 8 1.7648091 14.8 SDHB subunit B, iron sulfur (Ip)

217563. _at 1.76293438 1 34.65 1.7629343 65.75 CLOCK clock homolog (mouse)

Homo sapiens cDNA: FLJ21541 fis, clone COL06166, mRNA

216772. .at 1.76166287 1 10 1.7616628 19.7 sequence

212974. _at 1.76003106 1 20.9 1.7600312 38.3 KIAA0870 KIAA0870 protein

TAF9-Iike RNA polymerase II,

TATA box binding protein (TBP)-

221616. _s_at 1.7598231 1 20.85 1.7598232 39.8 TAF9L associated factor, 31kDa solute carrier family 18 (vesicular

207150. _at 1.75917101 1 11.3 1.759171 21.5 SLC18A3 acetylcholine), member 3

222238. _s_at 1.75911425 1 19.25 1.7591144 38 POLM polymerase (DNA directed), mu transcription factor 3 (E2A immunoglobulin enhancer binding

209152. _s_at 1.75892054 1 79.75 1.7589204 146.45 TCF3 factors E12/E47)

MAD, mothers against decapentaplegic homolog 4

202526. _at 1.75882392 1 15.95 1.7588239 30.6 MADH4 (Drosophila)

210618. _at 1.75844165 1 4.1 1.7584417 10.3 RAP1GA1 RAP1 , GTPase activating protein 1 roundabout homolog 4, magic

220758. _s_at 1.75788765 1 23.85 1.7578876 43.2 ROBO4 roundabout (Drosophila)

220313_ .at 1.75705558 1 6.6 1.7570555 11.8 GPR88 G-protein coupled receptor 88 glucocorticoid modulatory element

222251. _s_at 1.75663113 1 40.15 1.7566311 73.6 GMEB2 binding protein 2

Homo sapiens cDNA FLJ14046 fis, clone HEMBA1006461, mRNA

217164_ .at 1.75553355 1 19 1.7555337 35.35 sequence

Homo sapiens mRNA; cDNA

DKFZp586A0423 (from clone

DKFZp586A0423), mRNA

215525. _at 1.75478046 1 23.1 1.7547804 43.25 sequence hydroxysteroid (11-beta)

205404. _at 1.75383674 1 33.75 1.7538366 63.55 HSD11 B1 dehydrogenase 1

217313 at 1.753415 1 119.65 1.7534151 228.55

polymerase (RNA) Il (DNA

217415_at 1.75312585 1 10.9 1.7531259 21.15 POLR2A directed) polypeptide A, 22OkDa 210282_at 1.75295211 1 3.3 1.7529521 5.85 ZNF198 zinc finger protein 198 cadherin, EGF LAG seven-pass G- type receptor 3 (flamingo homolog,

40020_at 1.75236898 1 70.15 1.7523689 130.1 MEGF2 Drosophila) kallikrein 7 (chymotryptic, stratum

205778_at 1.75229394 1 10.85 1.7522938 19.5 KLK7 corneum) 214727_at 1.75229168 1 14.35 1.7522917 27.4 brca2 221717_at 1.75136912 1 52.75 1.7513691 98.3 Interferon, mRNA sequence

Wiskott-Aldrich syndrome (eczema-

205400_at 1.75126903 1 6.1 1.7512691 10.9 WAS thrombocytopenia) ribosomal protein S6 kinase,

203379_at 1.75048207 1 34.75 1.7504821 66.35 RPS6KA1 9OkDa, polypeptide 1 matrix metalloproteinase 11

213602_s_at 1.74985891 1 -5.5 1.7498589 10.5 MMP11 (stromelysin 3) cellular retinoic acid binding protein

205350_at 1.74964336 1 1.7 1.7496432 9.9 CRABP1 1

Homo sapiens cDNA: FLJ23167 fis, clone LNG09902, mRNA

215875_at 1.74947512 1 30.5 1.7494751 56.05 sequence 55583_at 1.74947035 1 48.7 1.7494702 88.6 KIAA1395 KIAA1395 protein ϊntegrϊn, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2,

216190_x_at 1.74884002 1 54.7 1.7488399 104.45 ITG B1 MSK12) 209502_s_at 1.74865561 1 56.9 1.7486556 105.6 BAIAP2 BAH -associated protein 2

Rho guanine nucleotide exchange

203055_s_at 1.74640382 1 145.75 1.7464039 270.6 ARHGEF- factor (GEF) 1

Homo sapiens cDNA: FLJ21707 fis, clone COL09953, mRNA

216173_at 1.74622416 1 2.45 1.746224 1.15 sequence 216103_at 1.7441787 1 23.05 1.7441787 43.15 THEA thioesterase, adipose associated 222312_s_at 1.74364534 1 2.55 1.7436452 8.25 PLN phospholamban 205046 at 1.74327081 1 28.55 1.7432709 50.55 CENPE centromere protein E, 312kDa

210182. _at 1.74263085 1 22.6 1.742631 42.05 CORT cortistatin

Homo sapiens cDNA FLJ11509 fis, clone HEMBA1002166, mRNA

215249. _at 1.74184407 1 18.1 1.7418442 32.4 sequence

216712. _at 1.74148738 1 5.65 1.7414874 10.3

212843. .at 1.74124129 1 23.9 1.7412412 41.2 NCAM1 neural cell adhesion molecule 1 fucosyltransferase 2 (secretor

210608. _s_at 1.74098825 1 28.3 1.7409883 51.9 FUT2 status included) solute carrier family 2 (facilitated

219991. .at 1.74031936 1 5.55 1.7403193 13.6 SLC2A9 glucose transporter), member 9 sodium channel, voltage-gated,

210853. .at 1.74018381 1 12.3 1.7401837 23.35 SCN11A type Xl, alpha polypeptide seizure related 6 homolog (mouse )-

213609. _s_at 1.74014171 1 8.8 1.7401419 15.8 SEZ6L like

207534~ .at 1.74005871 1 11.6 1.7400587 21 MAGEB1 melanoma antigen, family B, 1

214950. at 1.73911762 1 20.3 1.7391176 39 IL9R

220071. _x_at 1.73903691 1 117.3 1.7390368 211.45 FLJ 10460 hypothetical protein FLJ 10460

209251. _x_at 1.73902004 1 230.55 1.73902 453.7 TUBA6 tubulin alpha 6 solute carrier family 1 (glial high affinity glutamate transporter),

208389. _s_at 1.73769212 1 10.85 1.7376921 20.6 SLC1A2 member 2

202726. .at 1.73710692 1 19.7 1.7371069 37.5 LIG1 ligase I, DNA, ATP-dependent zinc finger protein of the

211463. .at 1.73618912 1 18 1.7361891 33.4 ZIC4 cerebellum 4 hypothetical protein

221316. .at 1.73568782 1 8.7 1.7356877 17.35 DKFZP434A1022 DKFZp434A1022

207823. _s_at 1.73494478 1 3.35 1.7349447 8.4 AIF1 allograft inflammatory factor 1

T-cell activation leucine repeat-rich

212976. .at 1.73485344 1 1 1.7348533 1.9 TA-LRRP protein

Homo sapiens cDNA: FLJ20890 fis, clone ADKA03323, mRNA

216155. .at 1.73416449 1 14.2 1.7341645 25.65 sequence

DnaJ (Hsp40) homolog, subfamily

204721 s at 1.73409782 1 5.2 1.734098 9.1 DNAJC6 C, member 6

219761_at 1.73395181 1 6.9 1.7339518 12.9 CLEC1 C-type lectin-like receptor-1 207844_at 1.73346593 1 20.45 1.733466 38 1L13 interleukϊn 13

Homo sapiens mRNA; cDNA

DKFZp566F1946 (from clone

DKFZp566F1946), mRNA

215186_at 1.73337865 1 32.7 1.7333786 61.05 sequence leucine zipper, putative tumor

222107__x_at 1.7333726 1 30.95 1.7333724 59.4 LZTS1 suppressor 1 212977_at 1.73319501 1 33.5 1.7331951 61.5 RDC1 G protein-coupled receptor 218792_s_at 1.73306271 1 18.35 1.7330627 32.25 BSPRY hypothetical protein FLJ20150

Homo sapiens cDNA: FLJ20872 fis, clone ADKA02604, mRNA

216737_at 1.73282701 1 1.6 1.7328271 2.8 sequence 221391_at 1.73209474 1 24.35 1.7320945 44.55 TAS2R14 taste receptor, type 2, member 14 207401_at 1.73193177 1 13.15 1.7319319 24.3 PROX1 prospero-related homeobox 1 solute carrier family 22 (organic

204981_at 1.73169923 1 80.35 1.7316992 147.4 SLC22A1L cation transporter), member 1-like 222274_at 1.73081171 1 6.45 1.7308116 11.25 FLJ31568 hypothetical protein FLJ31568 203045_at 1.73059804 1 140.25 1.7305981 270.85 NINJ1 ninjurin 1 hematopoietic PBX-interacting

207838_x_at 1.73007312 1 34.1 1.730073 48.7 HPIP protein

Homo sapiens mRNA; cDNA

DKFZp564O1763 (from clone

DKFZp564O1763), mRNA

51158_at 1.72988349 1 11.45 1.7298834 21.55 sequence tumor necrosis factor receptor

214581_x_at 1.72968901 1 10.9 1.7296891 20.7 TNFRSF21 superfamily, member 21 207501_s_at 1.72960332 1 19.6 1.729603 34.85 FGF12 fibroblast growth factor 12 215397_x_at 1.72897524 1 29.3 1.7289753 52.55 206045_s_at 1.72764748 1 7 1.7276474 12.95 NOL4 nucleolar protein 4

Homo sapiens mRNA; cDNA

DKFZp434D2416 (from clone

DKFZp434D2416), mRNA

216141 at 1.72740948 1 96.55 1.7274095 177.6 sequence

ecotropic viral integration site

204774_at 1.72623599 1 72.3 1.7262361 135.8 EVI2A 2A 204683_at 1.72570034 1 11.45 1.7257004 20.65 ICAM2 intercellular adhesion molecule 2 sialophorin (gpL115, leukosialin,

206057_x_at 1.72496267 1 9.45 1.7249626 18.45 SPN CD43) a disintegrin and metalloproteinase

206615_s_at 1.72417239 1 5.5 1.7241725 10.7 ADAM22 domain 22

ESTs, Weakly similar to TSG118.1 protein [Mus musculus]

213235_at 1.7239036 1 9 1.7239037 16.85 [M.musculus] neurofibromin 1 (neurofibromatosis, von Recklinghausen disease,

204323_x_at 1.72366639 1 22.75 1.7236664 42.3 NF1 Watson disease) 214438_at 1.72354794 1 12.85 1.7235479 22.85 HLX1 H2.0-like homeo box 1 (Drosophila) chromosome 21 open reading

221975_s_at 1.7229418 1 3 1.7229418 3.75 C21orf2 frame 2

Homo sapiens, clone 4-

IMAGE:5270727, mRNA, mRNA 00

222037_at 1.72255492 1 63.2 1.7225549 116.5 sequence 212381_at 1.72248142 1 60.9 1.7224814 111.15 USP24 ubiquitin specific protease 24 210138_at 1.72218311 1 12.1 1.7221831 24 RGS20 regulator of G-protein signalling 20 213430_at 1.72202668 1 6.6 1.7220267 12.2 RIPX rap2 interacting protein x 205945_at 1.7219489 1 4.95 1.7219489 8.4 SL8R interleukϊn 6 receptor sialyltransferase 8D (alpha-2, 8-

206925_at 1.72157645 1 15.35 1.7215765 29.75 SIAT8D polysialytransferase)

6-phosphofructo-2-kinase/fructose-

207537_at 1.72126723 1 36.55 1.7212672 65.25 PFKFB1 2,6-biphosphatase 1 seven transmembrane protein

217974_at 1.7208691 1 7.4 1.7208691 13.05 TM7SF3 TM7SF3 217244_at 1.72074668 1 0.45 1.7207465 6.15 pyruvate dehydrogenase kinase,

202590_s_at 1.72037458 1 91.45 1.7203746 168.15 PDK2 isoenzyme 2 potassium inwardly-rectifying

208566_at 1.72011309 1 -4.45 1.720113 8.8 KCNJ12 channel, subfamily J, member 12 1438 at 1.71981541 1 36.75 1.7198154 66.1 HEK2 EphB3

solute carrier family 7 (cationic amino acid transporter, y+ system),

206566_at 1.71979916 1 8.15 1.7197992 14.5 SLC7A1 member 1 218921_at 1.71946811 1 38.55 1.7194681 70.6 SIGIRR single Ig IL-1R-related molecule

PRO1097 [Homo sapiens], mRNA

221145_at 1.71926212 1 1.5 1.7192622 1.2 sequence

C1q and tumor necrosis factor

220988_s_at 1.71895109 1 20.25 1.718951 35.95 C1QTNF3 related protein 3 221467_at 1.71854573 1 25.25 1.7185457 46.75 MC4R melanocortin 4 receptor 210723_x_at 1.7185104 1 26.05 1.7185104 47.25 MGC4771 hypothetical protein MGC4771 221154_at 1.71842968 1 12.95 1.7184296 23.2 RNF18 ring finger protein 18 217634_at 1.71813809 1 7.5 1.718138 13.95 SViL supervillin pleckstrin homology-like domain,

218000_s_at 1.71772876 1 220.25 1.7177287 406.5 PHLDA1 family A, member 1 dentatorubral-pallidoluysian

40489_at 1.71741183 1 150 1.717412 270.1 DRPLA atrophy (atrophin-1 ) 208200_at 1.71717941 1 9.65 1.7171793 17.85 IL1A interleukin 1, alpha 4- 33148_at 1.71707819 1 5.75 1.7170781 10.9 ZFR zinc finger RNA binding protein 218848_at 1.71668633 1 49.4 1.7166861 90.65 MGC2655 hypothetical protein MGC2655

Homo sapiens, clone

IMAGE:4477095, mRNA, mRNA

213402_at 1.71576199 1 20.2 1.7157619 35.35 sequence protocadherin gamma subfamily A,

211877_s_at 1.71561552 1 7.85 1.7156155 15.85 PCDHGA11 11 protein phosphatase 1, regulatory

201957_at 1.71552001 1 -5.5 1.7155201 5.05 PPP1R12B (inhibitor) subunit 12B sine oculis homeobox homolog 2

206511_s_at 1.71528864 1 18.7 1.7152886 34.95 SIX2 (Drosophila) pyrimidinergic receptor P2Y, G-

208373_s_at 1.71473254 1 33 1.7147324 56.85 P2RY6 protein coupled, 6 201959_s_at 1.71402678 1 46.5 1.7140268 74.45 KIAA0916 KIAA0916 protein 217627_at 1.71385724 1 7.95 1.7138573 14.05 FLJ30921 hypothetical protein FLJ30921 210712 at 1.71377236 1 8.6 1.7137723 15.2 LDHL lactate dehydrogenase A -like

Homo sapiens cDNA: FLJ21726 fis, clone COLF1088, mRNA

216200_at 1.7126873 1 8.25 1.7126873 15.45 sequence 208181_at 1.71197659 1 5.45 1.7119765 10.4 HIST1H4H H4 histone family, member H 214444_s_at 1.71104372 1 19.85 1.7110438 37.25 PVR poliovirus receptor 220177_s_at 1.71076566 1 26.1 1.7107656 47.15 TMPRSS3 transmembrane protease, serine 3 calcitonin/calcitonin-related

217561_at 1.71022265 1 11.65 1.7102226 21.35 CALCA polypeptide, alpha 211998_at 1.70944337 1 114 1.7094433 208.65 H3F3B H3 histone, family 3B (H3.3B) 214744_s_at 1.70930386 1 25.75 1.7093039 48.6 221627_at 1.70921059 1 23.7 1.7092106 42.6 TRIM10 tripartite motif-containing 10 transcription factor 7 (T-cell

205255_x_at 1.70920909 1 147.15 1.7092092 261.4 TCF7 specific, HMG-box) cytochrome P450, subfamily HA (phenobarbital-inducible),

211295_x_at 1.70834411 1 155.55 1.7083442 281.95 CYP2A6 polypeptide 6 202545_at 1.70833158 1 3 1.7083315 14.2 PRKCD protein kinase C, delta O 216550_x_at 1.70806759 1 3.1 1.7080675 5.85 KIAA0874 KIAA0874 protein wingless-type MMTV integration

208570_at 1.70795344 1 -1 1.7079535 11.8 WNT1 site family, member 1 Wolf-Hirschhorn syndrome

203112_s_at 1.70708143 1 46.75 1.7070813 83.35 WHSC2 candidate 2 207323_s_at 1.70670754 1 35.9 1.7067075 64.9 MBP myelin basic protein 220067_at 1.70655741 1 13.3 1.7065575 23.5 SPTBN5 spectrin, beta, non-erythrocytic 5 220883_at 1.70511017 1 5 1.7051101 9.4 PRO2012 hypothetical protein PRO2012 209242_at 1.70473903 1 13.05 1.704739 23.55 PEG3 paternally expressed 3 CDC42 effector protein (Rho

214721_x_at 1.70467739 1 80.85 1.7046773 146.55 CDC42EP4 GTPase binding) 4 216705_s_at 1.70446958 1 29.5 1.7044696 54.6 ada 212965_at 1.70288207 1 16.1 1.7028822 27.45 HIC2 hypermethylated in cancer 2 chromodomain helicase DNA

201182_s_at 1.70276025 1 8.65 1.7027602 14.8 CHD4 binding protein 4 208176_at 1.70256438 1 12.65 1.7025645 23.9 DUX1 double homeobox, 1 218724 s at 1.7018957 1 14.7 1.7018957 26.6 TGIF2 TGFB-induced factor 2 (TALE

family homeobox)

214554_at 1.70164092 1 4 1.7016411 7.15 H2AFI H2A histone family, member I

Homo sapiens cDNA: FLJ23014 fis, clone LNG00806, mRNA

216786_at 1.70149306 1 4.85 1.701493 8.85 sequence

204129_at 1.70135366 1 123.2 1.7013535 220.3 BCL9 B-cell CLL/lymphoma 9

204375_at 1.70049677 1 36.4 1.7004967 66 CLSTN3 calsyntenin 3

X-ray repair complementing defective repair in Chinese hamster

210812_at 1.70048067 1 -0.9 1.7004805 8.5 XRCC4 cells 4

203612_at 1.70034814 1 139.7 1.7003481 248.15 BYSL bystin-like giant axonal neuropathy

220124_at 1.70034526 1 1.65 1.7003453 3.7 GAN (gigaxonin) regulatory factor X, 3 (influences

207234_at 1.6996035 1 31.45 1.6996036 55.4 RFX3 HLA class Il expression) hypothetical protein

218726_at 1.69922124 1 26.65 1.6992213 76.15 DKFZp762E1312 DKFZp762E1312 ϊnhifoin. beta A (activin A, actϊvin

204926_ai 1.69871569 1 34.7 1.8987157 82.35 INHBA AB alpha polypeptide)

38766_at 1.69847565 1 69.8 1.6984756 124.55 KIAA0309 Snf2-related CBP activator protein nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent

208196_x_at 1.69805692 1 14.3 1.6980567 24.15 NFATC1 1

206639_x_at 1.69699994 1 38.85 1.6969998 70.25 HTN 1 histatin 1

SRY (sex determining region Y)-

219993_at 1.69685052 1 8.8 1.6968504 15.4 SOX17 box 17

206705_at 1.69661177 1 11.45 1.6966119 20.65 TULP1 tubby like protein 1 tumor necrosis factor receptor superfamily, member 10c, decoy

206222_at 1.69618151 1 5.5 1.6961813 10.65 TNFRSF10C without an intracellular domain

207474_at 1.69565108 1 2.8 1.695651 4.35 SNRK SNF-1 related kinase

Homo sapiens mRNA; cDNA

DKFZp434C2331 (from clone

216688 at 1.69475842 1 31.1 1.6947584 56.75 DKFZD434C2331), mRNA

sequence

216696_s_at 1.69474826 1 53.9 1.6947482 101.2 PRODH2; HSPOX1 phosphatidylinositol-3 phosphate 3-

220953_s_at 1.69453273 1 67.3 1.6945326 121.1 3PAP phosphatase adaptor subunit

209725_at 1.69414333 1 23.95 1.6941433 45.8 DRIM down-regulated in metastasis

ESTs, Moderately similar to

SC14_HUMAN SEC14-like protein

217667_at 1.69398441 1 -2.15 1.6939844 2.45 1 [H.sapiens] calcium/calmodulin-dependent

210349_at 1.6934626 1 25.25 1.6934626 46.75 CAMK4 protein kinase IV

Homo sapiens mRNA; cDNA

DKFZp586C1923 (from clone

DKFZp586C1923), mRNA

215534_at 1.69319223 1 19.85 1.6931922 35.9 sequence

219849_at 1.69305088 1 3.05 1.6930509 16.8 FLJ23506 hypothetical protein FLJ23506

210626_at 1.69286576 1 2.7 1.6928656 5.3 AKAP 1 A kinase (PRKA) anchor protein 1 K> hypothetical protein MGC3279

219873_at 1.6923856 1 39.7 1.6923856 72.85 MGC3279 similar to collectins

46947_at 1.6915258 1 9.55 1.6915257 16.85 FLJ10613 hypothetical protein FLJ 10613 olfactory receptor, family 2,

221409_at 1.6910687 1 15.9 1.6910688 29.25 OR2S2 subfamily S, member 2 ectonucleoside triphosphate

207372_s_at 1.69027689 1 7.4 1.6902769 12.8 ENTPD2 diphosphohydrolase 2

Homo sapiens mRNA; cDNA

DKFZp761 P1114 (from clone

DKFZp761P1114), mRNA

216683_at 1.68956474 1 5.65 1.6895647 9.45 sequence

206167_s_at 1.68948174 1 8.85 1.6894817 15.8 ARHGAP6 Rho GTPase activating protein 6

SRY (sex determining region Y)-

213721_at 1.68845123 1 12.1 1.6884513 22 SOX2 box 2

213479_at 1.68815878 1 8.2 1.6881588 13.75 NPTX2 neuronal pentraxin Il

216291_at 1.68784187 1 4.1 1.6878419 2.95

AFFX-TrpnX-5_at 1.687655 1 8.3 1.687655 14.05

213723_s_at 1.68744898 1 11.8 1.687449 20.85 IDUA iduronidase, alpha-L- transient receptor potential cation

215288_at 1.68709913 1 23.75 1.687099 42.7 TRPC2 channel, subfamily C₁ member 2 purinergic receptor P2Y, G-protein

207455_at 1.68709154 1 11.6 1.6870916 21.1 P2RY1 coupled, 1 betaine-homocysteine

206119_at 1.68647731 1 24.75 1.6864772 47.25 BHMT methyltransferase

204799_at 1.68546482 1 35.2 1.6854649 60.6 ZBED4 KIAA0637 gene product

Homo sapiens mRNA; cDNA

DKFZp434P088 (from clone

216533_at 1.68525884 1 -0.9 1.6852589 -1.55 DKFZp434P088), mRNA sequence

216273_at 1.68510162 1 13.85 1.6851016 27 ZNF272 zinc finger protein 272

ZFM1 protein, alternatively spliced product [Homo sapiens], mRNA

210172_at 1.68479611 1 23.7 1.6847961 40.15 sequence

220252_x_at 1.68467363 1 26.9 1.6846738 48 FLJ 11577 hypothetical protein FLJ 11577

215520_at 1.684528 1 15.8 1.6845281 29.95 PYG01 pygopus 1

207727_s_at 1.68431755 1 68.55 1.6843176 125.25 MUTYH mutY homolog (E. coli) achaete-scute complex-like 1

209988_s_at 1.68367116 1 -0.75 1.6836711 1.75 ASCL1 (Drosophila)

218564_at 1.68364919 1 27.9 1.6836493 50.55 FLJ 10520 hypothetical protein FLJ10520

ESTs, Weakly similar to hypothetical protein FLJ20489

217653_x_at 1.68364165 1 21.55 1.6836416 38.15 [Homo sapiens] [H.sapiens]

216229_x_at 1.68356478 1 24.9 1.6835648 44.25 HCGII-7 HCGII-7 protein

Homo sapiens mRNA; cDNA

DKFZp564F112 (from clone

213605_s_at 1.68341948 1 25.45 1.6834196 45.35 DKFZp564F112), mRNA sequence

Cyclophilin-LC [Homo sapiens],

217136_at 1.68335193 1 6.15 1.683352 11.5 mRNA sequence phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase,

210005 at 1.68318736 1 52.3 1.6831872 94.15 GART phosphoribosylaminoimidazole

synthetase

218032_at 1.68285485 1 207.15 1.6828549 373.7 SNN stannin 206787_at 1.68118038 1 2.6 1.6811805 8.05 BRDT bromodomain, testis-specific 207867_at 1.68080908 1 35.2 1.680809 62 PAX4 paired box gene 4 35160 at 1.68060612 1 139.45 1.6806061 250.75 CLIM2 LIM domain binding 1 suppressor of variegation 3-9

(Drosophila) homolog 2;

219262_at 1.67981113 4.05 1.6798112 7.35 SUV39H2 hypothetical protein FLJ23414 208448 x at 1.6792916 170.7 1.6792915 302.85 IFNA16 interferon, alpha 16 intsgrin, alpha 2b (platelet glycoprotein Hb of itb/lila

216966_at 1.87921822 0.15 1.8702182 3.75 complex, antigen CD41B) 219466 s at 1.67879485 1.9 1.6787949 4.8 APOA2 apolipoprotein A-Il

MCM7 minichromosome maintenance deficient 7 (S.

210983_s_at 1.67783174 1 34.45 1.6778316 62.1 MCM7 cerevisiae)

BRF1 homolog, subunit of RNA polymerase III transcription

203754_s_at 1.67744761 1 31.55 1.6774476 55.8 BRF1 initiation factor IHB (S. cerevisiae) fibronectin leucine rich 219250 s at 1.67731067 1 4.5 1.6773108 8.05 FLRT3 transmembrane protein 3

Homo sapiens cDNA FLJ11801 fis, clone HEMBA1006253, weakly similar to DNA-DAMAGE-

REPAIR/TOLERATION PROTEIN

DRT111 PRECURSOR, mRNA

213744_. .at 1.67704941 1 22.75 1.6770494 40.9 sequence 221920_ _s_at 1.67614899 1 94 1.6761489 169.6 MSCP mitochondrial solute carrier protein

DKFZP586P0123

213199. .at 1.6758747 1 19.2 1.6758746 29.15 DKFZP586P0123 protein

G protein-coupled receptor kinase

208365_. -S_at 1.67580662 1 21.05 1.6758066 36.5 GPRK2L 2-like (Drosophila) 207976 at 1.67410855 1 31.7 1.6741085 55.8 KIAA0795 KIAA0795 protein

205494_at 1.67367141 1 19.85 1.6736715 37.25 LOC55565 hypothetical protein LOC55565

Homo sapiens cDNA FLJ12380 fis, clone MAMMA1002556, mRNA 215032_at 1.67335509 63.4 1.6733551 112.3 sequence killer cell immunoglobulin-like receptor, two domains, long

211245_x_at 1.67251118 1 26.3 1.672511 46.35 KIR2DL4 cytoplasmic tail, 4

E2F transcription factor 4,

38707_r_at 1.67218227 1 313.3 1.6721823 549.7 E2F-4 p107/p130-binding

Orf [Homo sapiens], mRNA

215234_at 1.67196184 1 12 1.6719618 20.9 sequence

MCF.2 protein (568 AA) (1 is 2nd base in codon) [Homo sapiens],

217004_s_at 1.67173624 1 28.3 1.6717362 49.75 mRNA sequence 203645_s_at 1.67156695 1 10.35 1.6715671 19.5 CD163 CD163 antigen 221168_at 1.67124306 1 7.75 1.671243 13.5 PRDM13 PR domain containing 13 20971 O_at 1.67082107 1 14.75 1.6708211 25.55 MGC2306 hypothetical protein MGC2306 protein phosphatase 2A, regulatory Ul

206452_x_at 1.67014538 1 246.45 1.6701453 434.7 PPP2R4 subunit B¹ (PR 53) 217239_x_at 1.66938448 1 -0.55 1.6693845 2.65

PWP2 periodic tryptophan protein

209336_at 1.66898848 1 23.25 1.6689885 43.65 PWP2H homolog (yeast) cytochrome P450, subfamily 46 220331_at 1.66773641 1 7.85 1.6677364 14.4 CYP46A1 (cholesterol 24-hydroxylase) CD69 antigen (p60, early T-cell

209795_at 1.66739684 1 5.55 1.6673968 9.5 CD69 activation antigen) 216816_at 1.66691087 1 94.95 1.6669108 168.65 206274_s_at 1.66658256 1 30.7 1.6665825 54.35 KIAA0445 KIAA0445 gene product splicing factor, arginine/serine-rich

8 (suppressor-of-white-apricot

202775_s_at 1.66639376 1 62.4 1.6663938 108.05 SFRS8 homolog, Drosophila) mitochondrial ribosomal protein

215919_s_at 1.66621326 1 3.9 1.6662133 7.1 MRPS11 S11 206352 s at 1.66603436 1 40.25 1.6660345 96.65 PEX10 peroxisome biogenesis factor 10

Homo sapiens cDNA FLJ 12370 fis, clone MAMMA1002428, weakly similar to LYSOSOME

MEMBRANE PROTEIN II, mRNA

215754_at 1.66595225 1 27.95 1.6659522 50.55 sequence cubilin (intrinsic factor-cobalamin

206775_at 1.66436514 1 11.55 1.664365 22.2 CUBN receptor) 215599 at 1.66434982 1 8.55 1.6643498 15.25 SMA4 SMA4

ESTs, Weakly similar to hypothetical protein FLJ20489

222026_at 1.66288105 1 19.7 1.6628811 34.75 [Homo sapiens] [H.sapiens] frequently rearranged in advanced

209864_at 1.66168534 1 19.85 1.6616852 34.65 FRAT2 T-cell lymphomas 2 220182_at 1.66164901 1 18 1.6616491 31 MGC2615 hypothetical protein MGC2615 214878_at 1.66130537 1 6.8 1.6613054 11.55 ZNF37A zinc finger protein 37a (KOX 21 ) likely ortholog of mouse fibronectin

218843_at 1.66097217 1 -9.75 1.6609722 14.6 FRCP1 type III repeat containing protein 1 microtubule-interacting protein that 214458_at 1.6603135 1 9.15 1.6603136 15.7 MIP-T3 associates with TRAF3

Langerhans cell specific c-type

220428_at 1.6593302 1 18.05 1.6593302 31.5 LANGERIN lectin

218980_at 1.65884885 1 83.8 1.6588488 141.5 KIAA1695 hypothetical protein FLJ22297

216548_x_at 1.65790069 1 13.05 1.6579006 22.7

216830_at 1.65639064 1 5.25 1.6563907 -1.6

Homo sapiens cDNA FLJ32454 fis, clone SKNMC1000007, mRNA

221742 at 1.65612112 1 121.15 1.6561213 212.4 sequence

Homo sapiens cDNA: FLJ23070 fis, clone LNG05629, mRNA

215079_at 1.65550124 1 6 1.6555011 10.55 sequence 210918_at 1.65535528 1 8 .95 1.6553552 22.9 ESTs

Homo sapiens cDNA FLJ20779 fis,

215226_at 1.65490856 1 11 .15 1.6549087 19.05 clone COL05077, mRNA sequence 219826 at 1.65467987 1 -1 1.6546799 0.25 FLJ23233 hypothetical protein FLJ23233

Homo sapiens mRNA full length insert cDNA clone EUROIMAGE

215180_at 1.65454156 1 6.3 1.6545416 9.35 25206, mRNA sequence 206719_at 1.65441754 1 19.65 1.6544175 34.25 SYNG R4 synaptogyrin 4 amiloride-sensitive cation channel

205156_s_at 1.65382242 1 44.45 1.6538224 78.8 ACCN2 2, neuronal 200810_s_at 1.65326286 1 499.9 1.6532629 880.1 CIRBP cold inducible RNA binding protein 218496_at 1.65304562 1 104.9 1.6530454 173.15 RNASEH1 ribonuclease H1 likely ortholog of mouse widely-

221785_at 1.65303535 1 76.25 1.6530354 135.15 WIZ interspaced zinc finger motifs 211203_s_at 1.65275946 1 15.95 1.6527594 29.6 CNTN 1 contactin 1 cyclin-dependent kinase inhibitor

213182_x_at 1.65232705 1 33 1.6523271 54.9 CDKN1C 1C (p57, Kip2) chromosome 20 open reading

218145_at 1.6513684 1 396.6 1.6513684 675.05 C20orf97 frame 97 a disintegrin and metalloproteinase

221446_at 1.65084319 1 10.35 1.6508431 19.1 ADAM30 domain 30 solute carrier family 17 (sodium- ' dependent inorganic phosphate

204230_s_at 1.65047792 1 26.05 1.6504779 47.05 SLC17A7 cotransporter), member 7 complement component (3b/4b) receptor 1, including Knops blood

217552_x_at 1.64965184 1 5.3 1.6496519 9 CR1 group system likely ortholog of mouse tumor necrosis-alpha-induced adipose-

220187_at 1.64964378 1 10.05 1.6496438 17.25 FLJ23153 related protein 221412_at 1.64898197 1 7.9 1.6489818 13.45 VN1 R1 V1R-like 1

Homo sapiens mRNA; cDNA DKFZp566C0224 (from clone DKFZp566C0224), mRNA

216626_at 1.64897354 1 -4.2 1.6489736 7.9 sequence

Unnamed protein product [Homo

220712_at 1.64861279 1 95.9 1.6486127 165.9 sapiens], mRNA sequence solute carrier family 23 (nucleobase

211572 s at 1.6470446 1 34.65 1.6470447 61 SLC23A1 transporters), member 1

iduronate 2-sulfatase (Hunter

211782_at 1.64673915 1 7.9 1.6467392 14.1 IDS syndrome)

213613_s_at 1.64656489 1 17.35 1.6465648 31.75 FLJ 13052 NAD kinase

MAD, mothers against decapentaplegic homolog 6

207069_s_at 1.64646637 1 8.4 1.6464664 20.3 MADH6 (Drosophila)

C-type (calcium dependent, carbohydrate-recognition domain)

221698_s_at 1.64583851 1 21.5 1.6458385 37.1 CLECSF12 lectin, superfamily member 12 protein phosphatase 2 (formerly

2A), regulatory subunit B (PR 52),

213849_s_at 1.64568054 1 60.15 1.6456804 107.6 PPP2R2B beta isoform

Unnamed protein product [Homo

220897_at 1.64552308 1 52.95 1.6455231 92.05 sapiens], mRNA sequence

207491_at 1.64464732 1 31.05 1.6446474 53.7 MGAT2 hypothetical protein FLJ22644

Usher syndrome 1C (autosomal

211184_s_at 1.64443761 1 11.25 1.6444376 19.4 USH1C recessive, severe)

Homo sapiens cDNA FLJ 12055 fis, OO clone HEMBB1002049, mRNA

214967_at 1.64431808 1 4.05 1.644318 10.5 sequence

216680_s_at 1.64412379 1 87 1.6441238 150.2 EPHB4 EphB4 hypothetical protein

221541_at 1.64400249 1 79.1 1.6440024 140.25 DKFZP434B044 DKFZp434B044 collagen, type IV, alpha 3

222073_at 1.64393472 1 6 1.6439347 9.9 COL4A3 (Goodpasture antigen)

216997_x_at 1.64358555 1 7.65 1.6435854 13.75

219875_s_at 1.64324957 1 81.3 1.6432495 143.1 PNAS-4 CGI-146 protein

207436_x_at 1.64289255 1 141.1 1.6428926 243.95 KIAA0894 KIAA0894 protein hydroxyprostaglandin

211548_s_at 1.64234965 1 12.25 1.6423497 22.55 HPGD dehydrogenase 15-(NAD)

220485_s_at 1.64139001 1 13.25 1.64139 24.45 SIRPB2 signal-regulatory protein beta 2

Homo sapiens mRNA; cDNA

DKFZp564D193 (from clone

216478_at 1.64103131 1 -2.6 1.6410315 4 DKFZp564D193), mRNA sequence

203088 at 1.64082521 1 671.9 1.6408253 1170.15 FBLN5 fibulin 5

Homo sapiens cDNA FLJ10586 fis, clone NT2RP2003986, mRNA

215625_at 1.64056939 1 5.8 1.6405694 9.75 sequence 215010_s_at 1.64037831 1 8 1.6403784 13.6 STK29 serine/threonine kinase 29 203234_at 1.6396262 1 163.9 1.639626 294.05 UP uridine phosphorylase

N-deacetylase/N-sulfotransferase

202608_s_at 1.639342 1 31.9 1.639342 56.3 NDST1 (heparan glucosaminyl) 1 pre-B-cell colony-enhancing

217739_s_at 1.63820824 1 121.45 1.6382083 213.55 PBEF factor chromatin assembly factor 1 ,

203976_s_at 1.63819844 1 23.2 1.6381984 41.75 CHAF1A subunitA (p150)

3',5'-cyclic AMP phosphodiesterase

HSPDE4A7A [Homo sapiens],

211447_s_at 1.63749496 1 5.2 1.637495 8.75 mRNA sequence chondroitin sulfate proteoglycan 6

209257_s_at 1.63746074 1 18.3 1.6374606 31.7 CSPG6 (bamacan) protein tyrosine phosphatase,

212588_at 1.63729601 1 4.65 1.6372961 8.65 PTPRC receptor type, C U 221915_s_at 1.63710035 1 17.45 1.6371005 31.4 HTF9C Hpall tiny fragments locus 9C gamma-aminobutyric acid

208217_at 1.63671833 1 33.1 1.6367183 58.15 GABRR2 (GABA) receptor, rho 2

Rho guanine nucleotide exchange

216912_at 1.63612918 1 -1.7 1.6361291 2.45 ARHGEF4 factor (GEF) 4 proteasome (prosome, macropain)

209334_s_at 1.63583387 1 29.9 1.635834 53.35 PSMD9 26S subunit, non-ATPase, 9 209869_at 1.6357266 1 26.4 1.6357267 43.35 ADRA2A adrenergic, alpha-2A-, receptor likely ortholog of mouse RNA polymerase I associated factor, 53

218997_at 1.63563776 1 125.45 1.6356378 224.95 PAF53 kD solute carrier family 22 (organic

221661_at 1.63550457 1 8.85 {.6355045 14.95 SLC22A7 anion transporter), member 7 endo-beta-N-

220349_s_at 1.63512971 1 23.6 1.6351298 40.65 FLJ21865 acetylglucosaminidase dickkopf homolog 2 (Xenopus

219908 at 1.6346549 1 3.95 1.6346549 7.25 DKK2 laevis)

Homo sapiens cDNA: FLJ22786 fis, clone KAIA2150, mRNA

216427_at 1.63406621 1 4.7 1.6340662 8.85 sequence 220545_s_at 1.63374713 1 15 1.633747 26.7 TSKS testis-specific kinase substrate 220669_at 1.63271774 1 11.45 1.6327178 19.5 HSHIN1 Hin-1

DEAD/H (Asp-Glu-Ala-Asp/His) box

209178_at 1.63233283 1 64.05 1.6323327 111.3 DDX38 polypeptide 38 220851_at 1.63139743 1 7.8 1.6313975 13.75 PRO1600 PRO1600 protein

ESTs, Moderately similar to hypothetical protein FLJ20378

217708_x_at 1.63129046 1 2.45 1.6312906 -7.5 [Homo sapiens] [H. sapiens] 205949_at 1.63076804 1 18.95 1.6307681 35.4 CA1 carbonic anhydrase I 215991_s_at 1.63049457 1 5.75 1.6304946 9.65 KIAA0090 KIAA0090 protein 214904_at 1.63041428 1 0.15 1.6304142 2.8 ZNF41 zinc finger protein 41

Homo sapiens mRNA; cDNA

DKFZp434N021 (from clone

216068_at 1.63022727 1 2.6 1.6302273 4.45 DKFZp434N021), mRNA sequence o

Wilms' tumour 1 -associating

210285_x_at 1.63011801 1 363 1.630118 644.65 WTAP protein glutamine-fructose-6-phosphate

205100_at 1.62849456 1 113.1 1.6284945 197.8 GFPT2 transaminase 2 222074_at 1.62779772 1 16.95 1.6277977 29.4 UROD uroporphyrinogen decarboxylase interiβukin 18 (interferon-

206295_at 1.6272316 1 9 1.6272316 15.3 1L18 gamma-ϊnducing factor)

205718 at 1.6272221 1 13.55 1.6272221 23.15 ITGB7 integrin, beta 7 caspase 2, apoptosis-related cysteine protease (neural precursor cell expressed, developmentally down-regulated

208050. _s_at 1.62718544 1 28.45 1.6271853 48.5 CASP2 2)

CD2 antigen (p50), sheep red

205831_ .at 1.62623843 1 37.2 1.6262383 65.4 CD2 blood cell receptor

210359. _at 1.62556165 1 -9.85 1.6255617 -11.05 KIAA0429 KIAA0429 gene product

201937_. _s_at 1.6252002 1 89.35 1.6252002 153.65 DNPEP aspartyl aminopeptidase

213680 at 1.62482109 1 21.3 1.624821 36.7 KRT6B keratin 6B

TIA1 cytotoxic granule-associated

217500_at 1.62414402 1 14.25 1.6241441 24.45 TIAL1 RNA binding protein-like 1 216755_at 1.62388644 1 43.95 1.6238863 75.25 OSBPL10 oxysterol binding protein-like 10 210884_s_at 1.62342644 1 35.95 1.6234264 62.8 SPAG 11 sperm associated antigen 11 221115_s_at 1.62335157 1 43.25 1.6233516 74.6 LENEP lens epithelial protein MADS box transcription enhancer factor 2, polypeptide C (myocyte

207968_s_at 1.62270688 1 15.85 1.6227069 28.5 MEF2C enhancer factor 2C) 219349_s_at 1.62249274 1 50.1 1.6224928 84.7 SEC5 homolog of yeast Sec5 neuropeptide FF-amide peptide

214184_at 1.6222994 1 1.8 1.6222994 2.85 NPFF precursor

210367_s_at 1.62214544 1 174.4 1.6221455 298.5 PTGES prostaglandin E synthase thyroid hormone receptor-

221544_s_at 1.62130214 1 52.9 1.6213021 92.9 TRAP95 associated protein, 95-kD subunit 214254_at 1.62088727 1 9.55 1.6208873 16 MAGEA4 melanoma antigen, family A, 4 215492_x_at 1.62034765 1 128.75 1.6203477 224.55 PTCRA pre-T-cell receptor alpha precursor potassium inwardly-rectifying c

\

208359_s_at 1.61875868 1 -5 1.6187587 11.65 KCNJ4 channel, subfamily J, member 4 211342_x_at 1.618756 1 99.25 1.618756 170.25 213608_s_at 1.61871122 1 136.9 1.6187112 231.95 TFIP11 tuftelin interacting protein 11 206579_at 1.61853409 1 10.15 1.6185341 17.05 ZNF192 zinc finger protein 192 nuclear receptor subfamily 1, group

204760_s_at 1.61812918 1 36.2 1.6181291 59.4 NR1D1 D, member 1 222184_at 1.61811956 1 10.9 1.6181197 18.75 synaptosomal-associated protein,

202507_s_at 1.61810914 1 80.2 1.618109 141.45 SNAP25 25kDa

CDC14 cell division cycle 14

205288_at 1.6176066 1 5.15 1.6176066 8.55 CDC14A homolog A (S. cerevisiae)

220299_at 1.61674649 1 21.55 1.6167464 38.1 SPATA6 spermatogenesis associated 6

Homo sapiens mRNA; cDNA

DKFZp667F1223 (from clone

DKFZp667F1223), mRNA

202913_at 1.61651789 1 79.55 1.616518 129.8 V sequence glucocorticoid receptor DNA

202044 at 1.61636027 1 25 1.6163604 43.15 GRLF1 binding factor 1

Wilms' tumour 1 -associating

203137. .at 1.61531231 1 462.95 1.6153122 814 WTAP protein

213622_ .at 1.61405854 1 52.95 1.6140585 90.4 COL9A2 collagen, type IX, alpha 2 oligodendrocyte myelin

207093_ _s_at 1.61358066 1 35.3 1.6135806 63.3 OMG glycoprotein potassium inwardly-rectifying

210119_ .at 1.61349633 1 17.05 1.6134963 30.7 KCNJ15 channel, subfamily J, member 15 Homo sapiens mRNA; cDNA DKFZp564H203 (from clone

214180_ .at 1.61318914 1 44.75 1.6131892 76.4 DKFZp564H203), mRNA sequence

210292_ _s_at 1.61285972 1 0.05 1.6128597 0.5 PCDH11X protocadherin 11 X-linked 5-hydroxytryptamine (serotonin)

207135. .at 1.6127001 1 19.3 1.6127001 33.05 HTR2A receptor 2A

205115. _s_at 1.61249149 1 40.7 1.6124915 70 KIAA0682 KIAA0682 gene product

205166 at 1.61191847 1 94.6 1.6119183 164.65 CAPN5 calpain 5

ESTs, Highly similar to trinucleotide repeat containing 11 (THR-associated protein, 230 kD subunit); trinucleotide repeat containing 11 (THR-associated protein, 230 kDa subunit); thyroid hormone receptor-associated protein, 230 kDa subunit [Homo

214275_at 1.61164508 1 24.8 1.611645 43.25 TNRC11 sapiens] [H.sapiens] 216336_x_at 1.61141228 1 483.7 1.6114123 842.9 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,

215904_at 1.6106037 1 12.8 1.6106036 22.4 MLLT4 Drosophila); translocated to, 4 221961_at 1.6102815 1 -1.6 1.6102815 13.25 CLCN7 chloride channel 7

BTB and CNC homology 1 , basic

221234_s_at 1.61022699 1 34.1 1.610227 56.7 BACH2 leucine zipper transcription factor 2 216302_at 1.60925232 1 11.65 1.6092522 20.15 LOC65122 219367_s_at 1.60902798 1 57.4 1.609028 95.15 NRP2 hypothetical protein PRO2714 210883_x_at 1.60839353 1 56.6 1.6083934 95.7 EFNB3 ephrin-B3 215398 at 1.60827465 1 18.7 1.6082747 33.35 Homo sapiens clone 23821 mRNA

sequence

213733_ .at 1.6079878 1 15.15 1.6079876 26 MYO1F myosin IF

211475. _s_at 1.60701462 1 250.05 1,6070144 431.65 BAG1 BCL2-associated athanogene

214031. _s_at 1.6069518 1 19.05 1.606952 32.25 KRT7 keratin 7

205789_ .at 1.60688506 1 1.5 1.6068851 5.8 CD1D CD1 D antigen, d polypeptide

221028_ _s_at 1.60616906 1 63.3 1.6061691 107.55 MGC11335 hypothetical protein MGC11335

206225_ .at 1.60604926 1 43.9 1.6060493 75.1 KIAA1084 KIAA1084 protein

CDK5 regulatory subunit

220935_ _s_at 1.60595831 1 63.05 1.6059585 109.9 CDK5RAP2 associated protein 2

205663_ .at 1.60569928 1 23.7 1.6056992 40.25 PCBP3 poly(rC) binding protein 3 sema domain, immunoglobulin domain (Ig), short basic domain,

206832 s at 1.60555993 1 40.75 1.6055598 68.5 SEMA3F secreted, (semaphorin) 3F

ESTs, Moderately similar to

AMYP-HUMAN Alpha-amylase, pancreatic precursor (1 ,4-alpha-D- glucan glucanohydrolase)

(Pancreatic alpha-amylase) (PA)

214416_at 1.60533844 1 12.65 1.6053386 21.8 [H.sapiens] 216798 at 1.60512296 1 13.35 1.6051228 22.5 FLJ23519 hypothetical protein FLJ23519

ESTs, Weakly similar to hypothetical protein FLJ20378

213751_at 1.60494155 1 13.75 1.6049416 22.55 LOC284352 [Homo sapiens] [H.sapiens]

Homo sapiens cDNA: FLJ22256 fis, clone HRC02860, mRNA

214036_at 1.60474261 1 38.65 1.6047426 88.7 sequence glycerol-3-phosphate

210007_s_at 1.60453629 1 10.05 1.6045363 17.2 GPD2 dehydrogenase 2 (mitochondrial) activation-induced cytidine

219841_at 1.60417442 10.75 1.6041744 19.75 AICDA deaminase

ELL gene (11-19 lysine-rich

204095_s_at 1.60377322 42.5 1.6037731 72.6 ELL leukemia gene) 221087_s_at 1.60353355 12.5 1.6035335 20.95 APOL3 apolipoprotein L, 3 transcription factor 7 (T-cell

205254 x at 1.60342927 1 22.95 1.6034293 39.05 TCF7 specific, HMG-box)

microsomal triglyceride transfer

205675_at 1.60267769 1 3.65 1.6026776 6.25 MTP protein (large polypeptide, 88kDa) 216566_at 1.60265661 1 7.2 1.6026566 12.35 IGLJ3 immunoglobulin lambda joining 3 discs, large (Drosophila) homolog 3

207732_s_at 1.60216324 1 18.3 1.6021632 31.6 DLG3 (neuroendocrine-dlg) 210354_at 1.60203435 1 19.7 1.6020344 33.7 IFNG interferon, gamma phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole

214664_at 1.60193295 1 22.65 1.601933 37.55 PAICS succinocarboxamide synthetase 220509_at 1.60176753 1 13.15 1.6017675 22.25 PRO1777 hypothetical protein PRO1777

210271_at 1.60170837 1 35,05 1.6017063 S8.9 NEUROD2 neurogenic differentiation 2 Homo sapiens mRNA; cDNA DKFZp434A1611 (from clone DKFZp434A1611), mRNA

217541_x_at 1.59993937 1 50.65 1.5999392 87.05 sequence collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, 4-

217312_s_at 1.59953554 1 127.05 1.5995356 221 COL7A1 dominant and recessive) epidermal growth factor receptor

221056_x_at 1.59859692 1 -3.1 1.598597 -1.45 EPS15R substrate EPS15R hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid

215665_at 1.59852698 1 8.8 1.5985271 15.35 HSD3B1 delta-isomerase 1

Homo sapiens cDNA FLJ20528 fis,

201328_at 1.59777664 1 42.65 1.5977767 69 clone KAT10770, mRNA sequence solute carrier family 6 (neurotransmitter transporter),

219795_at 1.59756422 1 4.85 1.5975642 8.2 SLC6A14 member 14 amiloride-sensitive cation channel

207561_s_at 1.5974135 1 16.05 1.5974135 27.4 ACCN3 3, testis 214731_at 1.59688173 1 19.2 1.5968816 32.75 chloride channel, calcium activated,

206166_s_at 1.59666846 1 -4.1 1.5966684 -5.95 CLCA2 family member 2 213030 s at 1.59656203 1 31.45 1.596562 53 PLXNA2 plexin A2

follicle stimulating hormone, beta

214489_at 1.59651484 1 6.75 1.5965147 11.45 FSHB polypeptide

206813_at 1.59615418 1 29.45 1.5961542 48.95 CTF 1 cardiotrophin 1 cytochrome P450, subfamily

XXVIIB (25-hydroxyvitamin D-1-

205676_at 1.59572381 1 18.75 1.5957239 33.55 CYP27B1 alpha-hydroxylase), polypeptide 1

- lipocalin 1 (protein migrating faster

207930_at 1.59548682 1 9.95 1.5954869 18.8 LCN1 than albumin, tear prealbumin) solute carrier family 6

(neurotransmitter transporter,

206836_at 1.59485315 1 39.45 1.5948532 69.7 SLC6A3 dopamine), member 3

205776_at 1.59430141 1 10.15 1.5943015 17.9 FMO5 flavin containing monooxygenase 5

Human EST clone 251800 mariner transposon Hsmari sequence,

216877_at 1.59411481 1 13.4 1.5941148 21.1 mRNA sequence

216062_at 1.59382776 1 14.2 1.5938277 23.8

Homo sapiens clone 23583 mRNA

214344_at 1.59370754 1 13.6 1.5937074 23 LOC92973 sequence Ul

207311_at 1.59345261 1 51.25 1.5934525 87.85 DOC2B double C2-like domains, beta

205549_at 1.59318884 1 1.05 1.5931889 -2.1 PCP4 Purkinje cell protein 4

215881_x_at 1.59248705 1 16.2 1.592487 29.1 SSX3 synovial sarcoma, X breakpoint 3

215218_s_at 1.59228226 1 27.95 1.592282 45.7 DKFZP434J046 DKFZP434J046 protein ribonuclease, RNase A family, 2

(liver, eosinophil-derived

206111_at 1.59183067 1 80.65 1.5918307 138.1 RNASE2 neurotoxin) lysophosphatidic acid

219693_at 1.59166906 1 54 1.591669 90.7 LPAAT-delta acyltransferase-delta

216973_s_at 1.59162246 1 22.45 1.5916224 38.45 HOXB7 homeo box B7 diphtheria toxin receptor (heparin- binding epidermal growth factor-like

203821_at 1.59006176 1 206.65 1.5900617 350.4 DTR growth factor)

220936_s_at 1.58954668 1 12.3 1.5895467 20.25 H2AFJ H2A histone family, member J

214841_at 1.58941541 1 50.25 1.5894156 81.9 FLJ38993 hypothetical protein FLJ38993

222358 x at 1.58902963 1 30.25 1.5890298 49.85

214701_s_at 1.58888823 1 400.65 1.5888882 671.75 FN1 fibronectin 1 phospholipase C, gamma 1

216551_x_at 1.58885405 1 115.9 1.5888542 197.35 PLCG1 (formerly subtype 148)

218677_at 1.58820814 1 24.9 1.5882082 43.7 S100A14 S100 calcium binding protein A14

219944_at 1.58797032 1 38.3 1.5879705 66.5 FLJ21069 hypothetical protein FLJ21069 nuclear receptor subfamily 1 , group

206340_at 1.58780959 1 10.6 1.5878097 17.6 NR1 H4 H, member 4 ubiquitin specific protease 7

222032_s_at 1.58763959 1 9.7 1.5876396 15.6 USP7 (herpes virus-associated)

220656_at 1.58620893 1 2.75 1.5862088 4.75 PRO2435 hypothetical protein PRO2435

214984_at 1.58591194 1 9.55 1.585912 15.7

213383_at 1.5855019 1 14 1.5855019 45.85 KIAA0685 KIAA0685 gene product

208586_s_at 1.58494158 1 2.25 1.5849416 3.25 SSX4 synovial sarcoma, X breakpoint 4

216629_at 1.58485346 1 3.7 1.5848534 6.8 hypothetical protein

216605_s_at 1.58465015 1 10.55 1.58465 18.95 R29124_1 ; FLJ 13540 R29124_1 interleukϊn 12A (natural killer ceii stimulatory factor 1, cytotoxic lymphocyte maturation factor 1,

207160_at 1.58382906 1 41.6 1.5838292 72.5 1L12A p35) inhibitor of growth family, member

209808_x_at 1.58312047 1 71.25 1.5831205 119.4 ING1 1

219616_at 1.58291501 1 32.05 1.5829151 55.55 FLJ21963 hypothetical protein FLJ21963

DEAD/H (Asp-Glu-Ala-Asp/His) box

201584_s_at 1.58222603 1 408.25 1.582226 701.25 DDX39 polypeptide 39 tight junction protein 3 (zona

35148_at 1.58214857 1 9.6 1.5821486 16.3 TJP3 occludens 3)

211488_s_at 1.58185328 1 17.4 1.5818534 29.1 ΪTGB8 integrin, beta 8 mitogen-activated protein kinase

214969_at 1.58135839 1 30.8 1.5813584 50.5 MAP3K9 kinase kinase 9 ubiquitously transcribed tetratricopeptide repeat gene, Y

210322 x at 1.5812953 1 25.15 1.5812953 41.75 UTY chromosome

major histocompatibility complex,

217362_x_at 1.58047932 1 6.15 1.5804793 7.7 HLA-DRB6 class II, DR beta 6 (pseudogene)

Homo sapiens cDNA FLJ14122 fis, clone MAMMA1002033, mRNA

222180_at 1.58025532 1 9 1.5802553 14.85 sequence dimethylarginine

202262_x_at 1.57967477 1 196.2 1.5796747 320.6 DDAH2 dimethylaminohydrolase 2 206663_at 1.57957014 1 9.2 1.5795703 15.25 SP4 Sp4 transcription factor

RAB9, member RAS oncogene

208245_at 1.57929964 1 0.8 1.5792997 1.35 RAB9P1 family, pseudogene 1 201420_s_at 1.57923551 1 146.3 1.5792356 252.55 MEP50 MEP50 protein

H.sapiens mRNA for TRE5, mRNA

222187_x_at 1.57922423 1 59.4 1.5792242 99.65 sequence 216622_at 1.57917738 1 9.75 1.5791774 16.25 LAMB4 faminin, beta 4 glial cells missing homolog 2

220799_at 1.57896164 1 3.35 1.5789617 5.75 GCM2 (Drosophila) 204420_at 1.57895249 1 370.15 1.5789526 616.4 FOSL1 FOS-like antigen 1 -4

T-cell receptor beta, mRNA

217060_at 1.57885517 1 22.75 1.5788553 38.05 sequence hypothetical protein

212712_at 1.57864024 1 101.4 1.5786402 168.9 DKFZp434G2311 DKFZp434G2311

Ankyrin 1 [Homo sapiens], mRNA

207089_at 1.57830775 1 5.6 1.5783076 15.75 sequence chromosome 14 open reading

220701_at ^■ 1.57796799 1 17.3 1.5779679 28.95 C14orf107 frame 107 matrix metalloproteinase 11

203876_s_at 1.5776695 1 6.75 1.5776695 11.7 MMP11 (stromeiysin 3) 216775_at 1.57700753 1 0.5 1.5770074 1.65 KIAA1350 KIAA1350 protein 212784_at 1.57681665 1 387.3 1.5768166 632.1 CIC capicua homolog (Drosophila) 216453_at 1.57643962 1 19.1 1.5764396 32.45 ZNF287 zinc finger protein 287 215545_at 1.57622268 1 55.3 1.5762228 91.65 214116_at 1.57605135 1 23.65 1.5760514 40.05 BTD biotinidase 212931 at 1.57570869 1 82.95 1.5757086 133.85 TCF20 transcription factor 20 (AR1 )

RAB26, member RAS oncogene

219562_at 1.57545222 1 15.45 1.5754523 26.85 RAB26 family 209873_s_at 1.57531565 1 59.6 1.5753157 100.2 PKP3 plakophilin 3 210200_at 1.5741746 1 86.2 1.5741744 143.15 WWP2 Nedd-4-like ubiquitin-protein ligase

Homo sapiens cDNA: FLJ21735 fis, clone COLF3350, mRNA

216729_at 1.57382561 1 2.3 1.5738256 4.05 sequence 205662_at 1.57333744 1 37.45 1.5733374 63.9 EPPB9 B9 protein apolipoprotein B mRNA editing

207158_at 1.57314332 1 11.7 1.5731434 19.15 APOBEC1 enzyme, catalytic polypeptide 1

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b,

212167_s_at 1.57268766 1 238.3 1.5726879 398.2 SMARCBI member 1 cytochrome P450, subfamily NB

(phenobarbital-inducible),

206754_s_at 1.57220895 1 28.05 1.572209 46.9 CYP2B6 polypeptide 6 oviductal glycoprotein 1, 12OkDa oe

205432_at 1.57199883 1 37.4 1.5719988 62.45 OVGP1 (mucin 9, oviductin) 41387_r_at 1.57176015 1 58.15 1.57176 96.95 KIAA0346 KIAA0346 protein

Homo sapiens cDNA FLJ12058 fis, clone HEMBB1002092, mRNA

215971_at 1.57143334 1 21 1.5714333 35.2 sequence 207154_at 1.57127947 1 25.8 1.5712795 44.65 DIO3 deiodinase, iodothyronine, type III p21/Cdc42/Rac1 -activated kinase 1

209615_s_at 1.57117085 1 14.35 1.5711708 24.7 PAK1 (STE20 homolog, yeast) 207655_s_at 1.57059282 1 7.3 1.5705929 12.5 BLNK B-cell linker 218672_at 1.57049328 1 -8.55 1.5704933 91.1 MGC3180 hypothetical protein MGC3180 213105_s_at 1.57037179 1 94.05 1.5703717 153.3 BAIAP3 BAH -associated protein 3 219155_at 1.57004786 1 224.05 1.5700479 372.7 RDGBB retinal degeneration B beta

DnaJ (Hsp40) homolog, subfamily

206782_s_at 1.56999991 1 106.85 1.57 180.1 DNAJC4 C, member 4 220336_s_at 1.56900588 1 23.35 1.5690057 38.65 GP6 glycoprotein Vl (platelet)

Unnamed protein product [Homo

207572 at 1.56890857 1 20.5 1.5689086 33.25 sapiens], mRNA sequence

Unnamed protein product [Homo

49051_g_at 1.56847479 1 48.7 1.5684747 81.45 sapiens], mRNA sequence 208081_s_at 1.56843204 1 7.25 1.568432 11.6 ZNF442 hypothetical protein FLJ 14356 cytochrome P450, subfamily ME

1431_at 1.56838469 1 35.3 1.5683846 59.95 CYP2E (ethanol-inducible), polypeptide 1 204649_at 1.56770779 1 101.1 1.5677078 168.45 TROAP trophinin associated protein (tastin)

Unknown [Homo sapiens], mRNA

215287_at 1.56736301 1 8.15 1.567363 13.15 sequence phosphoinositide-3-kinase,

203879_at 1.56664239 1 103.35 1.5666423 173.15 PIK3CD catalytic, delta polypeptide 220463_at 1.56662344 1 23.7 1.5666234 40 TRPM3 hypothetical protein FLJ11726 chromosome 20 open reading

50314_i_at 1.56599152 1 129.2 1.5659915 220.35 C20orf27 frame 27

MAP/microtubule affinity-regulating

221560_at 1.56550335 1 55.65 1.5655034 94.25 MARK4 kinase 4

Homo sapiens cDNA: FLJ20895 fis, clone ADKA03483, mRNA

221892_at 1.56549492 1 34.9 1.565495 55.75 sequence 218607_s_at 1.56522776 1 327.25 1.5652277 553.25 FLJ 10498 hypothetical protein FLJ10498 221315_s_at 1.56494611 1 17.85 1.5649462 29.4 FGF22 fibroblast growth factor 22

CCAAT/enhancer binding protein

213006_at 1.56491166 1 23.3 1.5649116 37.4 CEBPD (C/EBP), delta 201562_s_at 1.56483895 1 69.55 1.5648389 112.15 SORD sorbitol dehydrogenase

Homo sapiens mRNA; cDNA

DKFZp586O2023 (from clone

DKFZp586O2023), mRNA

215351_at 1.56450006 1 6.15 1.5645001 9.95 sequence transcriptional adaptor 2 (ADA2

209938_at 1.56441218 1 96.85 1.5644121 163.05 TADA2L homolog, yeast)-like methyl-CpG binding domain protein

202485_s_at 1.56416557 1 58.6 1.5641657 96.25 MBD2 2 220523_at 1.56352727 1 5.7 1.5635272 9.6 FLJ22843 hypothetical protein FLJ22843 219954_s_at 1.56333644 1 10.35 1.5633365 17.1 GBA3 glucosidase, beta, acid 3 (cytosolic) solute carrier family 1 (giutamate

210923 at 1.56269638 1 35.8 1.5626963 59.4 SLC1A7 transporter), member 7

206772_at 1.5623458 1 7.8 1.5623457 12.25 PTHR2 parathyroid hormone receptor 2 nucleosome assembly protein 1-

219368_at 1.56205253 1 3.55 1.5620525 5.8 NAP1L2 Iike 2 lung type-l cell membrane-

221898_at 1.56182853 1 105.8 1.5618286 167.45 T1A-2 associated glycoprotein

212543_at 1.56166771 1 55.3 1.5616678 91.35 AIM1 absent in melanoma 1 cytochrome P450, subfamily I

(aromatic compound-inducible),

207608_x_at 1.56149901 1 36.5 1.5614991 61.8 CYP 1A2 polypeptide 2

OLF-1/EBF associated zinc finger

214761_at 1.56142247 1 30 1.5614223 50.25 OAZ gene

219593_at 1.56102579 1 2 1.5610257 9.55 PHT2 peptide transporter 3

216428_x_at 1.56093109 1 14.2 1.5609311 23.15 FLJ00060 hypothetical gene FLJ00060

207005_s_at 1.56055131 1 17 1.5605514 28.75 BCL2 B-cell CLL/lymphoma 2 cyclin-dependent kinase 5,

204995_at 1.56043066 1 1.7 1.5604308 3.55 CDK5R1 regulatory subunit 1 (p35)

220245_at 1.56004882 1 47.85 1.5600488 82.4 MATP AIM-1 protein

205607_s_at 1.55904563 1 32.5 1.5590457 55.45 PACE-1 ezrin-binding partner PACE-1

219044_at 1.55884321 1 7.15 1.5588431 12.05 FLJ10916 hypothetical protein FLJ 10916

ESTs, Highly similar to A55178 neurotrophin receptor trkG

21S115_x_at 1.55873191 1 18.9 1.5587319 31.95 NTRK3 precursor - human [H.sapiensϊ

217224_at 1.55867116 1 20.55 1.5586711 35.4

203520_s_at 1.5586287 1 30.4 1.5586288 50.35 ZFP318 endocrine regulator

205865_at 1.5586209 1 24.3 1.5586209 39.7 DRIL1 dead ringer-like 1 (Drosophila)

207123_s_at 1.55861037 1 3.45 1.5586103 5.75 MATN4 matrilin 4

211298_s_at 1.55840802 1 8.15 1.558408 13.95 ALB albumin solute carrier family 12

(potassium/chloride transporters),

209400_at 1.5582892 1 19.25 1.558289 30.6 SLC12A4 member 4

207445_s_at 1.55820477 1 15.5 1.5582048 26 CCR9 chemokine (C-C motif) receptor 9

214942_at 1.55815852 1 6.9 1.5581585 11.3 KIAA0117 KIAA0117 protein

206438_x_at 1.55731689 1 113.4 1.5573168 189.05 FLJ12975 hypothetical protein FLJ12975

207188 at 1.55709548 1 15.1 1.5570954 21.7 CDK3 cyclin-dependent kinase 3

Prostate-specific membrane antigen PSM [Homo sapiens],

217487_x_at 1.5567206 1 13.75 1.5567207 22.5 mRNA sequence blocked early in transport 1

220470_at 1.5561402 1 35.35 1.5561402 61 BET1 L homolog (S. cerevisiae) like

207747_s_at 1.55594207 1 14.55 1.555942 22.45 DOK4 docking protein 4 chromosome 15 open reading

208109_s_at 1.55549863 1 1.25 1.5554987 2.15 C15orf5 frame 5

SPRY domain-containing SOCS

221769_at 1.55538319 1 39.3 1.5553832 68.2 SSB3 box protein SSB-3

205783_at 1.55500095 1 32.65 1.5550009 52.55 KLK13 kallikrein 13 protein kinase, cGMP-dependent,

207505_at 1.55499509 1 148.85 1.5549951 252.15 PRKG2 type Il

Usher syndrome 2A (autosomal

207706_at 1.5543429 1 4.75 1.5543427 8.1 USH2A recessive, mild)

220239_at 1.55407624 1 102.6 1.5540762 175.35 SBBI26 SBBI26 protein

215604_x_at 1.55394532 1 61.35 1.5539453 101.85 transducin-like enhancer of split 3

212770_at 1.55364727 1 43.95 1.5536473 74.9 TLE3 (E(sp1) homolog, Drosophila) cylindromatosis (turban tumor

60084_at 1.55326252 1 39.95 1.5532625 60.85 CYLD syndrome)

212849_at 1.55301327 1 67.3 1.5530133 107.75 AXIN1 axin 1 mesenchymal stem cell protein

218500_at 1.55287724 1 23.85 1.5528772 41.5 LOC51337 DSCD75

207343_at 1.55263883 1 57 1.5526388 96 LOC57151 lysozyme homolog nuclear pore complex interacting

215921_at 1.55260861 1 20.4 1.5526086 34.5 NPIP protein nuclear receptor subfamily 4, group

204622_x_at 1.55257916 1 40.45 1.5525792 68.35 NR4A2 A, member 2

220056_at 1.55246006 1 26.25 1.55246 43.15 1L22R ϊnterleukiπ 22 receptor, alpha 1

39313_at 1.55233788 1 10 1.5523379 16.6 KIAA0344 protein kinase, lysine deficient 1

218481_at 1.55178422 1 82.8 1.5517843 136.75 RRP46 exosome component Rrp46

205748_s_at 1.55159232 1 98.05 1.5515922 163.25 FLJ20552 hypothetical protein FLJ20552

205092_x_at 1.54998774 1 11.85 1.5499876 19.15 ZBTB1 KIAA0997 protein

211773_s_at 1.54945335 1 65.85 1.5494534 110.8 ZNF306 zinc finger protein 306

212156_at 1.54940706 1 129.8 1.549407 211.15 VPS39 Vam6/Vps39-like 207835_at 1.54931158 1 35.2 1.5493116 56.2 FBLN1 fibulin 1 son of sevenless homolog 2

211665_s_at 1.54876999 1 63.05 1.5487702 103.5 SOS2 (Drosophila) 203924_at 1.54763593 1 12 1.547636 20.2 GSTA2 glutathione S-transferase A1 222235_s_at 1.54708317 1 88.9 1.5470831 147.75 dJ19N1.1 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin),

210236_at 1.54695307 1 15.35 1.546953 25.6 PPFIA1 alpha 1 213306_at 1.54678002 1 68.1 1.5467801 112.8 MPDZ multiple PDZ domain protein 202580_x_at 1.5464361 1 170.95 1.5464361 271.75 FOXM 1 forkhead box M1 Homo sapiens cDNA: FLJ21899 fis, clone HEP03467, mRNA

216783_at 1.54638792 1 12.45 1.5463879 20.35 sequence 210134_x_at 1.54638483 1 11.85 1.5463848 19.75 SHOX2 short stature homeobox 2 218704_at 1.54626561 1 4.1 1.5462656 7.15 FLJ20315 hypothetical protein FLJ20315 ~4 K> 203751 _x_at 1.54603019 1 158.45 1.5460303 259.3 JUND jun D proto-oncogene Williams-Beuren Syndrome critical

213670_x_at 1.54580498 1 66.1 1.545805 114.35 WBSCR20C region protein 20 copy B arylsulfatase E (chondrodysplasia

205894_at 1.54558374 1 33.75 1.5455837 54.15 ARSE punctata 1) chromosome 21 open reading

208395_s_at 1.54548265 1 4.45 1.5454826 18.05 C21orf108 frame 108 204273_at 1.5452981 1 4.35 1.5452981 6.95 EDNRB endothelin receptor type B solute carrier family 17 (sodium- dependent inorganic phosphate

220551_at 1.54522539 1 -0.85 1.5452255 1.55 SLC17A6 cotransporter), member 6 cadherin, EGF LAG seven-pass G-type receptor 3 (flamingo

205185_at 1,5448423 1 12.35 1.5448424 19.05 CELSR3 homolog, Drosophila} 205522_at 1.54477617 1 16.1 1.5447762 26.15 HOXD4 homeo box D4 208004_at 1.54438633 1 26.75 1.5443864 43.8 PROL1 proline rich 1

Homo sapiens germline mRNA

213676 at 1.54411979 1 24.4 1.5441198 40.7 sequence

UDP glycosyltransf erase 1 family,

221305_s_at 1.54371101 1 7.35 1.543711 11.45 UGT1A8 polypeptide A8 209371_s_at 1.54350066 1 -7.5 1.5435007 15.9 SH3BP2 SH3-domain binding protein 2 210057_at 1.54314971 1 5.3 1.5431497 8.5 SMG1 PI-3-kinase-related kinase SMG-1 endothelial differentiation, sphingolipid G-protein-coupled

204642_at 1.54299493 1 29.9 1.542995 48.95 EDG1 receptor, 1 208940_at 1.54280932 1 88.35 1.5428094 145.4 SPS selenophosphate synthetase

206176_at 1.54264719 1 14.65 1.5426471 25,25 BMP6 bone morphogenetic protein 8 pre-B-cell leukemia transcription

209151_x_at 1.54251273 1 20.1 1.5425127 31.75 PBX1 factor 1 34408_at 1.5421256 1 365.65 1.5421257 582.1 RTN2 reticulon 2 likely ortholog of mouse kinesin

218906_x_at 1.54182331 1 123.65 1.5418233 202.55 KLC2 light chain 2 215899_at 1.54171811 1 47.1 1.541718 75.4 210133_at 1.54115606 1 -3.2 1.5411559 -0.3 CCL11 chemokine (C-C motif) ligand 11 219740_at 1.54111728 1 -16.1 1.5411172 2 FLJ 12505 hypothetical protein FLJ 12505 -4 cholinergic receptor, nicotinic,

206533_at 1.54086795 1 24.45 1.540868 39.5 CHRNA5 alpha polypeptide 5 ESTs, Highly similar to myoferiin, isoform a; fer-1-like 3 [Homo

217518_at 1.54080819 1 26.7 1.5408082 43.7 sapiens] [H.sapiens] ARF-GAP, RHO-GAP, ankyrin repeat and plekstrin homology

218950_at 1.54058124 1 76.2 1.5405812 127.1 ARAP3 domains-containing protein 3 transient receptor potential cation

216489_at 1.54008126 1 14.65 1.5400813 24.3 TRPM3 channel, subfamily M, member 3 213008_at 1.5394665 1 35.25 1.5394665 57.55 FLJ 10719 hypothetical protein FLJ10719 210219_at 1.53940208 1 34.2 1.5394021 55.6 SP100 nuclear antigen Sp100 diacylglycerol O-acyltransferase

203669_s_at 1.53934819 1 72.6 1.5393481 120 DGAT1 homolog 1 (mouse) erythrocyte membrane protein band 4.1 (elliptocytosis 1 , RH-

207793 s at 1.5389729 1 1.85 1.5389729 2.9 EPB41 linked)

214714_at 1.53897208 1 18.15 1.538972 30.2 FLJ 12298 hypothetical protein FLJ 12298

201287_s_at 1.53871119 1 360.1 1.5387111 593.55 SDC1 syndecan 1

211993_at 1.53843884 1 16.85 1.5384388 27.3 PRKWNK1 protein kinase, lysine deficient 1

205933_at 1.53826086 1 11.35 1.5382608 20.9 SETBP 1 SET binding protein 1

Homo sapiens cDNA FLJ12411 fis, clone MAMMA1002964, mRNA

215385_at 1.53815106 1 -0.7 1.538151 3.9 sequence vitamin D (1 ,25-

204255_s_at 1.53738832 1 44.9 1.5373883 72.4 VDR dihydroxyvltamϊn D3) receptor

202392_s_at 1.53705525 1 64.25 1.5370553 108.6 PISD phosphatidylserine decarboxylase serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),

211361_s_at 1.53613532 1 6.15 1.5361353 10.1 SERPINB13 member 13

ESTs, Weakly similar to

PRPP HUMAN SALIVARY

PROLINE-RICH PROTEIN 11-1

222380_s_at 1.53517336 1 38.25 1.5351734 61.4 [H.sapiens]

213611_at 1.53511933 1 -26.4 1.5351193 27.6 AQP5 aquaporin 5

207269_at 1.53511114 1 16.55 1.5351112 27.35 DEFA4 defensin, alpha 4, corticostatin serine palmitoyltransferase, long

202278_s_at 1.53440234 1 120.45 1.5344023 194.5 SPTLC1 chain base subunit 1

209990_s_at 1.53438978 1 7.15 1.5343897 11.85 GPR51 G protein-coupled receptor 51

203317_at 1.53404281 1 67.15 1.5340427 110.45 TIC SEC7 homolog

206978_at 1.53384611 1 18.6 1.5338461 29.1 CCR2 chemokine (C-C motif) receptor 2 solute carrier family 16

(monocarboxylic acid transporters),

217691_x_at 1.53378692 1 148.35 1.5337868 247.45 SLC16A3 member 3

ESTs, Weakly similar to hypothetical protein FLJ20378

221137_at 1.53378218 1 28.3 1.5337822 45.85 [Homo sapiens] [H.sapiens] putative N-acetyltransferase

206964_at 1.5333371 1 -1 1.5333371 5.75 CML2 Camello 2

220685_at 1.53326468 1 5.45 1.5332649 9.25 FLJ20506 hypothetical protein FLJ20506 integrin, beta 3 (platelet

211579 at 1.53240119 1 17.55 1.5324011 29.25 ITGB3 glycoprotein Ilia, antigen CD61 )

205238_at 1.53232415 1 91.85 1.5323242 150.4 FLJ12687 hypothetical protein FLJ 12687

Homo sapiens clone 23872 mRNA 212605 s at 1.53230666 1 55.4 1.5323067 90.2 sequence

Homo sapiens cDNA: FLJ21237 fis, clone COL01114, mRNA

216748_at 1.53203464 1 79.9 1.5320346 134.2 sequence

221443_x_at 1.5318135 1 43.4 1.5318135 72.65 PRH preproprolactin-releasing peptide

216238_s_at 1.53175187 1 17.75 1.5317519 28.9 FGB fibrinogen, B beta polypeptide

Wolf-Hirschhorn syndrome

209052_s_at 1.53107704 1 53.35 1.5310771 85 WHSC1 candidate 1 215359_x_at 1.53079791 1 40.05 1.530798 64.1 ZNF44 zinc finger protein 44 (KOX 7) 207478_at 1.53078066 1 19.65 1.5307806 32.25 PRO2958 hypothetical protein PRO2958 221469 at 1.53040379 1 12.75 1.5304039 20.1 GPR32 G protein-coupled receptor 32

ESTs, Weakly similar to hypothetical protein FLJ20489

217713_x_at 1.53038435 1 145.35 1.5303843 239 [Homo sapiens] [H. sapiens] 205481_at 1.53001411 1 32.35 1.530014 51.1 ADORA1 adenosine A1 receptor -4 glutamate receptor, ionotropic, N-

206534_at 1.52968709 1 31.95 1.529687 51.55 GRIN2A methyl D-aspartate 2A matrix metalloproteinase 17 206234 s at 1.52965045 1 68.75 1.5296504 108.4 MMP17 (membrane-inserted)

Homo sapiens cDNA: FLJ21256 fis, clone COL01402, mRNA

216166_at 1.52951314 1 19.05 1.5295131 31.2 sequence 206297 at 1.52931184 1 34.4 1.5293119 56.25 CTRC chymotrypsin C (caldecrin) sema domain, immunoglobulin domain (Ig), short basic domain,

206805_at 1.52909969 1 22.75 1.5290997 37.5 SEMA3A secreted, (semaphorin) 3A 212619_at 1.52892145 1 17.1 1.5289216 27.6 KIAA0286 KIAA0286 protein peroxisome proliferative activated

208044_s_at 1.52878004 1 86.75 1.52878 139.4 PPARD receptor, delta

Unnamed protein product [Homo 211076_x_at 1.5283503 1 18.85 1.5283501 30.8 sapiens], mRNA sequence nuclear factor of kappa light

201502 s at 1.52802259 1 245.65 1.5280225 406.8 NFKBIA polypeptide gene enhancer in B-

cells inhibitor, alpha a disintegrin and metalloproteinase

217007_s_at 1.52781171 1 40.9 1.5278118 62.05 ADAM 15 domain 15 (metargidin) 203955_at 1.52761808 1 39.45 1.527618 60.05 KIAA0649 KIAA0649 gene product 220991_s_at 1.52754197 1 6.2 1.5275419 9.75 RNF32 ring finger protein 32 204733_at 1.5275055 1 34.7 1.5275054 55.15 KLK6 kallikrein 6 (neurosin, zyme) 203117_s_at 1.52729075 1 44.45 1.5272907 73.45 KIAA0710 KIAA0710 gene product

POU domain, class 4, transcription

206940_s_at 1.52689701 1 40.45 1.526897 66.9 POU4F1 factor 1 205318_at 1.52641216 1 29 1.5264122 48.25 KIF5A kinesin family member 5A 206502_s_at 1.52595174 1 0.15 1.5259517 0.85 INSM1 insulinoma-associated 1 213955_at 1.525604 1 10.25 1.525604 46.25 MYOZ3 myozenin 3 206403_at 1.52547167 1 28.6 1.5254714 45.9 KIAA0390 KIAA0390 gene product cardiotrophin-like cytokine; neurotrophin-1/B-cell stimulating

219500_at 1.52490161 1 78.65 1.5249016 127.45 CLC factor-3 - 203554_x_at 1.52474133 1 688.3 1.5247414 1114.2 PTTG 1 pituitary tumor-transforming 1 linked to Surfeit genes in Fugu

221817_at 1.52471539 1 146.6 1.5247154 235.9 DOLPP1 rubripes 2; LSFR2 gene 2 cell death-inducing DFFA-like

221295_at 1.52465996 1 11.25 1.5246599 17.3 CIDEA effector a hypothetical protein

221245_s_at 1.52465694 1 34.2 1.5246569 54.65 DKFZP43 DKFZp434E2135 potassium intermediate/small conductance calcium-activated

220116_at 1.52387034 1 1.75 1.5238702 7.35 KCNN2 channel, subfamily N, member 2 MLL-AF4 der(11 ) fusion protein,

211826_s_at 1.5234691 1 26.35 1.5234692 43.55 mRNA sequence 211358_s_at 1.52334672 1 160.45 1.5233467 259.2 CIZ1 Cip1-interacting zinc finger protein ESTs, Moderately similar to hypothetical protein FLJ20378

222006 at 1.52299477 1 64.1 1.5229948 104.3 LETM 1 [Homo sapiens] [H.sapiens]

219880_at 1.52286187 31.6 1.522862 51.55 FLJ23053 hypothetical protein FLJ23053 Homo sapiens, clone IMAGE:3860421, mRNA, mRNA

217609_at 1.52273032 1 30.7 1.5227304 51.1 sequence phosphatidylinositol-4-phosphate 5-

205632_s_at 1.52268232 1 26.2 1.5226824 41.95 PIP5K1 B kinase, type I, beta 207387_s_at 1.52228482 1 13.05 1.5222847 22.2 GK glycerol kinase chromosome 4 open reading frame

207241 _at 1.5222733 1 0.7 1.5222734 0.25 C4orf6 6 eukaryotic translation elongation 213907_at 1.52170421 1 59.6 1.5217042 97.3 EEF1 E1 factor 1 epsilon 1 pregnancy specific beta-1-

207733_x_at 1.5214219 1 30.6 1.5214219 51.2 PSG9 glycoprotein 9 221673_s_at 1.52132119 1 21.9 1.5213213 34.9 CSNK1G1 casein kinase 1 , gamma 1 212947_at 1.5210931 1 40.6 1.521093 63.15 KIAA0939 KIAA0939 protein Hypothetical protein [Homo

213394_at 1.52062567 1 42.5 1.5206256 71.65 MAPKBP1 sapiens], mRNA sequence -4 receptor (TNFRSF)-interacting -4

209941_at 1.52010034 1 50.95 1.5201004 84.45 RIPK1 serine-threonine kinase 1 221236_s_at 1.52000213 1 23.3 1.5200021 38.2 STMN4 stathmin-like 4

DEAD/H (Asp-Glu-Ala-Asp/His) box

208719_s_at 1.51956736 1 8.95 1.5195673 15.85 DDX17 polypeptide 17, 72kDa retinal outer segment membrane 205806 at 1.51955934 1 4.85 1.5195595 7.65 ROM1 protein 1 fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratin ocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pferffβr syndrome, Jackson-Weiss

208228 s at 1.51847339 1 19.85 1.5194734 31.2 FOFR2 syndrome)

Similar to tyrosine kinase, nonreceptor, 1 [Homo sapiens], mRNA

217149 x at 1.51941653 1 67.45 1.5194166 109.9 TNK1 sequence

Homo sapiens mRNA; cDNA DKFZp434G1615 (from clone DKFZp434G1615), mRNA

215801. _at 1.51912309 1 9.9 1.5191231 15.85 sequence

216546_, _s_at 1.51881794 1 3.7 1.518818 6.95

213131. .at 1.51880503 1 17.95 1.518805 28.95 OLFM1 olfactomedin 1

209193 at 1.5186227 1 154 1.5186226 243.55 PIM 1 pim-1 oncogene

Homo sapiens cDNA FLJ34531 fis, clone HLUNG2008225, moderately similar to TRANSCRIPTIONAL

REPRESSOR PROTEIN YY1 ,

216531_at 1.51836217 1 17.5 1.5183622 24.45 mRNA sequence

UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide

206233_at 1.51831345 1 -2.7 1.5183134 1.25 B4GALTI 6 gem (nuclear organelle) associated

205527_s_at 1.51796444 1 16.5 1.5179644 27.95 GEMIN4 protein 4 ~4 hyperpolarization activated cyclic 00 nucleotide-gated potassium

214893_x_at 1.5179144 1 12.25 1.5179143 19.65 HCN2 channel 2

Unnamed protein product [Homo

49049_at 1.51773584 1 76.15 1.5177358 124.35 sapiens], mRNA sequence prostaglandin E receptor 3

210834_s_at 1.51750619 1 11 1.5175064 19.35 PTGER3 (subtype EP3) insulin-like growth factor binding

205302_at 1.51680329 1 18.7 1.5168034 29,4 IGFBP1 protein 1 206721_at 1.51660515 1 13.25 1.5166051 21.9 LOC578; hypothetical protein LOC57821 205950_s_at 1.51657963 1 47.5 1.5165796 77.4 CA1 carbonic anhydrase I

X-ray repair complementing defective repair in Chinese hamster

207598_x_at 1.51655954 1 14.75 1.5165596 23.75 XRCC2 cells 2 210442__at 1.51650822 1 1.85 1.5165082 -17.5 IL1 RL1 interleukin 1 receptor-like 1 203369_x_at 1.51650137 1 130.7 1.5165014 213.6 ENIGMA enigma (LIM domain protein) 214597_at 1.51640031 1 7.25 1.5164003 11.75 SSTR2 somatostatin receptor 2 206020 at 1.51623935 1 32.45 1.5162394 52.35

killer cell immunoglobulin-like receptor, two domains, long

208426_x_at 1.51620105 1 24.55 1.5162011 38.9 KIR2DL4 cytoplasmic tail, 4 zinc finger protein 36, C3H type-

201369_s_at 1.51589575 1 69.9 1.5158958 108.25 2FP36L2 like 2

202455_at 1.51528051 1 107.45 1.5152806 175.6 HDAC5 histone deacetylase 5 zinc finger protein 37 homolog

207068_at 1.5150888 1 11.65 1.5150888 17.65 ZFP37 (mouse)

Homo sapiens mRNA; cDNA

DKFZp566D153 (from clone

216466_at 1.51477495 1 5.8 1.5147748 9.45 DKFZp566D153), mRNA sequence

207446_at 1.51450458 1 -6.7 1.5145046 11.05 TLR6 toll-like receptor 6 protein phosphatase 1, regulatory

220082_at 1.51444514 1 67.7 1.5144452 110.45 PPP1 R14D (inhibitor) subunit 14D

213968_at 1.51433124 1 21.85 1.5143313 36.35 TM4SF9 tetraspan 5 met proto-oncogene (hepatocyte

213816_s_at 1.51418866 1 16.5 1.5141888 27.05 MET growth factor receptor) transcription factor 3 (E2A -4 immunoglobulin enhancer binding

209153_s_at 1.51412198 1 117.95 1.5141219 186.15 TCF3 factors E12/E47) hepatoma-derived growth factor

216484_x_at 1.51362963 1 434.75 1.5136297 706.15 HDGF (high-mobility group protein 1-like) solute carrier family 7 (cationic amino acid transporter, y+ system),

204588_s_at 1.51315661 1 44.05 1.5131565 72.45 SLC7A7 member 7

Homo sapiens mRNA full length insert cDNA clone EUROIMAGE

215126_at 1.51296875 1 35.65 1.5129687 56.1 208948, mRNA sequence

202344_at 1.51286964 1 99.95 1.5128698 162.25 HSF1 heat shock transcription factor 1

207648_at 1.5128631 1 35.65 1.5128632 56.3 DRP2 dystrophin related protein 2

Homo sapiens cDNA: FLJ21721 fis, clone COLF0381 , mRNA

214364_at 1.51285636 1 22.35 1.5128564 37.45 sequence

219846_at 1.51283003 1 45.3 1.51283 70.95 FLJ23040 hypothetical protein FLJ23040

203504 s at 1.51245858 1 127.25 1.5124586 202.35 ABCA1 ATP-binding cassette, sub-family A

(ABC1), member 1

205954_at 1.51203437 1 21.05 1.5120344 34.25 RXRG retinoid X receptor, gamma retinal degeneration, slow (retinitis

206625_at 1.51114574 1 47.75 1.5111458 78.1 RDS pigmentosa 7) formyltetrahydrofolate

215798_at 1.51100208 1 31.15 1.5110021 50 FTHFD dehydrogenase 216481_at 1.51088075 1 49.55 1.510881 79.3 KIAA1719 Kl AA1719 protein

EH domain-binding mitotic

221141_x_at 1.51074751 1 24.8 1.5107476 38.1 EPN 1 phosphoprotein 206549_at 1.51035899 1 14.15 1.510359 21.85 INSL4 insulin-like 4 (placenta)

Homo sapiens cDNA FLJ 12570 fis, clone NT2RM4000895, mRNA

214755_at 1.51026738 1 191.5 1.5102675 311.1 sequence 219879_s_at 1.5096516 1 9.55 1.5096517 8.2 MGC3130 hypothetical protein MGC3130 208544_at 1.50960147 1 16.8 1.5096015 26.8 ADRA2B adrenergic, alpha-2B-, receptor 204828_at 1.50956647 1 54.75 1.5095664 88.25 RAD9 RAD9 homolog (S. pombe)

CD5 antigen-like (scavenger

206680_at 1.50931711 1 6.7 1.5093172 11.2 CD5L receptor cysteine rich family) pleckstrin homology-like domain,

217999_s_at 1.50876045 1 309.75 1.5087605 493.7 PHLDA1 family A, member 1 219447_s_at 1.50839734 1 49.4 1.5083973 82.65 OVCOV1 ovarian cancer overexpressed 1 220458_at 1.50811952 1 16.95 1.5081196 26.75 FLJ 10246 hypothetical protein FLJ10246 215909_x_at 1.50797144 1 118.7 1.5079713 188.9 MINK misshapen/NIK-related kinase prostate derived STE20-like kinase

204877_s_at 1.5078475 1 9.35 1.5078475 14.5 PSK PSK 208515_at 1.50764488 1 13 1.5076449 21.7 HIST1H2BM H2B histone family, member E hypothetical protein

212300_at 1.50725438 1 102.4 1.5072544 162.6 DKFZp451J0118 DKFZp451J0118

Rho-related BTB domain

216049_at 1.5072325 1 33.3 1.5072325 54.05 RHOBTB3 containing 3

Ras protein-specific guanine

215688_at 1.50685951 1 33.6 1.5068594 52.9 RASGRF1 nucleotide-releasing factor 1 220826_at 1.50648199 1 43.7 1.5064819 72.05 FLJ 10932 hypothetical protein FLJ10932 protein kinase, AMP-activated,

218292 s at 1.50598388 1 74.5 1.505984 124.9 PRKAG2 gamma 2 non-catalytic subunit

Homo sapiens cDNA FLJ20854 fis, clone ADKA01341 , mRNA

215639_at 1.50590213 1 14.3 1.5059022 23.7 sequence hypothetical protein

207470_at 1.5056214 1 11.5 1.5056214 18.75 DKF2p566H0824 DKFZp566H0824

Homo sapiens mRNA; cDNA DKFZp586N1918 (from clone DKFZp586N1918), mRNA

213739_at 1.50535947 1 29.65 1.5053594 46.35 sequence 211905_s_at 1.50530879 1 16.15 1.5053087 26.1 ITGB4 integrin, beta 4 221189_s_at 1.50519301 1 31.75 1.505193 49.9 FLJ 12528 hypothetical protein FLJ 12528 221733_s_at 1.5051623 1 28.65 1.5051622 45.9 FLJ20249 DKFZP434F1735 protein sorbin and SH3 domain containing

211819_s_at 1.50494526 1 23.8 1.5049453 38.25 SORBS1 1 202327_s_at 1.5047662 1 33.4 1.5047661 52.65 PKD1 ubiquitin-like 5 cadherin 17, LI cadherin (liver-

209847_at 1.50465336 1 10.45 1.5046533 17.45 CDH17 intestine) olfactory receptor, family 10,

221346_at 1.50463893 1 54.85 1.5046389 85.7 OR10J1 subfamily J, member 1 MHC DO-alpha cell surface

217001_x_at 1.50457722 1 30.2 1.5045772 46.5 glycoprotein, mRNA sequence CD79A antigen (immunoglobulin-

205049_s_at 1.50431902 1 9.15 1.504319 15.45 CD79A associated alpha) Human BRCA2 region, mRNA

214753_at 1.50429451 1 23.6 1.5042944 37.65 sequence CG006 chromosome 21 open reading

220372_at 1.50404894 1 2.2 1.504049 4.1 C21orf55 frame 55 220370_s_at 1.50404757 1 18.25 1.5040476 29.45 KIAA1453 KIAA1453 protein 216986_s_at 1.50352958 1 18.3 1.5035295 28.2 IRF4 interferon regulatory factor 4 213060_s_at 1.50287895 1 44.15 1.5028789 70.45 CHI3L2 chitinase 3-like 2 RAB30, member RAS oncogene

206530_at 1.50264832 1 23 1.5026484 42.35 RAB30 family corticotropin releasing hormone

208593 x at 1.5024875 1 14.4 1.5024875 22.7 CRHR1 receptor 1

218125_s_at 1.50213446 1 52.65 1.5021346 83 FLJ 10853 hypothetical protein FLJ10853 204450_x_at 1.50173663 1 12.9 1.5017366 21.05 APOA1 apolipoprotein A-I AFFX-r2-Bs-thr- M_s_at 1.50161566 1 29.85 1.5016158 48.15 nuclear receptor subfamily 4, group

210226 at 1.50141755 1 39.15 1.5014174 61.3 NR4A1 A, member 1

Norepinephrine transporter isoform

2 [Homo sapiens], mRNA

217213_at 1.50100579 1 3.35 1.5010056 5.1 sequence 205660 at 1.50084168 1 37.35 1.5008416 59.7 OASL 2'-5'-oligoadenyiate synthetase-like serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),

211428_at 1.50083754 1.25 1.5008374 -3.65 SERPINA1 member 1 neurofibroma 2 (bilateral acoustic

217150_s_at 1.50060809 1 34.65 1.5006081 55.25 NF2 neuroma) 205701 at 1.50011617 1 26.35 1.5001161 42 IPO8 RAN binding protein 8 90 κ>

Example II

Production of Natively Glycosylated Mammalian Biological Molecules (FGBb, G-CSF, GM-CSF, VEGF, IL-6 and IL-8) in a TVEMF Bioreactor

In a preferred embodiment of the invention, NHNP were pooled from three donors to diminish donor-to-donor variations and grown in T-75 flasks as in

Example I. As in Example 1, and a small sample was enzymatically dissociated and assayed for viability before the NHNP were further cultured. Of the small sample assayed, 98% were found to be viable. The assayed cells were discarded thereafter and the rest of the NHNP cells cultured as indicated herein.

A) Two-dimensional Protocol With TVEMF Expansion

Initially, a metal electrode was placed inside a 100 mm petri dish and centered. The petri dish was tissue culture treated to prevent adherence of the cells to the surface. The electrode was made of platinum and stainless steel. To inoculate the culture, NHNP were seeded at 2.5 x 10⁵ cells in 0.7 ml of media comprising GTSF-2, with 10% fetal bovine serum, Ciprofloxin and Fungizone, and carefully dropped on the electrode in a concentrated bubble.

Cells were incubated for 2 days. The second day after cell inoculation was considered day 0 of the experiment protocol. At day 0, each dish was given 15 ml of media and TVEMF was applied to the electrodes. Cells were fed with 15 ml of media at day 3 and with 13 ml every three days thereafter at day 6, 9, and 12. At days

14 and 17, the cells were fed again with 15 ml of media. At day 19, the cells were incubated for 10 minutes in a Collagenase/DNase cocktail, then trypsin was directly applied to the cocktail and the cells were further incubated for 3 more minutes. The cocktail mix was pipetted up and down several times before the GTSF-2 media with 10% fetal bovine serum, ciprofloxin, and fungizone was added to deactivate the trypsin. The cells were washed twice with 1 X PBS, resuspended in media, and placed on ice. The cells were observed under a dissecting microscope, counted, and assessed for viability. The viability assay was performed with a small sample of the cells and determine to be 98% viable. Media was removed throughout the process and components therein were directly analyzed by the Luminex system and protocol, as discussed in Example I above. B) Three-dimensional Protocol Without TVEMF Expansion

NHNP were placed in a bioreactor without TVEMF and were expanded under identical conditions as in the Three-dimensional TVEMF Expansion Protocol of Example 1, but without TVEMF.

C) Three-dimensional TVEMF Expansion Protocol

Three-dimensional TVEMF expanded NHNP were subjected to the same conditions as in Example 1, Three-dimensional TVEMF Expansion Protocol. The three-dimensional TVEMF NHNP expansion, was performed under identical conditions as the two-dimensional TVEMF expansion experimental conditions, and the three-dimensional experimental conditions without TVEMF expansion. The culture media was tested for the particular natively glycosylated mammalian biological molecules for the number of days indicated in Table II.

Media containing glycosylated mammalian biological molecules was removed from each of the NHNP culture conditions (two-dimensional TVEMF, three-dimensional, and three-dimensional TVEMF) and analyzed by the Luminex system technology. The results are shown in Table II herein. In Table II, "WF" refers to samples which have been subjected to three-dimensional TVEMF expansion, "NWF" refers to samples which have been subjected to three-dimensional expansion without TVEMF, and "2D" refers to samples which have been subjected to TVEMF under two-dimensional conditions. It should also be noted that eight samples were run each day for each of the above-mentioned three-dimensional or two-dimensional protocols.

TABLE II

FGFb GCSF GMCSF

Day Condition Mean Cone STD DEV Mean ConeSTD DEV Mean ConeSTD DEV

2 WF 00092 0 0019 614474 8 4929 184483 10597

NWF 0057 0 0074 1773796 15 2944 389951 12935

2D 00361 0 0018 182586 0 7053 29589 03688

4 WF 00246 0 0034 1008314 23 3936 172225 37557

NWF 00979 0 0094 4869218 79 2349 411087 02252

2D 00219 0 0045 499236 11 6439 89178 11277

6 WF 00186 0 0004 1098673 23 0463 478682 26871

NWF 00804 0 0071 4628362 57 7776 466831 71883

2D 00064 0 0019 271722 1 8316 156419 12139

8 WF 00786 0 0067 448161 3 0952 614237 85078

NWF 01296 0 1296 3809804 380 9804 1067562 1067562

2D 0527 0 0267 89642 1 0385 70219 03727

9 WF 01434 0 0235 346516 4 7383 647196 36556

NWF 03178 0 0218 2222086 18 6588 847117 8378

2D 00249 0 0021 1516 0 1093 13764 07527

11 WF 18325 0 0161 1270726 192 0431 6707203 937273

NWF 06302 0 0207 3314476 5 9772 1782236 174708

2D 00012 0 0012 09391 0 2855 18966 04401

13 WF 14992 0 2271 1366976 316 3289 5503927 674697

NWF 01776 0 1776 606051 60 6051 37644 37644

2D 00117 0 0016 08111 0 1378 22401 01507

15 WF 09697 0 0894 6196369 64 7008 3281485 673657

NWF 09627 0 0026 3666054 10 7536 2728803 23251

2D 00064 0 0064 03958 0 3958 07883 07883

TABLE II

VEGF IL6 IL8

Day Condition Mean ConeSTD DEV Mean Cone STD DEV Mean ConeSTD DEV

2 WF 112577 97272 3459498 1389 7241367 3397378

NWF 148586 230095 8041367 460798 8947914 1083328

2D 138036 1.6093 288801 51116 7413675 794468

4 WF 2347853 663999 1342548 1863368 9354937 413954

NWF 3836621 543841 1194558 1955911 9250418 1397596

2D 305865 61794 3992504 1499172 481112 2754453

6 WF 8835639 3168509 3262756 5561502 9096906 4244565

NWF 4619312 194686 360316 6731835 138806 4727945

2D 314962 19734 5286405 772233 6512101 1436058

8 WF 1187365 6235878 3067685 5755069 1096355 2657979

NWF 6704693 6704693 3300821 1027327 108324 4549349

2D 436168 34105 2029502 582175 9174888 2279873

9 WF 183643 3107255 2787833 397033 9618643 2007578

NWF 9805912 1132059 2074221 7786195 1151644 4350584

2D 289144 07455 64216 57862 1322979 5838308

11 WF 1888231 6105438 8348812 1627775 1739448 6599258

NWF 107789 628381 2968499 1570741 1169258 3538616

2D 904925 184154 805551 87317 3643086 1430946

13 WF 2075767 1011982 8450832 1388268 9996796 5390403

NWF 1561844 1561844 1048765 942269 4729,761 2141279

2D 715864 44769 671565 104464 1478277 2491653

15 WF 1288796 308327 500827 1867714 494645 1043931

NWF 102035 2476614 4777665 575862 4261961 2677796

2D 493304 493304 276689 37658 2174318 1721657

17 WF 5742379 8291752 4871887 3813742

NWF 6660929 4331665 1921248 1921248

2D 712376 396524 3222547 4355581

19 WF 4752068 1603732 3102588 1212663

NWF 443978 22258 2738361 1532301

2D 285076 395547 2060407 2993398

Table II shows the mean concentration (pg/ml) for each of the natively glycosylated mammalian biological molecules on each day. A statistical standard deviation within each of the samples has also been provided. Figures 9- 14 provide the data from Table II in the form of 6 graphs, each directed to a different natively glycosylated mammalian biological molecules.

It should be noted that there is a significant increase in the production of the natively glycosylated mammalian biological molecules as a result of three- dimensional TVEMF expansion. While Table II and Figures 9- 14 indicate that natively glycosylated mammalian biological molecule production is particularly high at days 11 and 13 for all natively glycosylated mammalian biological molecules tested and that natively glycosylated mammalian biological molecule production drops thereafter, subsequent studies have shown that frequent changes to the media fed sustaining the mammalian cells, particularly in the TVEMF bioreactor, will diminish and even negate the production decline seen after 15 days. Subsequent results also indicate that production of natively glycosylated mammalian biological molecules continues to increase after day 13.

Claims

C L A I M S

1. A composition comprising a natively glycosylated mammalian biological molecule produced from a living mammalian cell exposed to an electromagnetic force.

2. The composition as in claim 1, wherein the electromagnetic force is a time varying electromagnetic force.

3. The composition as in claim 2, wherein the time varying electromagnetic force is in the form of a square wave.

4. The composition according to claim 3 wherein the square wave time varying electromagnetic force is of from about 0.05 gauss to about 6 gauss.

5. The composition as in claim 1, wherein the natively glycosylated mammalian biological molecule is selected from protein, peptide, polypeptide, glycoprotein, cytokine, post-translational protein, post-translational peptide and post- translational polypeptide.

6. The composition according to claim 1, wherein the natively glycosylated mammalian biological molecule is at least one of the group consisting of granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, erythropoietin, human growth factor, interleukin, leukemia inhibitory factor and RANTES.

7. The composition according to claim 6, wherein the interleukin is at least one of IL-2, IL-6, IL-8 and IL-12.

8. The composition according to claim 1, wherein the natively glycosylated mammalian biological molecule is a natively glycosylated human biological molecule, and wherein the living mammalian cells are human mammalian cells.

9. The composition according to claim 1, wherein said composition is a pharmaceutical composition.

10. A natively glycosylated mammalian biological mixture comprising a natively glycosylated mammalian biological molecule produced from a living mammalian cell exposed to an electromagnetic force.

11. The natively glycosylated mammalian biological mixture as in claim 10, wherein the electromagnetic force is a time varying electromagnetic force.

12. The natively glycosylated mammalian biological mixture as in claim 11 , wherein the time varying electromagnetic force is in the form of a square wave.

13. The natively glycosylated mammalian biological mixture according to claim 12 wherein the square wave time varying electromagnetic force is of from about 0.05 gauss to about 6 gauss.

14. The natively glycosylated mammalian biological mixture as in claim 10, wherein the natively glycosylated mammalian biological molecule is selected from proteins, peptides, polypeptides, glycoproteins, cytokines, post-translational proteins, post-translational peptides and post-translational polypeptides.

15. The natively glycosylated mammalian biological mixture according to claim 10, wherein the natively glycosylated mammalian biological molecule is at least one of the group consisting of granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, erythropoietin, human growth factor, interleukin, leukemia inhibitory factor and RANTES.

16. The natively glycosylated mammalian biological mixture according to claim 15, wherein the interleukin is at least one of IL-2, IL-6, IL-8 and IL-12.

17. The natively glycosylated mammalian biological mixture according to claim 15, comprising at least two of the natively glycosylated mammalian biological molecules.

18. The natively glycosylated mammalian biological mixture according to claim 15, comprising at least two of the natively glycosylated mammalian biological molecules in an amount of at least 100 pg/ml of mixture.

19. The natively glycosylated mammalian biological mixture according to claim 18, wherein said amount is at least 1000 pg/ml.

20. The natively glycosylated mammalian biological mixture according to claim 19, wherein said amount is at least 10,000 pg/ml.

21. The natively glycosylated mammalian biological mixture according to claim 18, wherein said at least two natively glycosylated mammalian biological molecules is selected from the group consisting of granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, and IL-6.

22. The natively glycosylated mammalian biological mixture according to claim 10, wherein at least one of the natively glycosylated mammalian biological molecules selected from the group consisting of granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, erythropoietin, human growth factor, interleukin, leukemia inhibitory factor and RANTES has been removed from the mixture.

23. The natively glycosylated mammalian biological mixture according to claim 10, wherein at least one mammalian cell is present in the mixture.

24. The natively glycosylated mammalian biological mixture according to claim 10, wherein no mammalian cell is present in the mixture.

25. The natively glycosylated mammalian biological mixture according to claim 10, wherein a carrier medium is present in the mixture.

26. The natively glycosylated mammalian biological mixture according to claim 25, wherein said carrier medium is GTSF-2.

27. The natively glycosylated mammalian biological mixture according to claim 10, wherein a carrier medium present in the mixture has been removed and replaced with an acceptable carrier.

28. A composition of claim 1, comprising a natively glycosylated mammalian molecule that has been separated from a natively glycosylated mammalian biological mixture according to claim 10.

29. The natively glycosylated mammalian biological mixture according to claim 10, wherein the natively glycosylated mammalian biological molecule is a natively glycosylated human biological molecule, and wherein the living mammalian cells are human mammalian cells.

30. A method for producing natively glycosylated mammalian biological molecules comprising the step subjecting a living mammalian cell to an electromagnetic force until an amount of a natively glycosylated mammalian biological molecule is produced.

31. The method according to claim 30, wherein the electromagnetic force is a time varying electromagnetic force.

32. The method according to claim 31 , wherein the time varying electromagnetic force is in the form of a square wave.

33. The method according to claim 32, wherein the square wave time varying electromagnetic force is of from 0.05 gauss to 6 gauss.

34. The method according to claim 33, wherein the square wave time varying electromagnetic force is of from 0.05 gauss to 0.5 gauss.

35. The method according to claim 30, wherein the natively glycosylated mammalian biological molecules are selected from proteins, peptides, polypeptides, glycoproteins, cytokines, post-translational proteins, post-translational peptides and post-translational polypeptides.

36. The method according to claim 30, wherein the subjecting step occurs in one of the group selected from a petri dish, a flask, or a bioreactor cell culture chamber.

37. The method of claim 30, wherein the subjecting step further comprises producing the natively glycosylated mammalian biological molecules in a natively glycosylated mammalian biological molecule mixture, and then further comprising the step of separating the amount of natively glycosylated mammalian biological molecules from the mixture.

38. The method of claim 3O₃ wherein the natively glycosylated mammalian biological molecule is at least one of the group consisting of granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, erythropoietin, human growth factor, interleukin, leukemia inhibitory factor and RANTES.

39. The composition according to claim 38, wherein the interleukin is at least one of IL-2, IL-6, IL-8 and IL-12.

40. A method for producing natively glycosylated mammalian biological molecules comprising the steps of: a) placing a mammalian cell mixture into a cell culture chamber of a TVEMF-bioreactor; b) rotating the cell culture chamber at a rotational speed sufficient to prevent mammalian cells in the mammalian cell mixture from substantially contacting walls of the chamber until natively glycosylated mammalian biological molecules are present in an amount in the carrier medium; and c) separating one or more of the natively glycosylated mammalian biological molecules from the carrier medium.

41. The method according to claim 40, wherein an electromagnetic force is applied to the chamber.

42. The method according to claim 43, wherein the electromagnetic force is a time varying electromagnetic force.

43. The method according to claim 42, wherein the time varying electromagnetic force is in the form of a square wave.

44. The method according to claim 43, wherein the square wave time varying electromagnetic force is of from 0.05 gauss to 6 gauss.

45. The method according to claim 44, wherein the square wave time varying electromagnetic force is of from 0.05 gauss to 0.5 gauss.

46. The method according to claim 40, wherein prior to separating the one or more of the natively glycosylated mammalian biological molecules, a sample of the carrier medium is screened for the presence of natively glycosylated mammalian biological molecules.

47. The method according to claim 40, wherein the natively glycosylated mammalian biological molecule is granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, erythropoietin, human growth factor, interleukin, leukemia inhibitory factor and RANTES.

48. The method according to claim 40, wherein the cells are multipotential hematopoietic cells and the carrier medium comprises soluble interleukin 6 receptor (s- IL-6R) , interleukin 6 (IL-6) and stem cell factor (SCF).